0001104659-15-044096.txt : 20150609 0001104659-15-044096.hdr.sgml : 20150609 20150608213632 ACCESSION NUMBER: 0001104659-15-044096 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20150430 FILED AS OF DATE: 20150609 DATE AS OF CHANGE: 20150608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO REFERENCE LABORATORIES INC CENTRAL INDEX KEY: 0000792641 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 222405059 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-15266 FILM NUMBER: 15919686 BUSINESS ADDRESS: STREET 1: 481 EDWARD H ROSS DR CITY: ELMWOOD PARK STATE: NJ ZIP: 07407-3118 BUSINESS PHONE: 2017912186 MAIL ADDRESS: STREET 1: 481 EDWARD H ROSS DRIVE CITY: ELMWOOD PARK STATE: NJ ZIP: 07407-3118 FORMER COMPANY: FORMER CONFORMED NAME: MED MOBILE INC DATE OF NAME CHANGE: 19891115 10-Q 1 a15-7384_110q.htm 10-Q

Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 

FORM 10-Q

 

(Mark One)

x     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the quarterly period ended April 30, 2015

 

Or

 

o        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                to               

 

Commission File Number  000-15266

 

BIO-REFERENCE LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

 

NEW JERSEY

 

22-2405059

(State or other jurisdiction of incorporation or organization)

 

(IRS Employer Identification No.)

 

481 Edward H. Ross Drive, Elmwood Park, NJ

 

07407

(Address of principal executive offices)

 

(Zip Code)

 

(201) 791-2600

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated file in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o

 

Accelerated Filer x

 

 

 

Non-accelerated Filer o

 

Smaller reporting company o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of the issuer’s common stock, as of the latest practicable date: 27,802,976 shares of Common Stock ($.01 par value) at June 3, 2015.

 

 

 



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC.

 

FORM 10-Q

 

April 30, 2015

 

I N D E X

 

 

 

Page

 

 

 

PART I.  FINANCIAL INFORMATION

 

 

 

 

Item 1.      Financial Statements

 

 

 

 

 

Consolidated Balance Sheets as of April 30, 2015 (unaudited) and October 31, 2014.

1

 

 

 

 

 

 

Consolidated Statements of Operations (unaudited) for the three months and six-months ended April 30, 2015 and April 30, 2014

3

 

 

 

 

 

 

Consolidated Statements of Cash Flows (unaudited) for the six-months ended April 30, 2015 and April 30, 2014

4

 

 

 

 

 

 

Notes to consolidated financial statements (unaudited)

6

 

 

 

Item 2.      Management’s Discussion and Analysis of Financial Condition and Results of Operations

10

 

 

 

Item 3.      Quantitative and Qualitative Disclosures About Market Risk

16

 

 

 

Item 4.      Controls and Procedures

16

 

 

 

PART II.      OTHER INFORMATION

17

 

 

 

Item 1.     

Legal Proceedings

17

 

 

 

Item 5.     

Other Information

17

 

 

 

Item 6.      Exhibits

17

 

 

 

Signatures

 

18

 



Table of Contents

 

PART I — FINANCIAL INFORMATION

 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

 

CONSOLIDATED BALANCE SHEETS

[Dollars In Thousands Except Share and Per Share Data]

 

ASSETS

 

 

 

April 30,

 

October 31,

 

 

 

2015

 

2014

 

 

 

(Unaudited)

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

 

 

 

 

 

Cash and Cash Equivalents

 

$

25,146

 

$

17,507

 

Accounts Receivable - Net

 

285,361

 

263,346

 

Inventory

 

20,783

 

20,791

 

Other Current Assets

 

9,224

 

10,165

 

Deferred Tax Assets

 

39,456

 

40,040

 

TOTAL CURRENT ASSETS

 

379,970

 

351,849

 

 

 

 

 

 

 

PROPERTY AND EQUIPMENT - AT COST

 

172,893

 

156,342

 

LESS: Accumulated Depreciation

 

(101,250

)

(89,954

)

PROPERTY AND EQUIPMENT - NET

 

71,643

 

66,388

 

 

 

 

 

 

 

OTHER ASSETS:

 

 

 

 

 

Investments in Unconsolidated Affiliate

 

5,290

 

5,153

 

Deposits

 

1,127

 

1,056

 

Goodwill - Net

 

35,185

 

35,185

 

Intangible Assets - Net

 

13,450

 

14,403

 

Other Assets

 

1,615

 

1,415

 

Deferred Tax Asset

 

4,438

 

3,414

 

 

 

 

 

 

 

TOTAL OTHER ASSETS

 

61,105

 

60,626

 

 

 

 

 

 

 

TOTAL ASSETS

 

$

512,718

 

$

478,863

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

1



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

 

CONSOLIDATED BALANCE SHEETS

[Dollars In Thousands Except Share and Per Share Data]

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

April 30,

 

October 31,

 

 

 

2015

 

2014

 

 

 

(Unaudited)

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

Accounts Payable

 

$

66,073

 

$

71,166

 

Accrued Salaries and Commissions Payable

 

26,950

 

15,822

 

Accrued Taxes and Expenses

 

11,493

 

15,620

 

Other Short Term Acquisition Payable

 

1,695

 

1,924

 

Revolving Note Payable - Bank

 

49,315

 

33,380

 

Current Maturities of Long-Term Debt

 

541

 

524

 

Capital Lease Obligations - Short-Term Portion

 

6,259

 

6,128

 

TOTAL CURRENT LIABILITIES

 

162,326

 

144,564

 

 

 

 

 

 

 

LONG-TERM LIABILITIES

 

 

 

 

 

Capital Lease Obligations - Long-Term Portion

 

10,863

 

12,252

 

Long - Term Debt — Net of Current Portion

 

2,871

 

3,145

 

TOTAL LONG-TERM LIABILITIES

 

13,734

 

15,397

 

 

 

 

 

 

 

SHAREHOLDERS’ EQUITY

 

 

 

 

 

Preferred Stock $.10 Par Value;

 

 

 

 

 

Authorized 1,666,667 shares, including 3,000 shares of Series A Junior Preferred Stock None Issued

 

0

 

0

 

Common Stock, $.01 Par Value; Authorized 35,000,000 shares:

 

 

 

 

 

Issued and Outstanding 27,798,976 and 27,272,644 at April 30, 2015 and at October 31, 2014, respectively

 

278

 

277

 

 

 

 

 

 

 

Additional Paid-In Capital

 

40,640

 

39,979

 

Retained Earnings

 

295,740

 

278,646

 

 

 

 

 

 

 

TOTAL SHAREHOLDERS’ EQUITY

 

336,658

 

318,902

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

 

$

512,718

 

$

478,863

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

2



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF OPERATIONS

[Dollars In Thousands Except Share and Per Share Data]

[UNAUDITED]

 

 

 

Three months ended

 

Six months ended

 

 

 

April 30,

 

April 30,

 

 

 

2015

 

2014

 

2015

 

2014

 

 

 

 

 

 

 

 

 

 

 

NET REVENUES:

 

$

223,986

 

$

201,366

 

$

432,820

 

$

382,635

 

 

 

 

 

 

 

 

 

 

 

COST OF SERVICES:

 

 

 

 

 

 

 

 

 

Depreciation and Amortization

 

5,091

 

4,659

 

10,057

 

9,234

 

Employee Related Expenses

 

56,491

 

51,566

 

110,176

 

100,676

 

Reagents and Laboratory Supplies

 

42,977

 

38,352

 

83,559

 

75,583

 

Other Cost of Services

 

20,444

 

18,240

 

40,290

 

36,439

 

TOTAL COST OF SERVICES

 

125,003

 

112,817

 

244,082

 

221,932

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT ON REVENUES

 

98,983

 

88,549

 

188,738

 

160,703

 

 

 

 

 

 

 

 

 

 

 

GENERAL AND ADMINISTRATIVE EXPENSES:

 

 

 

 

 

 

 

 

 

Depreciation and Amortization

 

1,606

 

1,586

 

3,174

 

2,700

 

General and Administrative Expenses

 

58,797

 

50,992

 

117,056

 

100,578

 

Bad Debt Expense

 

19,654

 

17,092

 

37,654

 

32,665

 

TOTAL GENERAL AND ADMINISTRATIVE EXPENSES

 

80,057

 

69,670

 

157,884

 

135,943

 

 

 

 

 

 

 

 

 

 

 

INCOME FROM OPERATIONS

 

18,926

 

18,879

 

30,854

 

24,760

 

 

 

 

 

 

 

 

 

 

 

OTHER (INCOME) EXPENSE:

 

 

 

 

 

 

 

 

 

Interest Expense

 

666

 

597

 

1,226

 

1,206

 

Interest Income

 

(23

)

(12

)

(45

)

(26

)

Other (Income) Expense

 

2

 

56

 

(112

)

86

 

TOTAL OTHER (INCOME) EXPENSES - NET

 

645

 

641

 

1,069

 

1,266

 

 

 

 

 

 

 

 

 

 

 

INCOME BEFORE INCOME TAXES

 

18,281

 

18,238

 

29,785

 

23,494

 

Provision for Income Taxes

 

7,820

 

7,965

 

12,691

 

10,267

 

 

 

 

 

 

 

 

 

 

 

NET INCOME

 

$

10,461

 

$

10,273

 

$

17,094

 

$

13,227

 

 

 

 

 

 

 

 

 

 

 

NET INCOME PER COMMON SHARE - BASIC:

 

$

0.38

 

$

0.37

 

$

0.62

 

$

0.48

 

WEIGHTED AVERAGE NUMBER OF SHARES - BASIC:

 

27,786,309

 

27,716,644

 

27,781,143

 

27,712,525

 

 

 

 

 

 

 

 

 

 

 

NET INCOME PER COMMON SHARE - DILUTED:

 

$

0.38

 

$

0.37

 

$

0.61

 

$

0.47

 

WEIGHTED AVERAGE NUMBER OF SHARES - DILUTED:

 

27,881,908

 

27,857,467

 

27,874,074

 

27,855,141

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

3



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

[Dollars In Thousands Except Share and Per Share Data]

[UNAUDITED]

 

 

 

Six months ended

 

 

 

April, 30

 

 

 

2015

 

2014

 

OPERATING ACTIVITIES:

 

 

 

 

 

Net Income

 

$

17,094

 

$

13,227

 

Adjustments to Reconcile Net Income to Cash Provided by (Used for) Operating Activities:

 

 

 

 

 

Depreciation and Amortization

 

13,231

 

11,934

 

Deferred Income Tax (Benefit) Expense

 

(440

)

5,976

 

Stock Based Compensation

 

40

 

290

 

(Gain) Loss on Disposal of Fixed Assets

 

173

 

109

 

Undistributed Equity Method (Income) Loss

 

(112

)

86

 

Change in Assets and Liabilities, (Increase) Decrease in:

 

 

 

 

 

Accounts Receivable

 

(20,244

)

(13,227

)

Provision for Doubtful Accounts

 

(1,771

)

(14,480

)

Inventory

 

8

 

(855

)

Other Current Assets

 

941

 

87

 

Other Assets

 

(200

)

(200

)

Deposits

 

(71

)

(38

)

Increase (Decrease) in:

 

 

 

 

 

Accounts Payable and Accrued Liabilities

 

1,908

 

(3,097

)

 

 

 

 

 

 

NET CASH - OPERATING ACTIVITIES

 

10,557

 

(188

)

 

 

 

 

 

 

INVESTING ACTIVITIES:

 

 

 

 

 

Acquisition of Equipment and Leasehold Improvements

 

(15,739

)

(7,048

)

Business Acquisitions and Related Costs

 

(254

)

(258

)

 

 

 

 

 

 

NET CASH - INVESTING ACTIVITIES

 

(15,993

)

(7,306

)

 

 

 

 

 

 

FINANCING ACTIVITIES:

 

 

 

 

 

Payments of Long-Term Debt

 

(257

)

(243

)

Payments of Capital Lease Obligations

 

(3,225

)

(2,933

)

Increase (Decrease) in Revolving Line of Credit

 

15,935

 

17,021

 

Proceeds from Exercise of Options

 

622

 

177

 

 

 

 

 

 

 

NET CASH - FINANCING ACTIVITIES

 

13,075

 

14,022

 

 

 

 

 

 

 

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

 

7,639

 

6,528

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIODS

 

17,507

 

17,952

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS AT END OF PERIODS

 

$

25,146

 

$

24,480

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

Interest

 

$

1,189

 

$

1,166

 

Income Taxes

 

$

16,538

 

$

9,867

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

4



Table of Contents

 

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

[Dollars In Thousands]

[UNAUDITED]

 

During the six-month periods ended April 30, 2015 and April 30, 2014, the Company entered into capital leases totaling $1,967 and $5,905, respectively.

 

During the six-month periods ended April 30, 2015 and April 30, 2014, the Company wrote-off approximately $1,155 and $920 of property and equipment, most of which were fully depreciated.

 

5



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

[Dollars In Thousands Except Share and Per Share Data, Or Unless Otherwise Noted]

(UNAUDITED)

 

[1] Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the instructions to Form 10-Q and, therefore, do not include all information and footnotes necessary for complete audited financial statements. However, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial position and operating results have been included in these statements. Interim results are not necessarily indicative of results for a full year. Reference is made to the October 31, 2014 audited consolidated financial statements of Bio-Reference Laboratories, Inc.(“BRLI” or the “Company”) contained in its Annual Report on Form 10-K for the year ended October 31, 2014.

 

The consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes for the year ended October 31, 2014 as filed with the Securities and Exchange Commission in the Company’s Annual Report on Form 10-K. Significant accounting policies followed by the Company are set forth in Note 2 to the Company’s 2014 Annual Report on Form 10-K.

 

[2] Fair Value Measurements

 

As of April 30, 2015, the Company’s financial instruments primarily consist of cash, short-term trade receivables and payables for which their carrying amounts approximate fair values, and long term debt, for which based on the borrowing rates currently available to the Company for bank loans with similar terms and average maturities, its carrying amount approximates its fair value.

 

[3] New Accounting Pronouncements

 

Removed and Reserved.

 

[4] Revenue Recognition and Contractual Adjustments

 

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

 

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.  Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by BRLI are to patients covered under a third party payor contract.  In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly; in the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.  Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.  Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.  The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.  This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.  The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

 

6



Table of Contents

 

 

 

($)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

[Unaudited]

 

[Unaudited]

 

 

 

2015

 

2014

 

2015

 

2014

 

Gross Service Revenues

 

1,175,282

 

1,017,621

 

2,240,575

 

1,927,499

 

 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

101,262

 

94,520

 

195,325

 

183,439

 

All Other Third Party Payors*

 

838,004

 

706,234

 

1,587,205

 

1,330,379

 

Total Contractual Adjustments and Discounts

 

939,266

 

800,754

 

1,782,530

 

1,513,818

 

Service Revenues Net of Contractual Adjustments and Discounts

 

236,016

 

216,867

 

458,045

 

413,681

 

Patient Service Revenue Provision for Bad Debts**

 

12,030

 

15,501

 

25,225

 

31,046

 

Net Revenues

 

223,986

 

201,366

 

432,820

 

382,635

 

 


* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

 

** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.  The remaining bad debt expense is presented as part of operating expenses.  The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

 

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial.  A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries.  One such legislation is Protecting Access to Medicare Act of 2014 (Public Law 113—93)(“PAMA”) was signed into law on April 1, 2014.  The legislation directed CMS to conduct a market survey and to determine whether Medicare is reimbursing at a commercially reasonable rates.  To date, CMS has fallen behind the schedule legislated in PAMA. As the result, the current reimbursement rates remain unchanged, subject to typical annual reviews, until 2017.

 

[5] Accounts Receivable Allowances

 

It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary.   BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

 

7



Table of Contents

 

 

 

($)

 

 

 

[Unaudited]

 

 

 

 

 

April 30,

 

October 31,

 

 

 

2015

 

2014

 

 

 

 

 

 

 

Contractual Credits/Discounts

 

582,180

 

513,466

 

Doubtful Accounts

 

81,505

 

83,276

 

Total Allowance

 

663,685

 

596,742

 

 

[6]  Intangible Assets

 

The following disclosures present certain information on the Company’s intangible assets as of April 30, 2015 (Unaudited) and October 31, 2014. All intangible assets are being amortized over their estimated useful lives, as indicated below, with no estimated residual value.

 

April 30, 2015

 

 

 

Weighted-Average

 

 

 

Accumulated

 

 

 

 

 

Amortization Period

 

 

 

Amortization

 

Net of Accumulated

 

Intangible Asset

 

Years

 

Cost ($)

 

($)

 

Amortization ($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

8,738

 

3,469

 

5,269

 

Covenants Not-to-Compete

 

5

 

11,131

 

6,325

 

4,806

 

Patents and Licenses

 

17

 

5,297

 

1,922

 

3,375

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

25,166

 

11,716

 

13,450

 

 

October 31, 2014

 

 

 

Weighted-Average

 

 

 

Accumulated

 

 

 

 

 

Amortization Period

 

 

 

Amortization

 

Net of Accumulated

 

Intangible Asset

 

Years

 

Cost ($)

 

($)

 

Amortization ($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

$

8,738

 

$

3,275

 

$

5,463

 

Covenants Not-to-Compete

 

3

 

11,131

 

5,738

 

5,393

 

Patents and Licenses

 

17

 

5,297

 

1,750

 

3,547

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

$

25,166

 

$

10,763

 

$

14,403

 

 

The aggregate intangible amortization expense for the three months ended April 30, 2015 and 2014 was $474 and $730, respectively.  The aggregate intangible amortization expense for the six months ended April 30, 2015 and 2014 was $952 and $959, respectively.  The estimated intangible asset amortization expense for the remainder of fiscal year ending October 31, 2015 and for the four subsequent years is as follows:

 

October 31,

 

($)

 

2015

 

900

 

2016

 

1,540

 

2017

 

1,063

 

2018

 

946

 

2019

 

904

 

Thereafter

 

8,097

 

 

 

 

 

Total

 

13,450

 

 

[7] Revolving Note Payable - Bank

 

On February 3, 2014, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A. (“PNC Bank Credit Line”).  This amendment increased the maximum credit line to $70,000.  The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i) $70,000 or (ii) 50% of the Company’s

 

8



Table of Contents

 

qualified accounts receivable, as defined in the agreement.  The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank’s base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage.  The additional interest percentage charge on bank’s base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company.  At April 30, 2015, the Company elected to have all of the total advances outstanding to be subject to the bank’s base rate of interest of 3.50%.  The credit line is collateralized by substantially all of the Company’s assets. The line of credit is available through October 2016 and may be extended for annual periods by mutual consent, thereafter.  The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, and the prohibition of the payment of cash dividends by the Company. As of April 30, 2015, the Company utilized $49,315 of the available credit under this revolving note payable loan agreement.

 

On May 14, 2015 a date subsequent to the period covered in these financial statements the Company further amended its PNC Bank Credit Line to increase the maximum that can be borrowed under the credit line to $120,000 as well as extended the credit line through October 2020. This amendment is effective as of May 5, 2015.  The other terms of the amendment remained substantially unchanged.

 

[8] Long-Term Debt - Bank

 

In December 2010, the Company issued a seven-year term note for $5,408 at the rate of interest of 6.12% per annum for the financing of new equipment.  The note is payable in 84 equal monthly installments commencing on January 29, 2011 of $61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of  December 29, 2017.  The balance on this note as of April 30, 2015 is approximately $3,412.

 

[9] Provision for Income Taxes

 

The provision for income taxes for the three-months ended April 30, 2015 consists of a current tax provision of $9,400 and a deferred tax benefit of $1,580.

 

The provision for income taxes for the six-months ended April 30, 2015 consists of a current tax provision of $13,131 and a deferred tax benefit of $440.

 

The provision for income taxes for the three-months ended April 30, 2014 consists of a current tax provision of $7,508 and a deferred tax provision of $457.

 

The provision for income taxes for the six-months ended April 30, 2014 consists of a current tax provision of $4,291 and a deferred tax provision of $5,976.

 

On April 30, 2015, the Company had a current deferred tax asset of $39,456 and a long-term deferred tax asset of $4,438 included in other assets.  On April 30, 2014, the Company had a current deferred tax asset of $35,964 and a long-term deferred tax asset of $2,291 included in other assets.

 

[10] Subsequent events

 

On June 3, 2015 the Company,  OPKO Health, Inc., a Delaware corporation (“OPKO”) and Bamboo Acquisition, Inc., a New Jersey corporation and a direct wholly owned subsidiary of OPKO (“Sub”), entered into an agreement and plan of merger (the “Merger Agreement”). Pursuant to the Merger Agreement, Sub will be merged with and into the Company (the “Merger”) and the Company will be the surviving corporation and OPKO’s wholly owned subsidiary. The Merger is intended to qualify as a reorganization within the meaning of the Internal Revenue Code of 1986, as amended (the “Code”).

 

At the effective time of the Merger (the “Effective Time”), each issued and outstanding share of the Company’s common stock, par value $0.01 per share (the “Company Common Stock”), (other than any shares of the Company Common Stock (including shares held in treasury by the Company) held by OPKO or any OPKO subsidiary or the Company or any Company subsidiary) will automatically be converted into and exchanged for the right to receive 2.75 shares (the “Exchange Ratio”) of OPKO’s common stock, par value $0.01 per share (the “OPKO Common Stock”). No fractional shares of OPKO Common Stock will be issued in the Merger, and the Company’s shareholders will receive one share of OPKO Common Stock in lieu of any fractional shares, after taking into account all of the shares of the Company Common Stock represented by certificates or book-entries, delivered by such shareholder.

 

In addition, subject to certain limitations described in the Merger Agreement, each option to purchase shares of the Company Common Stock will be converted into and become rights with respect to the OPKO Common Stock and OPKO will assume each such option, in accordance with the terms of the applicable option plan and/or stock option agreement. The number of shares of OPKO Common Stock subject to such options will be equal to the number of shares of Company Common Stock subject to such options multiplied by 2.75, rounded down to the nearest whole share. The per share exercise price under each option will be adjusted by dividing the per share exercise price of such option by 2.75 and rounding up to the nearest cent.

 

9



Table of Contents

 

The obligations of the Company and OPKO to consummate the Merger are subject to customary conditions, including, but not limited to, obtaining the required approval of the Company’s shareholders.

 

Subject to the satisfaction or waiver of the foregoing conditions and the other terms and conditions contained in the Merger Agreement, the transaction is expected to close in the second half of 2015.

 

The Merger Agreement contains certain termination rights for both the Company and OPKO in certain circumstances.

 

If the Merger Agreement is terminated under certain circumstances specified in the Merger Agreement, the Company will be required to pay OPKO a termination fee of up to $54,000,000. In addition, under certain circumstances, the Company would be obligated to reimburse OPKO’s out of pocket expenses incurred in connection with the Merger Agreement up to $3,000,000.

 

Forward-Looking Statements

 

Statements included in this Annual Report on Form 10-Q (Quarterly Report) that are not historical in nature, are intended to be, and are hereby identified as “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of Bio-Reference Laboratories, Inc. and its subsidiaries. Such statements concern matters that involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods, performance or achievements, or industry results, to be materially different from any future results, performance or achievements described, implied or suggested herein. Although we believe our expectations are based upon reasonable assumptions, there can be no assurance that our financial goals will be realized.

 

Factors could cause actual results, performance or achievement to differ materially from those expressed or implied from these forward-looking statements include, but are not limited to, the factors discussed under “Risk Factors” as well as elsewhere herein, which may include:

 

Loss or suspension of a license or imposition of a fine or penalties under, or future changes in, the law or regulations of CLIA, or those of state laboratory licensing laws;

Failure to comply with HIPAA, which could negatively impact profitability and cash flows;

FDA regulation of Laboratory Developed Tests and clinical laboratories;

Failure to comply with federal and state anti-kickback laws;

Failure to maintain the security of patient-related information;

Failure to comply with the Federal Occupational Safety and Health Administration requirements and Needlestick Safety and Prevention Act;

Failure to comply with federal and state laws and regulations related to submission of claims for our services;

Changes in regulation and policies, including increasing downward pressure on health care reimbursement;

Changing relationships with payers, including the various state and multi-state Blues programs, suppliers and strategic partners; Efforts by third-party payors to reduce utilization and reimbursement for clinical testing services;

Failure to timely or accurately bill for our services;

Failure to integrate newly acquired businesses and the costs related to such integration;

Increased competition, including price competition;

Ability to attract and retain experienced and qualified personnel;

Failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients;

Adverse litigation results; and

Failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this filing. We assume no obligation to update the forward-looking statements to reflect actual results or changes in the factors affecting such forward-looking statements.

 

Item 2. — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

[Dollars In Thousands Except Per Share Data, Total Patient Data Or Unless Otherwise Noted]

 

Overview

 

We are a clinical diagnostic laboratory headquartered in northeastern New Jersey. We are a national laboratory in certain focused areas of laboratory testing and a full service laboratory in the larger metropolitan areas of New York, New Jersey, Maryland, Pennsylvania, Delaware, Washington DC, Florida, California, Texas, Illinois and Massachusetts.

 

We have developed a national reputation for our expertise in certain focused areas of clinical testing.  GenPath Oncology, the name by which we are known for our cancer and oncology services, is recognized for the superior hematopathology services it provides throughout the country. Our Women’s Health initiative, through which we provide dedicated services for obstetrics and gynecology practices, including a technically advanced multiplex process for identifying sexually transmitted infections, is offered as GenPath Women’s Health.  We are a full-service laboratory that primarily services physician office practices; our drivers pick up samples and deliver reports and supplies, we provide sophisticated technical support, phlebotomy services or patient service centers where appropriate, and electronic communication services in many cases.  Physicians outside of our regional footprint send samples to our laboratory in order to take advantage of the expertise that we are able to provide in blood-based cancer pathology and associated diagnostics or to take advantage of the superior service,

 

10



Table of Contents

 

support and technologically advanced testing we offer in our Women’s Health initiative. These accounts frequently send routine testing to us for processing along with specialized testing in order to simplify their diagnostic ordering and review procedures and to take advantage of our outstanding capability, service and support.  Our correctional healthcare services are used throughout the country at prisons and jails. The focused markets we serve on a national basis outside of our regional footprint do not require many of the logistical and other ancillary support services required within the region. Even within our regional footprint, we provide the same services that we provide on a national basis as well as some regional focused diagnostic services, such as histology and pathology support services, substance abuse testing, fertility testing, hemostasis testing, women’s health testing, and molecular diagnostics that are unavailable from many of the smaller regional competitors; testing in some of these areas may be provided outside of physician offices.  Laboratorio Buena Salud is the first national testing laboratory dedicated to serving Spanish-speaking populations in the United States.  All business is conducted in Spanish, including patient and physician interactions.

 

Over the last few years, there have been fundamental changes in the laboratory services industry. In the 1990s, the industry was negatively impacted by the growth of managed care, increased government regulation, and investigations into fraud and abuse. These factors led to revenue and profit declines and industry consolidations, especially among commercial laboratories. There are currently only three US publicly traded full service laboratories operating primarily in the U.S. While that means that the two national mega-laboratories and Bio-Reference Laboratories are the only remaining publicly traded full service commercial laboratories, there are numerous hospital outreach programs and smaller reference laboratories that compete for the commercial clinical laboratory business scattered throughout the country. Clinical laboratories have had to improve efficiency, leverage economies of scale, comply with government regulations and other laws and develop more profitable approaches to pricing. Moreover, there has been a proliferation of technology advancements in clinical diagnostics over the last decade that has created significant opportunities for new testing and growth.

 

As a full service clinical laboratory, we are constantly looking for new technologies and new methodologies that will help us to grow. Since the turn of the century, our size alone has made us attractive to companies that are driving the advances in technology. We represent a significant opportunity for these companies to market their products with a nationally recognized specialty provider in our focused areas of specialty or in one of the major population centers of the world—the New York Metropolitan area. We have had several successful strategic relationships with such technology opportunities. In addition to new technology opportunities, we have an extremely seasoned and talented management staff that has been able to identify emerging laboratory markets that are under-served or under-utilized. We have recently developed programs for cardiology, histology and women’s health to go along with our existing hemostasis, hematopathology and correctional healthcare initiatives which have already been established and in which we have been increasing our market share for the past several years. We offer a comprehensive pre-natal program to leverage our presence in the women’s health environment and we will continue to vigilantly seek focused diagnostic marketing opportunities where we can provide information, technology, service or support that expand and grow our clinical laboratory.

 

While we recognize that we are a clinical laboratory that processes samples, we also understand that we are an information company that needs to effectively communicate the results of our efforts back to healthcare providers. Laboratory results play a major role in the implementation of physician healthcare. Laboratory results are used to diagnose, monitor and classify health concerns. In many cases, laboratory results represent the confirming data in diagnosing complicated health issues. Since laboratory results play such an important role in routine physician care, we have developed informatics solutions that leverage our role in healthcare. We built a web-based solution to quickly, accurately, conveniently and competitively collect ordering information and deliver results.  That solution is called CareEvolve.  CareEvolve has been essential to our own operations. We license the technology to other laboratories throughout the country that they utilize to more effectively compete against the national laboratories. These other laboratories licensing our technology are typically not our competitors since they are outside our regional footprint.

 

We have also created our PSIMedica business unit that has developed a Clinical Knowledge Management (CKM) System that takes data from enrollment, claims, pharmacy, laboratory results and any other available electronic source to provide both administrative and clinical analysis of a population. The system uses proprietary algorithms to cleanse and configure the data and transfer the resulting information into a healthcare data repository. Using advanced cube technology methodologies, the data can be analyzed from a myriad of views and from highly granular transactional detail to global trended overview. Events such as the Hurricane Katrina in Louisiana and general pressures from the government have made development of an electronic medical record system and Pay-for Performance reimbursement priority goals in the healthcare industry. A large portion of an individual’s medical record consists of laboratory data and a key performance indicator in any Pay-for-Performance initiative is laboratory result data. Our CKM system is a mature, full functioning solution that will allow us to play a role in these important national initiatives.

 

To date, neither our PSIMedica business unit nor CareEvolve has produced significant revenues relative to the primary laboratory operations.

 

11



Table of Contents

 

Second Quarter Fiscal 2015 Compared to Second Quarter Fiscal 2014

 

NET REVENUES:

 

Net revenues for the three-month period ended April 30, 2015 were $223,986 as compared to $201,366 for the three-month period ended April 30, 2014.  This represents an 11% increase in net revenues. This increase is due to an 8% increase in patient counts and an increase in revenue per patient of 3%. The number of patients serviced during the three-month period ended April 30, 2015 was 2,559, which was 8% greater when compared to the prior fiscal year’s corresponding three-month period.  This increase in patient counts is mainly due to the overall success of all our lines of business.  Net revenue per patient for the three-month period ended April 30, 2015 was $86.69 compared to net revenue per patient of $84.18 for the three-month period ended April 30, 2014, an increase of 3%.

 

Our revenues and patient counts could be adversely affected by a number of factors, including, but not limited, to an extended economic downturn in general or healthcare economic conditions, an unexpected reduction in reimbursement rates, increased market penetration by our competitors or a substantial adverse change in federal regulatory requirements governing our industry.

 

COST OF SERVICES:

 

Cost of services increased from $112,817 for the three-month period ended April 30, 2014 to $125,003 for the three-month period ended April 30, 2015, an increase of 11%. This increase was related largely to our continuing integration expenses of our California operations.

 

GROSS PROFITS:

 

Gross profits increased to $98,983 for the three-month period ended April 30, 2015 from $88,549 for the three-month period ended April 30, 2014, an increase of 12%. This increase is in line with the increase in revenues.

 

GENERAL AND ADMINISTRATIVE EXPENSES:

 

General and administrative expenses for the three-month period ending April 30, 2014 were $69,670 as compared to $80,057 for the quarter ended April 30, 2015, an increase of 15%. This increase is slightly more than the increase in our net revenues and is mainly due to an increase in marketing expenses we incurred as the result of expanding our sales and marketing operations.

 

INTEREST EXPENSE:

 

Interest expense increased to $666 during the three-month period ending April 30, 2015 from $597 during the three-month period ended April 30, 2014. This increase is due to an increase in the utilization of our PNC Bank’s credit line.

 

NET INCOME:

 

We realized net income of $10,461 for the three-month period ended April 30, 2015, as compared to $10,273 for the three-month period ended April 30, 2014, an increase of 2%. Pre-tax income for the period ended April 30, 2014 was $18,238, compared to $18,281 for the three-month period ended April 30, 2015, an increase of less than 1%.  This small increase was primarily caused by an increase in our marketing expenses.The provision for income taxes decreased to $7,820 for the three-month period ended April 30, 2015 from $7,965 for the period ended April 30, 2014.

 

Six Months 2015 Compared to Six Months 2014

 

NET REVENUES:

 

Net revenues for the six-month period ended April 30, 2015 were $432,820 as compared to $382,635 for the six-month period ended April 30, 2014. This represents a 13% increase in net revenues. This increase is due to a 7% increase in patient counts while the revenue per patient increased by 6%.  The number of patients serviced during the six-month period ended April 30, 2015 was 4,911, which was 7% greater when compared to the prior fiscal year’s corresponding six-month period. This increase in patient counts is mainly due to the overall success of all our lines of business. Net revenue per patient for the six-month period ended April 30, 2014 was $82.73 compared to net revenue per patient for the six-month period ended April 30, 2015 of $87.36, an increase of 6%.

 

Our revenues and patient counts could be adversely affected by a number of factors, including, but not limited, to an extended economic downturn in general or healthcare economic conditions, an unexpected reduction in reimbursement rates, increased market penetration by our competitors or a substantial adverse change in federal regulatory requirements governing our industry as well as a failure to continue the sizeable annual percentage increase in base business.

 

12



Table of Contents

 

COST OF SERVICES:

 

Cost of services increased to $244,082 for the six-month period ended April 30, 2015 from $221,932 for the six-month period ended April 30, 2014. This represents a 10% increase in direct operating costs.

 

GROSS PROFITS:

 

Gross profits on net revenues increased to $188,738 for the six-month period ended April 30, 2015 from $160,703 for the six-month period ended April 30, 2014, an increase of 17%.  Gross profit margins were 44% for the six-month period ended April 30, 2015 compared to 42% in the corresponding six-month period ended April 30, 2014.

 

GENERAL AND ADMINISTRATIVE EXPENSES:

 

General and administrative expenses for the six-month period ended April 30, 2015 were $157,884 as compared to $135,943 for the six-month period ended April 30, 2014.  This represents an increase of 16%. This increase is 3% more than the increase in net revenues and is mainly due to additional marketing expenses incurred as we expanded our marketing operations.

 

INTEREST EXPENSE:

 

Interest expense increased to $1,226 during the six-month period ending April 30, 2015 as compared to $1,206 during the six-month period ending April 30, 2014, an increase of $20.  This increase is due to an increase in the utilization of our PNC Bank credit line.

 

INCOME:

 

We realized net income of $17,094 for the six-month period ended April 30, 2015 as compared to $13,227 for the six-month period ended April 30, 2014, an increase of 29%.  Our operating income increased by 25% for the six-month period ended April 30, 2015 as compared to the six-month period ended April 30, 2014.  Pre-tax income for the six-month period ended April 30, 2015 was $29,785 as compared to $23,494 for the period ended April 30, 2014, an increase of 27%.  The provision for income taxes increased from $10,267 for the period ended April 30, 2014, to $12,691 for the current six-month period, an increase of 24%.

 

LIQUIDITY AND CAPITAL RESOURCES:

 

Our working capital at April 30, 2015 was $217,644 as compared to $207,285 at October 31, 2014, an increase of 5%.  Our cash increased by $7,639 during the current period.  We increased our short-term debt by $17 and repaid $274 in existing debt. We had current liabilities of $162,326 at April 30, 2015. We generated $10,557 in cash from operations, compared to utilizing 188 for the six-month period ended April 30, 2014, an overall increase of $10,745 in cash generated from operations year over year.

 

On May 14, 2015 a date subsequent to the period covered in these financial statements the Company further amended its PNC Bank Credit Line to increase the maximum that can be borrowed under the credit line to $120,000 as well as extended the credit line through October 2020. This amendment is effective as of May 5, 2015.  The other terms of the amendment remained substantially unchanged.

 

Accounts receivable, net of allowance for doubtful accounts, totaled $285,361 at April 30, 2015, an increase of $22,015 or 8% from October 31, 2014. Cash collected during the three-month period ended April 30, 2015 increased 11% over the comparable prior year three-month period.

 

Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising our client base.  We have significant receivable balances with government payors and various insurance carriers.  Generally, we do not require collateral or other security to support customer receivables. However, we continually monitor and evaluate our client acceptance and collection procedures to minimize potential credit risks associated with our accounts receivable and establish an allowance for uncollectible accounts. As a consequence, we believe that our accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.

 

A number of proposals for legislation continue to be under discussion that could substantially reduce Medicare and Medicaid reimbursements to clinical laboratories.  Depending upon the nature of regulatory action, and the content of legislation, we could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on us. We are unable to predict, however, the extent of which such actions will be taken if at all.

 

Billing for laboratory services is complicated and we must bill various payors, such as the individual, the insurance company, the government (federal or state), the private company or the health clinic. Other factors that may complicate billing include:

 

13



Table of Contents

 

Differences between fee schedules and actual reimbursement rates.

Incomplete or inaccurate billing information provided by physicians or clinics.

Disparity in coverage and information requirements.

Disputes with payors.

Internal and external compliance policies and procedures.

 

Significant costs are incurred as a result of our participation in government programs since billing and reimbursement for laboratory tests are subject to complex regulations. We perform the requested tests and report the results whether the billing information is correct or not or even missing. This adds to the complexity and slows the collection process and increases the aging of our accounts receivable (“A/R”). When patient invoices are not collected in a timely manner, the item is written off to the allowance. Days Sales Outstanding (“DSO”) for the period ended April 30, 2015 was 113 days, an increase of 10 days, or about 10%, from the 103 days that we reported for the period ended April 30, 2014.  On a rolling basis, our actual collections represent between 98% and 102% of our net collectable revenues.

 

See Notes to our consolidated financial statements for the information on our short and long term debt.

 

We intend to expand our laboratory operations organically through marketing while also diversifying into related medical fields through acquisitions.  These acquisitions may involve cash, notes, common stock and/or combinations thereof.

 

Tabular Disclosure of Contractual Obligations

 

 

 

Next Four Years and
Thereafter ($)

 

FY 2015 ($)

 

Long-Term Debt

 

3,145

 

524

 

Capital Leases

 

12,789

 

6,624

 

Operating Leases

 

4,637

 

8,909

 

Purchase Obligations

 

128,626

 

73,709

 

Long-Term Liabilities under Employment and Consultant Contracts

 

9,113

 

4,582

 

 

Our cash balance at April 30, 2015 totaled $25,146 as compared to $17,507 at October 31, 2014.  We believe that our cash position, the anticipated cash generated from future operations and the availability of our credit line with PNC Bank will meet our anticipated cash needs for the next 12 months.

 

Impact of Inflation

 

To date, inflation has not had a material effect on our operations.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods.

 

Accounting for Intangible and Other Long-Lived Assets

 

We evaluate the possible impairment of our long-lived assets, including intangible assets. We review the recoverability of our long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable.  Evaluation of possible impairment is based on our ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and the carrying amount of the asset.

 

Accounting for Revenue

 

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

 

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.  Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial

 

14



Table of Contents

 

insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by BRLI are to patients covered under a third party payor contract.  In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly; in the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.  Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.  Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.  The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.  This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.  The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

 

 

 

($)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

[Unaudited]

 

[Unaudited]

 

 

 

2015

 

2014

 

2015

 

2014

 

Gross Service Revenues

 

1,175,282

 

1,017,621

 

2,240,575

 

1,927,499

 

 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

101,262

 

94,520

 

195,325

 

183,439

 

All Other Third Party Payors*

 

838,004

 

706,234

 

1,587,205

 

1,330,379

 

Total Contractual Adjustments and Discounts

 

939,266

 

800,754

 

1,782,530

 

1,513,818

 

Service Revenues Net of Contractual Adjustments and Discounts

 

236,016

 

216,867

 

458,045

 

413,681

 

Patient Service Revenue Provision for Bad Debts**

 

12,030

 

15,501

 

25,225

 

31,046

 

Net Revenues

 

223,986

 

201,366

 

432,820

 

382,635

 

 


* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

 

** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.  The remaining bad debt expense is presented as part of operating expenses.  The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

 

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial.   A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries.  One such legislation is Protecting Access to Medicare Act of 2014 (Public Law 113—93)(“PAMA”) was signed into law on April 1, 2014.  The legislation directed CMS to conduct a market survey and to determine whether Medicare is reimbursing at a commercially reasonable rates.  To date, CMS has fallen behind the schedule legislated in PAMA. As the result, the current reimbursement rates remain unchanged, subject to typical annual reviews, until 2017.

 

15



Table of Contents

 

It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary.   BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

 

 

 

($)

 

 

 

[Unaudited]

 

 

 

 

 

April 30,

 

October 31,

 

 

 

2015

 

2014

 

 

 

 

 

 

 

Contractual Credits/Discounts

 

582,180

 

513,466

 

Doubtful Accounts

 

81,505

 

83,276

 

Total Allowance

 

663,685

 

596,742

 

 

OPKO Merger Agreement

 

On June 3, 2015 the Company, OPKO Health, Inc., a Delaware corporation (“OPKO”) and Bamboo Acquisition, Inc., a New Jersey corporation and a direct wholly owned subsidiary of OPKO (“Sub”), entered into an agreement and plan of merger (the “Merger Agreement”).  Pursuant to the Merger Agreement, Sub will be merged with and into the Company (the “Merger”) and the Company, as the surviving corporation, will become OPKO’s wholly owned subsidiary. At the effective time of the Merger, each issued and outstanding share of the Company’s common stock will automatically be converted into and exchanged for the right to receive 2.75 shares of OPKO’s common stock.  For further information about the Merger, see Note 10, “Subsequent Events” of the Notes to Consolidated Financial Statements in Part I herein.

 

Item 3 — QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK [Not in Thousands]

 

We do not invest in or trade instruments that are sensitive to market risk. We also do not have any material foreign operations or foreign sales so we have no exposure to foreign currency exchange rate risk.

 

We do have exposure to both rising and falling interest rates. At April 30, 2015, advances of approximately $49,315,000 under our PNC Bank Credit Line were subject to interest charges at the bank’s then prime rate of 3.50%.

 

We estimate that our monthly cash interest expense at April 30, 2015 was approximately $204,000 and that a one percentage point increase or decrease in short-term rates would increase or decrease our monthly interest expense by approximately $29,000.

 

Item 4 — CONTROLS AND PROCEDURES

 

An evaluation was performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, as to the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our principal executive officer and our principal financial officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC forms and rules, and include controls and procedures designed to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosures.

 

There have been no changes in our internal control over financial reporting during the fiscal quarter ended April 30, 2015 that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

16



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC.

PART II—OTHER INFORMATION

 

Item 1 — Legal Proceedings

 

Bio-Reference Laboratories, Inc. v. Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey

 

On December 18, 2013, the Company filed an action in the Superior Court of New Jersey against Horizon Blue Cross Blue Shield of New Jersey (“Horizon”), captioned Bio-Reference Laboratories, Inc. v. Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey, Docket No. BER L-009748-13 (N.J. Super. Ct. Bergen Cnty.).  The Company has been an in-network provider to Horizon’s preferred provider organization (“PPO”) members for more than 20 years and filed the lawsuit after attempts to resolve its dispute with Horizon were unsuccessful.

 

The Company currently provides services to Horizon pursuant to an Ancillary Services Provider Agreement entered into in 2003 and amended in 2007.  The central claims in the lawsuit arise from the Company’s performance of laboratory services since at least 2008 for members of Horizon’s NJ DIRECT plan, who receive benefits under a program that Horizon has bid, promoted, and represented to be a PPO product for New Jersey state, county, and municipal workers and teachers.  The lawsuit alleges that, despite these representations, Horizon has been improperly treating NJ DIRECT as a Managed Care program in its dealings with the Company, thereby costing the Company more than $20,000,000 in unreimbursed services and depriving state beneficiaries of valuable rights and benefits to which they are entitled.  The lawsuit alleges that Horizon furthered its fraud against the Company by means of a sham Request for Proposal issued in 2011 and through false and incorrect communications to the Company and other providers.  The Company asserts claims for breach of contract, breach of the implied covenant of good faith and fair dealing, and fraud against Horizon.  In addition to compensatory damages, the Company seeks to recover punitive damages from Horizon due to Horizon’s intentional and malicious misconduct.  The Company also seeks declaratory and injunctive relief.

 

On February 5, 2014, Horizon filed a motion to dismiss the complaint, which the Company opposed.  On March 28, 2014, the Honorable Robert C. Wilson of the Superior Court of New Jersey issued an oral ruling denying Horizon’s motion to dismiss without prejudice pending the completion of discovery.  The Company and Horizon are conducting discovery, which is currently scheduled to close on July 30, 2015.  The Company intends to vigorously prosecute its claims against Horizon.

 

Item 5 — OTHER INFORMATION

 

On June 3, 2015, the Company entered into a new employment agreement (the “CEO Contract”) with its Chief Executive Officer, Dr. Marc D. Grodman, and OPKO, effective as of, and contingent upon, the closing of the transactions contemplated by the Merger Agreement. The disclosure regarding, and the copy of, the CEO Contract that was filed by the Company on Form 8-K with the Securities and Exchange Commission on June 4, 2015 (the “June 4 Form 8-K”) contained a typographical error with respect to Dr. Grodman’s base salary. Dr. Grodman’s current annual base salary is $1,175,676. A corrected version of the CEO Contract is filed hereto as Exhibit 10.3 to this Form 10-Q, which is incorporated herein by reference and replaces Exhibit 10.1 filed with the June 4 Form 8-K.

 

Item 6 — EXHIBITS

 

10.1                        Fourteenth Amendment to Loan Documents

10.2                        Thirteenth Amended and Restated Secured Revolving Note

10.3                        Employment Agreement dated as of June 3, 2015 among Bio-Reference Laboratories, Inc., OPKO Health, Inc. and Marc D. Grodman

31.1                        Certification of Chief Executive Officer

31.2                        Certification of Chief Financial Officer

32.1                        Certification Pursuant to 18 U.S.C. Section 1350 of Chief Executive Officer

32.2                        Certification Pursuant to 18 U.S.C. Section 1350 of Chief Financial Officer

101                           Interactive Data File

 

17



Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BIO-REFERENCE LABORATORIES, INC.

 

(Registrant)

 

 

 

 

 

/S/ Marc D. Grodman M.D.

 

Marc D. Grodman, M.D.

 

President and Chief Executive Officer

 

 

 

 

 

/S/ Nicholas Papazicos

 

Nicholas Papazicos

 

Senior Vice President, Chief Financial and Chief Accounting Officer

 

 

 

 

Date: June 8, 2015

 

 

18


EX-10.1 2 a15-7384_1ex10d1.htm EX-10.1

Exhibit 10.1

 

Fourteenth Amendment to Loan Documents

 

THIS FOURTEENTH  AMENDMENT TO LOAN DOCUMENTS (this “Amendment”) is made as of May 5, 2015, and is by and among Bio-Reference Laboratories, Inc. (“BRLI”), and GeneDX, Inc. (formerly known as BRLI No. 2 Acquisition Corp.), which conducts business as GeneDx (referred to herein from time to time as “GeneDx” and a “Subsidiary Party”) (BRLI and the Subsidiary Party herein each a “Borrower” and, collectively, “Borrowers”), the financial institutions which are party hereto (collectively, the “Lenders” and individually a “Lender”) and PNC BANK, NATIONAL ASSOCIATION in its capacity as the agent for the Lenders and, as of the date hereof, as the sole Lender (in each such capacity, the “Bank”).

 

BACKGROUND

 

A.                                    The Borrowers have executed and delivered to the Bank, one or more promissory notes, letter agreements, loan agreements, security agreements, mortgages, pledge agreements, collateral assignments, and other agreements, instruments, certificates and documents, some or all of which are more fully described on attached Exhibit A, which is made a part of this Amendment (collectively as amended from time to time, the “Loan Documents”) which evidence or secure some or all of the Borrowers’ obligations to the Bank for one or more loans or other extensions of credit (the “Obligations”).

 

B.                                    The Borrowers and the Bank desire to amend the Loan Documents to (i) increase the Maximum Revolving Advance Amount, (ii) extend the Term and (iii) effect certain additional amendments, as provided for in this Amendment.

 

NOW, THEREFORE, in consideration of the mutual covenants herein contained and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.                                      Certain of the Loan Documents are amended as set forth in Exhibit A.  Any and all references to any Loan Document in any other Loan Document shall be deemed to refer to such Loan Document as amended by this Amendment.  This Amendment is deemed incorporated into each of the Loan Documents. Any initially capitalized terms used in this Amendment without definition shall have the meanings assigned to those terms in the Loan Documents.  To the extent that any term or provision of this Amendment is or may be inconsistent with any term or provision in any Loan Document, the terms and provisions of this Amendment shall control.

 

2.                                      (a) Each of the Borrowers hereby certifies that: (a) all of its representations and warranties in the Loan Documents, as amended by this Amendment, are, except as may otherwise be stated in this Amendment: (i) true and correct as of the date of this Amendment, (ii) ratified and confirmed without condition as if made anew, and (iii) incorporated into this Amendment by reference.

 

(b) Each of the Borrowers hereby certifies that (i) no Event of Default or event which, with the passage of time or the giving of notice or both, would constitute an Event of Default, exists under any Loan Document which will not be cured by the execution and effectiveness of this Amendment, (ii) no consent, approval, order or authorization of, or registration or filing with, any third party is required in connection with the execution, delivery and carrying out of this Amendment or, if required, has been obtained or shall be obtained on a timely basis pursuant to the terms of this Amendment and (iii) this Amendment has been duly authorized, executed and delivered so that it constitutes the legal, valid and binding obligation of each Borrower, enforceable in accordance with its terms.  The Borrowers confirm that the Obligations remain outstanding without defense, set off, counterclaim, discount or charge of any kind as of the date of this Amendment.

 

3.                                      Each of the Borrowers hereby confirms that any collateral for the Obligations, including liens, security interests, mortgages, and pledges granted by the Borrowers or third parties (if applicable), shall continue unimpaired and

 

1



 

in full force and effect, and shall cover and secure all of the Borrowers’ existing and future Obligations to the Bank, as modified by this Amendment.

 

4.                                      As a condition precedent to the effectiveness of this Amendment, the Borrowers shall comply with the terms and conditions (if any) specified in Exhibit A.

 

5.                                      To induce the Bank to enter into this Amendment, to the extent permitted by law, each of the Borrowers waives and releases and forever discharges the Bank and its officers, directors, attorneys, agents, and employees from any liability, damage, claim, loss or expense of any kind that it may have against the Bank or any of them arising out of or relating to the Obligations.  Each of the Borrowers further agrees to indemnify and hold the Bank and its officers, directors, attorneys, agents and employees harmless from any loss, damage, judgment, liability or expense (including attorneys’ fees) suffered by or rendered against the Bank or any of them on account of any claims arising out of or relating to the Obligations.  Each of the Borrowers further states that it has carefully read the foregoing release and indemnity, knows the contents thereof and grants the same as its own free act and deed.

 

6.                                      This Amendment may be signed in any number of counterpart copies and by the parties to this Amendment on separate counterparts, but all such copies shall constitute one and the same instrument.   Delivery of an executed counterpart of a signature page to this Amendment by facsimile transmission shall be effective as delivery of a manually executed counterpart.  Any party so executing this Amendment by facsimile transmission shall promptly deliver a manually executed counterpart, provided that any failure to do so shall not affect the validity of the counterpart executed by facsimile transmission.

 

7.                                      This Amendment will be binding upon and inure to the benefit of each Borrower and the Bank and their respective heirs, executors, administrators, successors and assigns.

 

8.                                      This Amendment will be interpreted and the rights and liabilities of the parties hereto determined in accordance with the laws of the State of New Jersey, excluding its conflict of laws rules.

 

9.                                      Except as amended hereby, the terms and provisions of the Loan Documents remain unchanged, are and shall remain in full force and effect unless and until modified or amended in writing in accordance with their terms, and are hereby ratified and confirmed.  Except as expressly provided herein, this Amendment shall not constitute an amendment, waiver, consent or release with respect to any provision of any Loan Document, a waiver of any Default or Event of Default under any Loan Document, or a waiver or release of any of the Bank’s rights and remedies (all of which are hereby reserved).  Each of the Borrowers expressly ratifies and confirms the waiver of jury trial provisions contained in the Loan Documents.

 

[Signature page follows.]

 

2



 

WITNESS the due execution of this Fourteenth Amendment to Loan Documents as a document under seal as of the date first written above.

 

ATTEST:

 

 

BIO-REFERENCE LABORATORIES, INC.

 

 

 

 

 

 

 

 

By:

/S/ Nicholas Papazicos

 

By:

/S/ Marc D. Grodman

Name:

NICHOLAS PAPAZICOS

 

 

Name:

MARC D. GRODMAN (SEAL)

Title:

Secretary

 

 

Title:

President

 

 

 

 

 

 

 

 

ATTEST:

 

 

GENEDX, INC. (formerly known as

 

 

 

BRLI NO. 2 ACQUISITION CORP.,

 

 

 

doing business as GeneDx

 

 

 

a Subsidiary Party)

 

 

 

 

 

 

 

 

By:

/S/ Nicholas Papazicos

 

 

By:

/S/ Marc D. Grodman

Name:

NICHOLAS PAPAZICOS

 

 

(SEAL)

Title:

Secretary

 

 

Name:

MARC D. GRODMAN

 

 

 

Title:

President

 

 

 

 

 

 

 

 

 

 

 

PNC BANK, NATIONAL ASSOCIATION

 

 

 

(as Agent and the sole Lender)

 

 

 

 

 

 

 

By:

/S/ Parameswar Sivaramakrishnan

 

 

 

(SEAL)

 

 

 

Name:

PARAMESWAR SIVARAMAKRISHNAN

 

 

 

Title:

Vice President

 

3



 

EXHIBIT A TO

FOURTEENTH AMENDMENT TO LOAN DOCUMENTS

 

A.                                    The “Loan Documents” that are the subject of this Amendment include the following (as any of the foregoing have previously been amended, modified or otherwise supplemented):

 

1.                                      Amended and Restated Loan and Security Agreement dated as of September 30, 2004, as amended by that certain:  (a) letter amendment dated April 20, 2005, (b) Second Amendment to Loan Documents dated as of January 19, 2006, (c) Third Amendment to Loan Documents dated September 13, 2006, (d) Fourth Amendment to Loan Documents Dated as of October 1, 2006, (e) Fifth Amendment to Loan Documents dated as of October 31, 2007, (f) Sixth Amended to Loan Documents dated as of May 12, 2008, (g) Seventh Amended to Loan Documents dated as of October 22, 2010, (h) Eighth Amendment to Loan Documents dated as of October 31, 2011, (i) Ninth Amendment to Loan Documents dated November 30, 2011, (j) Tenth Amendment to Loan Documents dated June 7, 2013, (k) Eleventh Amendment to Loan Documents and Waiver Agreement, dated as of September 30, 2013, (l)  Twelfth Amendment to Loan Documents dated as of October 28, 2013, and (m)  Thirteenth Amendment to Loan Documents dated as of February 3, 2014 (as amended, the “Loan Agreement”).

 

2.                                      All other documents, instruments, agreements, and certificates executed and delivered in connection with the Loan Documents listed in this Section A.

 

B.                                    The Loan Agreement is hereby amended as follows:

 

1.              Definitions. As of the Fourteenth Amendment Date, Section 1.2 of Article 1 (General Terms) of the Loan Agreement is hereby amended to amend and restate, in their entirety, the following definitions:

 

Maximum Revolving Advance Amount” shall mean One Hundred Twenty Million Dollars ($120,000,000.00).

 

Revolving Credit Note” shall mean that certain Thirteenth Amended and Restated Revolving Loan Note to be executed on the Fourteenth Amendment Date, made by Borrowers and payable to PNC, in the face amount of One Hundred Twenty Million Dollars ($120,000,000.00), a copy of which is attached hereto as Exhibit B, as such note may be amended, modified, extended, renewed, restated or substituted from time to time.

 

2.              New Definitions.  As of the Fourteenth Amendment Date, Section 1.2 of Article 1 of the Loan Agreement (General Terms) is hereby amended to add the following new definitions:

 

Fourteenth Amendment” shall mean the Fourteenth Amendment to Loan Documents dated as of the Fourteenth Amendment Date.

 

Fourteenth Amendment Date” shall mean May 5, 2015.

 

Medicare and Medicaid Payments” shall have the meaning set forth in Section 4.15(d) hereof.

 

3.              Amendment to Section 4.15(d) of the Loan Agreement.  As of the Fourteenth Amendment Date, Section 4.15(d) of the Loan Agreement (Collection of Receivables) is hereby deleted in its entirety and replaced with the following:

 

(d)  Collection of Receivables.  Until any Borrower’s authority to do so is terminated by Agent (which notice Agent may give at any time following the occurrence of an Event of Default or a Default or when Agent in its sole discretion, exercised in a commercially reasonable manner,

 

4



 

deems it to be in Lender’s best interests to do so), each Borrower will, at such Borrower’s sole cost and expense, but on Agent’s behalf and for Agent’s account, collect as Agent’s property and in trust for Agent all amounts received on Receivables, and shall not commingle such collections with any Borrower’s funds (except as hereinafter provided or as otherwise authorized by Agent in writing) or use the same except to pay Obligations.  Each Borrower shall, upon request of Agent, deliver to Agent, or deposit in the Blocked Account, in original form and on the date of receipt thereof, all checks, drafts, notes, money orders, acceptances, cash and other evidences of Indebtedness.  Notwithstanding anything contained herein to the contrary, Borrowers agree that they shall cause all payments in respect of the Medicare and Medicaid programs made by the U.S. Government and state agencies, or other entities making payments in their behalf (“Medicare and Medicaid Payments”) and all other Collateral proceeds to be deposited within one (1) Business Day into one or more Blocked Accounts or Depository Accounts under Agent’s control, as designated by Agent, provided, however, with respect to GeneDx Collateral proceeds, so long as the GeneDx Receivables are not included in computing the Formula Amount and so long as no Default or Event of Default shall have occurred and be continuing, such GeneDx Collateral proceeds need not be deposited into a Blocked Account or a Depository Account.  All Medicare and Medicaid Payments shall, so long as they remain on deposit in deposit accounts that are not Blocked Accounts or Depository Accounts, be owned by and under the control of such Borrower.

 

4.              Amendment to Section 4.15(h) of the Loan Agreement.  As of the Fourteenth Amendment Date, Section 4.15(h) of the Loan Agreement (Establishment of a Lockbox Account, Dominion Account) is hereby amended by inserting as new material at the end of such Section, the following:

 

Notwithstanding anything contained herein to the contrary, all Medicare and Medicaid Payments shall be initially deposited into deposit accounts owned by and under the control of such Borrower before being deposited into a Blocked Account or Depository Account.

 

5.              Amendment to Section 9.2 of the Loan Agreement.  As of the Fourteenth Amendment Date, Section 9.2 of the Loan Agreement (Schedules) is hereby deleted in its entirety and replaced with the following:

 

9.2                          Schedules.  Deliver to Agent (i) on or before the fifteenth (15th) day of each month as and for the prior month (a) accounts receivable ageing (and if requested by Agent, such report shall be inclusive of reconciliations to the general ledger and such report shall be delivered to Agent within thirty (30) days after such request), (b) a report of sales and collections since the prior such report, (c) accounts payable schedules (and if requested by Agent, such report shall be inclusive of reconciliations to the general ledger and such report shall be delivered to Agent within thirty (30) days after such request), and (d) a Borrowing Base Certificate in form and substance satisfactory to Agent (which shall be calculated as of the last day of the prior month and shall not be binding upon Agent or restrictive of Agent’s rights under this Agreement).  In addition, each Borrower will deliver to Agent at such intervals as Agent may require: (i) confirmatory assignment schedules; (ii) copies of Customer’s invoices; (iii) evidence of shipment or delivery; and (iv) such further schedules, documents and/or information regarding the Collateral as Agent may require including trial balances and test verifications.  Agent shall have the right to confirm and verify all Receivables by any manner and through any medium it considers advisable and do whatever it may deem reasonably necessary to protect its interests hereunder.  The items to be provided under this Section are to be in form satisfactory to Agent and executed by each Borrower and delivered to Agent from time to time solely for Agent’s convenience in maintaining records of the Collateral, and any Borrower’s failure to deliver any of such items to Agent shall not affect, terminate, modify or otherwise limit Agent’s Lien with respect to the Collateral.

 

6.              Amendment to Article X Article X of the Loan Agreement (Events of Default) is hereby amended by inserting, as new material, the following section and moving inserting the word “or” at the end of Section 10.19:

 

5



 

10.20 Sweep of Medicare and Medicaid Payments.  Failure by any Borrower to cause all funds each Government Payment Account to be deposited within one Business Day into a Blocked Account or a Depository Account as designated by Agent.

 

7.              Amendment to Section 11.1 of the Loan Agreement.  As of the Fourteenth Amendment Date, Section 11.1 (Rights and Remedies) is hereby amended by inserting, as new material after subsection (b) thereof, the following:

 

(c) Agent may seek a court order directing all Medicare and Medicaid Payments be made to a Depository Account.  Borrowers hereby waive and an all defenses and counterclaims they may have or could impose in any action or procedure brought by Agent to obtain an order of a court recognizing the assignment of, Lien of the Agent in and to any Collateral, whether or not payable by a Medicare or Medicaid account debtor.

 

8.              Amendment to Section 11.3 of the Loan Agreement.  As of the Fourteenth Amendment Date, Section 11.3 (Setoff) is hereby amended by inserting, as new material at the end of such Section, the following:

 

Notwithstanding anything contained herein to the contrary, Agent and Lenders hereby waive any right of set-off in any deposit account into which any of the Medicare and Medicaid Payments are, in the first instance, deposited (such waiver of setoff to be effective until such Medicare and Medicaid Payments are subsequently deposited into a Blocked Account or Depository Account under the control of Agent).

 

9.              Amendment to Sections 13.1 and 13.2 of the Loan Agreement.  Effective as of the Fourteenth amendment Date, Section 13.1 (“Term”) and Section 13.2 (Termination by Borrowers) of the Loan Agreement are hereby deleted and replaced with the following:

 

13.1                        Term.  This Agreement, which shall inure to the benefit of and shall be binding upon the respective successors and permitted assigns of each Borrower, Agent and each Lender, shall become effective on the date hereof and shall continue in full force and effect until October 31, 2020 (the “Term”) unless sooner terminated as herein provided.

 

13.2                        Termination by Borrowers.  Borrowers may terminate this Agreement at any time upon not less than sixty (60) days’ prior written notice and payment in full of the Obligations.  In the event the Obligations are prepaid in full prior to the last day of the Term (the date of such prepayment hereinafter referred to as the “Early Termination Date”), Borrower shall pay to Agent for the benefit of Lenders an early termination fee in an amount equal to:

 

(a)                                 if the Early Termination Date occurs on or after the Fourteenth Amendment Date, but before October 31, 2016, three-eighths of one percent (0.375%) of the total of the Maximum Revolving Advance Amount;

 

(b)                                 if the Early Termination Date occurs on or after October 31, 2016, but before October 31, 2017, one-quarter of one percent (0.25%) of the total of the Maximum Revolving Advance Amount;

 

(c)                                  if the Early Termination Date occurs on or after October 31, 2017, but before October 31, 2018, one-eighth of one percent (0.125%) of the total of the Maximum Revolving Advance Amount; or

 

(d)                                 if the Early Termination Date occurs on or after October 31, 2018, zero percent (0%),

 

6



 

provided also, however, in the event that this Agreement is terminated as a result of Borrowers’ entering into a refinancing transaction with the corporate banking division of PNC, then the requirement to pay the early termination fee shall be waived upon the closing of such refinancing.

 

10.       Amendment and Replacement of Certain Schedules to the Loan Agreement.  Schedules 4.5 (Equipment and Inventory Locations), 4.15(c) (Location of Executive Offices), Schedule 4.15(h) (Deposit Accounts and Investment Accounts), 4.19 (Real Property), 5.2(a) (Dates of Qualification and Organizational Numbers), 5.2(b) (Subsidiaries), 5.6 (Prior Names; Acquisitions), 5.7 (Environmental Matters), 5.8(b) (Litigation), 5.8(d) (Plans), 5.9 (Intellectual Property), 5.10 (License and Permits; Source Code Escrow Agreements) and 5.14 (Labor Disputes) are hereby amended and restated as set forth on the restated schedules which are attached to this Exhibit A and hereby made a part of this Fourteenth Amendment and the Loan Agreement.

 

C.                                    Conditions to Effectiveness of Amendments.  Bank’s willingness to agree to the amendments set forth in this Exhibit A and the continuing effectiveness of such amendments are subject to the satisfaction of the following conditions:

 

1.                                      Execution by all parties and/or delivery to Bank of the following:

 

(a)                                 this Amendment (and the annexed Consent), in form and substance acceptable to Bank;

 

(b)                                 a Thirteenth Amended and Restated Secured Revolving Loan Note in the amount of One Hundred Twenty Million Dollars ($120,000,000.00) executed by Borrowers;

 

(c)                                  an enabling resolution on behalf of each of the Borrowers and Guarantors, in form and substance satisfactory to Bank.

 

2.                                      Bank shall have received an executed legal opinion of the Borrowers’ and the Guarantors’ counsel, which shall cover such matters incident to the transactions contemplated by this Amendment and related agreements as Bank may reasonably require and each of the Borrowers and Guarantors hereby authorizes and directs such counsel to deliver such opinions to Agent and Lenders.

 

3.                                      Payment by Borrowers of an amendment and extension fee of One Hundred Twenty Thousand Dollars ($120,000.00), which fee shall be deemed fully earned and non-refundable upon the execution of this Amendment by Borrowers and which may be paid by Bank’s making a Revolving Loan in the amount of such fee and retaining the proceeds in satisfaction of same.

 

4.                                      Bank shall be in receipt of copies of any amendments to each of the Borrowers’ and Guarantors’ organizational documents previously furnished to the Bank that were executed and/or delivered after February 3, 2014 or confirmation that the Borrowers’ and Guarantors’ organizational documents have not been modified, amended or restated and remain in full force and effect.

 

5.                                      Bank shall be in receipt of good standing searches of each of the Borrowers and Guarantors in their jurisdictions of organization and each applicable jurisdiction where the conduct of each of the Borrowers’ and Guarantors’ business activities or the ownership of their properties necessitates qualification, issued by the Secretary of State or other appropriate official of each such jurisdiction.

 

6.                                      Bank shall have received any and all Consents necessary to permit the effectuation of the transactions contemplated by this Amendment and Agent shall have received such Consents and

 

7



 

waivers of such third parties as might assert claims with respect to the Collateral, as Agent and its counsel shall deem necessary.

 

7.                                      Such other documents, agreements and instruments as Bank shall reasonably require.

 

D.                                    Additional Conditions Subsequent.  The Borrowers shall furnish to the Bank the following, no later than July 6, 2015, which documents shall be in form and substance satisfactory to Bank:

 

1.              Bank shall be in receipt of UCC, federal tax lien, state tax lien, judgment, bankruptcy and pending suit searches for each of the Borrowers and Guarantors in their respective jurisdiction of formation and in each jurisdiction where they are authorized to do business.

 

2.              Bank shall be in receipt of franchise tax searches (or equivalent status) of each of the Borrowers and Guarantors in their jurisdictions of organization and each applicable jurisdiction where the conduct of each of the Borrowers and Guarantors business activities or the ownership of their properties necessitates qualification, as evidenced by franchise tax searches (or the equivalent thereof issued by any applicable jurisdiction) issued by the Secretary of State or other appropriate official of each such jurisdiction.

 

3.              Bank shall have entered into deposit account control agreements with applicable financial institutions with respect to such deposit accounts, as determined by Bank, maintained by the Borrowers and Guarantors at such financial institutions.

 

4.              Bank shall have received collateral access or lien waiver agreements with respect to all locations or places at which the Borrowers and Guarantors Inventory, equipment and books and records are located, as required by Bank.

 

5.              Bank shall have received evidence that adequate insurance, including without limitation, casualty and liability insurance, required to be maintained under the Loan Agreement and Other Documents are in full force and effect, (ii) insurance certificates issued by the Borrowers’ and the Guarantors’ insurance broker(s) containing such information regarding each of the Borrowers’ and the Guarantors’ casualty and liability insurance policies as Bank shall request and naming Bank as an additional insured and lenders loss payee, as applicable, and (iii) loss payable endorsements issued by each of the Borrowers’ and the Guarantors’ insurer(s) naming Bank as lenders loss payee.

 

6.              Reimbursement by Borrowers of the fees and expenses of Bank’s counsel, whether incurred in connection with this Amendment or in conjunction with the continuing commercial lending relationship between Bank and Borrowers, which fees and expense may be paid by Bank making a Revolving Loan, from time to time, in the amount of such fees and expenses and retaining the proceeds in satisfaction of same.

 

Failure to furnish any of the deliverables set forth in this Part D as aforesaid shall, at Bank’s option, constitute an Event of Default; provided, however, if Borrowers and the Guarantors, as applicable, have not secured all required deposit account control agreements and/or all collateral access or lien waiver agreements, as set forth in items 3 and 4 above of this Part D by July 6, 2015, and have demonstrated to the reasonable satisfaction of Bank, they have used commercially reasonable efforts in attempting to do so, such failure to deliver such documents to Bank shall not constitute an Event of Default.

 

[End of Exhibit A]

 

8



 

CONSENT BY GUARANTORS

 

The undersigned Guarantors consent to the provisions of the foregoing Amendment (the “Amendment”) and all prior amendments and confirms and agrees that:

 

(a)                                 CareEvolve.com Inc.’s obligations under its:  (i) Continuing Unlimited Corporate Guaranty dated as of September 30, 2004, (ii) Amended and Restated Continuing Unlimited Corporate Guaranty dated as of October 31, 2006, and (iii) Guarantor’s Security Agreement dated as of September 30, 2004 (collectively, the “Care Evolve Guaranty Documents”), relating to the Obligations, shall be unimpaired by the Amendment; and

 

(b)                                 Genome Diagnostics Ltd.’s and BRLI-Genpath Diagnostics, Inc.’s obligations under their respective Continuing Unlimited Corporate Guaranties each dated as of October 31, 2011 (collectively the “Genome and Genpath Guaranty Documents”) relating to the Obligations, shall be unimpaired by the Amendment; and

 

(c)                                  Florida Clinical Laboratory, Inc.’s and Meridian Clinical Laboratory Corp.’s obligations under their respective Continuing Unlimited Corporate Guaranties each dated as of June 7, 2013 (collectively the “FCL and MCL Guaranty Documents” and together with the Care Evolve Guaranty Documents and the Genome and Genpath Guaranty Documents, the “Guaranty Documents”), relating to the Obligations, shall be unimpaired by the Amendment; and each Guarantor has no defenses, set offs, counterclaims, discounts or charges of any kind against the Bank, its officers, directors, employees, agents or attorneys with respect to their respective Guaranty Documents; and

 

(d)                                 all of the terms, conditions and covenants in the Guaranty Documents remain unaltered and in full force and effect and are hereby ratified and confirmed and apply to the Obligations, as modified by the Amendment.

 

Each Guarantor certifies that all representations and warranties made in the Guaranty Documents to which such Guarantor is a party are true and correct.

 

Each Guarantor hereby confirms that any collateral for the Obligations, including liens, security interests, mortgages, and pledges granted by such Guarantor or third parties (if applicable), shall continue unimpaired and in full force and effect, shall cover and secure all of such Guarantor’s existing and future Obligations to the Bank, as modified by this Amendment.

 

Each Guarantor ratifies and confirms the waiver of jury trial provisions contained in the Guaranty Documents to which each such Guarantor is a party.

 

[Signature Page Follows]

 

9



 

WITNESS the due execution of this Consent as a document under seal as of the date of this Amendment, intending to be legally bound hereby.

 

ATTEST:

 

 

CareEvolve.com, Inc.

 

 

 

 

 

 

 

By:

/S/ Nicholas Papazicos

 

By:

/S/ Marc D. Grodman

Name:

Nicholas Papazicos

 

 

Name:

MARC D. GRODMAN (SEAL)

Title:

Secretary

 

 

Title:

President

 

 

 

 

ATTEST:

 

 

Genome Diagnostics, Ltd.

 

 

 

 

 

 

 

 

By:

/S/ Nicholas Papazicos

 

By:

/S/ Marc D. Grodman

Name:

Nicholas Papazicos

 

 

Name:

MARC D. GRODMAN (SEAL)

Title:

Secretary

 

 

Title:

President

 

 

 

 

ATTEST:

 

 

BRLI- Genpath Diagnostics, Inc.

 

 

 

 

 

 

 

 

By:

/S/ Nicholas Papazicos

 

By:

/S/ Marc D. Grodman

Name:

Nicholas Papazicos

 

 

Name:

MARC D. GRODMAN (SEAL)

Title:

Secretary

 

 

Title:

President

 

 

 

 

ATTEST:

 

 

Florida Clinical Laboratory, Inc.

 

 

 

 

 

 

 

 

By:

/S/ Nicholas Papazicos

 

By:

/S/ Marc D. Grodman

Name:

Nicholas Papazicos

 

 

Name:

MARC D. GRODMAN (SEAL)

Title:

Secretary

 

 

Title:

President

 

 

 

 

ATTEST:

 

 

Meridian Clinical Laboratory Corp.

 

 

 

 

 

 

 

 

By:

/S/ Nicholas Papazicos

 

 

By:

/S/ Marc D. Grodman

Name:

Nicholas Papazicos

 

 

Name:

MARC D. GRODMAN (SEAL)

Title:

Secretary

 

 

Title:

President

 

10


EX-10.2 3 a15-7384_1ex10d2.htm EX-10.2

Exhibit 10.2

 

THIRTEENTH AMENDED AND RESTATED SECURED REVOLVING NOTE

(PNC Bank, National Association)

 

$120,000,000.00

May 5, 2015

 

FOR VALUE RECEIVED, BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation with an address at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07497 and its Subsidiary or Subsidiaries party hereto (collectively, jointly and severally the “Borrowers”), promise to pay on the earlier of demand made in accordance with the terms of the Loan Documents (as defined herein) or October 31, 2016, to the order of PNC BANK, NATIONAL ASSOCIATION (the “Lender”), in lawful money of the United States of America in immediately available funds at the Payment Office of PNC Bank, National Association as the Agent for the Lenders (the “Agent”) at its offices located at Two Tower Center Boulevard, East Brunswick, New Jersey 08816, or at such other location as Lender may designate from time to time, the principal sum of ONE HUNDRED TWENTY MILLION DOLLARS ($120,000,000.00) (the “Facility”) or such lesser amount as may be advanced to or for the benefit of Borrowers hereunder, together with interest accruing on the outstanding principal balance from the date hereof, as provided below:

 

1.              Rate of InterestAmounts outstanding under this Note will bear interest at a rate per annum which, as Borrowers shall elect in accordance with the terms of the Loan Documents, shall be at all time equal to either (a) the Alternate Base Rate per annum plus the Applicable Margin with respect to Domestic Rate Loans or (b) the Eurodollar Rate plus the Applicable Margin with respect to Eurodollar Rate Loans.  Interest will be calculated on the basis of a year of 360 days for the actual number of days in each interest period.  For all Domestic Rate Loans, if and when the Alternate Base Rate changes, the rate of interest on this Note will change automatically without notice to Borrowers, effective on the date of any such change.  In no event will the rate of interest hereunder exceed the maximum rate allowed by law.

 

2.              Advances. Borrowers may request advances, repay and request additional advances hereunder, subject to the terms and conditions of this Note and the Loan Documents.  In no event shall the aggregate unpaid principal amount of advances under this Note exceed the face amount of this Note.

 

3.              Payment Terms.  The outstanding principal balance and any accrued but unpaid interest shall be due and payable to Agent on the earlier of demand made in accordance with the Loan Documents or October 31, 2020.  Accrued interest will be due and payable in the absence of demand on the first (1st) day of each month with respect to Domestic Rate Loans and on the last day of each Interest Period (or calendar quarter within an Interest Period, in the case of Interest Periods exceeding three months) with respect to Eurodollar Rate Loans.  If any payment under this Note shall become due on a Saturday, Sunday or public holiday under the laws of the State of New Jersey, such payment shall be made on the next succeeding Business Day and such extension of time shall be included in computing interest in connection with such payment.  Borrowers hereby authorize Agent to charge Borrowers’ deposit account at Agent for any payment when due hereunder.  Payments received will be applied to charges, fees and expenses (including attorneys’ fees), accrued interest and principal in any order Agent may choose, in its sole discretion.

 

4.              Late Payments; Default Rate.  If Borrowers fail to make any payment of principal, interest or other amount coming due pursuant to the provisions of this Note within ten (10) calendar days of the date due and payable, Borrowers also shall pay to Lender a late charge equal to two percent (2%) of the amount of such payment.  Such ten (10) day period shall not be construed in any way to extend the due date of any such payment.  The late charge is imposed for the purpose of defraying Lender’s expenses incident to the handling of delinquent payments and is in addition to, and not in lieu of, the exercise by Agent or Lender of any rights and remedies hereunder, under the other Loan Documents or under applicable laws, and any fees and expenses of any agents or attorneys which Agent or Lender may employ.  Upon the occurrence of an Event of Default under the Loan Documents, at the option of the Required Lenders, this Note shall bear interest at a rate per annum (based on a year of 360 days and actual days elapsed) which shall be two percent (2%) per annum in excess of the interest rate in effect from time to time with respect to Domestic Rate Loans but not more than the maximum rate allowed by law (the “Default Rate”).  The Default Rate shall continue to apply whether or not judgment shall be entered on this Note.

 

5.              Prepayment.  The indebtedness evidenced by this Note may be prepaid in whole or in part at any time without penalty, subject, however, to the provisions of the Loan Documents, so that the outstanding principal balance hereof may be reduced to Zero ($0) Dollars from time to time.

 

6.              Other Loan Documents.  This Note is issued in connection with the Amended and Restated Loan and Security Agreement dated as of September 30, 2004, as heretofore and as may in the future be amended from time to time (the “Credit Agreement”)

 

1



 

and the Other Documents executed in conjunction therewith, as the same have been and may hereafter be amended from time to time, the terms of which are incorporated herein by reference (the “Loan Documents”) and is secured by the property described in the Loan Documents and by such other collateral as previously may have been, is, or in the future may be granted to Agent to secure this Note.  Any capitalized term not defined herein shall be defined as set forth in the Credit Agreement, the terms and conditions of which are incorporated herein by reference as if set forth herein at length.

 

7.              Advance ProceduresA request for advance made by telephone must be promptly confirmed in writing by such method as Agent may require.  Borrowers authorize Agent to accept telephonic requests for advances, and Agent shall be entitled to rely upon the authority of any person providing such instructions.  Borrowers hereby indemnify and hold Agent harmless from and against any and all damages, losses, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) which may arise or be created by the acceptance of such telephone requests or making such advances.  Agent will enter on its books and records, which entry when made will be presumed correct, the date and amount of each advance, as well as the date and amount of each payment made by Borrowers.

 

8.              Events of Default.  The occurrence of any of the Events of Default set forth in the Loan Documents will be deemed to be an “Event of Default” under this Note.  Upon the occurrence of an Event of Default:  (a) Lender shall be under no further obligation to make advances hereunder; (b) if an Event of Default specified in Section 10.5 or 10.6 of the Credit Agreement shall occur, the outstanding principal balance and accrued interest hereunder together with any additional amounts payable hereunder shall be immediately due and payable without demand or notice of any kind; (c) if any other Event of Default shall occur, the outstanding principal balance and accrued interest hereunder together with any additional amounts payable hereunder, at the option of the Required Lenders and without demand or notice of any kind, may be accelerated and become immediately due and payable; (d) at the option of Agent or at the discretion of the Required Lenders, this Note will bear interest at the Default Rate from the date of the occurrence of the Event of Default; and (e) Agent and Lender may exercise from time to time any of the rights and remedies available to Agent and Lender under the Loan Documents or under applicable law.

 

9.              Right of Setoff.  In addition to all liens upon and rights of setoff against the money, securities or other property of Borrowers given to Lender by law, Lender shall have, with respect to Borrowers’ obligations to Lender under this Note and to the extent permitted by law, a contractual possessory security interest in and a contractual right of setoff against, and Borrowers hereby assign, convey, deliver, pledge and transfer to Lender all of Borrowers’ right, title and interest in and to, all deposits, moneys, securities and other property of Borrowers now or hereafter in the possession of or on deposit with, or in transit to, Lender whether held in general or special account or deposit, whether held jointly with someone else, or whether held by Lender for safekeeping or otherwise, excluding, however, all IRA, Keogh, and trust accounts.  Every such security interest and right of setoff may be exercised without demand upon or notice to Borrowers.  Every such right of setoff shall be deemed to have been exercised hereunder without any action of Lender, although Lender may enter such setoff on its books and records at a later time.

 

10.       Miscellaneous.  No delay or omission of Agent or Lender to exercise any right or power arising hereunder shall impair any such right or power or be considered to be a waiver of any such right or power, nor shall Agent’s or Lender’s action or inaction impair any such right or power.  Borrowers agree to pay on demand, to the extent permitted by law, all costs and expenses incurred by Agent and Lender in the enforcement of their rights in this Note and in any security therefor, including without limitation reasonable fees and expenses of their counsel.  If any provision of this Note is found to be invalid by a court, all the other provisions of this Note will remain in full force and effect.  Borrowers and all other makers and endorsers of this Note hereby forever waive presentment, protest, notice of dishonor and notice of non-payment.  Borrowers also waives all defenses based on suretyship or impairment of collateral.  If this Note is executed by more than one Borrower, the obligations of such persons or entities hereunder will be joint and several.  This Note shall bind Borrowers and their successors and assigns, and the benefits hereof shall inure to the benefit of Lender and its successors and assigns.

 

This Note has been delivered to and accepted by Lender and will be deemed to be made in the State of New Jersey.  THIS NOTE WILL BE INTERPRETED AND THE RIGHTS AND LIABILITIES OF LENDER AND  BORROWERS DETERMINED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW JERSEY, EXCLUDING ITS CONFLICT OF LAWS RULES.  The jurisdiction and venue provisions of the Credit Agreement are incorporated in this Note by reference as though set forth herein at length.

 

11.       Waiver of Jury Trial.  BORROWERS IRREVOCABLY WAIVE ANY AND ALL RIGHTS BORROWERS MAY HAVE TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR CLAIM OF ANY NATURE RELATING TO THIS NOTE, ANY DOCUMENTS EXECUTED IN CONNECTION WITH THIS NOTE OR ANY TRANSACTION CONTEMPLATED IN ANY SUCH DOCUMENTS.  BORROWERS ACKNOWLEDGE THAT THE FOREGOING WAIVER IS KNOWING AND VOLUNTARY.

 

12.       Substitution of Note.  This Note evidences indebtedness created under the Credit Agreement, which indebtedness is in full force and effect on a continuing basis, unimpaired and undischarged, under the Credit Agreement.  This Note is issued in substitution

 

2



 

for and replacement of, but not in payment or satisfaction of, that certain Twelfth Amended and Restated Secured Revolving Note dated February 3, 2014, in the face amount of $70,000,000.00.

 

Borrowers acknowledge that they have read and understood all the provisions of this Note, including the waiver of jury trial, and have been advised by counsel as necessary or appropriate.

 

WITNESS the due execution of this Thirteenth Amended and Restated Secured Revolving Note as a document under seal, as of the date first written above, with the intent to be legally bound hereby.

 

 

ATTEST:

 

BIO-REFERENCE LABORATORIES, INC.,

 

 

 

a New Jersey corporation

 

 

 

 

 

 

 

 

By:

/S/ Nicholas Papazicos

 

By:

/S/ Marc D. Grodman

 

Nicholas Papazicos, Secretary

 

MARC D. GRODMAN, President

 

 

 

 

 

 

 

ATTEST:

 

GENEDX, INC.

 

 

 

(formerly known as BRLI No. 2 Acquisition Corp.),

 

 

 

a New Jersey corporation,

 

 

 

 

 

 

 

 

By:

/S/ Nicholas Papazicos

 

By:

/S/ Marc D. Grodman

 

Nicholas Papazicos, Secretary

 

MARC D. GRODMAN, President

 

3


EX-10.3 4 a15-7384_1ex10d3.htm EX-10.3

Exhibit 10.3

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (this “Agreement”) dated as of June 3, 2015, among Bio-Reference Laboratories, Inc., a New Jersey corporation with its principal place of business at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407 (the “Company”), OPKO Health, Inc., a Delaware corporation with its principal place of business at 4400 Biscayne Boulevard, Miami, Florida 33137 (“OPKO”), and Marc D. Grodman, M.D., residing at R.D. No. 1, P.O. Box 309, Califon, New Jersey 07830 (the “Employee”).

 

This Agreement will be effective as of, and contingent upon, the closing of the Agreement and Plan of Merger among Bio-Reference Laboratories, Inc., OPKO Health, Inc., and Bamboo Acquisition, Inc. dated as of June 3, 2015 (the “Merger Agreement”), whereby the Company will become an indirect wholly-owned subsidiary of OPKO (the “Merger”).  In the event that the Merger is not consummated, this Agreement will be null and void ab initio and without any effect.

 

Upon closing of the Merger, this Agreement will supersede and replace the Employment Agreement dated as of December 31, 2010 between the Company and the Employee.

 

W I T N E S S E T H:

 

WHEREAS, the Company is primarily engaged in the operation of a clinical laboratory in northern New Jersey, and

 

WHEREAS, the Employee currently serves as the President and Chief Executive Officer of the Company,

 

WHEREAS, the Company will become an indirect wholly-owned subsidiary of OPKO upon closing of the Merger,

 

WHEREAS, the Company and OPKO desire to avail themselves of the Employee’s knowledge and experience and the Company desires to continue to employ the Employee as the President and Chief Executive Officer of the Company after closing of the Merger on the terms and conditions hereinafter set forth, and

 

WHEREAS, the Employee desires to continue to be employed by the Company after closing of the Merger on the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, in consideration of the mutual covenants herein contained, the parties agree as follows effective as of, and contingent upon, the closing of the Merger:

 

1.                                      Employment Term.  The Company agrees to employ the Employee as its President and Chief Executive Officer, and the Employee agrees to accept such employment with the Company, for a term of five (5) years (the “Term”) commencing upon the closing of the Merger (the “Effective Date”).  Notwithstanding the foregoing, the Employee’s employment hereunder may be earlier terminated by either the Company or the Employee in accordance with the terms of this Agreement.  The period of time between the Effective Date and the termination of the Employee’s employment hereunder will be referred to herein as the “Employment Period.”

 

1



 

2.                                      Duties.

 

(a)                                 During the Employment Period, the Employee will perform such duties and exercise such powers related to the Company as are commensurate with the office of President and Chief Executive Officer, including, without limitation, (i) the allocation of Company capital and resources, (ii) ultimate authority with respect to the employment, termination, and compensation of all other Company employees, and (iii) direct reporting of all other Company employees to either the Employee or his designee(s), and such other duties consistent with his position assigned to him by Phillip Frost, M.D. (“Frost”); provided, however, that the Employee will coordinate with OPKO on the Company’s finance and human resources policies and will be required to comply with OPKO’s authorization and approval guidelines and policies; provided, however, that the Employee’s compliance with OPKO’s insider trading policies shall be as set forth in Section 12; provided, further, that in no event will Employee’s level of authorization be less than any other President or CEO of any of OPKO’s other business operating divisions or subsidiaries.  The Employee will report directly to Frost. In the event that Frost ceases to be affiliated with OPKO, Employee will thereafter report directly to the Chief Executive Officer of OPKO and all references to “Frost” in this Agreement will be deemed to mean the Chief Executive Officer of OPKO.

 

(b)                                 During the Employment Period, the Employee will devote substantially all of his time, ability and attention during normal business hours to the business of the Company, faithfully perform the duties of his employment with the Company, and do all reasonably in his power to promote, develop, and extend the business of the Company.

 

(c)                                  During the Employment Period, the Employee will not, except as a representative of the Company or with written consent of the Company, be directly or indirectly engaged, concerned or interested in the conduct of any other business competing or likely to compete with the Company, provided, that notwithstanding anything contained in this Agreement to the contrary, the Employee will not be precluded from devoting a reasonable amount of his time to:

 

(i)                                     serving, with the prior written approval of Frost, as a director or member of a committee of any organization involving no conflict of interest with the business of the Company;

 

(ii)                                  managing his personal investments, provided that such activities will not materially interfere with the Employee’s performance of his duties hereunder;

 

(iii)                               participating in such courses of instruction and rendering such services as are consistent with the maintenance of his skills as a medical doctor;

 

2



 

(iv)                              performance as a member of the faculty of Columbia University Medical Center and the Attending Staff of New York-Presbyterian Hospital or the performance of similar services at any similar institutions; and

 

(v)                                 civic and charitable activities.

 

(d)                                 The Employee will be employed at the offices of the Company located in Elmwood Park, New Jersey, provided, that the Employee acknowledges and agrees that the proper performance of his duties may make it necessary to spend reasonable periods of time in other parts of the country.

 

3.                                      Compensation.

 

(a)                                 During the Employment Period, the Company will pay the Employee as compensation for his services under this Agreement commencing as of the Effective Date, a minimum annual base compensation at the rate of $1,175,676 (the “Base Compensation”).   Employee’s Base Compensation under this Agreement shall be reviewed at least annually by Frost or OPKO’s Board.

 

(b)                                 During the Employment Term, the Employee will be eligible to receive an annual incentive payment under the Company’s management incentive bonus plan as in effect for the applicable year (the “Annual Bonus”).  In addition, the Employee will also be eligible to receive discretionary bonus payments as determined by Frost and, to the extent required by applicable law, the Compensation Committee of the Board of Directors of OPKO.

 

(c)                                  On, or as soon as practicable after the Effective Date, OPKO will grant the Employee options under the OPKO Health, Inc. 2007 Equity Incentive Plan (the “Plan”) as set forth on the Schedule 4.14(e) of the Merger Agreement, with an exercise price equal to the Fair Market Value (as such term is defined in the Plan) of a share of OPKO’s common stock on the date of grant and subject to the terms of the Plan and the grant award notification and nonqualified stock option award agreement, provided, that the options will vest in equal annual installments over four years and the Employee will fully vest in any then-unvested options that were granted pursuant to this Section 3(c) upon the earliest of (i) any Change in Control (as defined in subparagraph (e) of Section 7 hereof) of the Company or OPKO, (ii) the Employee’s death, (iii) any termination of the Employee’s employment by the Company without Cause (as defined in subparagraph (b) of Section 6 hereof) or due to the Employee’s Total Disability (as defined in subparagraph (g) of Section 4 hereof), or (iv) any voluntary termination of the Employee’s employment by the Employee for Good Reason (as defined in subparagraph (d) of Section 6 hereof).

 

(d)                                 To the extent that any annual or periodic equity grants are made to OPKO executives during the Employment Period, the Employee will be eligible to also receive grants of such types and in such amounts as shall be determined by the Compensation Committee of the Board of Directors of OPKO.

 

3



 

(e)                                  The Company will lease and insure, under the Company’s policy, an automobile for the benefit of the Employee.  The Company will be responsible for maintenance, gasoline, repair and all other such costs but only to the extent such expenses relate to the business use of the automobile.  At the end of the lease term, or in the event of the termination of this Agreement for any reason, including non-renewal, the Employee will have the following options:

 

(i)                                     surrender the automobile to the Company,

 

(ii)                                  assume the Company’s lease payment obligation; or

 

(iii)                               exercise the purchase option of the lease, if any.

 

In addition, the Company will provide the Employee upon reasonable advance notice with access for personal use of the Company’s airplane, which use will be taxable to the Employee.

 

(f)                                   The Company will promptly pay or reimburse the Employee for all expenses incurred by the Employee in the performance of his duties under this Agreement.  Such expenses will be limited to the reasonable out-of-pocket expenses necessarily and actually incurred by the Employee in the performance of his duties at the level reimbursed by the Company to the Employee immediately prior to the Effective Date and in no event at a level less than any OPKO executive other than Frost.

 

(g)                                  The Employee will be entitled to participate in any fringe benefit and bonus plans available to the Company’s employees as in effect from time to time, and to the extent that the Employee may be eligible to do so under the applicable provisions of the plans, including but not limited to pension, profit sharing, stock option, and similar plans for life and medical insurance plans or coverage maintained by the Company for senior personnel and/or all personnel.

 

(h)                                 The Employee will be entitled to such vacation, personal time, and holidays as he is eligible for under the Company’s Employment and Personnel Policy as the same presently exists or may hereinafter be amended.

 

(i)                                     The Company and OPKO will provide the Employee with indemnification (including advancement of legal fees) to the maximum extent permitted by law and coverage under any directors’ and officers’ insurance policies, on terms no less favorable than provided to any other Company or OPKO executive officer or director.  Such coverage will continue after the Employment Period while any potential liability exists.

 

4



 

(j)                                    Within thirty (30) days upon presentation of appropriate documentation, the Company will pay all documented legal fees and related expenses incurred in connection with the drafting, negotiation and execution of this Agreement and, in the event of any dispute regarding this Agreement in which the Employee prevails, all documented legal fees and related expenses incurred in connection with the dispute.

 

4.                                      Disability.  If during the Employment Period, the Employee incurs a Total Disability (as defined in subparagraph (g) of this Section 4) then, subject to the earlier termination of this Agreement or the earlier termination of the disability, the Company will compensate the Employee as provided in subparagraphs (a), (b), (c), and (d) of this Section 4.

 

(a)                                 For the month in which the Employee incurs the Total Disability, and for the following thirty-six (36) months of the disability, the Company will compensate the Employee at a rate equal to his then-current Base Compensation.

 

(b)                                 For a period of three (3) months commencing upon the termination of the thirty-six (36) month period described in subparagraph (a) of this Section 4, the Company will not pay the Employee any portion of his Base Compensation and Employee will be on an unpaid leave of absence.

 

(c)                                  If the Employee’s Total Disability terminates at any time prior to the expiration of the three (3) month period described in subparagraph (b) of this Section 4, then the Employee will return to full and active employment with the Company under the terms of this Agreement, provided, that if the Employee again incurs a Total Disability within a period of three (3) months after such return, and such Total Disability is related to his prior Total Disability, then the Employee will be deemed to have been continuously disabled from the date he incurred the prior Total Disability.

 

(d)                                 Upon expiration of the three (3) month period described in subparagraph (b) of this Section 4 without the Employee returning to full and active employment during such period, the employment of the Employee will terminate, unless an additional leave of absence is granted by the Company, in which event the employment of the Employee will terminate upon the expiration of the additional leave of absence.

 

(e)                                  In the event the Employee incurs a disability that is not a Total Disability, during the period of such disability, the Employee’s Base Compensation shall be equitably adjusted according to the time that he is able to devote to the affairs of the Company.

 

(f)                                   In addition to the foregoing, the Employee will be entitled to receive the amounts, if any, as may be payable to him by reason of his disability under policies of insurance maintained by the Company, if any.

 

(g)                                  As used in this Agreement, the term “Total Disability” means a disability such that:

 

(i)                                     the Employee is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, or

 

5



 

(ii)                                  the Employee is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, receiving income replacement benefits for a period of not less than three (3) months under an accident and health plan covering employees of the Company.

 

5.                                      Insurance.  The Company maintains a second to die insurance policy insuring the Employee and his wife Pam.  On the Effective Date or as soon as practicable thereafter, the Company will transfer such policy to the Employee without requiring the Employee to reimburse the Company for prior premiums paid on such policy.  The Employee will thereafter pay any premiums under such policy. The Employee and the Company will cooperate with respect to the tax treatment and any applicable tax and withholding obligations.

 

6.                                      Termination.

 

(a)                                 Termination by Death.  If the Employee dies while employed by the Company, the Company’s employment obligation under this Agreement will terminate at the date of death and the Employee’s estate will be entitled to (i) any earned but unpaid Base Compensation, (ii) unreimbursed business expenses, (iii) any earned but unpaid bonuses for the year(s) prior to the Employee’s termination date, and (iv) any vested benefits or amounts to which the Employee (or his beneficiaries or estate) is entitled pursuant to the terms of any employee benefit plan, equity plan, practice, program, or arrangement maintained by the Company (the “Accrued Amounts”). The Accrued Amounts will be paid within thirty (30) days of the Employee’s death, provided, that the amount described in clause (iii) of the foregoing sentence may be paid later to the extent necessary to determine the Company’s actual financial results for the applicable bonus period, but in no event later than the termination of the short term deferral period as defined in Treasury Regulation § 1.409A-1(b)(4), and the amounts in clause (iv) of the foregoing shall be paid in accordance with the terms of the applicable plan, practice, program or arrangement.  In addition, the Employee’s estate (or such other named beneficiary) will be entitled to the amounts, if any, as may be payable to his estate or beneficiaries under policies of insurance maintained by the Company.  In addition, if the Employee dies while employed by the Company, the Company will pay a death benefit to his estate equal to twenty-four (24) months of his monthly Base Compensation at the time of his death, payable in equal amounts over twenty-four (24) months.

 

(b)                                 Termination for Cause.  The Employee’s employment with the Company may be terminated by the Company for Cause at any time in accordance with subparagraph (e) of this Section 6.  In the event the Employee is terminated for Cause, the Employee will be entitled to all arrearages of Base Compensation and expenses through his termination date, but will not be entitled to further compensation.  As used in this Agreement, the term “Cause” means:

 

(i)                                     any act or acts of dishonesty (other than good faith disputes regarding the Employee’s business expense account) constituting criminal acts by the Employee resulting or intending to

 

6



 

result directly or indirectly in material gain to, or personal enrichment of, the Employee at the Company’s expense;

 

(ii)                                  the Employee’s indictment, conviction, or pleading of guilty or nolo contendere, to a felony; or

 

(iii)                               the Employee’s material breach of this Agreement, provided, that the Company provides Employee with written notice of such breach and a twenty (20) day period to cure the breach.

 

(c)                                  Termination at the Option of the Employee.  This Agreement and the Employee’s employment with the Company may be terminated at any time and for any reason, at the election of the Employee in accordance with subparagraph (e) of this Section 6.

 

(d)                                 Termination without Cause or for Good Reason.  If the Employee’s employment by the Company is terminated (i) by the Company without Cause, or (ii) by the Employee for Good Reason, the Employee will be entitled to (x) the Accrued Amounts, and (y) a lump sum payment equal to three (3) times the sum of Employee’s then-current Base Compensation, target bonus and the Employee’s annual COBRA premium at the time of termination, provided, that if Employee’s termination date is prior to October 31, 2017, an amount equal to the Employee’s then-current Base Compensation and COBRA premium will be paid from the date of termination to October 31, 2017 in accordance with the normal payroll practices of the Company, and such amount will be deducted from the Employee’s lump sum payment amount, and (z) a pro-rata bonus based on any applicable performance metrics for the Employee’s year of termination as determined using the Company’s actual performance for such year and paid when it otherwise would have been paid for such year. All of the foregoing amounts, other than the Accrued Amounts, shall be subject to and conditioned upon the execution by the Employee of a release satisfactory to the Company that becomes irrevocable within 30 days following the date on which the Employee’s employment with the Company is terminated, and the foregoing amounts shall be paid or commence upon the 30th day following the date on which the Employee’s employment is terminated.  The first such cash payment shall include payment of all amounts that otherwise would have been due under the terms of this Agreement had such payments commenced immediately upon the date on which the Employee’s employment with the Company is terminated, and any payments made thereafter shall continue as provided herein.  As used in this Agreement, the term “Good Reason” means:

 

(1)         a diminution in the Employee’s Base Compensation;

 

(2)         a diminution in the Employee’s authority, duties or responsibilities;

 

7



 

(3)         a material change in the geographic location at which the Employee provides his services under this Agreement;

 

(4)         a change in the Employee’s reporting lines; or

 

(5)         any other action or inaction that constitutes a material breach by the Company of this Agreement.

 

(e)                                  Notice of Termination.

 

(i)                                     Any election by the Company to terminate the Employee’s employment hereunder for “Cause” will be communicated by a written notice of termination (the “For Cause Notice of Termination”) forwarded to the Employee.  The For Cause Notice of Termination will recite the facts and circumstances claimed to provide the basis for such termination and will specify the purported date of termination of the Employee’s employment hereunder (the “For Cause Date of Termination”).  The For Cause Date of Termination will not be less than seven (7) days from the date of receipt by the Employee of the For Cause Notice of Termination.  If within said seven (7) day time period, the Company receives written notice from the Employee, given in good faith, that a dispute exists concerning such termination, and provided the Employee pursues resolution of the dispute with reasonable diligence, the Company will, subject to resolution of the dispute, continue to pay the Employee his full Base Compensation as in effect as of the date of his receipt of the For Cause Notice of Termination and continue the Employee as a participant in all compensation, benefit, and insurance plans in which he was participating at such date, until the dispute is resolved.  If the dispute resolution determines that the Employee’s employment was properly terminated for “Cause,” he will not be entitled to retain any payments with respect to periods after the For Cause Date of Termination and will promptly return such amounts to the Company.

 

(ii)                                  Any election by the Employee to terminate his employment hereunder for “Good Reason” will be communicated by a written notice of termination (the “Good Reason Notice of Termination”) forwarded to the Company.  The Good Reason Notice of Termination will recite the facts and circumstances claimed to constitute “Good Reason” and will specify the purported date of termination of the Employee’s employment hereunder (the “Good Reason Date of Termination”).  The Good Reason Date of Termination will not be less than forty (40) days or more than sixty (60) days after receipt by the Company of the Good Reason Notice of Termination.  The Good Reason Notice of Termination must be received by the Company not more than ninety (90) days after the initial existence of the condition on which the Good Reason Notice of Termination is based and the Company will have thirty (30) days after receipt of the Good Reason Notice of Termination to remedy the condition.  In the event of such remedy, the Employee’s employment will continue in accordance with this Agreement.

 

8



 

(iii)                               Any termination by the Employee without Good Reason or by the Company without Cause shall be communicated by written notice to the other party and shall be effective thirty (30) days following receipt by the Employee or the Company, as applicable, of the written notice; provided, however, that in the event of a termination of the Employee’s employment by the Employee without Good Reason under this Section 6(e), the Company may in its sole and absolute discretion, by written notice to the Employee, accelerate the date of termination and still have it treated as a termination by the Employee without Good Reason.

 

7.                                      Change in ControlIn the event of a “Change in Control” of the Company or OPKO as hereinafter defined, the Employee may elect as a result thereof to terminate his employment with the Company.  Such election must be effected by a written notice of termination (the “CIC Notice of Termination”) which must be received by the Company no later than thirty (30) days after such Change in Control occurs.  The CIC Notice of Termination must state a date of termination of employment effective at the earlier of forty-five (45) days after the occurrence of the Change in Control or the next to the last day of the calendar year in which the Change in Control occurs.  Subject to this Section 7, in the event of such election and timely filing by the Employee of the CIC Notice of Termination, the Employee will receive the amounts described in subparagraph (d) of Section 6 (without regard to the timing of payment proviso in subparagraph (d)(ii)(y)) hereof subject to and conditioned upon the execution by the Employee of a release satisfactory to the Company that becomes irrevocable within 30 days following the date on which the Employee’s employment with the Company is terminated.  Payment shall be made upon the 30th day following the date on which the Employee’s employment is terminated.

 

(a)                                 If any payment or benefit (including payments and benefits pursuant to this Agreement) that the Employee would receive from the Company or otherwise in connection with a Change in Control (“Transaction Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this Section 7, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Company will cause to be determined, before any amounts of the Transaction Payment are paid to Employee, which of the following two alternative forms of payment would result in the Employee’s receipt, on an after-tax basis, of the greater amount of the Transaction Payment notwithstanding that all or some portion of the Transaction Payment may be subject to the Excise Tax: (1) payment in full of the entire amount of the Transaction Payment (a “Full Payment”), or (2) payment of only a part of the Transaction Payment so that the Employee receives the largest payment possible without the imposition of the Excise Tax (a “Reduced Payment”).

 

(b)                                 For purposes of determining whether to make a Full Payment or a Reduced Payment, the Company will cause to be taken into account all applicable federal, state and local income and employment taxes and the Excise Tax. If a Reduced Payment is made, (x) the Employee will have no rights to any additional payments and/or benefits constituting the Transaction Payment, and (y) reduction in payments and/or benefits will occur in the manner that results in the greatest economic benefit to the Employee as determined in this paragraph. If more than one method of reduction will result in the same economic benefit, the portions of the Transaction Payment will be reduced pro rata.

 

9



 

(c)                                  The independent registered public accounting firm engaged by the Company as of the day prior to the effective date of the Change in Control will make all determinations required to be made under this Section 7.  If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized independent registered public accounting firm that is reasonably acceptable to the Employee (and such acceptance will not be unreasonably withheld) to make the determinations required hereunder. The Company will bear all reasonable expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.  The independent registered public accounting firm engaged to make the determinations hereunder will provide its calculations, together with detailed supporting documentation, to the Company and the Employee within fifteen (15) calendar days after the date on which the Employee’s right to a Transaction Payment is triggered or such other time as reasonably requested by the Company or the Employee.  If the independent registered public accounting firm determines that no Excise Tax is payable with respect to the Transaction Payment, either before or after the application of the Reduced Amount, it will furnish the Company and the Employee with detailed supporting calculations of its determinations that no Excise Tax will be imposed with respect to such Transaction Payment.  Any good faith determinations of the accounting firm made hereunder will be final, binding and conclusive upon the Company and the Employee.

 

(d)                                 Notwithstanding the foregoing, to the extent that neither the Company nor OPKO has any readily tradable public stock, and in the event that it will be determined that any right to receive any Transaction Payment would not be deductible, in whole or part when aggregated with any other right, payment or benefit to or for the Employee under all other agreements or benefit plans of the Company or OPKO, by the Company or the person making such payment or distribution or providing such right or benefit as a result of Section 280G of Code and the Employee waives any Transaction Payment subject to stockholder approval, the Company or OPKO, as applicable, will use its commercially reasonable best efforts to prepare and deliver to its stockholders the disclosure required by Section 280G(b)(5)(B) of the Code with respect to any Transaction Payment to obtain the approval of the Company’s or OPKO’s, as applicable, stockholders in accordance with Section 280G(b)(5)(B) of the Code and Treasury Regulation § 1.280G-1.

 

(e)                                  As used in this Agreement, the term “Change in Control” means a “Change in Effective Control” under Treasury Regulation § 1.409A-3(i)(5)(vi) or “A Change in the Ownership of a Substantial Portion of a Corporation’s Assets,” under Treasury Regulation § 1.409A-3(i)(5)(vii) and means either (i) or (ii) below with regard to a change arising from the acquisition of the Company’s stock or appointment of new Directors (for a Change in Control), or a disposition of the corporate business (for A Change in the Ownership of a Substantial Portion of a Corporation’s Assets) as defined in (iii) below:

 

(i)                                     The date any one person, or more than one person acting as a group (as determined under paragraph Treasury Regulation § 1.409A-3(i)(5)(v)(B)), acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) ownership of stock of the

 

10



 

Company or OPKO possessing thirty percent (30%) or more of the total voting power of the stock of the Company or OPKO.

 

(ii)                                  The date a majority of the members of the Company’s or OPKO’s Board of Directors is replaced during any twelve (12) month period by directors whose appointment or election is not endorsed by a majority of the members of the Company’s or OPKO’s Board of Directors before the date of the appointment or election.

 

(iii)                               A change in the ownership of a substantial portion of the Company’s or OPKO’s assets occurs on the date that any one person, or more than one person acting as a group (as determined under Treasury Regulation § 1.409A-3(i)(5)(v)(B)), acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets from the Company or OPKO that have a total gross fair market value equal to or more than forty percent (40%) of the total gross fair market value of all of the assets of the Company or OPKO immediately before such acquisition or acquisitions.

 

For the avoidance of doubt, the Merger shall not constitute a Change in Control under this Agreement.

 

8.                                      Section 409A Compliance.  It is the intent of the parties that the payments and benefits under this Agreement comply with (or be exempt from) Section 409A of the Code and the regulations and guidance promulgated thereunder (“Code Section 409A”), and, accordingly, to the maximum extent permitted, this Agreement will be interpreted in accordance therewith.  If the Employee notifies the Company (with specificity as to the reason therefor) that the Employee believes that any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause the Employee to incur any additional tax or interest under Code Section 409A, and the Company concurs with such belief or the Company independently makes such determination, the Company will, after consulting with the Employee, reform such provision to try to comply with Code Section 409A through good faith modification to the maximum extent reasonably appropriate to comply with Code Section 409A, provided, that this provision will not require the Company to incur any additional cost with respect to such arrangements.  To the extent that any provision hereof is modified in order to comply with Code Section 409A, such modification will be made in good faith and will, to the maximum extent reasonably possible, maintain the original intent and economic benefit to the Employee and the Company of the applicable provision without violating the provisions of Code Section 409A, provided, that this provision will not require the Company to incur any additional cost with respect to such arrangements.  A termination of employment will not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that are considered “nonqualified deferred compensation” under Code Section 409A unless such termination is also a “separation from service” within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or like terms will mean “separation from service.” If the Employee is deemed on the date of termination to be a “specified employee” within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment that is considered non-qualified deferred compensation under Code Section 409A payable on account of a “separation from service,” such payment or benefit will be made or provided at the date which is the earlier of (i) the expiration of the six (6)-month period measured from the date of such “separation from service” of the Employee, and (ii) the date of the Employee’s death (the “Delay Period”). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this Section 8 (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) will be paid or reimbursed to the Employee in a lump sum without interest, and any remaining payments and benefits due under this Agreement will be paid or provided in accordance with the normal payment dates specified for them herein.  The Employee’s right to receive any installment payments pursuant to this

 

11



 

Agreement will be treated as a right to receive a series of separate payments.  To the extent that any expense reimbursement provided for by this Agreement does not qualify for exclusion from U.S. Federal income taxation, the Company will make the reimbursement to the Employee no later than December 31 of the calendar year following the calendar year in which the expense was incurred; the amount of expenses eligible for such reimbursement during a calendar year will not affect the amount of expenses eligible for such reimbursement in another calendar year; and the Employee’s right to such reimbursement is not subject to liquidation or exchange for another benefit from the Company.  Notwithstanding the foregoing, the Company does not make any representation to the Employee that the payments or benefits provided under this Agreement are exempt from, or satisfy, the requirements of Code Section 409A, and the Company shall have no liability or other obligation to indemnify or hold harmless the Employee or any beneficiary of the Employee for any tax, additional tax, interest or penalties that the Employee or any beneficiary of the Employee may incur in the event that any provision of this Agreement, or any amendment or modification thereof, or any other action taken with respect thereto, is deemed to violate any of the requirements of Code Section 409A.

 

9.                                      Confidential Information.  The Employee acknowledges an obligation of confidentiality to the Company and will not divulge, disclose or communicate any trade secret, private or confidential information or other proprietary knowledge of the Company or its associated companies obtained or acquired by him while so employed.  The foregoing will not apply to information that (i) was known to the public prior to its disclosure to the Employee, (ii) becomes generally known to the public subsequent to disclosure to the Employee through no wrongful act of the Employee or any representative of the Employee, (iii) the Employee is required to disclose by applicable law, regulation, or legal process, or (iv) the Employee discloses in the good faith performance of his duties under this Agreement. Notwithstanding the foregoing, nothing in this Section 9 shall prohibit the Employee from participating in protected whistleblower activities under the Dodd-Frank Act.

 

10.                               Return of Information.  Upon termination of employment, the Employee agrees to not take with him and to deliver to the Company all records, notes, data, memoranda, models, equipment, blueprints, drawings, manuals, letters, reports and all other materials of a secret or confidential nature relating to the business of the Company which are in possession or control of the Employee, other than the Employee’s address book (in electronic and/or physical form) to the extent it only contains contact information.

 

11.                               Employee’s Restrictive Covenants.

 

(a)                                 At all times during the Restricted Period, the Employee shall not, directly or indirectly (whether as a principal, agent, partner, employee, officer, investor, owner, consultant, board member, security holder, creditor or otherwise), engage in any Company Competitive Activity or OPKO Competitive Activity, or have any direct or indirect interest in any sole proprietorship, corporation, company, partnership, association, venture or business or any other person or entity that directly or indirectly (whether as a principal, agent, partner, employee, officer, investor, owner, consultant, board member, security holder, creditor, or otherwise) engages in a Company Competitive Activity or OPKO Competitive Activity; provided that the foregoing shall not apply to the Employee’s ownership of common stock of the Company, OPKO or OPKO Subsidiary or the acquisition by the Employee, solely as an investment, of securities of any issuer, so long as the Employee does not control, acquire a controlling interest in or become a member of a group which exercises direct or indirect control of, more than five percent (5%) of any class of capital stock of such corporation; provided, however, that the Employee may be employed by or otherwise associated with a business or entity of which a subsidiary, division, segment, unit, etc. is in material direct competition with the Company, OPKO or OPKO Subsidiary but as to which such subsidiary, division, segment, unit, etc. the Employee has no direct or indirect responsibilities or involvement and provided that the Employee does not

 

12



 

breach any of the covenants in this Agreement.

 

For purposes of this Agreement:

 

Company Competitive Activity” means an activity that is in competition with the Company in any country in which the Company conducts business with respect to a business in which the Company engaged while the Employee was employed by the Company.

 

OPKO Competitive Activity” means an activity that is in competition with OPKO or OPKO Subsidiary in any country in which OPKO or any of the OPKO Subsidiaries conducts business with respect to a business in which OPKO or any of the OPKO Subsidiaries engaged while the Employee was employed by the Company.

 

OPKO Subsidiary” means all those corporations, associations or other business entities of which OPKO either (i) owns or controls fifty percent (50%) or more of the outstanding equity securities either directly or through an unbroken chain of entities as to each of which fifty percent (50%) or more of the outstanding equity securities is owned directly or indirectly by its parent (provided, that there shall not be included any such entity the equity securities of which are owned or controlled in a fiduciary capacity); (ii) in the case of partnerships, serves as a general partner; (iii) in the case of a limited liability company, serves as a manager or a managing member; (iv) otherwise has the ability to elect fifty percent (50%) or more of the directors, trustees, managers, or managing members thereof; or (v) under GAAP consolidates in its financial statements or accounts for under the equity method.

 

Restricted Period” shall mean (i) with respect to Company Competitive Activity, three years following termination of employment for any reason and (ii) with respect to OPKO Competitive Activity, (x) in the event of termination of employment by the Employee for Good Reason or by the Company without Cause and the Employee has received or is receiving severance pursuant to Section 6(d), three years following such termination of employment and (y) in the event of any other termination of employment, one year following such termination of employment.

 

(b)                                 At all times during the Restricted Period, the Employee shall not, directly or indirectly, for himself or for any other person, firm, corporation, partnership, association or other entity (i) employ, solicit for employment or attempt to employ any employee, consultant or independent contractor performing services for the Company, OPKO or OPKO Subsidiary, unless such employee, consultant or independent contractor, has not been employed or engaged by the Company, OPKO or OPKO Subsidiary for a period in excess of six (6) months, and/or (ii) call on, solicit, or engage in business with, any of the customers or clients of the Company, OPKO or OPKO Subsidiary on behalf of any person or entity in connection with any Company Competitive Activity or OPKO Competitive Activity and/or (iii) encourage any persons or entities with whom the Company, OPKO or OPKO Subsidiary does business or has some business relationship to cease doing business or to terminate its business relationship with the Company, OPKO or OPKO Subsidiary or to engage in any Company Competitive Activity or OPKO Competitive Activity on its own or with any competitor of the Company, OPKO or OPKO Subsidiary; provided, that nothing contained in this Section 11(b) will prohibit public advertising or general solicitations so long as the advertising and solicitations are not specifically directed to employees, consultants, independent contractors, customers, clients and/or business relations of the Company, OPKO or OPKO Subsidiary.

 

(c)                                  The Employee acknowledges and confirms that the restrictive covenants contained in this Section 11 (including without limitation the length of the term of the provisions of this Section 11) are reasonably necessary to protect the legitimate business interests of the Company, OPKO or OPKO Subsidiary, and are not overbroad or unfair and are not the result of overreaching, duress or coercion of any kind. The Employee further acknowledges and confirms that the compensation payable to the Employee

 

13



 

under this Agreement is in consideration for the duties and obligations of the Employee hereunder, including the restrictive covenants contained in this Section 11, and that such compensation is sufficient, fair and reasonable. The Employee further acknowledges and confirms that his full and faithful observance of each of the covenants contained in this Section 11 will not cause him any undue hardship, financial or otherwise. The Employee further acknowledges that the restrictions contained in this Section 11 are intended to be, and shall be, for the benefit of and shall be enforceable by, the Company’s successors and assigns.  The Employee expressly agrees that upon any breach or violation of the provisions of this Section 11, the Company shall be entitled, as a matter of right, in addition to any other rights or remedies it may have, to (i) temporary and/or permanent injunctive relief in any court of competent jurisdiction, and (ii) such damages as are provided at law or in equity. The existence of any claim or cause of action against the Company, OPKO or OPKO Subsidiary, whether predicated upon this Agreement or otherwise, shall not constitute a defense to the enforcement of the restrictions contained in this Section 11. It is recognized and hereby acknowledged by the parties hereto that a breach by the Executive of any of the covenants contained in Section 11 of this Agreement will cause irreparable harm and damage to the Company, OPKO or OPKO Subsidiary, the monetary amount of which may be virtually impossible to ascertain.  As a result, the Employee recognizes and hereby acknowledges that the Company, OPKO or OPKO Subsidiary shall be entitled to an injunction from any court of competent jurisdiction enjoining and restraining any violation of any or all of the covenants contained in Section 11 of this Agreement by the Employee or any of his affiliates, associates, partners or agents, either directly or indirectly, and that such right to injunction shall be cumulative and in addition to whatever other remedies the Company, OPKO or OPKO Subsidiary may possess.

 

12.                               Company Securities.  Except as otherwise prohibited by applicable securities laws, the Employee is permitted to purchase or sell shares of OPKO at any time and for any reason; provided that (1) the Employee does not possess any material non-public information and (2) the Employee shall abide by any blackout periods that OPKO may establish pursuant to its insider trading policies that are generally applicable to management-level employees; provided, further, that the Employee shall not at any time be subject to pre-clearance requirements of OPKO. The parties agree that the Employee is not an executive officer of OPKO and accordingly, will not be designated as such by OPKO without the Employee’s express agreement or as required by applicable securities law in light of changes in facts and circumstances.

 

13.                               General Provisions.

 

(a)                                 This Agreement contains the entire transaction among the parties, and there are no other representations, warranties, conditions or agreements relating to the subject matter of this Agreement.

 

(b)                                 The waiver by any party of any breach or default of any provision of this Agreement will not operate or be construed as a waiver of any subsequent breach.

 

(c)                                  This Agreement may not be changed orally, but only by an Agreement in writing duly executed on behalf of the party against which enforcement of any waiver, change, modification, consent or discharge is sought.

 

(d)                                 This Agreement will be binding upon and be enforceable against the Company and its successors and assigns and, as applicable, OPKO and its successors and assigns.  Insofar as the Employee is concerned, this Agreement is personal, is binding on the Employee, his estate and his heirs, and cannot be assigned.  Neither the Company nor OPKO may assign this Agreement, except upon a sale of substantially all of the assets of Company or OPKO, and then only to a successor who assumes this Agreement in writing.

 

14



 

(e)                                  This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

 

(f)                                   This Agreement will be construed pursuant to and in accordance with the laws of the State of New Jersey.

 

(g)                                  If any term or provision of this Agreement is held or deemed to be invalid or unenforceable, in whole or in part, by a court of competent jurisdiction, this Agreement will be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement.

 

(h)                                 Any dispute, grievance, or controversy arising under or in conjunction with this Agreement will be referred to Frost and will be dealt with by personal discussion, and if not satisfactory resolved, will be submitted under the Rules of the American Arbitration Association of New York City (except with respect to the Employee’s Restrictive Covenant).

 

(i)                                     The Company and OPKO shall be jointly and severally liable for all financial obligations under this Agreement.

 

(j)                                    Any consent of the Company required under this Agreement will not be unreasonably withheld or delayed.

 

[Signature pages follow]

 

15



 

IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above written.

 

 

COMPANY:

 

Bio-Reference Laboratories, Inc.

 

 

 

/s/ Richard L. Faherty

 

By: Richard L. Faherty

 

 

 

OPKO:

 

OPKO Health, Inc.

 

 

 

/s/ Adam Logal

 

By: Adam Logal

 

 

 

EMPLOYEE:

 

 

 

/s/ Marc D. Grodman

 

Marc D. Grodman, M.D

 

16


EX-31.1 5 a15-7384_1ex31d1.htm EX-31.1

Exhibit 31.1

 

CHIEF EXECUTIVE OFFICER CERTIFICATION

 

I, Marc D. Grodman, certify that:

 

1. I have reviewed this report on Form 10-Q of Bio-Reference Laboratories, Inc. (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)                                 Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)                                 Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)                                  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)                                 Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s second quarter) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

(a)                                 All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)                                 Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Dated: June 8, 2015

 

 

/S/ Marc D. Grodman M.D.

 

Marc D. Grodman

 

President and Chief Executive Officer

 

Principal Executive Officer

 


EX-31.2 6 a15-7384_1ex31d2.htm EX-31.2

Exhibit 31.2

 

CHIEF FINANCIAL OFFICER CERTIFICATION

 

I, Nicholas Papazicos, certify that:

 

1. I have reviewed this report on Form 10-Q of Bio-Reference Laboratories, Inc. (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)                                 Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)                                 Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)                                  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)                                 Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s second quarter ) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)                                 All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)                                 Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: June 8, 2015

 

 

/S/ Nicholas Papazicos

 

Nicholas Papazicos

 

Senior Vice President, Chief Financial and

 

Chief Accounting Officer

 


EX-32.1 7 a15-7384_1ex32d1.htm EX-32.1

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the “registrant”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(a)                                 The Periodic Report on Form 10-Q of the registrant for the period ended April 30, 2015, which this certification accompanies (the “Periodic Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

(b)                                 Based on my knowledge, the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the registrant.

 

 

Dated: June 8, 2015

 

 

 

/S/ Marc D. Grodman M.D.

 

Marc D. Grodman

 

President and Chief Executive Officer

 

Principal Executive Officer

 


EX-32.2 8 a15-7384_1ex32d2.htm EX-32.2

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Nicholas Papazicos, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the “registrant”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(a)           The Periodic Report on Form 10-Q of the registrant for the period ended April 30, 2015, which this certification accompanies (the “Periodic Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

(b)           Based on my knowledge, the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the registrant.

 

 

Dated: June 8, 2015

 

/S/ Nicholas Papazicos

 

Nicholas Papazicos

 

Senior Vice President, Chief Financial and

 

Chief Accounting Officer

 


EX-101.INS 9 brli-20150430.xml XBRL INSTANCE DOCUMENT 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2015-04-30 0000792641 brli:AllowanceForContractualCreditsDiscountsMember 2015-04-30 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2014-10-31 0000792641 brli:AllowanceForContractualCreditsDiscountsMember 2014-10-31 0000792641 us-gaap:RevolvingCreditFacilityMember 2015-04-30 0000792641 us-gaap:RevolvingCreditFacilityMember 2015-05-05 0000792641 us-gaap:NoncompeteAgreementsMember 2014-11-01 2015-04-30 0000792641 us-gaap:CustomerListsMember 2014-11-01 2015-04-30 0000792641 brli:PatentsAndLicensesMember 2014-11-01 2015-04-30 0000792641 us-gaap:NoncompeteAgreementsMember 2013-11-01 2014-10-31 0000792641 us-gaap:CustomerListsMember 2013-11-01 2014-10-31 0000792641 brli:PatentsAndLicensesMember 2013-11-01 2014-10-31 0000792641 us-gaap:NoncompeteAgreementsMember 2014-10-31 0000792641 us-gaap:CustomerListsMember 2014-10-31 0000792641 brli:PatentsAndLicensesMember 2014-10-31 0000792641 us-gaap:MediumTermNotesMember 2015-04-30 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateEurodollarMember 2014-02-03 2014-02-03 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateBaseRateMember 2014-02-03 2014-02-03 0000792641 us-gaap:RevolvingCreditFacilityMember us-gaap:MaximumMember brli:DebtInstrumentVariableRateEurodollarMember 2015-04-30 2015-04-30 0000792641 us-gaap:RevolvingCreditFacilityMember us-gaap:MinimumMember brli:DebtInstrumentVariableRateEurodollarMember 2014-11-01 2015-04-30 0000792641 us-gaap:RevolvingCreditFacilityMember us-gaap:MinimumMember brli:DebtInstrumentVariableRateBaseRateMember 2014-02-03 2014-02-03 0000792641 us-gaap:RevolvingCreditFacilityMember us-gaap:MaximumMember brli:DebtInstrumentVariableRateBaseRateMember 2014-02-03 2014-02-03 0000792641 2014-04-30 0000792641 2013-10-31 0000792641 us-gaap:NoncompeteAgreementsMember 2015-04-30 0000792641 us-gaap:CustomerListsMember 2015-04-30 0000792641 brli:PatentsAndLicensesMember 2015-04-30 0000792641 2015-04-30 0000792641 2014-10-31 0000792641 2015-06-03 0000792641 us-gaap:SeriesAPreferredStockMember 2015-04-30 0000792641 us-gaap:SeriesAPreferredStockMember 2014-10-31 0000792641 brli:BambooAcquisitionInc.Member us-gaap:ParentCompanyMember us-gaap:SubsequentEventMember 2015-06-03 0000792641 us-gaap:RevolvingCreditFacilityMember 2014-02-03 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateBaseRateMember 2015-04-30 0000792641 us-gaap:MediumTermNotesMember 2014-11-01 2015-04-30 0000792641 us-gaap:MediumTermNotesMember 2010-12-01 2010-12-31 0000792641 2015-02-01 2015-04-30 0000792641 2014-11-01 2015-04-30 0000792641 2014-02-01 2014-04-30 0000792641 2013-11-01 2014-04-30 iso4217:USD xbrli:shares xbrli:shares xbrli:pure brli:item iso4217:USD 32665000 17092000 37654000 19654000 1513818000 800754000 1782530000 939266000 1330379000 706234000 1587205000 838004000 183439000 94520000 195325000 101262000 5408000 84 0.0350 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;">[7]</font><font style="display: inline;font-weight:bold;"> Revolving Note Payable - Bank</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">On February&nbsp;3, 2014, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A. (&#x201C;PNC Bank Credit Line&#x201D;).&nbsp; This amendment increased the maximum credit line to $70,000.&nbsp;&nbsp;The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i)&nbsp;$70,000 or (ii)&nbsp;50% of the Company&#x2019;s qualified accounts receivable, as defined in the agreement.&nbsp;&nbsp;The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank&#x2019;s base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage.&nbsp; The additional interest percentage charge on bank&#x2019;s base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company.&nbsp; At April&nbsp;30, 2015, the Company elected to have all of the total advances outstanding to be subject to the bank&#x2019;s base rate of interest of 3.50%.&nbsp; The credit line is collateralized by substantially all of the Company&#x2019;s assets. The line of credit is available through October&nbsp;2016 and may be extended for annual periods by mutual consent, thereafter.&nbsp; The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, and the prohibition of the payment of cash dividends by the Company. As of April&nbsp;30, 2015, the Company utilized $49,315 of the available credit under this revolving note payable loan agreement.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">On May&nbsp;14, 2015 a date subsequent to the period covered in these financial statements the Company further amended its PNC Bank Credit Line to increase the maximum that can be borrowed under the credit line to $120,000 as well as extended the credit line through October&nbsp;2020. This amendment is effective as of May&nbsp;5, 2015.&nbsp;&nbsp;The other terms of the amendment remained substantially unchanged.</font> </p> <p><font size="1"> </font></p> </div> </div> 0.50 3000000 54000000 800 0 1 2.75 3000 3000 31046000 15501000 25225000 12030000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;">[4] Revenue Recognition and Contractual Adjustments</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.&nbsp;&nbsp;Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by BRLI are to patients covered under a third party payor contract.&nbsp;&nbsp;In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly; in the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.&nbsp;&nbsp;Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.&nbsp;&nbsp;Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.&nbsp;&nbsp;The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.&nbsp;&nbsp;This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.&nbsp;&nbsp;The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.</font> </p> <p style="margin:0pt;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:36pt;"> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="7" valign="bottom" style="width:59.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:03.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Six&nbsp;Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">April&nbsp;30,</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">April&nbsp;30,</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">[Unaudited]</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">[Unaudited]</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:03.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:03.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Gross Service Revenues</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,175,282&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,017,621&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,240,575&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,927,499&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Contractual Adjustments and Discounts:</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Medicare/Medicaid Portion</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101,262&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94,520&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195,325&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>183,439&nbsp; </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">All Other Third Party Payors*</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>838,004&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>706,234&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,587,205&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,330,379&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Total Contractual Adjustments and Discounts</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>939,266&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>800,754&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,782,530&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,513,818&nbsp; </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Service Revenues Net of Contractual Adjustments and Discounts</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>236,016&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>216,867&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>458,045&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>413,681&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Patient Service Revenue Provision for Bad Debts**</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,030&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,501&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,225&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,046&nbsp; </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>223,986&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>201,366&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>432,820&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>382,635&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No.&nbsp;2011-7.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.&nbsp;&nbsp;The remaining bad debt expense is presented as part of operating expenses.&nbsp;&nbsp;The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. </font><font style="display: inline;"> A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries.&nbsp; One such legislation is Protecting Access to Medicare Act of 2014&nbsp;(Public Law 113&#x2014;93)(&#x201C;PAMA&#x201D;) was signed into law on April&nbsp;1, 2014.&nbsp; The legislation directed CMS to conduct a market survey and to determine whether Medicare is reimbursing at a commercially reasonable rates. &nbsp;To date, CMS has fallen behind the schedule legislated in PAMA. As the result, the current reimbursement rates remain unchanged, subject to typical annual reviews, until 2017.</font> </p> <p><font size="1"> </font></p> </div> </div> 413681000 216867000 458045000 236016000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;"></font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:36pt;"> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="7" valign="bottom" style="width:59.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:03.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Six&nbsp;Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">April&nbsp;30,</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">April&nbsp;30,</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">[Unaudited]</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:28.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">[Unaudited]</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:03.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:03.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Gross Service Revenues</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,175,282&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,017,621&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,240,575&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,927,499&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Contractual Adjustments and Discounts:</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Medicare/Medicaid Portion</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101,262&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94,520&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195,325&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>183,439&nbsp; </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">All Other Third Party Payors*</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>838,004&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>706,234&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,587,205&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,330,379&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Total Contractual Adjustments and Discounts</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>939,266&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>800,754&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,782,530&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,513,818&nbsp; </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Service Revenues Net of Contractual Adjustments and Discounts</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>236,016&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>216,867&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>458,045&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>413,681&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Patient Service Revenue Provision for Bad Debts**</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,030&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,501&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,225&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,046&nbsp; </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>223,986&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>201,366&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>432,820&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>382,635&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No.&nbsp;2011-7.</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;"></font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 53.00%;margin-left:108pt;"> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">[Unaudited]</font></p> </td> <td valign="bottom" style="width:04.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">April&nbsp;30,</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Contractual Credits/Discounts</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>582,180&nbsp; </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>513,466&nbsp; </td> <td valign="bottom" style="width:01.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Doubtful Accounts</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81,505&nbsp; </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83,276&nbsp; </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Total Allowance</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>663,685&nbsp; </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>596,742&nbsp; </td> <td valign="bottom" style="width:01.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 135943000 69670000 157884000 80057000 920000 1155000 false --10-31 Q2 2015 2015-04-30 10-Q 0000792641 27802976 Yes Accelerated Filer BIO REFERENCE LABORATORIES INC 71166000 66073000 263346000 285361000 15620000 11493000 89954000 101250000 0 0 0 0 39979000 40640000 959000 730000 952000 474000 478863000 512718000 351849000 379970000 60626000 61105000 6128000 6259000 5905000 1967000 12252000 10863000 17952000 24480000 17507000 25146000 0.01 0.01 0.01 35000000 35000000 27272644 27798976 27272644 27798976 277000 278000 221932000 112817000 244082000 125003000 9234000 4659000 10057000 5091000 75583000 38352000 83559000 42977000 4291000 7508000 13131000 9400000 0.04 0.01 0.01 0.04 base rate Eurodollar rate 0.0612 61000 P7Y 5976000 457000 -440000 -1580000 35964000 40040000 39456000 2291000 3414000 4438000 1056000 1127000 2700000 1586000 3174000 1606000 11934000 13231000 0.48 0.37 0.62 0.38 0.47 0.37 0.61 0.38 15822000 26950000 5153000 5290000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;">[2] Fair Value Measurements</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">As of April&nbsp;30, 2015, the Company&#x2019;s financial instruments primarily consist of cash, short-term trade receivables and payables for which their carrying amounts approximate fair values, and long term debt, for which based on the borrowing rates currently available to the Company for bank loans with similar terms and average maturities, its carrying amount approximates its fair value.</font> </p> <p><font size="1"> </font></p> </div> </div> 10763000 1750000 3275000 5738000 11716000 1922000 3469000 6325000 8097000 900000 904000 946000 1063000 1540000 25166000 5297000 8738000 11131000 25166000 5297000 8738000 11131000 14403000 3547000 5463000 5393000 13450000 3375000 5269000 4806000 P17Y P20Y P3Y P17Y P20Y P5Y -109000 -173000 100578000 50992000 117056000 58797000 35185000 35185000 160703000 88549000 188738000 98983000 23494000 18238000 29785000 18281000 -86000 112000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;">[9] Provision for Income Taxes</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">The provision for income taxes for the three-months ended April&nbsp;30, 2015 consists of a current tax provision of $9,400 and a deferred tax benefit of $1,580.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">The provision for income taxes for the six-months ended April&nbsp;30, 2015 consists of a current tax provision of $13,131 and a deferred tax benefit of $440.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">The provision for income taxes for the three-months ended April&nbsp;30, 2014 consists of a current tax provision of $7,508 and a deferred tax provision of $457.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">The provision for income taxes for the six-months ended April&nbsp;30, 2014 consists of a current tax provision of $4,291 and a deferred tax provision of $5,976.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">On April&nbsp;30, 2015, the Company had a current deferred tax asset of $39,456 and a long-term deferred tax asset of $4,438 included in other assets.&nbsp;&nbsp;On April&nbsp;30, 2014, the Company had a current deferred tax asset of $35,964 and a long-term deferred tax asset of $2,291 included in other assets.</font> </p> <p><font size="1"> </font></p> </div> </div> 9867000 16538000 10267000 7965000 12691000 7820000 -3097000 1908000 13227000 20244000 -38000 -71000 855000 -8000 -87000 -941000 200000 200000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;">[6]&nbsp;&nbsp;Intangible Assets</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">The following disclosures present certain information on the Company&#x2019;s intangible assets as of April&nbsp;30, 2015 (Unaudited) and October&nbsp;31, 2014. All intangible assets are being amortized over their estimated useful lives, as indicated below, with no estimated residual value.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 54pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">April&nbsp;30, 2015</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-Average</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;Period</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Net&nbsp;of&nbsp;Accumulated</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Intangible&nbsp;Asset</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Years</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Cost&nbsp;($)</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;($)</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Customer Lists</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">20</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,738&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,469&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,269&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Covenants Not-to-Compete</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">5</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,131&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,325&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,806&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Patents and Licenses</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">17</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,297&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,922&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,375&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,166&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,716&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,450&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 54pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">October&nbsp;31, 2014</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-Average</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;Period</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Net&nbsp;of&nbsp;Accumulated</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Intangible&nbsp;Asset</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Years</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Cost&nbsp;($)</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;($)</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Customer Lists</font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">20</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,738&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.28%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,275&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:16.70%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,463&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Covenants Not-to-Compete</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">3</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,131&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,738&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,393&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Patents and Licenses</font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">17</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,297&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,750&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,547&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,166&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,763&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:16.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,403&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt 0pt 0pt 36pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">The aggregate intangible amortization expense for the three months ended April&nbsp;30, 2015 and 2014 was $474 and $730, respectively.&nbsp;&nbsp;The aggregate intangible amortization expense for the six months ended April&nbsp;30, 2015 and 2014 was $952 and $959, respectively.&nbsp;&nbsp;The estimated intangible asset amortization expense for the remainder of fiscal year ending October&nbsp;31, 2015 and for the four subsequent years is as follows:</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 36.00%;margin-left:180pt;"> <tr> <td valign="bottom" style="width:57.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:06.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:06.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>900&nbsp; </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:06.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,540&nbsp; </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:06.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,063&nbsp; </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:06.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>946&nbsp; </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:06.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>904&nbsp; </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:06.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,097&nbsp; </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;text-decoration:underline;">Total</font></p> </td> <td valign="bottom" style="width:06.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,450&nbsp; </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 14403000 13450000 1206000 597000 1226000 666000 1166000 1189000 20791000 20783000 100676000 51566000 110176000 56491000 478863000 512718000 144564000 162326000 15397000 13734000 -17021000 -15935000 70000000 120000000 33380000 49315000 49315000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;">[5] Accounts Receivable Allowances</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary.&nbsp;&nbsp;&nbsp;BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer&#x2019;s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:</font> </p> <p style="margin:0pt;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 53.00%;margin-left:108pt;"> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">[Unaudited]</font></p> </td> <td valign="bottom" style="width:04.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">April&nbsp;30,</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Contractual Credits/Discounts</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>582,180&nbsp; </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>513,466&nbsp; </td> <td valign="bottom" style="width:01.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Doubtful Accounts</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81,505&nbsp; </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83,276&nbsp; </td> <td valign="bottom" style="width:01.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:50.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Total Allowance</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>663,685&nbsp; </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>596,742&nbsp; </td> <td valign="bottom" style="width:01.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 3412000 524000 541000 3145000 2871000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;">[8]</font><font style="display: inline;font-weight:bold;"> Long-Term Debt - Bank</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">In December&nbsp;2010, the Company issued a seven-year term note for $5,408 at the rate of interest of 6.12% per annum for the financing of new equipment.&nbsp;&nbsp;The note is payable in 84 equal monthly installments commencing on January&nbsp;29, 2011 of $61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of&nbsp;&nbsp;December&nbsp;29, 2017.&nbsp;&nbsp;The balance on this note as of April&nbsp;30, 2015 is approximately $3,412.</font> </p> <p><font size="1"> </font></p> </div> </div> 6528000 7639000 14022000 13075000 -7306000 -15993000 -188000 10557000 13227000 10273000 17094000 10461000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;">[3] New Accounting Pronouncements</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Removed and Reserved.</font> </p> <p><font size="1"> </font></p> </div> </div> -1266000 -641000 -1069000 -645000 24760000 18879000 30854000 18926000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;">[1] Basis of Presentation</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the instructions to Form&nbsp;10-Q and, therefore, do not include all information and footnotes necessary for complete audited financial statements. However, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial position and operating results have been included in these statements. Interim results are not necessarily indicative of results for a full year. Reference is made to the October&nbsp;31, 2014 audited consolidated financial statements of Bio-Reference Laboratories,&nbsp;Inc.(&#x201C;BRLI&#x201D; or the &#x201C;Company&#x201D;) contained in its Annual Report on Form&nbsp;10-K for the year ended October&nbsp;31, 2014.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">The consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes for the year ended October&nbsp;31, 2014 as filed with the Securities and Exchange Commission in the Company&#x2019;s Annual Report on Form&nbsp;10-K. Significant accounting policies followed by the Company are set forth in Note 2 to the Company&#x2019;s 2014 Annual Report on Form&nbsp;10-K.</font> </p> <p><font size="1"> </font></p> </div> </div> 10165000 9224000 1415000 1615000 36439000 18240000 40290000 20444000 1924000 1695000 -26000 -12000 -45000 -23000 -86000 -56000 112000 -2000 258000 254000 7048000 15739000 0.10 0.10 1666667 1666667 0 0 177000 622000 156342000 172893000 66388000 71643000 -14480000 -1771000 2933000 3225000 243000 257000 278646000 295740000 1927499000 1017621000 2240575000 1175282000 382635000 201366000 432820000 223986000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;;font-size: 10pt;font-family:CG Times;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;"></font><font style="display: inline;"></font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 36.00%;margin-left:180pt;"> <tr> <td valign="bottom" style="width:57.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:06.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:06.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>900&nbsp; </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:06.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,540&nbsp; </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:06.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,063&nbsp; </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:06.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>946&nbsp; </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:06.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>904&nbsp; </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:06.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,097&nbsp; </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;text-decoration:underline;">Total</font></p> </td> <td valign="bottom" style="width:06.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:32.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,450&nbsp; </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 54pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">April&nbsp;30, 2015</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-Average</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;Period</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Net&nbsp;of&nbsp;Accumulated</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Intangible&nbsp;Asset</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Years</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Cost&nbsp;($)</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;($)</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Customer Lists</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">20</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,738&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,469&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,269&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Covenants Not-to-Compete</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">5</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,131&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,325&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,806&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Patents and Licenses</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">17</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,297&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,922&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,375&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,166&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,716&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,450&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 54pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">October&nbsp;31, 2014</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-Average</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;Period</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Net&nbsp;of&nbsp;Accumulated</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Intangible&nbsp;Asset</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Years</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Cost&nbsp;($)</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;($)</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Customer Lists</font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">20</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,738&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.28%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,275&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:16.70%;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,463&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Covenants Not-to-Compete</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">3</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,131&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,738&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,393&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Patents and Licenses</font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">17</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,297&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,750&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,547&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:23.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:23.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,166&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,763&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:16.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:CG Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,403&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:CG Times;font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 290000 40000 318902000 336658000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;font-weight:bold;">[10] Subsequent events</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">On June&nbsp;3, 2015 the Company,&nbsp;&nbsp;OPKO Health,&nbsp;Inc., a Delaware corporation (&#x201C;OPKO&#x201D;) and Bamboo Acquisition,&nbsp;Inc., a New Jersey corporation and a direct wholly owned subsidiary of OPKO (&#x201C;Sub&#x201D;), entered into an agreement and plan of merger (the &#x201C;Merger Agreement&#x201D;). Pursuant to the Merger Agreement, Sub will be merged with and into the Company (the &#x201C;Merger&#x201D;) and the Company will be the surviving corporation and OPKO&#x2019;s wholly owned subsidiary. The Merger is intended to qualify as a reorganization within the meaning of the Internal Revenue Code of 1986, as amended (the &#x201C;Code&#x201D;).</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">At the effective time of the Merger (the &#x201C;Effective Time&#x201D;), each issued and outstanding share of the Company&#x2019;s common stock, par value $0.01 per share (the &#x201C;Company Common Stock&#x201D;), (other than any shares of the Company Common Stock (including shares held in treasury by the Company) held by OPKO or any OPKO subsidiary or the Company or any Company subsidiary) will automatically be converted into and exchanged for the right to receive 2.75 shares (the &#x201C;Exchange Ratio&#x201D;) of OPKO&#x2019;s common stock, par value $0.01 per share (the &#x201C;OPKO Common Stock&#x201D;). No fractional shares of OPKO Common Stock will be issued in the Merger, and the Company&#x2019;s shareholders will receive one share of OPKO Common Stock in lieu of any fractional shares, after taking into account all of the shares of the Company Common Stock represented by certificates or book-entries, delivered by such shareholder.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">In addition, subject to certain limitations described in the Merger Agreement, each option to purchase shares of the Company Common Stock will be converted into and become rights with respect to the OPKO Common Stock and OPKO will assume each such option, in accordance with the terms of the applicable option plan and/or stock option agreement. The number of shares of OPKO Common Stock subject to such options will be equal to the number of shares of Company Common Stock subject to such options multiplied by 2.75, rounded down to the nearest whole share. The per share exercise price under each option will be adjusted by dividing the per share exercise price of such option by 2.75 and rounding up to the nearest cent.</font> </p> <p style="margin:0pt;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">The obligations of the Company and OPKO to consummate the Merger are subject to customary conditions, including, but not limited to, obtaining the required approval of the Company&#x2019;s shareholders.</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">Subject to the satisfaction or waiver of the foregoing conditions and the other terms and conditions contained in the Merger Agreement, the transaction is expected to close in the second half of 2015.</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">The Merger Agreement contains certain termination rights for both the Company and OPKO in certain circumstances.</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:CG Times;font-size: 10pt"> <font style="display: inline;">If the Merger Agreement is terminated under certain circumstances specified in the Merger Agreement, the Company will be required to pay OPKO a termination fee of up to $54,000,000. In addition, under certain circumstances, the Company would be obligated to reimburse OPKO&#x2019;s out of pocket expenses incurred in connection with the Merger Agreement up to $3,000,000.</font> </p> <p><font size="1"> </font></p> </div> </div> 596742000 513466000 83276000 663685000 582180000 81505000 27855141 27857467 27874074 27881908 27712525 27716644 27781143 27786309 EX-101.SCH 10 brli-20150430.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Revenue Recognition and Contractual Adjustments (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Intangible Assets (Details) (Calc 2) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Revenue Recognition and Contractual Adjustments link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accounts Receivable Allowances link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Revolving Note Payable - Bank link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Long-Term Debt - Bank link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Provision for Income Taxes link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Revenue Recognition and Contractual Adjustments (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accounts Receivable Allowances (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accounts Receivable Allowances (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Revolving Note Payable - Bank (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Long-Term Debt - Bank (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 brli-20150430_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 12 brli-20150430_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT EX-101.PRE 13 brli-20150430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 14 brli-20150430_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT GRAPHIC 15 g73841km01i001.gif GRAPHIC begin 644 g73841km01i001.gif M1TE&.#EAD@`8`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y M!`$`````+`````"1`!<`AP````````L+"PD)"1<7%P4%!1P<'!,3$P\/#Q\? M'QX>'A@8&`8&!@("`A(2$@@("`P,#!`0$`H*"AD9&0<'!P0$!`$!`145%186 M%AH:&CL[.S(R,B8F)C7D%!049&1EA86$1$1$Q,3%!04$]/3TY.3DU-35]?7U-34UU=7514 M5%5554A(2%965EM;6U=75UQ<7$5%14='1TI*2D)"0EE964-#0V=G9VIJ:GEY M>7=W=V%A87U]?7AX>'M[>W]_?WQ\?&UM;6MK:V)B8G)R'AYF9F9&1D9*2DHR,C)J:FH*"@H:&AIR7EYZ>GK:VMJZNKJ^OK[V]O:"@H**B MHJRLK+BXN+2TM*.CHZ>GIZNKJ[N[N[*RLJ2DI*BHJ+^_O[.SL[R\O+FYN:FI MJ:VMK:6EI;>WM\/#P]/3T];6UL3$Q,?'Q\_/S]SGIZ>_O[^[N[NWM[>3DY/S\_.?GY^KJZN+BXOW]_?/S\_O[ M^____P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$" M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$" M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+D)'$BPH,&#"!,J7,BPH<.'$",6_#5J MT:A?$C-JW,BQHT-@4@*('!E@BL>3*%.J),B&I$N1;1"Z>0,GCDTY<^BX841J M8"DJ=>S8O).P$9Y@!AU5L:'AAI4\P@0ZNG)'CLTX>NCL>60*X3`L-7$6/)7E MCLTYJ!#B@70P%1\JQ!QN"-"'FQ8!'%X&Z'#0D1\/)`<0*##R0S%C>W"0S($0 M1`!5!/F,-!!"Q$@=W%9MZ>#R`,D1!H7=R2N2%<%6=TB01!@`@<%((B4YO"%R MX(Y%D_3R2%A"I"N">T:>$DB)9%V#)@*\&I@\P(F"C@,D&`A+Y`V"7$:R%HGB M8(J1*@X&_U!0L(O(8PXK:1\80."?EY80AA#9DR">]9<"]!B)S.`*Y0+-(=(" MXHDTBD#`B.1#02R(%(=!6P3`@$C+%?1#`*H%\&!!XQ'40@`<0+3:0+&X,)`7 M+B$T@DAI$93,2,IP(TD`7\BR'D')53C2+`T)(Q(0!8$A4A@&U292"`8%T=Y( M<1'4(3?&-!"`$!!A,J)`RP1`RT#':#"2;`:M&$`M!3$S4C,R!B`&-T,<6=!_ MR]5RXT(^!@`D03J(E$E!@`1@!3?S!8`104H:\XI(#G!(GBTB!1+1#E=R\T`` M$!1T2P0!$'&0F&02Y,9Z,_[)C00BV4$0G-P(,J!#=19!D"8B,?]@$&',<%.* M2$84I"12Y@6`A9,;6")2*1*]<"4<(^EAD`(P;"J2,P0%\J5`,ZX)Y4C%#(1J MA`%XP*I("HQ!QA$CE6'0)@%<)]`$M1$:`%+<""#2,^R-!$U&\MZ88D&##.!L M`#&X<`*F(LEPRT#5#L3)C:A>L6J/(D5`0@0C:,Y,F_G28D-X(C'=,$@-Q0(!(A$-MI$!$B_<%--0%4H(HINNAB MBBNSW%AUO4N2QPW7`2PBHD@6[&&W06+L&Z9(F2.TN4"=B"1`GA5^,F="==Y) MD!HB:<%-&0'@<9"2`;!%]>$$@2*2$T]R4\Q(CSP$:P`%'&!0(2]%HB*+"RTO M$!DD5` MPDFC&"LT2"/L0(@8*00;AMA$0GJA!SCPD""PJ((/PA$)[0QD&;481`+$0HB9(2'O;U&#Y0X2#;@D`@_\`(BV'M)%P3BBRPH E@A$K":8PAZF09(Q"%*98!D&@<8UM-(F8T(RF-*=)S6HJ)"``.S\_ ` end EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#2;URCR@$``.`1```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-]*PS`4QN\%WZ'D5M8L M];^L\V+JI0KJ`\3D;"U+DY!DNKV]IYT.D;DQ''AN&MHDW_=K*!\]9W`];TSV M!B'6SI9,Y'V6@55.UW92LI?GN]X%RV*25DOC+)1L`9%=#P\/!L\+#S'#W3:6 MK$K)7W$>506-C+GS8'%F[$(C$]Z&"?=23>4$>-'OGW'E;`*;>JG58,/!#8SE MS*3L=HZ/ER0!3&39:+FP]2J9]-[42B8DY6]6_W#I?3KDN+-;$ZO:QR/$8'RM M0SOSN\'GO@<\FE!KR!YE2/>R00P^-_S=A>FK<]-\L\@:2C<>UPJT4[,&3R"/ M/H#4L0)(C_[I68INP?XKKV%0TFC1A66O'L^A)7N)G^LPQ^#\Q$[$@%V!_AJ.;2[>QZ% M(*0:5DV'=<7[RA&[&;L;_N@>0-LOT:#7>/.N/S/\````__\#`%!+`P04``8` M"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^U MC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B M(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[ MRW;E0V8+J<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@ MH@0!**```0`````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````"\F,M.PS`0 M1?=(_$/D/77&?:.F78"0NH7R`5;B)E$3.[+-HW^/52"A4AE86+.)9$<97YVY M,YEDM7EOF^1565<;G3$8I2Q1.C=%K\>;A8L<5[J0C9&JXP=E6.;]?75 MZE$UTH>'7%5W+@E1M,M8Y7UWR[G+*]5*-S*=TN'.WMA6^K"T)>]D?I"EXB)- M9]S^C,'69S&3;9$QNRW"^;MC%T[^.[;9[^MD"M!E`Y@GJV$?AP$W7Z=)6TJGCR-GQYN*'9 MG&UCQ@'J+@QH%X:H7?@?905+C`YUD:,U3HT&)0/4:`!E(\@G+734$E&G8N>/ M3?A_T'][?ZZ_?8QS=[_/4FL+4C'! M>[9[X=@6\$C$C"<]^T?X\.W:MI2F/*:IX-"S#Z#L^_[7+W<[(=^70KQ;*,!5 MSUYKO;GM=%2TAHRJ"[$!CC,K(3.J<2B3CMI(H+%:`^@L[7B.<]7)*./V4>%6 M_H^&6*U8!&,1Y1EP?121D%*-]M6:;93=OUNQ%%Z/%5ETLYG2#'WO4]M*J=)! MS#3$/?L2AV('M1LRWPQSEN+LC>_X=J=?%3F75@PKFJ!I,1P%9/`9!N#`DL.`/#>\,#3*GAHQOJ)1A_]7)(D1# MS\$T7)#9`YG-`T.E:ZAT/_525QD-S)(P^"J5RZ;*D"JFB%B1N02%U)6P&1:\ M[\;J$@:SD@?*)'FE:0[D&:C*)?+#M3+7XQ:KWOZ]^?8I[,@@BD2.3>4)>A`< MKZ.VRHVA8$M<+3P`I%(."NV2XG*2'`M:UU!2BLS-TV9WT94H0-L2Y5RI:`6A^\9#MP6HUB)2+=%%%.A`9$ZE"Z& ME+\;F?HF76X+TB?!DQ!D1L:PU*2YUF3*;:&)'=BRXG-)<'OA)HM$!B2D^WK] M)E%N"\Q%OE3P,T<02("-J==O;B^W1>/GG<38JZWNFURZ+3`_[V5-R`34;1': M:B:F@9VMX6#"Z9Y))_)0U=0U\73/Y+,F9`**G^;&E[!=TQ@T9:E9E%>3.`=4 MQ,ZHR3.!QT'#2IM57-[TTJUIG,%LH65Z,=GW_LWM'ZQX)OHX*$ZOLG]X9$4T MC?`L+7[*PZA[>84I%D^<_D[T?P$``/__`P!02P,$%``&``@````A`(9&81^E M!@``\!@``!@```!X;"]W;W)KWH;QTW1JV]F#")=IYY_F^?JXW4[-J>WK:3-"L;B;5]W%U]%>!Q_),9P.'1-6P[-:]]>9A5D;,_U#/E/ MI^XZW:+US8^$Z^OQT^OUH1GZ*X1XZ<[=_'4)ZGM]\_CQ>!G&^N4,O+_PL&YN ML9=?G/!]UXS#-!SF#83;JD1=SMDVVT*DYZ=]!PQDV;VQ/>S\]_RQ$IF_?7Y: M"O1/U[Y-UL_>=!K>?AF[_6_=I85JPSK)%7@9AD\2^G$O3?#PUGGZP[("?XS> MOCW4K^?YS^'MU[8[GF98[D@^T@QG>!/\Z_6=[`&@7G]9_G_K]O-IYP?Q)DI8 MP$7D>R_M-'_HY+.^U[Q.\]#_JT!PE?'H)D)[!^?DZ"I^UG*%&C M(;F")+YG(!&&%#>(K),,6]X,YAF.'ZEN"+D:D/H]?Z@)S3]@]W2EEZ0;XL"Y M"Q$84;B(),:0TH60()6+L((@1L%W&4DO-(]=W00GDRM(N+2.K&Y!#24U5)8! MY1*B7&Y-(*T['QB9%4Y)#@J2+ATB1)"EI&(%`C`>Q`10VH`P$*E@^!65#0A2 M$0>FRQ`'Z&JK0VXADSWR M\\AI`=O/.>/6CEG&1H4`H'P6`#&07PJ4*XC*7[`P-"N\^`O;SU,1 MDO8K;7_(1$;\E>T/XC`P#8CRYR"L*PNPF`D#DF&N,8H"B"5CA&.!$5RDG*Q2 MB1`B#%E*UJG"",&SP"`P$ZE#;BMQ)4_V2$S-.%)KH3&*299FUF*KQ4"`-(U" M4\T%4"(`3],D(&.WPHB8P0'C/M0P#ZE'*SR43($ M2M00#Q-!][;"Z)7(XHB4LH!#L1Q6&I`PEX<-"!(G0H4B!"*.S?["+*2H&1;+ MB=8Z$7*E>8@-V6>YQJAD4U?%IJ'K;`!@YF$`16*(,(D-I7` MJR*5;H6%$D![WM!30LX5QIXWU%(ZF,JVX$RD9JUDHJ0,U9/LM9PK3+B8;?%#F>_KI_"U<^,M%JN,2I[DER!G'0$ELC[P"FU"ODMF<"I0V]8 MC4,'BY!NL@"D1KG&Z`:B)2R(FQRG2^W6#<1BLEDK[(<)>=^KF,>ZX`I7<#,3 M03<0$MP4CEKW5RR`0@>Y31Q!#R@E`L"!FIZ2*@P(0JL-,(MUT16NZ-*-F&N, M2C)Q/BP+[`#RRUS@YW)1>.4[@YH"_V M[=T!U]#7^MC^7H_'[C)YY_8`(=DF@0$QJAMK]KTI=AA@OHY<<3_&6A MA1M$M@'P81CFVR_R%O;^MXKG_P```/__`P!02P,$%``&``@````A`+F<3S@1 M`P``9`@``!D```!X;"]W;W)K&ULC%;);MLP$+T7 MZ#\0O$>K=U@.8J=I`Z1`470YTQ)E$9%$@:3CY.\[)*V%LAO$A]@:/K[W9C@< M97W[6I7HA0K)>)W@T`LPHG7*,U8?$OS[U\/-`B.I2)V1DMI\>*ULJ2"%H2!?YEP1K9LE7I1^@J(IZ/S4W*JP8H M]JQDZLV08E2EJ\=#S079EY#W:S@A:.3";W1)'-6O`3@O8`3=D0W6SA"IAU"G$`I4SUXIU>-1@(2XB^;.)H MLO9?H"CI&;.]AIFZF-TE)NP0/CCI[$"2[]C1JZZ=J.RT%$X:T=B,9*PF('$(.!(S*Y*Z.@XB^5(PF+`>I]I M'+B878O1=W'8+'#*5Q+3T9%J/.X2BUF8CIY.@E'>.[ML\G8$]>#^_V71JV/A MR$UE:S&#BMK`+#969EX8+H>?^9>;GL&QLG2LM*VIHV,+\!8``!D```!X;"]W M;W)K&ULE)AM;^(X$,??GW3?(@4`&K);;O M5MJ33J=[>)V&`%$)04E:=K_]C>.$>&:RI=L7I?P\'OZ>L?VG67WZ5IR*)#^[)L-3]9$GF] M/*1E<8$4S_DI;[ZW25VG2)^^',YEE3R?8-W?@FF2]KG;-RQ]D:=569?[9@+I M/".4KWGI+3W(M%GMRR??)Z:OXJK[]G^>'80+MG M>DI:GN"3X+=3Y'H/P-*3;^WK-=\UQ[4;S2>S1S\*PIGK/&=UHW(]UW72U[HI MB_],4-"E,DG"+LD49';CL\DTG#TN?B8+?%XK!5[[+)#X@Q+FW61X[28O)^%B M%LSF]]?AF9JTM11)DVQ657EU8(/"JNM+HK=[\`2)=1$C'YJ9ZL'/>K2-`5P# M?=M$_FSEO4%;TBYF.Q8SQS$QCPEPA.`1D4^RR#Y&MUC+4Q;P8#VW14%-WUF4 M'L6+"HF:+0^)_$>L..8Q(8X0=R/D2`1)HDS(/&RK/PV#<'G[%+3F"*VY;Z"F MT%'7L1JXN"5HJ[@U,=-VN^NRQA0("B0%R@)(%1P7JQ.]*DW7+JS,4C4LRZ@R M,98J`^:F#LLH(/M0W!F79GQA=G$4+7QWW$'>F.5S29Z:,\_$3R@9Q'\=,S)/M491.\.&T8P^+H M91<8/\&+)-\AMEW0L#]B1@0CDA%E$RQ2^\<@\K:=C:WY:GQA)'%@>U:H7C$A&E$VP5NTB@U;6 M;6,R6#.]>@-J33$C@A')B+()%JGM8A!YZ[9QD3O=MJRFZS8E(J!$,J)L@L5I M7Q@19^P"5XYUVP0-W2:W6QQ8IM-UFQ+)8I1-D-;P?:MJAXE5A>2;RK8+&HY& MS(A@1#*B;()%CEM5^!&KZH)L<"&A>YTVUF-2$E M@A')B+()%J>M8*3;QB'N=)O:2`S/"7'_14>&_I,;7[(I^F'C+8G1:IX=FN== ME^20_9%4A_Q<.Z=L#U^"_BX;>!#8_GF$)[P9/!6! M?^=<9U^63?\&[AWO]LQX\S\```#__P,`4$L#!!0`!@`(````(0#(Q64AXP<` M`.4B```9````>&PO=V]R:W-H965TF']KN])!D-VDR:T[;[KD]O3PD?_\E/MPFLV&L3\_UH3LU M#\GW9D@^/O[\T_U;UW\9]DTSSF2$T_"0[,?Q?#>?#]M]I0?^Y?Y<.Z;^GDB'0_S/$V7\V/=GA*(<-?_2(QNMVNW#>NVK\?F-$*0OCG4 MH\Q_V+?GP40[;G\DW+'NO[R>/VR[XUF&>&H/[?A]"IK,CMN[SR^GKJ^?#K+N M;UE9;TWLZ4,0_MAN^V[H=N.-##>'1,.:U_/U7$9ZO']N906J[;.^V3TDG[([ M41;)_/%^:M`_;?,V>'_/AGWW]DO?/O_6GAK9;;E.:@6>NNZ+*LNT.\DKRY^S8JAF0I=??IM]O[?.X M?TB*YKB0R!OP<0-248!1@%-`>`#*+I.W`9%& M3[#J]*17:4:WI;9#E]9,MUT&=IUSZAU-H*#:[C)@ M5Q@\8`@?P3DK/8KD##)E1$$@D][L1]2%RB58"P`.$!(GP$MUF)2B0YT!JY MT[R;OV`^/$'2QP5%6$81'B#"1W!R2E-<K*,RX@+:&X$U%\-O*D!8@/`` M$3Z"DXR+IOJ_T/7Q\"4P-AY@=\DS'?;R>%"&P(S+XQ&7T#PBH7FP6<')I5EI MFD-8@/``$3Z">QQ7Q1Q4$0\`%1[MY%*I`H0%"`\0X2,X.:5:EX4G!U&3V]JJ M8R@\VLE/DFHALSY^(/I0:)W<[C*!?)IK$BX%:Z@]ZD+MS->!\(`33&:69071 MQ"HW"FA28QJY2.$!1;Q#097(9UI_44PE$TP/;3K.V@G26A9TW"MM=XO%KC!X MP!"(L?!E&I<1E]`B)J%4>[03E%'>IL1>:;M?AB^A(8,'#(&NL2C6%^:J4*+F MMHA=#=`Z?VOD],%A,W'576U$3"IKM#-ED8@[MT;C+GP$=Q[+)=6>`F03'SU4 M>[23ZW`5("Q`>(`('\%)8H&T?05AQ'TER[\IP.GR>(#=)<^N,+BV.X9`C'?& M0XE69#Q`RU`9>=!C*GA501$6(#Q`A(_@'L>%L0#-PP/@QA\>BK63ZT@5("Q` M>(`('\')86$,IC1\;`RUIP`G/TF*,.OCBPA1`&Z=W.XR@>(T7`J643O+H7R& MVE.`$\SR(CA#*FUW);(K#!XPQ&4&+B,NH45,0@/A01*Z]KX7@B=F'<0OXWT& M#QA"(]"J;.7]^Q^54<;UZZ",K3=*^,*@P<,@1F+TCVQ MX#+B^EG&]-.%@,VKG>+"8XUFUIE%8L)CC<9=^`A.68FB.PSIEBZ5^=J_Z+63 MZW`5("Q`>(`('\%)8G4TFU5^WW_]H4<[P?>`L?&`("YY=H7!M=TQU(L'*A%] MC7`\X*T"^![]V/0O3=4<#L-LV[V>Y%VZ^M^L1>%MADUV5TUO!!"<97?RBVVY MJG-KD.\>G.N7YO>Z?VE/P^S0[&3(]&8E9:F'UQ3@P]B=IR^MG[I1OG4P_;F7 MKY,T\OO:]$8Z[[IN-!_4!>P+*H__`0``__\#`%!+`P04``8`"````"$`>/GX M(?8"```2"```&0```'AL+W=O(5DZFH]BO\\\?#38*1-K1*:2$KOL*O7./; M]<9%*5U,"MV@>Z5IRF[E!9 M!%$8QD%)186]PD*]1T-FF6#\7K)#R2OC110OJ('\=2YJ?58KV7OD2JJ>#O4- MDV4-$CM1"//J1#$JV>)Q7TE%=P7X?B$3RL[:[N9*OA1,22TS,P*YP"=Z[7D> MS`-06B]3`0YLV9'BV0K?D<66A#A8+UV!?@E^U*W_2.?R^$F)](NH.%0;^F0[ ML)/RR5(?4PO!X>#J](/KP#>%4I[10V&^R^-G+O:Y@79/[1$F"X@$OZ@4=@;` M.GUQUZ-(3;["XW@TG85C$DTQVG%M'H0]BQ$[:"/+WYY$3E)>)#J)P/4D0J(1 MF83Q?VB,3QIP;33>2B#P9EP1[JFAZZ621P23!>GJFMHY)0L0M.['(72!V8=W M]JGC`*P!?5Y'R7P9/$,]V8FS\9P91A=.E[$=8$0-)8!$FFR@+/_(QC[M94,: M'9?PQE-FKN;6P;8%="*!UU:DLU^+0@':7N9A+X3G3"XA6D`GQ&0PA$57&-*Z ME"N<]D)X3N(*'L?C..D1MFW"=![/)G^I)PSF@$N+=E,@\WY7/:?EL@5T7,:# M(2SZ5B$]IQ6B!71"P&P-N+!HUT5T54C/B5TAITE$DEXSMQT"&4_BN&E%)P6[ M[2^OR7E<+-I/X=()/Y&>TW+9`CHAYH,A+/I6(3VG%:(%=$+`'AVRX>"^C][( M;4XD/Y0)F?9K;9>T3?5$&$>S?BG]"O;;I^1JS[>\*#1B\E#!NQ!!DQK4K_X- M6<`+#9NXAV_AD^#PH'D`B[JF>_Z5JKVH-"IX!I+A:`93J_Q.]S=&UFZ#[*2! M%>W^YO#MY;`JPA&0,RG-^<9^-9JO^?H/````__\#`%!+`P04``8`"````"$` M8P2T!8$#```5"@``&````'AL+W=O8Q&K`K.UT>OY^JFP@X+"KWA*ZG8L0"_W^B<92VW?7F@+T6FI):YF0)= MZ#;ZZ/,Z7(?`M-N>!'B`80\4SQ.RIYN4SDFXV]H`_27X3?>>`WV1M\]*G+Z) MBD.T(4^&'7_G!<\,/T'F2(`9.4KY@DN_@BD"$6T!**+_:67V,:J$G4S_N95\ MMFG[504GGK-K87Z3MR]2(+MJ(\N_'8@V5(XD;DC@?FM(XND\7JR>_@_+K&&!>\-" M@?"_MQ`Z=VQ(/C'#=ELE;P$<2-BPKAD>;[J903PS-.[1FI`5I"`A&JRONV@; MOD(P*/B%F'&"A" MH$84T0I9['G@^^@0]LC:/:4]PT!@/BJ`UH3`+KL0S;O].1\=`JX=8C%$I"W" M#R*/EW,]:"_`%EZ.":!T*KCQ!A^B[^#1$I"W" M5X33-^(B6H>*ZR'?P2$6UL5Y3&,OZ*G[;K,Z2"+.@<=*0.M0C_K'Q$&Q M8DE;A._B>E02K9ZDEZ6#@V`:\]UD0J/)#!`YUNDD]K!IB_7%*738$8>MV9/W M*N_08/I9I??:<[7281YTL3$\!IJZ?M$O%^JE[M!@!KI^Q728!UWL%W?=`%O] M#$>(W>\>>Z@?=K]Z&DRO(S26I4U[O'J*XO7JOFIPOBAVC[M^I^N:RL!OOXCL MTH2XLHTC^N#SOS4FF+>CFFCVJ>$X1YY>+;FAZR9,R=69 MI[PH=)#):P7AIA"FSMK]%>S=N.X^P-BMV9E_9^HL*AT4/(>ET70%K4FY">U> MC*SM_#I*`P/7/E[@]XO#](BF`,ZE-.T+'H;NAV[W$P``__\#`%!+`P04``8` M"````"$`]+TL#WL#``"!"@``&0```'AL+W=OZ8^*Z#FY+N27-GG"-^(2VN`'+@;(:"7AD M1X^W#*-]YU177NC[4Z]&I'&5PH*]1X,>#J3$&2W/-6Z$$F&X0@+BYR?2\EZM M+M\C5R/V?&X?2EJW(+$C%1%OG:CKU.7BR[&A#.TJR/LUB%'9:WA`3D/-4H..<4R_U0&F]W!/(0);=8?BPN_7?XB5X^ M,;+_2AH,Q88VR0;L*'V6U"]["8&S-_(NN@9\9\X>']"Y$C_HY3,FQY.`;B?2 MI:05O`F^G9K($8#,T6OW>R%[<5JYT722S/PH"!/7V6$N"B)]7:<\8OD MF`8+$+QF?TUAJ`=TI93L)TGOG"!3#NC+.HJF2^\%"EQ>.1O%F;G.P)DE)F7; M4V25I6[6`S>?P'3)>T;O4BB@*Z\'R0P908GMC")_2$!:S01"ZTV;.Q0SENV8 M,;.*D(TIH2F2CQFV2#&FA#<5(^G(2+KOED1A3+5.I#,SBHVBQ-V0RDYL;2"S M@=P&"@TP@HKO!B71E0NI#>,11794BC/O!BR-?=\,>JN;9XD_-\V9;@XB^)CV M7+?'86J9"V7N2F*D`VM6&ZR^QA(U:QQ%5D`;Q=&*;`.9#>0V4&B`$14LVCM1 M2=0N&?>Q?Z';H<7SKLI$@;"1W M$I2HE:`FT&TJ&\51"<:QW96M;@Y'8Y#IYK%WKIO'WH5NCN+@5CLC-WF'N.V^ M_4A)U!JIV!K2C>)H(V4#F0WD-E!H@!%5>C&ULE%9=;]HP%'V?M/\0^;WY(($6!%2E4;=*FS1-^W@VB4.L)G%DF]+^^UW; M$&P'M5T?"CGW^-SC>V]LEKUV*_3[U\/5#0J$ MQ%V)&]:1%7HE`MVN/W]:'AA_$C4A,@"%3JQ0+66_B")1U*3%(F0]Z2!2,=YB M"8]\%XF>$USJ16T33>)X%K68=L@H+/A'-%A5T8+DK-BWI)-&A),&2_`O:MJ+ MDUI;?$2NQ?QIWU\5K.U!8DL;*E^U*`K:8O&XZQC'VP;V_9)DN#AIZX>1?$L+ MS@2K9`ARD3$ZWO,\FD>@M%Z6%':@RAYP4JW07;+(DP1%ZZ4NT!]*#L+Z'HB: M';YP6GZC'8%J0Y]4![:,/2GJ8ZD@6!R-5C_H#OS@04DJO&_D3W;X2NBNEM#N MJ5I2L`8RP?^@I6H&8.OX17\>:"GK%4IGX?0Z3I/)%`5;(N0#56M14.R%9.U? M0]+6!Y')400^CR+))$RR>/8?&NE1([,TWC,0F%1\C'EG"8"BX-/ M*-@%GPJ%/J#`\IFY+C:&D^F.JLW=^T!N`4Y.T+5R!FHRTGBHD8JN$*P=UH@ZRM&1N>G,(=_C'?F.^8YV(FA(!2=5#,.-`F[N.?,@6:_/^BV3<&WIKS7\ M'B%P5L8AD"O&Y.E!W:3#+YSU/P```/__`P!02P,$%``&``@````A`/MBI6V4 M!@``IQL``!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8 ME@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;` MU#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$& M%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!` MAA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5 MD1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM' M+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO= M?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JV MY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77 MY44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29 M#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H< M8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AF MBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[ M$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.O MA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/, M>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q M@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8, M[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QI MT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD* M0Y/L(&,<8[Z4%3]F\=%]BWOAS;`DW=FEW?3%LF8/9\Y<]G"U#^^_=J?@2S.,;7_>AN(N"H/F M7/>[]GS8AG_]^>E=%@;C5)UWU:D_-]OP6S.&[Q]__.'AI1\^C\>FF0+P;S5@?FZX:[_I+ZDX;&47)IJO: M[H?O\='O]VW=?.SKYZXY3^AD:$[5!/S'8WL9K]ZZ^GO<==7P^?GRKNZ["[AX M:D_M]&UQ&@9=??_+X=P/U=,)\OXJ=%5??2]?//==6P_]V.^G.W"W0:)^SODF MWX"GQX=="QG,90^&9K\-/XC[4HMP\_BP%.COMGD9K?^#\=B__#2TNU_;

1$C(.@Z=FG#ZU\[-A4#^/4]_]@Z"% M^LV))"?P24Z$O!,Z2OZ'#T4^X//FX[\(;#"9I0@?JZEZ?!CZEP`F"^B.EVJ> M4W$/#N?L501=J.?%#_/J@@'S"-8OCS)ZV'R!QQHB M),'X6:P2I\@E`R1*60P9@V25P6QU&#@9%@@A!E&:.3THG?7<$&3Q8297*C!; MG?BF@E@!A&#\7$JG0:6]+"*1F`*R\/,+PNRLZXC-5B=\YC0`(1A>Y3IVRE/: MZSJ*M-F1+'Z^&G^V.O%S)SY"*'Z:YZD)L-2G9(!89-IX8`P$B/%*"18SYZ"< M$`5AD(1(99:[0\`1<:+T*Z(BN,1=&[&8'19FD'`0"(,LWD&O9>P0+3DDR_/8 MC`LOQBQ%_CP(5"A;$91)A&@@!FFD(M%>+6Q`DJC,C!3G,(O5"@?4,/A[4R7E MA"B$I7,X!;:%1^'2Y[U3?`U4IF:4,6(PXUCF7M79NH@-6\YD703A]>YN`F4V M,3&P54X(Z6A$23YH0"-KDW(&ZR(H?!54SC8O"(,1%&PSAV+Y!H!S6!="X2NA MF0O08N;G+TO4J1(H==8! MC)Y:+#S7=;63J&0L5\.3HB"&ZIU$J0,HR0D"4B&2U^K]MA9*7PNUF1[B8FN= M3')O#Y(3Y"+B3)KW!Z_'NAK.OSR<(X%VQJL@#(40VGL;NY=6SC#-;54/IJJ%TU)`Q&@!I84K-0+!E`*969 M]Q;GL*Z&TE=#[>RQ@C!Z.9['[B8M^?*K->!:Z+ZAI:^)UA&/NF%K(OQZ=32S M)!]8JT1(DP>K!/S67%."Q9#*TCQL!T=H.$F;O<59K*NB0E4$ M+;B=BV)7%0ECZ9%MX5&XZKE55ZALMB[%9B=CU0E#.4>VP%+*Z(0`4EH>.!>N MC1X77R.M,Q9QL3529JE3F5+9ZTI8FL*9<(6\'L^5KXS6R9H8V,HH5.H>(TMR M0M6(56YV-.>PKHP*E1'R,/UW5*<@C-U_?,I_'RFN?4O-$W/7LBP[,V_>*I0Q M:B#D;1B9G&@$WL3PO+D6+HS2&*1E\?1!^9H8FWU,C!"#>B139[DD%]=EPY7S M6-=#Y>NAJS,%8;#%<(_F'IU*!E#P:]8H%>?`-?%6`U\+$Z/J5`-;"V4>ISX) MADBSQ'J[,19Z70\7,Y\-]UJF(`Q60JDD<7M5V>%W9-<.A*9O3:0SJ_OD,XR]A3F]6O"LNQ'TA MYZLYQU["'?)BW]P6X&;W4AV:WZKAT)['X-3LP65T!],?#'@)C%^F_K+<.3[U M$]SI+O\>X;*^@29<4-:E*'!]Y)"N8"7MMBGZ]?/^ZAHY0N*NQ`WK M2(I>B4`WZ\^?5GO>1-B'2`H1,IJJ7LEYXGBIJT6+BL)QUX*L9;+.&5;SW1 M*#:TH?)5DR*G+98/VXYQO&D@[Y<@PL7(K5].Z%M:<"98)5V@ M\XS0TYP7WL(#IO6JI)"!*KO#296BVV"9!S[RUBM=H-^4[,71;T?4;/^%T_(; M[0A4&_JD.K!A[$E!'TIE@L/>R>E[W8'OW"E)A7>-_,'V7PG=UA+:/5='"M9` M)/AV6JIF`%+'+_JYIZ6L4S2+W7GBSX)PCIP-$?*>JK/(*79"LO:/`04#E2$) M!Q)X#B1!Z`:1'_\'QVS@@.<;Q[\$>"89780[+/%ZQ=G>@&4BL8P>Q^B0V(K^$ ML#1$9S4HZT1#;$?(#"0R^=N^_+S/B@MS?)3[=!B4=Q)_DF%F(&/]_6D#WG5; M*F)+Q=@!99U$O[8SS`S$=&`V]_7'AN07(9:*Y*P*99VH6-@A,@,Q*L(D65PO MDDF;:&,,NQQUORB/F6=L)I2`4+QW<3F%YN[@?S(EFO=^.&25CW^F<-]SB! M/'T7P!5C!9E,[C<3\>3L;)]\_ND_39O_[P+__KNS2=1^P=I]\_NYO/ MI]^^?)GV[I)1G&Y,ILF8)S>3V2B>\Y^SVY?I=);$_?0N2>:CX8I2,YQ%@ M1.WQ?#"_CSIC=SY@?_=R_L-W+[74+=^+3B?C^5W*TG[2+S]M36<;T?9F(]K: M;.Z6'_YA,=Z(-K?K'_J;+Y/;03J?Q7G78WZIP=E5?[,X_`;A8/P:J??([^F-R7UV4DN+J?5JYL;J[_:>6& MBV0VF(AL_>@XGE?VMB!LWXC[>AC?ED\Y6LQF@!:]'J0]P/MS$L]6GA10\5LN MD^ED-D>,HNX\GB_2\M%_3BH_^1->#X;)+#H"V-O)K$*)5J^7\)RG?<#B7^6# M`QR3T6@RYO))[Y=&U+V+9TD:G2_F)LR`5=Z64;B(ZVLDKP)F>:6G<.W:/VV5 M[SDZ/^N>GW2.6U?MX^A5ZZ0E,>F^;;>ONM':N^YQ]/Q%>4MG'%W=318IXI\V M4)-ADJ;19'Z7S#X-TB1*ITEO<#.HBOIY;XZH-TV:=\J''KV[1$2OHE:WR]7? M5A['Z9WIVY'^T?[+8O`Q'B(*%6K`#VEL&ETFO81%U\,D6H_.DGGYQ,[X(_MK M.'HN3*(@:JTT3:JW'"M:ZBH_/N57G]2;O;_38"Q<5H,321.TXP9;U!/*\Q/"M/ M/VM73CZ_>MN^7$5\D2J=2RO3:#".WF&0Q^ED..@;"*V;F\$0""JZ#&R3=%`E MWIO)I/]I,!RNX@OF_78@OCG"UB]S7*HG?94[94(ZYA21KE_AI+'\+##UI--Z MU3GI7&%,*P*;R>%%?"\A+)_!\]D"`>K&PW@VP!;(F1QA)`:I?%\:/;(/P?.; MVI]Q<&G5?#D*=>\P>]%5,ALA-Z@-#.'X5:=?)A\GPX^RDF>3>1)6P8%7\?B7 M,@I!14ZQIS..!9[)370R&=^NVWW'R75%ZX[BZ6".Z3Y)8DS%^?5P<&NRFW*' M@>JV7LA65UWILDX5R%\&[>3\[,WZ5?OR-"HLJO#H(6!R-%;`DB\0GM&Z&1D1 M()!EQ3Z'0RV`92RZ;UN7[;?G)\?MR^[_-OMP]><*$A>S8(O,MT3/-YJ;,&X6 M_1@/%\GOH]9BC@@,_HJL-1M[>WO\WWZ4FO]IH,V]X4+!5;3=V-S<]+\+BRY^ M&H:V(F*0P606E:\Y(_R*.FF*#)?!_OKEZY?R;Y+LW/T]W]ALKH!Q>U>`%(#Y MUM]B"E)PF-'6?F/_\*!QN+]GC_C/K?VMQM[.3A3/(\*JP3"+JVP!O^*!)M<8 M]^"$&A%>&'N64QW_"4G0]Z<@0B(0A-Y@,"IQ>K/'N)R8V<1]$:AK\_&6*L MTF@*"4V"*J%!Y8""]#F9*^-;V>%DRDMB>?6R&&52_D3HEG<_"MKR\E\!5U%* MZ['.M*N$?AG?TN-&49NK.IR=6J^SY<.7!*9[102HZ*,;G;^.%):TKCK$AJM$ M93D(3#[WDNGU?AMA5VB0+=] M^6/GJ&9!,>(RN](:R5G]M38$:X^FP\E]DA"-NGAME;.^3.);%-2%`2?Q]82, M@M@TZBZFTR&&N(R##U(G9+W.6'\<]*JKG#$IHU0^Z\WE>;<;$2V^[H#Z64:; MRKID3*(S=$CW1X.QY9VRG5%`J^*=WCR^IWS-JYC44"[5'UI^[I!ZTSY#1$_, M.K:.3SMGG>Z51/;'=M3^MXOV6;?=+6\DWST_;4>O+\]/"P)>7N6"PC6W^$4X MK()89SQ/=XB6JVFYX]^:>\@M+H8KP^)0K8>HJ[BX&LA[)%^U7Y]? MMI7B"^6KUK]5R7$QFWPD',0K4[H@U1>8RF>J8B2%<2>5`CLW>DKSI0N*@[J%H]SMJ_B?AX& MY[AS\HX+?CN`UJ.E(U<`]8"9/6IUWT:O3\Y_6FEFO2$^>Q.UCA#N^ER#[-;S MK\R?5O_G1+55R0"EODHBZDUHFMO"*Y>D%BH MS#".C@25V",/W>O"9S?59X+MQ7P9J<+U0;48E`^ITIPG1<#_*%$^'EHEV M=$<"FBC3]0FH4K.307Q-FJLLIV';J2"FR0LL5<_^Q?(*5;(<,*]%E.]:5L+C MR>)Z?K,8*L6W*D9Y.>1UMZV%>U\\>+%/(IW)]AEG`9/R\=(?D\GU8""7!*^\ MO'/V8[M[U5E:4T.$/.N$8^+#-*N>6AIX-QGVH\YHBCU*K,A0ON?5(B6ZAON% M#-9YRN!6CW"$%3X6L*F#M'S+Z\X9Q:]'L(&@K@X"*LL98/FXXLJ5B69Y4SU_ MT=N0EI]`"$LR*3X-*MDUTM1+DGX:WLYU/ETP^1J`[],GC> MOEZV6]UVM';KUJO^F#@EEXOZ5"PP:61$RF94D<;8560W./$R#KF5JSK+ M[KN+BQ.+I(E.ND=OV\?O3MJ"Z>S\;-V0+P@CT-;1O0+(D@!5N/@3U9=D?7)S M(TZC1F"$J9/52H*VE3'`Z@ZL7$.&D1)XUAK>]\T/%'Z>L/`*,L:8K-$T'M^+ MKHMQ3%E!=G>I5'@S&,?X'VPW9>^Y4_;H+B:`O$Z2,:`GTUA554ROCIOU69U$ MGP9S:K_.(NIP4GL.F5)VCHB9%9(.P98Z_%07LE=VZU7L=W4I.@LSDE\C MBQ8,QCB'!2Y-Q39\X&OZ0U^_J'>A)0T=0F5E,DL:Y+W1>#)GAXHE8$KI^S$F\EDSAJN&E-W3M.8V)W-H$\&D%!*"_2H(\%&]';R*:'KI8*,03^9$EWC MZ^"G8!W%8](#LYK^ER-'ZX8!$Q>\_/+U<703#V8B;,;D<&8.B%5I=9LD1L+C MW#U[%D,RDIP_G@"!QEB6G(T;A!-$Q(-1%/;!22-;@&@`EP;XY!['PW$0"2M% M*"!=0-=[6CH;V#O*Z_3]X%(*\M`GYVE M6?+I7[^@U!MK?__;?[RZ/.G\_6__&0&4KN073VQ^?"%Y]K4>6$5Q.VJ-QPL$ MVO67%)]D@O1'DP"=(:SH8RJXJF"P45;-*S8\CHUXY02."V8)]$GIR>!(KQ/H M2@H%>)SR\V)L(NZ42+`$0?PU5XA!C^$1Q;@=0LM^?E4WZ6%FK3`L<-N?>RZR M@IZ^S!WD/:/POS](T(VH.[@=TUSJJ=U9-`ET(WJJ5]Y0HD*7+(@5Q/[@2,)( M(T<"7!7OIQ&[\Q!7*PQ[+16S:BOA99PN9O51S/NM#]$3E[;, M-%L-$U'WS6$S20&AO_\-2N4J[(R9BTPPCR-:"FB;6$P(+%7KX?D:$I'9?!TU M'47T=U$K>D>^2>;BJ:EK5HB.L^C3W:!W)[Z#7B^>SG=>\0,?!=;W\@Q?H5&RZ3$=%OWZAWB;&>\1\5 M$`@#D_%"Q:3>!#60Z[(-1]BD6=R;RPX5,KZR87F_\X&M_]015!A5:$)N[!BH MC5YY?VQNV#ED^6$+0>%AJ&3!8,LBA9MJ52AAZ#UH4$-UZ:@_B&_'A/*#'LPD MHH_2!1*(8;D>TC,$UWAXCT137"0$P)3Y_S8BZ.:P40Q"4/G_$^1LEF(WZ@!' M^D5'M49H#D@BYP-J(/:/,K2&:#)#_D:>3?J%@`6-RO:C*-HGI<`Z8VZPQ$-* M@VIF>L6I,+4"V;5%'5"U6)ZYQJ)+EQS%^T04,PIPW+*8DY7^50C?SI0@>_+F M'!(8,@`%&2G&"U)7\F27;FZH==.&M=!@LKC%4!+U$!U!&7SU5.;$DN#[$$1, M\>5HK,PHIL/TO,#R``M[AC!MI&JE(H"/@SZB:KUD';T1IHCX)0]/^40A MA*F&W6$DPOB@X`IN%\0!@JZ*3^"1L:&#_R:.I_0AXRW+*EKEY",N(]B<\$O` M#"SZ$T6@Q*H>FL+3\I8:L1S(SF>E:DIR1..E%&.DV27]CFDGAGHLI;'=+V M:^9/((%K!9I?+N]PPBC/Y"0FR$0`CX[9A%N.THA[SU* M>4,0;,R"$>;Q)=@AD1F[)$6#[,'4#YNK0@N#H8Y%#H1D(WPUN[RPN M45+T60#T$C)Q'@J>GQ?]6Q?"S.^PQS,EK^@>`K`@5;L/@T6]LF)RNA1;1V`W MC'\``L=D_TF(S5:,K/#G+IH39?1Q"C^9(QO@IR<+A3C#GJ9J$&V`Q0!AL&B9 M`B^X(&Q2F)DW'*,8?@;U-&@_`8#Y0B50BF`4APH"R84DAEB!V!3Y-F]0,#:Z MV]EN+[4IU0G$PF4\0?ODVU?:;A'8D,90B\= M%I&[0$H(LMW1"X@6T]2X?27%*[H/H6:VM$"R+%,+L5VH&]P1@6(MY=Z-)K;1 MQ7N!-`*)>;*`D]+H)H@5W,R']'[EN02Z^&H9RY'0:Y\E'%= M%MQ9#J7I@MI1M2BR?H/+5HSQ)E1#"X`#)9SZN%D=B5YZ-[C!/7O+%:(=!Q,B MX0('3T]N+9$.:A,=,80`*PER%)($/U(FJ`_T,F(*"8UA:(,1S@LY7/-+^=7I M54BEL_@!.XRF%>2*./D&$.XQUTCSF&(B<:BB`@F!$]WK!/8KE?CD(H/"[BQ7 M7Q&+P!7R"&7_W.KB(Q='.N?F0B2D5MH!0F`N@?'UF1)V+EO>_?A4+7A_*C-Q:.=7W/N2NFN MV6CN[S:V#K:J(S/-QF9SO[&WU:P^VFIL[6PV=O=WJX^:C4,F878.#ZN/C@HZ MW"J4C"2]-%5<"%@I/8;@ZF466UVX0*F,<'.SV=C:JT'D<*>QN[59A:=YN-O8 MWJK#X6"[L;-=@T&+6,UU3J\L&+RP8/!"!C[]I@S/P?8!8T0[U7OW-_<:6]LU M#YJ-W0.FB#;K0&ILDX=O[]<`=3710-N3B%L&\7#[$)+M54$\8`1J?[<6Q/V# MK<;N=ATY&[O-[<9!\Z!Z7%D*K?V',OU#0&]M[R&9-4!O-?<:!WO[U>MW=N'$ M3@U5=P"86?OJC@N?5Y0`5]9=Z%F'28'TFPKSFUN-S5HB[39V-VLNW$()ZT21 M.N/F3@VN9V15JW1Z:VN[<7A0LXG*4F.[CMT[VUN-@SH5V8;9>]LUE/LFJM<% MI\L*HYG=DEK(<#X'H)O*13PD:RO\2V659@@(HPG%N\@6[/*U?D2GX+,'N<#F*RPS* MYU0\P#??P)0I\23^WCLG*U?)<01A";,6Q`$X(3RQCS,MJKY6?FC;!2XHD73W M79/`90LAX4V7ZPG16EV:'>(D1ZTLRWX13!)% MVDC^NA))?$JRF/JP0CF]2QVR`,?%R\*Z171M#0<$$(130+ARUR*@]/%=4H.I]A;E)[T75FY$K^^ MS#1#E]>&CK_/&:+<.&])9<&[BBLFD6E,"2_7Z MFNE[Y8[7R?R3.I#%F-29.%=5#6GN1G2:M^)4@.$!^:,$4+AG"E]`J4"?>IK( M9!-3#RBI%FT6_YZHF3,8J9Q(SC;<8!I[O!AI@!F\,+$V!N.(.M1;8"YY)4L% MK%N?REKF-E#5V!UGF8Q5_!96Q?&5&((_>D=&5U-K:@]X!*X1$TFFY]R/(<^L M0H@*^<67<%R&H93.F6]BHJP4:.G_3#(WFWBSTE,Q4!-3$D8#3<-"5(U4*T"% MHG,*O"9]1=300D*`.;!I6XN>+SDHV=S^ M^]_^[^'V"[7X+EJG+>OF?8*%*2TE&&@*,60E4N\#?O^JDJ"1&2L"XAP2VXY. MNP(`+RL_H:)!//L%TTM1[F.B;,YL4Z:%D)M"!!S,(#9K[F@HG)2.<5HH7!K- MXY1JFVK(EC9O1&1C$TW94O#4]9+#&]B#_%XG=Y1+G!Y05>\OV!3`-APCH8X@ M.4G#RM+B=3)+!<&)TV1JI.?48Y]8M38QFQ;=JE6QB_LY5TIL M%2N=[WU)HNSVM67N>]GA4<`N+E&_-&VT)`$$I2 M^MW'&VJ^^,*@0AF4ENJX*X-+++$S.$AY/LM3-I:RUV(12D?F(87J6/+!E&XM MI#<7EDW]U$8;/KMA8X!,KP=QBF2&4]!!3*Z,"F:_+NBUP,CU9^;89`QS,,?[^?HZ!_&@>XM3O[ZQ6CU21-L8JZ&@@),;+XE8"-. M$*G17E]U5HS1#Y.R&2XX5FL:81NYLJ_>H7IM@8.XSPV-YB@ZD31Y_%#ZX(NT M37#,.4>`V(&R@YJX]0XXG%9`D#B,>B;\N5:-GXA%,0FS3!M9VA-N:.A(+A$V M(4>![*'KQ3W>0^&TA:/NUO_P(+3!EJU]@#URD;U2$LW6!3LN,B5C_0(_:_J- MX%Y"V6<(P#?6UQ)HR"_&>I\MZMWW`$H2;5D6,L)FFJ/6)':*JK@<$N0B++^+ MSTH+2@/J>0^W0$N]^](#1DM07,F\P`DED?DVT_Z`N9.OPEK'-2"Z)Q_3+*RG M]GTRLY$990,`IC>606O(Y`B?A*B-+F"Q&!4R!)I:1'6PR^?5>N:T00>%K$=L M*]H$IK5I'#I[4A'92JFU.!M6+A4>%2S-D3OUY7$HVI87[U(V:A[4U`A5(=RI MJT`].GE^0'&TKC!*J79KOZ;6Y:JBK:"T90CW]E3YJREL[1[N-?9W:JK(';*W MI??"RT>^W_N@1L6CZZZ6."=',9P076%^IBX\RD*;8O?8BX.?0S)9(F,($,7V ME0!Y!LUQJ*?3!N1+[Y@ASB'/71HU M6:2)WAH84A(B\`8*C0DP9\EZZ]9@>31#R[1`7J\!5QO#H"'(X%8EMR\A42;V M3U9#3/KK+?)NU+?\O)5_HZ#RJ/"^W-:UZ=FO"92\R+"06-_NZ8J+U6L MZ2=0B:[[^0C.,SV-,3F;,,,W69J^^U[#0.-FO4EY(= M7M(9KA/&M>H^,`"@AS75?G6@:O1WF^Y)C;Z;G:AP@G)\L\Y,@=Q^7>M!9FVW MQMY55*U,K>?E'V3.:L#N2Q%I;\!N=`%!3&M^7IRQ*U:X#([[N(8*&QM*SNJ9WJS\LFNV@A MK7C]P\T:P<7;[M3^O%DG$H=U+:K#NMXG0D(XJSBK+/BTZ.JTV?2SO/;]ODV2 M/OU3(>>,Q2?7LP6O13#0[+X`M#3/C.@!$_X*;I%=D0Q1BE#&1M;CKQEK8IOH MSRIA&O\MCPA>G!W1Y1GS>:6S#6I<5NCS/T4N9,(\CQ,5_EQ)3WS1-5;U((M1 MH,^58N0H9K9Y,8I<`(=GI1H)8,_W[=,4F:2'92[^D_/7YN*FE9/,Q1Z0-I4P M`C;[E63"U7O7!B^^?O'W*RU8&^B'W;MLQ0RRD#W@+EQ$A.;NW'^N])*,.(II(@AA]]@9\7(\+;T59E)W:* M^Q]5O@(I2Y1\^1!(7'+')[0P(JSS%/2X("*$+(0ND$`@7,-="[TT76:U`E%" M3]H+*LOV>0K_\TT.PW2X("HB$>[Y>4KEE`8-]PLT-]N'HF=@D_5J9HC`QDD* MEO7!51&%T1GS[45;!\7D3R5!5*+?^)E!6O%T3&$.G"Q#4%+!=U MTCVW>8>,H0PNB9HV;;?$7.U=Q;0"=^#X]@9B'`A=5!Y05I:(/^,E+PM_R61E M7KG0=R0*@!45P`7DRAS1+"DOU_B3I?7YZP5W5+$8=,[,.H[.?4_&Y[/)9P(A M&2++R%V)VU5;F$J_CT8+F[HGYU//V4R:MZ\!'V!G$M/D6C=G*J,TD>H&(I@/ MJJNIX^8;$%A?,I)QY\6QRQU1W4?NR`H)[;X0*A92;D#S MG$>-UXNX/F"][#HYXWMQRGT(B?`BC%9E`"JZBLA#)E45Y:]-J)XA= M[N:(\JRY9U-XQCXCVJZC&5)+=XF3W=Q%07CA6':("Y*`?%D7L_Y0A37+KTKK MTQ`UWQ-[?_"A]$[UBH4=/@)`E5"=4!N;(`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`D&&5]JMV*?EAC.IHTK=LHLF(+Y+@8RO8 M$Y#4`J-B66+)N71B'G[9:!HLT:\>YG!(.XO1KNA8>?YJ+B`$-Y"YZ+,U265@ MZ2ROI)8I*[A`-"E/Z[O3M`A=O3]ZOJEO<"K`<5O#Q4'!^5_MLV\TN>O7?$C( M"!`J31ZF*\VS%^[4W=D^??DKQ"Q^]5W"F)DHK5K+`DDF5BEL?\&[7?J&P3W? M'T+M2.YUD_V[*/TNYP^@^E7A/_.%O&8H"8T7U.;14$IYZ!+RB@LB\%=WQ"15 M(DNST(TV99'>S-XI0FY"K#[S: M4UF-ZE6<32=]H8?B405`KELY;UI(VG-L"F*P+$79.#`,0S)4[K!/0-C$`)\# MF$Q^6<>T:W"0;[4P2>FR.I;:_&`!PXKS[>3EGZ69ME!2L0:Q&7<57](>7Q,S MJ2FJ;&8ZL<`VN6.?6E(&2(FO1\_.B?,NQ%*C)7R"0.9W9YT7\6]$2)&_HW2O) MI'U8!X8KH.I\T@``U;H"VMDPE'U_@_ZSC$@!J(IAJB#5S65&^_3=P/3&64@Y MC4^Q;$`XE9R//]V@RT'00VRDU-9BG4.T*"SAGX+Z(877"3;DXN\FY%#]+;R2 MH,D"M>(,N10UYH*[>&C?Z2*UWZW@=<5Y/A+(S(I`$AS40GW]6NK)E[1,Y;Q5 M4%Y[#2Y%,AJ.IF]`$/;V!C/^>H"O?U?N[RP%(SD(X!4NA1Q.TFM/#)."CQ$M MB%]0D4PD9#:9)#*PF5DJ8'I#GQ(Y<6+_?'5YCQU+#6N"64YA/ MX7-)7CM,5+&LX9,$`L$DD3A+%T^)H.@>AM<\)/)*RBR<@47,M1E#S#Y++BI\ M])!O9X"7`\008EXB*4_XODNT=B6KG%8^@]H-H]]`71R,#*__KAAZA/3U;^>6 MX63PXH'Q[:>!Y3\C)+F5?(?/U[B")D$UFE(9F"K#06P>!G!LR"-]TM6EJ1Y" MP'"(RW_+MQ2IF7>5:YO(2].:*M?+Z#QZP:]F^[$^-S_D*QIK]7^@!;,[*F/1 M(A`^1RQG?ICNHO#J;'DMPQ\V(]GU[Y0%`"^6JG"O*`$UGV3LJ#%<5 M7RWT7L*IC,6`!E!Q*%!\/[;*4Q\E8\MGI$9 MN?*B_+"X`&%8CO$(%M"(KJH'0O;VK19C(K$[=;_O%W_>V4R9K?/"X..=2W26#4@@%F1"`TSNP3 M4-4/&^2G'N&F^)33ZYAO/_/=HO+UIW[8`9[ZD^6_BKVEO%GW\-C"JI/KSZ)X M0@3L&^U"2+D($.BUNC`$7CYQ)5+1_S%K%'7LNY[JK#2B'_6M$[TX17K.]W>4 MBNE?Y3.S9=3Q-&1`?;J\)!LX*#]8W@L."#Y-13*'-2LT>00K/OJWP`.43_$Q MS*F4H4)]BF2MSBZ4-_Q6X#A)^@U/SRG]P,7(%]3.,!J6/^F"@^:!9HI67_4VVS3()*W>4%QB4BM$ICE3_ MUM.5'J`1=<]6F&#%$[[$6;[+/IQHA2WU[:#"`CL3$VNIJ&\`X5W0E[5G^NW9"Q[6='C"&HYZ5H$9P^S_2LZ1 M%:'M[V]<\1<8BF5SJI+N\O,;GT66294+=*7NND)]\AV&3UZ0ZQ5JU-[ON@#] MP>IN&:`00L@8A-($"?NJ9;4I=9Y[RWOG6U_RMUU_^"\!````__\#`%!+`P04 M``8`"````"$`M\%X&*\+``!@:@``#0```'AL+W-T>6QE<'6#G(L6:(J"EBB;.;ZH%'6Q$^2_=V;Y M-BN)Y%)<:EV@$7*6*.W,,\_,SLXNE^35-R^^IWUQHHT;!C-]<-[7-2=8A$LW M>)KI?WNPSB:ZMHGM8&E[8>#,]%=GHW]S_=O?7&WB5\_Y].PXL08B@LU,?X[C M]66OMUD\.[Z].0_73@#?K,+(MV/X&#WU-NO(L9<;;.1[/:/?O^CYMAOHB81+ M?R$BQ+>CS]OUV2+TUW;L/KJ>&[\R6;KF+RX_/`5A9#]Z`/5E8-J+3#;[L"?> M=Q=1N`E7\3F(ZX6KE;MP]E%.>],>2+J^"K:^Y<<;;1%N@WBF&_DA+?GFPW*F M7^A:8O(\7`*(/_QG&\9?_R[Y\^Y/[][U__W5U__\WEG^ZX<_[G_WPU=Z+U-# M9((/JF6>]RO%PM>)Y%YJP?75*@R((2.P!(]<7VU^UK[8'D3"`)$L0B^,M!@< M"J:P(X'M.\DOYK;G/D8N_FQE^Z[WFAPV\`"+@?1WO@L>P8.]1,-I]3PBFLRF M"<+@;!KB$6J3#R;9>+#:)OO'`S9QND;UNMKPQ^EB5E3;)4W7?ESL<=A&5^XK MHB=Z>ISIE@7I8M#O(ZW481TIF\[[H.]DRBY&)[-L:`VML53+N%C<]QLJ'%HR MJ:Q1:+T?WYZ,3OG*RJQ+T_"I>@!V.+DLNM!U*_KWV,+7*>+DQ`-:-QYC4KFD MS[H>R8W?:@^N#_4:T,Z-O5R`'2\F<^7X?'^LVX4BIU9@M465R[=[Y2?L^ M].T`+:?C.$-52L5^=;!K11FA6QK8QQ.*?FDMBIFW`;M=S\LKU:&)!1X5=`/5]$BKL=S6_?HKLUX'!'-]+?EK38!-Z[A)1/,U9 M49D.ZO.+.VM^Q_029!BP(BA*A%K6?-R!T+N;Z5P^TOET*ENH8<%+LM#W(WQ) M%FK!?W-IG*9IW90%,I>GQ2[.]_KGX^ET.AE<3":3J3DX1R.9TI*OV M*D&@R*L$@2*OLGE(3T+F3WL*K+XH[JL$@2*O$@2*O#J6G(''RKU*$"CR*D&@ MR*NL/I;85V%54W%?)0@4>94@4.15:<5GFH&GRKU*$"CR*D%P:J]FTZKYW9W% MUE+V*[/R^IA-NF#N^!A&2S@EE)WG&.#I@>38]97GK&*8IT;NTS/^C<,U_/L8 MQC&<0+F^6KKV4QC8'KSM92VROQ4MX103G$V:Z?&SN_@,RK@Y?H(W4=&5ACP3 MF5CAFV.S/S9'QD4RB9*DVG>6[M;?MR[7?3!6@$;DMMYPPF&0*TG#H5A:ZZ$7 M4O<)MF"N9IX6;``QD86$8`L9-A;+S*(VDA9B-I(&@C:2%J(V0M+R=@>CZ`9(=O[N?'P0!%2<,,STX2 M3/,3GFE(SC4(I[O#YM:*)U:#A&;#E;`-1(EPF^/X%19_`-*.MV6Y8L_EK?2D M5004)0O'\SYAF?"/55Z9P`+<]=7+BFR5@/TKN,$`=V+@6UA$3M\F54CR`2"6 M-3)*&VGV>NV]WF_]1R>RV*86IH(=M4!/\>F&E4_%Y_>>^Q3X#EM"U!,QWT5A M["QBMNF&G3`HPS,LP3-(!8G@::/?+-$//`GST48_+%$=="+PHE0_!)>P?IGQ M@-N+TJ`&%]"@KL(C$P$L1&0(P`DJ$.!VJ)0#"$\5"&""ER&``"T0`)R*J&C3 M#P8DFT$,%"I!?UEG5+J0.RB9-("MKGLR>DIDC^(+-I@#@[&SM5'L.(_=GF&3BU6D+6$QU(ATO7(S=!3WR4V2O'YP7F(HF9\->5JT, MK,%4Z(?U=5UKHEPZ/RVP"'BZAHA:R]FDOG9A?BIC#+EPKI+ M1XT661%VMJNS'"?24FD_E!N:!"'.Y?XW`.'Z9%6?S):`:L>3SBB#B^O?!L+2 M*'LS"$O##I=?WX27*8?#W=6&*H06.S_0*`IQ@Q)?9FIXU1&>>:DO=[L&VB2; ME&.IBSR>M:/Z,MNTQ39\5H;K!2GVX=Y)HFW?!'=IJLK\2VG8@PE@@GOX[3&3E0^C_"R71 MI:)2#FLH+)V7T,$@6\UJ,H""WI70?+0401-MTL?"1LI53G^E6][6\4KGXZ5L MU%5M+=+;&R]%F@S]7/51-_*WH*P.4VDVDX:I4?\FY2//4!?39&F5-S_:UXP# M?#U2FI-I7,=H/0FKZ9U\TNMP/.L^Y&F":[D$L=,+:L8X"1R>9B"IRRX2 M##F">`.R\DIHGF3!&4]<1:TYT4T#H2MB^514,ZYTV*T,/%_>+7DT6^?U3'*C M$='U-(ZMFHS4H%XXB"RY"94R9#]N-[&[>N7/`!PL]NEV"_%M!H?W6QS1,[*A MKJA>LR.4UL/(P84JSORSC5*P-8I<:,I?9IIOI-+P%IMP]^_^[[4S[?T"+:+(*+RBK\",P1&]'DIK(*/X+CJ"PPN:FLPH^`D,@R04E3684?P0M4 M%H1;4UFY'TUP')$U$N3^XJ`?^5C%W98BN*BLPH]\K`X%8Y7**OS(QRJ:W!17 MX4>02O@RX8NFL@H_\GG"%,P3U,;"CSSW(T'N=S,J'_&&8,0G4@K?P3O"$=;@ M(APE4@JO\5$^%(SR1$KA+SZ^3<'X3J04G@)YQ"(3OA"W*/?1D&?7%&3WQEYF M69WQ'BTS_8;F*<0!"#<(U22-*SL_BLS>'F$+D@OC_@ M,"HBZ.YE[=F!'8?1JX:GA7)QO--'@N*^#<.<(UZ"`1]%`/T9GI4"CV'1@)>$ M(3Z&L:QK(B;O"SP]>#EA$S'0.D'#QQ].P9N(@=:)&#ZI8OTD(N9#L-[F'N)S M*0[=(B(^NL%G9\E'#L\P3AY%)-T[VSBR\_CCNY0A2,P]WE(DE\&GB.26XMG] M3]+Z\Q[N()*1B.4^Z3NXC"\"_*_;F-"(K8@0W/XH(N3!C>%^5%DGYD0@+"$1 M(>SJST7L9!1!&7^WHP!["]=U=V*TQ*+B&@FH_IUE&.\Q/DV(W7@FGP\`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`'0?^P`(N]&4'>DH[./ZGQY6M[?'O;?!Y0J MR'?'MZ5*/-$TH@@Q\6R"\ASAM-!62OR3DK\;TOQ1[!Z)?KN/KZ/;T3=:,BLC M\X`R0B*S$FK9*+.Y!(4$I025!+4$C02M!)T$,PGF$BP\,"(?GAU)D_A;CE3R MRI'6!0\6>)[E?LVLA%7))2@D*"6H)*@E:"1H)>@DF$DPEV#A`>8U"F#?:S;* M%*:$Z4?9^)I[X\'(Z-RK@B@#D@,I@)1`*B`UD`9("Z0#,@,R![+P"?,5K49A[QI"^ M>.RWM,P0EY]R0^C+O%`3*[4`M1)(!:0.FDYX$FA`K072^81Y0C4P7J%@,[7" MW!.&>)XPQ/.$(=P3*1]N`6HED`I('30]X:8;4&N#:I=_C.,574 MA:J,3R^;U9>'/=J/)9[EY&* MX[-B;A4O=0$OYJ)`C=)JT""\KQ*YJT+%.JPH,Q,JMF%%D2,ZILC]J$K.D!]U M*C\*A<)>=0JE03'_)I%F*E2LPXHB032H MV(8518KHF")WHRI'/3=^E-I4'2IRFT$B3$6ZR8P4"U-M*]5A*M-A@1JE192H M79@F(KXK*^561&T15Q1+J;%23K&UB"N*A=%9J5Z1^U=5L)Y_S^E-5[:DZ):[ M1K&?WHR4"[%<-?%J`MPN45CDI$J#]$E97Z]4*%6C5(-2+4IU3(K?KRI"O?O] M,)YTTI$C<49*;T]3.]02YA9Y%?()LS4X-X%R6VG@(52X.2Z_/>4B&J4;&Q4K3% MN.TU$IFW=5(V^#NT-;-2;A!S1`NFR-P9_Z0OZ#F/.XL\=UKD=LG<(NY.D?<+ M*^442X-\=R*J4;&Q4MR=8L-HG=39G6AKYJ3\J1%[R-Q)65L+9HM[6'0B'VW5 M,78H!GW0UUI%Y]/<(LJC7J2)LK6P4DZQ-"BA8MU3%,5FY:2L'VJTU3@I9PL: MWM9)65L=VIHY*6<+NN"YD[*V%LP6GQ_5D`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`N&N`-5K^@Y\)PO3`_I;Z0: M):X*S&)`.:("48FH0E0C:A"UB#I$,T1S1`N&F*,2T59^E"]Z^;[=]-;EM=@G M'HP4ZX.B&['&,VO+Y>#<(EK]YV4/+4AAI7I%?CNBA[/SGF"O9M!$UT'Q.!*K M/S,"?H:SB.VXJ;BOPDKAZ;=JTT)AV7/>Q!M$]5W_H[-Q)+)'9G7<=I4;I/+* MV7MQ*FJ/@BER[_VD<4BP<3"(-@DS/'DD:`28][29E-7V\H%JP13Y\'Y2'2=8 M'1ODO"?F*+,ZOO>T&>Z]B:A-"Z;(AZ<*N$#.271AYR=G@YSWQ!QE1H!YS]2' MW'NBW"V8(A^>**$^7.E86M'.@3W'1"S^S$CY/8=59"W$1.SF!5/D8U?50,BU MNDI@KM6(CA'.Y5]BD->^&C3Q2A4FQ;_]H]U8_-R!3L:4F]BH-)K02-S*G$#& M,8I^4!I%^G"*B<@%A?W&7I&/76R$,.NBDJ!M$,9N=D/GJ\Q(T819)^>("D0E MH@I1C:A!U"+J$,T0S1$M&&(.I$>&P=#K.9]D@\B6]4J&*$=4("H158AJ1`VB M%E&':(9HCDB]:Z#B0]^C=I1^=T#_RGJ[/CROL_7KZW&PVG_=44AN9FJR0A<2INZ$K_6V1I M*[JF*_T9O;P2TQ4J.`/68AHS55AXA?K'J6H8\0HUB%/5$>(5Z@"GJN7#*_2J MQZ<^AP\).3B`/^4DOW0;3RDY/F`PL-D2K^QQ('2B1'= M=DB#SG_HMD-7Z#2';CMTA8XYR%KH>^C0@JR%KM`1!%D+7:$#<[(67C>[(Z#U_43 M+>MQ_V._@WXA2/]QTD_=!Y_W)WJ_AU(CO5U!+VZMZ<1\?$'%R]-^?[)_T'!' MYU?![O\/``#__P,`4$L#!!0`!@`(````(0#X)Y:M1P0```T-```9````>&PO M=V]R:W-H965TN49+1!-*[ M(^U*J]5>G@EQ$M2`(R"=GK_?,@Y@%SW:>>E.RL>'.J<*N[+Y_%Y7SIMHNU(V M6Y>NB.N(II"GLKELW;__>OD4NT[7Y\TIKV0CMNXWT;F?=S__M'G(]K6["M$[ MP-!T6_?:][>UYW7%5=1YMY(WT<#*6;9UWL/7]N)UMU;DIV%377F,D-"K\[)Q M-<.Z_1$.>3Z7AA^IWY>C-S#EP5]71:M[.2Y7P&=IQ-=:DZ\Q`.F MW>94@@)EN].*\];]0M<'REUOMQD,^J<4C\[X['17^?BE+4^_E8T`MZ%.J@)' M*5\5].M)A6"SM]C],E3@C]8YB7-^K_H_Y>-745ZN/90[4%L*6<&3X*]3EZH' M0'K^/OQ_E*?^NG5YN`HBPBD+7.:`Y[8W7+5:G0-O$\!SRPF2>!LH=!?%'S8 M!,EV$'W;L=C?>&_@4?'$[#4F0^UMQQ&A"H'Y#X) M`%.P`$ZF?-4JRA<1[S^`V(].-<(2%-J0;`EA-N*P1$0SB:6(6XI&YU54*1DM MVX^!V3(68Y\U)IHV93AP,`)6$KZ5Q-`7AJUJ%5K8*#'U9S5#2?<:XT_/3G$@ MPX&#$;"2@<8T:CPZHJ);%WR=^HP&R("]QL1#IU(:!2Q&=4DM!*%1R%"#9":" M,9\$N)T/)H(F+/*39*J^)22TA&!7U2IR-203D7958PQ7<2##@8,1L)*!AO[` M515%KH;(D;W&A-I50EF(334!B1\PI"(SUVD2<(;J=K``,??Y=PQ5%^E\?(V= MH:*V!A;C]M08K2'F,2'H&$M-0`1G+$>`S`30((X8P2HL!.>$1]^1D5@R<%^H M55L.C7!)-$;+27C"0J0W-0&@-@JP'!-`HY@%'%7M8"$"RF,:3]UI=1:%B]0H M"]8S+&-!*-_]$Z05,1X2BA"IC:!A'$93.L];1>6Q=36''\3$QQ6R.'S*PW@V MUI:D[I^YTQ:2]/5D'D8L1NGLJ0;I="@CV.#4!@0!F9-Y"C(96,`6[XW%P"DQ M3F5;CKJ.9CGCBT/U+67*H(LWYPG2ARIC/,&(U$80L!75+K,0/H=C&3>;A>`Q M"_E<.UN*NL)F*8O*Z!O.E,3BN6_UJ0HSHFH4?SC1X.VP^RB=EL?+-UM$U)BI M*:8!14^->MJJ17L1J:BJSBGDO8$;*X!G35$]K>[I&B8CV(_BF9IB/XBG;)T. MPRW&LS5<]$N>`UO#?:_RFS;`C'K++^+WO+V43>=4X@RID54$-UJKQUG]I9>W M88PZRAZFT^'C%7YV")C=R`K`9RG[\8MZP/1#9OM_8DN]&G"*V[FJ!HMBVSXJMQ$)LRY"4S>Z_[U`D M)9)'2;TOZ_CSG"%Y-+Q(VOO?OI]/UK>\JHORLK&=N[%MY9=]>2@N+QO[[Z_! MEZ5MU4UV.62G\I)O[!]Y;?_V\.LO]^]E]5H?\[RQ*,.EWMC'IKFN1Z-Z?\S/ M67U77O,+_?)<5N>LH:_5RZB^5GEV:$7GT\@=C^>CV\OR7=.:M>WZY?]N7Y2BF>BE/1_&B3VM9Y MOXY?+F65/9UHW-^=:;:7N=LOD/Y<[*NR+I^;.THWXAW%,:]&JQ%E>K@_%#0" M9KM5Y<\;^]%9I^[$'CW=T$!=/:UOZM;LKSOSS($:EXDHE(0I\B MB3._8=$`^(#R0`$@*)@,1`$B"I2K31TS*GCEY6/\,T4TBF ME/_2/FLR[:M@!\8#X0`(@(9`(2`PD`9*J1!LV+=+JL,5J<+<@WAR+_>NV M;#<8:0<+;^V01;P5I-WQVIF]$Z0O`H^3"15>9Z(S&^LF^EV03!T`"8%$0&(@ M"9"4$[[G:G;0WJ/:(8?-L#YL091A"Z(,FY.)6CO.S%@8_2ZH&S:04*1>=?45 M=3&JHZ[N:-P%R=0)D%2D;GNM.4$+_I`3#.M."*(X(8CB!"<3JD*E`"9Z=_TN M2'8W`!)"ZJB+^21UW`7)U`F05$VM.<&.W;AA?CA%6+CND""*0X(H#G%B3)&I MX5`7)(<1``DA==3%J`X9J>,N2*9.@*1J:LTA.@?]C$,L7'=($,4A012'.''9 MAD1'D+$S,\P1BGZ2!*;"&',(;42FPF@CAC824V&TD:IM:)ZQ(Z!JFEQJ6JZ[ M(Y!+9Q=E^AA]V\DHMULE/(GT%H+950OC"32A<9^&"RL+?LT$OUYTX[M!.(TLLH3T;U M%>AC5(!1(49%&!5C5()1J1:ECY>=XH;&RT]WVG@YTLMG;FR_.T=$]=?$DZ@_ MU_@2]5&!1'U4*%$?%4G41\42]5&)1'U4*E$;I5M`M3)H`>/&#.*(+KDR@^;& M5KQCISPF5*M`"&ESZ*?>W-AH?10&`KFZT-CR0A1&PT)C68E1F`P+C54BU82Z MG>R,J%34_QT%'7ZFI(1RSFP%,BK-6&]V,JJ_[IY$M,,H-AOKC2^C>F$@D2XT MUIM01O7"2")=:*PWL8SJA8E$FG!AS*941K5"W69V]C1M;LMDX+A-)U0H98[T M4EY`*0NA6LI"2#M2[_$"2AF$@>B$JPNAE$$8#0NAE$&8#`NAE%6A[C$[U=[L ML3@"JW7,D5['"ZAC$=47A^=P1'?-JL=0QR`,AH50QR",AH50QR!,!H5+J&-5 MJ'O,SLLW>RP.UZK''.EUO(0Z%D*UCH50*\#HLW=CZ.]%)>0BF+*+64.9IHA\XEE#((`]$)0PBE M#,)H6`BE#,)D4+B"4E:%NLWLD&Z6LFKSU_)*KG9/PAP6;]C,D?H(2$0IR$/D M(PH0A8@B1#&B!%&J( M'CQ$/J(`48@H0A0C2A"E&M+=^>`.@TTMHQH$4B[]#I&'R$<4(`H118AB1`FB M5$/Z>#^XPW#Q#D,@XY(;2_*NC^HO.<^E&.5C5(`H1!0ABA$EB%(-Z1:PT[^R M,,B;2GHY")>+CY:\J^6NB MGC^T^8O`MO55MWTR: MW*5$[!["Y-1`>UXP^..4\@_]L)VNZ3GW0")G12VW%\9(M77'U'9[MH!?V#O@ MX>ZR_@YUV)NMZ5$SMN_-UT%[0VNT$?R*/%FAY;(O>6:WH. MB#Q:KNDA'O%1US"]7+YF+_D?6?527&KKE#_3Y1VWYXF*OX?F7QJ^X5E/94.O ME=G>9QWI_POD]$9GS+:#Y[)LY!?60/<_$![^`P``__\#`%!+`P04``8`"``` M`"$`MT#'-W<"``#Q!0``&````'AL+W=O11AQQ70F5)'BGS^V=P\864=51BNM>(K? MN,6/JX\?EB=M]K;DW"$@*)OBTKEZ08AE)9?4CG3-%?S)M9'4P=(4Q-:&TZS9 M)"LRCJ)[(JE0.!`6YCT,G>>"\2?-#I(K%R"&5]1!_+84M3W3)'L/3E*S/]1W M3,L:$#M1"??60#&2;/%<*&WHKH)SO\8)96=VL^CAI6!&6YV[$>!("+1_YCF9 M$R"MEIF`$_BT(\/S%*_CQ>8!D]6RR<\OP4_VZAO94I\^&Y%]%8I#LJ%,O@`[ MK??>]#GS$FPFO=W;I@#?#,IX3@^5^ZY/7[@H2@?5GOHM3%?@"9Y("M\"<'+Z MVKQ/(G-EBB?Q:!9'\\ELBM&.6[<5?B]&[&"=EK^#4=RB`F3<0N!]AD2CZ2R: MQ./_0D@(J#G($W5TM33ZA*`YP*6MJ6^U>#&&!#(OKKV:XAE&$)0%];B*D\F2 M'"$7K+79!!MX7FPZ"P+TS@7$.^#"J]Z%3Y;WN0G"-6\\S)L,\KP*:;T.IQ=R ML$F:FEY'F-P042CC"$ISSH+5A=AEHE>L4Q$DRG(3[ M0:97;YFM$OKX^LQ0W(&@O'H+:!68C4N=D^EP4/Y:ZS>35V^9K3*^%"*,6.A, MR4W!/_&JLHCI@P*WOC$[M9OL=;/_;SU9K)N))]T/&,2:%OR%FD(HBRJ>`S+R MY44FS&Q8.%U#F#".VL$(-I\E7*T^%NANZQ7?P```/__`P!0 M2P,$%``&``@````A`)C]?39U`@``\`4``!@```!X;"]W;W)KO#P_ED??TD._3(C15:E3A+4HRX8KH2JBGQC^]W9Y<8 M64=513NM>(F?N<77F_?OU@=M'FS+N4-`4+;$K7/]BA#+6BZI373/%?RIM9'4 MP=(TQ/:&TRILDAW)TW1))!4*1\+*O(6AZUHP?JO97G+E(L3PCCKPW[:BMT>: M9&_!26H>]OT9T[('Q$YTPCT'*$:2K>X;I0W==1#W4U90=F2'Q0E>"F:TU;5+ M`$>BHZ!-[RLOP69RLOLN%."K016OZ;YSW_3A$Q=-ZZ#:"[^%Z0Y. M@B>2PK<`1$Z?POL@*M>6."^2K$B7^0*C';?N3OBM&+&]=5K^BC;90(J,?&#` M>V"<+Y/%17J>_1]"HC\ACEOJZ&9M]`%!;\"1MJ>^T[)5#OEC7MQZM<07&(%3 M%M3'#?BZ)H^0"C;8W$0;>+[8C!8$Z.,1X._,$5[U1_A<^3-OHC#EY?.\\UF> M5TL,SQ=W3ER.-D4HZ=3#8I;H54C+OY.R3*1/J.A.U5P-S#'M0IG%G138? M^7*6Z=77S$$Y=0HJ.G$*A7;-%LEB++PW>,T:%!B-26+_4AE_JYTVDU=?,P_ M`0``__\#`%!+`P04``8`"````"$`X-T.UYL"``"6!@``&````'AL+W=OVSK-`3UT:H.L51$&+$:Z8R M41']N_U%Z4=3(8267 MU`2JX36\R966U,*C+HAI-*=9NTA6)`[#%9%4U-@3=OHM#)7G@O%[QV`]\TRGA.SY7]KBZ? MN"A*"^U.W!*F*M@)KD@*=P8@=?K<_EY$9DNXVP:;)%FN-NL$HQ,W]D&XQ1BQ ML[%*_NZB.I:GQ!T%?CO*8A4DZW`1Q?^%$.^HS>2>6GK8:W5!<#Q@2]-0=]BB M70PE9$X\.C7%:XS`E`'UZ1`M5GOR!,5@7;P%^9[9PJMO" M5>>%(2^>YRUF>4Y-,5Q?[4PL^YAEV]2AP^4LT:E0EG\CNR!_4(9,:,E, MUDYMF7W:G3+,.UJLYS-?S3*=.F9VRM04='1@"KD#&R=)`(?PVGD7,89U"GP= M@\INY@VZR38]34X=,SME:G`[`K0&HV74NW.OQZ1.&;O;SKN#63!GKY7'U*L4 MOQX5/P7\MR.Y+O@'7E4&,76N717!8J_VT^?8KO];7^Z.?BJ1_@T,BX86_"O5 MA:@-JG@.S-#U!6D_5_R#50T8A8FA+$R)]K:$^<_A^PD#",Z5LM<'-[GZ?Y3# M'P```/__`P!02P,$%``&``@````A`"`'=-H-!@``MQ8``!@```!X;"]W;W)K MJ.S>V\#__Z\_/#-@R&L;P=RVMWJ_?A]WH(/QQ^_FGWVO7?ADM=CX&T MWY2A_]N?U<._K\J@7M=OQROG5]^725<;^QN*PFV_K'PGS;5'TW=*=Q)@R MYFR=K:6EP^[8R`A4VH.^/NW#C^RQ$%FX/NQT@OYNZM?!^3L8+MWK+WUS_*VY MU3+;LDZJ`D]=]TU!OQS5D%R\7JS^K"OP>Q\*J'\7.CUH9!]3R,7?L/ M@)@Q!4:X,2(D33//5RR.-O]O8PU\=!R?RK$\[/KN-9#-(3T.]U*U&GN4=DT` MAL40B]KI0H_M0$K7YBQ+B`C!;J$`:981"@>8%Y^F\'A&0O>?$J*L?)W/" MU2R-U28+8@6,$ZLS@%QMD*LIG6H4Q[J-9JK@`2`;"%5P06I>H'F6"9L*Y%_V MHQ/JY%^-8O\LLKD"`H")-8&'.";\"I@&?DGV7C/)#0AZZH%'/+9-K3-28`1[?X&B!)F`:I;Z[7[D-#@Z4I24=!`''L M;%Z<#+_2L:74<5L]4WO`0.W)WBB,`=,8V\3*)':/=6[:??*DIEO`$4KC?M(S M==9E\2(#[O36*@=V[]<^MA0_00+,#<8$*&]WM//!AF<>,_"K'UO*G[`I-`E` M\K=L`33M\,?^_?+'0+[PGB.MGAN0N^5.(*'NGZ!SKWM1S>ICJ'>UY`S(S,$G M=<1%KM?N0R?M[@AV@Z6.IIW[),\RAC8SH$EKDE38\\3$#&8,(HUB:P*SP8JW M8.-3/N(KYP":ME5">K*@\^]1\7\H>XV1GYP8T)R3+B#P7&)&*R+813HA? M_=1'@[P`H,VWO%!/^J8^:?1=UBS3?8'=^%6.+U6.<7*`YP8TYYLT8T'F8YL* M3,$OZ.3EI+]R#B#P MQ9*,JG*!`6GD%`Z3P8HX*X!'"6G`.0<0%&5#:U:@:7DYF$\F1$#>L'SW#SU, M9'!Q]!N0R8*(4EH2#(@CAR,F@760ED2`'N*2V'B@/PP(R*2;A3RA^4W"WY$$ MH53,WL<65$#D,!5KRE`!D,E+FM`OED([FP`9"IO$N7&9=+N`;+NQ?8PY8*G4?>A\^@M0 M0W0X.()GN`#(S;HS@MUA49QT2'C$T/F`-VZ0&&9.1"9B=S[)G+<23,$OA?)Y MD'X$,"JWN0&9]Q;F?&<8"F`$YC/G+`<&\'X([VYMW9_KHKY>AZ#JGF_ZT>^P MFT?AW3*7[Y;Z[6\]3\C7Q'MYKK^6_;FY#<&U/LFET2J5?=O#PR/\&+N[?B1[ MZD;YCJC_O,@'XEJ^0T4K"3YUW3C]4/?G^&PO=V]R:W-H965T__K)]X.Z-7!&B%F1HR[K=/)6YND.)8U17]WB>UK:;L[%:'SCO[X&UR+["=_;8OT-\5 M>A#I?XM<\2/OJM/O58N@VM`GUH$CQF\L],N)04!V#';6=^#/SCJA!+\M9J*S0!8+S[ZZZ,ZT>O.#A:S^=(-/']N6T=$:%8Q MKFV5=T)Q\P\/\D0JGL072>`JDOB+E\FA(,-5D->SU7P>+E;+UQ7`XWH;@H4N9@>1R:L48.)",#088VAL84D8"D=0*1%(K M$-AS)+6A:CL50>MQ##,#R>74BEI8#IZH9:BJ5B"26H%(:@4"%TEMH*DU:-DS MVGJETG*9IAB`Y40R(-:@'\X1BU:-"40R)A#)F$"6?,UR/>WU20U&IC.TGN4R M0['#CA?3DCI,#T-5V1SQP['IL8B9C"0<"2(B2>BR@0&WR0BU6:A*SY\2E2LP5HNJ9[9G_X?DKOD%; MIY,*WV(5SQP*%N/$QIX!)2:4FE!F0KD"J=+9%CI)'Y8$MA=J+YZ`@FDGB$TH M,:'4A#(38J=Q]D2>GDODIVM^)FQ0=T$QJFMBE?C>PKN_@GJ.*#_5)^$&]E+8 M`S4<3ON'?DXT/&)?`4_B(W\#QR`S3Q1LX,AAXH=P@,/MU^N^GX-P2_H7R>K".F\$G`1LNZPK<>@J.5 M.X/-^(PQ'6[@T<[X];C_%P``__\#`%!+`P04``8`"````"$`OMT[A$\)``#K M*P``&````'AL+W=O8_V#X M?6)+BJ](,DBLNW:!Q6)V]]EQE,1HVPHLI=/][[??[;SN>UM/)NWNM3YNVZOFK3[1EN?F M?-QV].?Y9=*^G>OM4R\Z'B;A=#J?'+?[TUB.L#Y?,D;S_+S?U7&S>S_6ITX. M[<],VS]T5#3>1!XHYKR:K"8UT=_.TIPR$[:-S M_7P[O@_6512-)W:W*9Y$C/PV#3?1&CQ M)!"))Z!.^QGXUWGT5#]OWP_=OYN/O-Z_O'8TW3,AV34'VA/].SKN10U0ZML? MM^.0]K!_ZEYOQ]'\:K:81D$X&X\>Z[9+]T(['NW>VZXY_D\&!6HH.4BD!J%? M-4BPNEH$TU6TH$$^$5XK(?UJX>)J.9M=SY=?*&G<_KCI5RLOV^5<">E7"R_< MY4(IZ5N--`UX3XC]9^ MNMN)+*J^&.-MM[V[.3L=$1HMK%L+$+$A>D+LAMB3VU`*)@21`4B`9 MD!Q(`:0$4MF$Y4A39>?8+_3A[(H\D5=_7.J%@J0>2`$F!9$!R(`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`*@5]5R8N'NZ42V0EMU%1%HH1 M)8A21!FB'%&!J$14,<3SI3;&FZ_@SH(MD3/ESKJ["8#DHY)2#7?E\,\^O0%DGARZ7HA MD5,.3H^T44++L1A1@BA%E"'*$16(2D050]P>T9Q9]@SEH)HVZZY!/+0G5R+S M?'"#*$:4($H198AR1`6B$I'X[LT7>E,?#NUHU[R?Z!Z( MEL^[FP'+#^@>PM5:K#-T9KM;HBE]6]?W[+!%?'77?[H&6T+:TC>@L"727^JY M6^@`O/L/:/_R79:K"&=TS/TS/=@RIRW]@R?8LJ`M_;<_L&5)6_IWA\X6^KCP MWIL+I>_-GI+WQHO4/0[?7Z_O:1(]UE^OZ>L/#Z>\O6E3UMZD*6=ORI2Q+V%Z M-[@6K^9PSW$0KE-Z%X5;Z&T7:7Q;XB`BC2\_>A=$&M^6.+@FC2]W>B-"FG[+ M9)@G^@+S;?M2_W-[?MF?VM&A?J8RG_;+WEE^K"G_Z&3O/WIL.OKV4MP&C%[I MH]J:WDM-Q<<5STW3Z3\HQ[=_P$``/__`P!02P,$%``&``@````A`'>, MP>&2#```1#T``!D```!X;"]W;W)K&ULE)O;;N-( M#H;O%]AW,'P_<21+Z<1(,NA8YX.Q6,SN7KL=)S$ZC@/;/3WS]LN2BJXB?^70 M-^WT5R158K%8I&1?__[7]GGTYWI_V.Q>;L;!V?EXM'Y9[>XW+X\WX__\D?UV M.1X=CLN7^^7S[F5],_Y[?1C_?OO/?US_W.V_'Y[6Z^.(++P<;L9/Q^/K;#(Y MK)[6V^7A;/>Z?J&1A]U^NSS2?_>/D\/K?KV\[Y2VSY/P_/QBLEUN7L:]A=G^ M,S9V#P^;U3K9K7YLUR_'WLA^_;P\TOP/3YO7`UO;KCYC;KOWN/V!^NUGM=X?=P_&,S$WZ MB>(]7TVN)F3I]OI^0W=@W#[:KQ]NQE^#V2**QY/;Z\Y!_]VL?QZ\OT>'I]W/ M?+^Y;S8O:_(VK9-9@6^[W7#[^>_>S6&\> MGXZTW-WU5KMGNA+].]IN3`S0K2__ZCY_;NZ/3_37Q5EX&0?Q11B/1]_6AV.V M,K'X;C;_L]*FT[4Z0]V$V1 M/JU".#V+POC+Y4?>O+*:]&DUIV>7<1Q=7'YY?QD""K`^#$RD]2L\G7[J]H)3 M!-$??(.?6\.`P\;\P5?]Y(0Y<`(O[ MGR-*7'2GA]>E28/!S%BSN\LNZFF_T;9?&?&O1OYF3`%`&^E`],_;\/SR>O(G M;>"5E;E#F4!*S%G";#QC-M$@U2#3(->@T*#4H-*@UJ#1H-5@X8$)^?#D2%KW M7W*DD3>.9!?<,?`\J[S&$JR2:)!JD&F0:U!H4&I0:5!KT&C0:K#P@/`:Q;GO M-8XR@V_&].\[469E^I/`!-$<2`(D!9(!R8$40$H@%9`:2`.D!;+PB?`5[@41D!2(!F0'$@!I`12`:F!-$!:(`N?"&>9CLNK)3B9&RR=U1,_C(`D M0%(@&9`<2`&D!%(!J8$T0%H@"Y\(SU`5.^09@Z5G>A+3ATOF@:Z>3D*G,`*2 M`LF`Y$`*("60"D@-I`'2`EGX1#C+5/!#WNJX=)=%?B0A2A"EB#)$.:("48FH M0E0C:A"UB!8"24>96G1@PYD^1L45HZ[5[DKN.2-70"6,9!8+919+6,I.*%5*Q9JE.4CC*5IN)E^A4(YFRE%/,&$E% M5:_E+.44"T:^8A"K$[ID*:=8,?(5PU`IUBS5*4HWFQK5%X4DQL2BZL$\@9,"EJ)&Q!J5&%W"A2FTY*A;#BI"T8([5L*)* M&[6XHO0C[>M!/QJNCL$>13)$50J9!U;1Q4W"*.[\J!12'G4*F46AO)+*.3DJ M%L.**E.4J%@-*ZI,40M%Z4::JN_&#[.I`J5*E*I0JA92\GY-W>K=[X?QU->Y M(NWU2,;35*64>=!+B7BRBNXQ3HI2F441^=&+(95X*91.E4@G+V/+(K\30)0@2A%EB')$!:(2486H1M0@:A$M M!)(.?*,3"+$3L$BVF%.5B.=.B@_K!%&**$.4(RH0E8@J1#6B!E&+:"&0]-T; M_0)M/)W`+!)!UDMY*$&I%%&&*$=4("H158AJ1`VB%M%"(.DH4\9[F8\+V="6 M]UYAQ\@E[#DCE]831E27N$05J*,G92FGF%DTO3Q5A#FB`A5+EJ(ZV[NBRKR5 MD^+@K]%6PU)N$BVBA5"4[GRC+Z#C$>+.(M^=%CFO)*PHW:GR?LI23C&S2+BS M-^^A`A5+5B1ASYWJP*B?3A!%5@)YK5-F:LI13S"R:4E[Q%%6QF3LI]D.!MDHG MY6Q!SULY*;95HZW&23E;T`:W3HIM+80MN3ZF(?'6YY10;*/B)Y0>15>G'3\/ MK93S7<+(2:6,G%1F41R<;.6("E0L4:I"5*-B@U(MHH50E(XR?<20H_K^PJ\M M36=&,2QK2VBIK13E>EZFA!7?:*E1(W/(BXBI"O&<[;[;>!?.%D^H=.@=\]6@ M^:G:+K6SQ>8;A]XQWPZ:CU0_MG"VR+Q<.=/,#*V<;7+\$._1!TU\:!7=49`P MZIMX=9BE/.H4,HMBD6)"E6IS)\4^*]!6Z:0\-T:J[ZR<%-NJT5;CI'Q;JAYH MG13;6@A;TO^F8_+\_^$1T'=88D?9IHL.!Y>00Q5A\["7$CO**K[1_:-&9E$L M'J="]^^DV`$%VBJ=E#?M2$5'Y:385HVV&B?EVU*51>NDV-9"V!(+,U4M'^?^ MCLO6SB(ZY]GNG*5<4">,7*)/&3FIS*+8V-Z!49E%,*^HV")P#;(ORER>E8JA`\^6G MS%>#YB-5BM9HOOF4^7;8O$J9"V%>KJ)I$]_+0^H)ARG_5"EJT86+YCFB!%&* M*$.4(RH0E8@J1#6B!E&+:"&0=*!J/KMM$,9GE)7[[Y_B5Q6GV)=:1-VZ%X21 M?OCAI#CA)(A21!FB'%&!J$14(:H1-8A:1`N!I%M-(^;%Y2D-VP;-JT^F/?*> M=,P1)8A21!FB'%&!J$14(:H1-8A:1`N!I*-^L9><8B]ID>@E@RM5+\]9T9UC M"2._EX0V+F6I3E'.W71*0XML.RA_D7L4][5D>!ZH##HW6X<2DS@E+!)52Z3N M*Q6*H##QG'9X.GDC5;ZE0E-,S%?>0 M]VPE[GNO1W30]E^,UF]\YO0\!;QG=41_I-]+IT)13L]4F4/3ZZM/OY*=VH+T MY#VU1G,KX'T?(K%(>B]6]7TJ%,7TZ`7-X/0Z+NL\BYSWU!K-K8`?>ZPCO:=: MAE0HRNG]8G45875ED>S;8E5HSUG1"TQ6%&U8K"JB5"C*N:N:@G-WA+6#1?00 MG$^T.2/O$8!%L5?N"2EY]:$#.8C?_/:(27MJ-UL4BYT9ZXS#BK[G>ELQ;1VW MI:0=D@BA%E"'*$16(2D05HAI1@ZA% MM!!(.E"=AJ?0PU//=!VT[I0A7.@!2E`J190ARA$5B$I$%:(:48.H161^_N;N ML7=4_W.V_JB2DG]CU M>Q=&0AKIMK`>F=((E=/D=!B9TDAW:L%(1"-=:ZQ'(AJAHC9^9OAU' MJ$^?F<8<1^CWC5\'_4B+TN53[2NS)`-V[HS;!_C7:/:5`@@O?&=\/L0I3H;D MZ;G>S#RU0TOTE&YFGL'A"#USFYDG:CA"#Z/(VM"2T*,ELC8T0@^*R-K0"+W6 M(&M#LZ:7%&1M:(1>.9"UH1%ZA$_6AL*.GM&3M:$1>@A/UH9&Z'4B61M:&GI? M2-:&1NCM'UD;&J&W:61M:-WH=1E9&QJAEU]DK1N9G**)?MKZNGQ/U#B.._.UWW_*]C^/\?^NQ&C;[LC_:;5?$UB]$2_5E[3+Z+.37O\L-L= M^3^TS)/3[Y]O_P\``/__`P!02P,$%``&``@````A`.4\?F$R`P``S@D``!D` M``!X;"]W;W)K&ULC%9;;YLP%'Z?M/]@^;V`24(N M"JG:5=TF;=(T[?+L@`E6`2/;:=I_OV-#"!=G[0N7C^//W[GYL+U]*0OTS*3B MHHHQ\0*,6)6(E%>'&/_^]7BSPDAI6J6T$!6+\2M3^';W\-)4'7]62T=0N*@L_#(+(+RFO<,.PD>_A M$%G&$_8@DF/)*MV02%90#?I5SFMU9BN3]]"55#X=ZYM$E#50['G!]:LEQ:A, M-E\/E9!T7X#?+V1.DS.W?9G0ESR10HE,>T#G-T*G/J_]M0],NVW*P0,3=B19 M%N,[LKD/`^SOMC9`?S@[J=XS4KDX?98\_<8K!M&&/)D,[(5X,J9?4P/!8G^R M^M%FX(=$*D+XX=<0[H79DDB"M@)KJCDI@;`=?IB[R>>ZAR>5AZ9 M!U&XP&C/E'[D9BE&R5%I4?YM;5JFAB-L.>#>(D1B%*`/N_":+7UGR$426MSW]C`M;,A MG84/[-T6H->QA4'-%B969L_[!NCSA6Z^F9//H#&&:R=G*KFQF=N4]A7.G8P& MA;#\G[(U:LJDSPEY=7AM4,O9N=TB`[^CM=OSR,EIT"%GBTQ%049[HI`MU_4E M[>;SD*E%H#$N85T&;G7F4)N6DD&'G"TR5;<>$%AUX8IX4-WGNC060[(6&0J\ M4H@$K!P*+3QD/4-3C<24_<7+1N0LZ(NT)B,^LPJ@HM1*%LH&I3B$RI'-/&Y>M*A! M*,Q:H6&^VL<<_IL83)X``H4R(?3YQ6S0_8GM_@$``/__`P!02P,$%``&``@` M```A`)C5'E;W`@``@0@``!D```!X;"]W;W)K&UL MC%9=;YLP%'V?M/]@^;TQD(0L44B5KNI6:9.F:1_/#ABP"AC93M/^^UW;Q`F! M='V!^'!]?.ZGL[Y]J2OTS*3BHDEP.`DP8DTJ,MX4"?[]Z^'F$T9*TR:CE6A8 M@E^9PK>;CQ_6!R&?5,F81L#0J`276K4-=@PK^1X.D><\9?LT8Y$LHIJT*]*WJHC6YV^AZZF M\FG?WJ2B;H%BQRNN7RTI1G6Z>BP:(>FN`K]?PAE-C]QV,:"O>2J%$KF>`!UQ M0H<^+\F2`--FG7'PP(0=298G>!NN[L(8D\W:!N@/9P=U]ANI4AR^2)Y]XPV# M:$.>3`9V0CP9T\?,0+"9#'8_V`S\D"AC.=U7^JVZVI**"D^") M:FYJ`%RG+_9]X)DN$QS-)^$LB*,Y1CNF]`,W6S%*]TJ+^J^S"3LFQQ%U'/#N M.*;Q9+X(IN'_28C38_VXIYINUE(<$!0''*E::DHM7$40P-2`6X,F>($1B%*` M/F^6BS5YADBDG@V)G,;$+/!C MG`;M+N<^Z,>AS=0CTA0]K%$_'\V)FVK"2#-KG[)"A MOF6/8$2?,>AS=4A?WVQ<7PA6(P(MW&<]0D.)H:GZDY,C&JW%!9W9!%!?Y?R* MRO%V";OVF)X:Y@B-J#25_K9*UPM0W;X43:4/5<975([W3.B;YD1[M4=@3@Y4 M+@-?C/;S12"[=ND'\C28>F,'QOXYO9]LPX:QEG!2=)H,;N"[05DS6;#/K*H4 M2L6^@48P<]*C_J+9VOV7^&RU=1<0\5_@7FAIP;Y36?!&H8KEP!F81D3272%N MH44+JN!Z$!JN!/NSA*N>P;0,)F"<"Z&/"X@W\7\>-O\```#__P,`4$L#!!0` M!@`(````(0#G5L^0-@4````3```9````>&PO=V]R:W-H965TUUR^0+978W-DI8T419ODF<%M&XVA+6#&L_\^ MU1=T4\@S^[*LOZDJZNJN;C9?WZNK]4::MJ3UUO9FKFV1NJ#'LCYO[7]^I%_6 MMM5V>7W,K[0F6_LG:>VON]]_V]QI\])>".DLL%"W6_O2=;?(<=KB0JJ\G=$; MJ>$O)]I4>0<_F[/3WAJ2'[E2=75\UUTZ55[6MK`0-9^Q04^GLB`Q+5XK4G?" M2$.N>0?^MY?RUBIK5?$9O+S>OA2TNH&)Y_):=C^Y4=NJBNC;N:9-_GR% MN-^]>5XHV_P',E^514-;>NIF8,X1CN*80R=TP-)N&0-E!VBFOP%^- M=22G_/7:_4WO?Y#R?.F@W`NF4M`KO`G^M:J2]0"$GK_SY[T\=I>M';BSN;]8 MK3U_85O/I.W2DBG;5O':=K3Z3TAYTI:PXDLK\%16EK/%R@VXD0>*@52$IU3T MUC-_O?`62_;Z!YISJ0E/I1G.5IX;!JO'BO!7'C$\E>(G7[F4FO!4FN',F[L? MN;J2>O!4>H_?Z(@B\>+&>9?O-@V]6[!BH`KM+6?KSXO`FJRJ3%-?9VBW@DD_ M,?&M#8)0P!;HV\X+%QOG#1JGD#+["1E3XJ`D6/,PL_$8)&.0CD&F`0=BZ0." MAOF5@)@X"TBYLE=@B-`?>:\DE$H\!LD8I&.0:<#P'KI6\UYEG5%81@^S+F7$ MBF1)/2`2(Y(@DB*2Z<1P%A;*A+.,0C>!UH,>$4+!LL_[`9$8D021%)%,)X:W ML#HGO&64>ZNJN1J!7DBIQ8@DB*2(9#HQO(4=8<);1DUO!=$3B4B, M2()(BDBF$\,UR(SFFM@REHO9L$GB;8.IF'X+`G[K7;(:9;D7ZK.,2()(BDBF M$R,4=C@9=C^UW!@UO14DX..5[U@'1&)$$D121#*=&*Z%AFMR8^9)[BYE\;*G M?(0JEYFTZ;(D?*@+ER49=HA8D``VHV&I+ERS"$DOI(J0(I+IIHTH/#AG3&28 M8]-?A32'%=(\5@C2IKD\'[FLI,)^>TDQRA3BYDVOV7#!?>&)F0-;FTK%7B'= M:RFE>RV1T>V+8.PU4DR5>4,Q7)N*F9*:"(3-F2&0C[K($V/)"%`B/4")]``E M6O$C@>]ZHS-!HBP/.JE"OJ9@9BF9L;&H-L7W856+(&3$+!&498O;=\4$+KA>\GD-98HGF MT&]]LGP7K22DF$XKHI;3%"2S^_O*"_@`J\&^O$800# M''/X?O#$FPY9`D,3\GL_@EL,MK,/(K@Q8/XTCYXF'=K/(SBT8X7](H+C\01? M1G`VG>"0"YX*IX\`/DO<\C/Y,V_.9=U:5W*"!+O\$-6(+QCB1R<:V7JF'7R/ M8#UM7>!+$X%;E#N#+>%$::=^P(N=_MO5[G\```#__P,`4$L#!!0`!@`(```` M(0`?BTD\=0(``/`%```9````>&PO=V]R:W-H965T:VPWMT9QJF15MTJK-$V[/!.,;10#%I"F_?8[@.LFBS?U MQ39_'WZ<*ZO;9]FB)VZLT*K`69)BQ!73I5!U@7_^N+]:8&0=525MM>(%?N$6 MWZX_?E@=M=G;AG.'@*!L@1OGNB4AEC5<4IOHCBOX4VDCJ8.EJ8GM#*=EV"1; MDJ?IC$@J%(Z$I7D/0U>58/Q.LX/DRD6(X2UUX+]M1&=?:9*]!R>IV1^Z*Z9E M!XB=:(5["5",)%L^U$H;NFLA[N=L0MDK.RPN\%(PHZVN7`(X$AV]C/F&W!`@ MK5>E@`A\VI'A58$WV7*[P&2]"OGY)?C1GGPCV^CC9R/*KT)Q2#:4R1=@I_7> MFSZ47H+-Y&+W?2C`-X-*7M%#Z[[KXQ)9-\.E]D^12C';?N7OC-&+&#=5K^CE99SXJ4O*?`NZ=<8@5,6U*=U/KU9D2=( M!NMMMM$&GH---E@0H`]'@+\C1WC5'^&SY<_<1N&4EX_SKD=Y7BTP/`=W+EV. M-I-0U%,/)Z-$KT):_H_LC6*CG#*AKB-1>S4PA[![Y2SN63H>^6R4Z=5S9J]< M.@45/7$*A8:=9$/9_>]S4J_`:+RE=?:/.OM;[;*5O'K.[)7\K0QQPF)?2FYJ M_HFWK45,'Q0\ MFSBR<>%T!V[",&H'`Q@^&[A9.;1FFH!QI;5[7?A+8;BKUW\```#__P,`4$L# M!!0`!@`(````(0`ZR;XLG0(``)4&```9````>&PO=V]R:W-H965TD/#F^/%[CH]/=G/QYLU M1L;2MJ"-:GF.7[G!=_OW[W9GI9],S;E%0&A-CFMKNRTAAM5<4A.ICK?P2ZFT MI!9>=45,ISDM_"+9D#2.ET12T>)`V.JW,%19"L8?%#M)WMH`T;RA%OR;6G3F M0I/L+3A)]=.INV%*=H`XBD;85P_%2++MYZI5FAX;R/LER2B[L/W+!"\%T\JH MTD:`(\'H-.<-V1`@[7>%@`QG)KC M%49@RH#ZO,]6._(,M6!]R'T(@><0D@P1!.###F!W9@>GNAUGYMJTTYR MZIC9*U-_FQ'`^TO@GL`-N;2EBQC#>F5L<#UO$$;!G$,OCZD7*?W;*V$(A*LC MN:[X!]XT!C%U:J$T[N8,ZC!\#G[]OWJV/82A1(9?8%9TM.)?J:Y$:U##2V#& MT0K:0X>Q$EZLZL`H#`QE84CXKS6,?P[W)XX@N%3*7E[&UL(*($`2B@``$````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````````````G)%! M3\,@&(;O)OZ'AGL+;+HH:5FB9B>7F#BC\8;P;2,62@#M]N^E75=G].21O"\/ MS_=1SG>FSC[!!]W8"M&"H`RL;)2VFPH]K1;Y%'GSCP$<-(4LD&YAT%=K&Z!C&06[!B%"DADWANO%&Q'3T&^R$?!<;P!-" M9MA`%$I$@3M@[D8B&I!*CDCWX>L>H"2&&@S8&#`M*/[N1O`F_'FA3TZ:1L>] M2S,-NJ=L)0_AV-X%/1;;MBW:::^1_"E^6=X_]J/FVG:[DH!XMY]:A+A,JUQK M4#=[OGOS=1;"ML2_LU+)WHY)#R*"RM)[[&!W3)ZGMW>K!>(30B]S,LO)]8H2 M1BB[F+Z6^-@:[O,1:`:!?Q./`-Y[__QS_@4``/__`P!02P,$%``&``@````A M`!W'X.&L`@``CP<``!``"`%D;V-0&UL(*($`2B@``$````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````G)7?;YLP$,??)^U_0+RWI%D[ M316AH@E5*Z5)5&CW:#GF2*PZ-K,=ENROWP%+2AK(U+X9WP]__+WC[-]L5L(I M0!NNY,"]..^Y#DBF4BX7`_Y?N$;IWQNK"?39HJ5O*9EV2;(W#@AWDN.*,6;QD\G'C`H88N(@H\*`[[UM^/=`2]%FE&L3^(6]+H!9I1W# M_Z!L?=>94P,ESL`MJ.946L0JW>J/:BUR8W7P4^E7LP2PQO?0H=ZLEDW?YII? M!OVKR@-7AYYEAIH$#8>,";<"S#2;46W;D*^:S!5%35P#[:I(L#=()"WJ11YD M76VNFN3[.PRGDW@Z?AB%230BM^$XG`PC$M]'41)_U)_,Z/]#X@1/>HPF24RF M=V0ZBSX:,@S;P6ZIX8:HC,PT&.SDJJ]:D]]A.Y`7*M9`'H&:M8:R\P\*NY=G M`K])R)A:HYAR@;F5Q#4[$?$$!4A,_01,+20ON[LJQU!)J]L%^G>`*6.`%W0N M@(1"J-\43VKG>L`+R@6O/(UYUY9[>F11HBC!)\H"UF=;Y;ZE\K55F;&2BP3T MBHQ@;DFG&ZI0\'(X$6PM;#"F5D`2NNE@C==S`[_6J#&)4)L.I4_K=M'*>UJX M]I@CY9`<96R7^314_Q-0[3''4".PE(M.JJZR8N5:H8XKBY[=)W17N`QK/>&H MRFT''$R^=[-NS.6K>J7-/@+``#__P,`4$L#!!0`!@`( M````(0"GG[SWE0```*D````0````>&PO8V%L8T-H86EN+GAM;#R.00H",1`$ M[X)_&.;N9O4@*DD6%'R!/B!D1Q-()DLFB/[>>/'24#14MY[>.<&+JL3"!K?# MB$#LRQSY:?!^NVX."-(J6]2_X27&3H!A:#H;7EI)3X0-G) M4!;BWCQ*S:YUK$\E2R4W2R!J.:G=..Y5[@*TVD,U>#XBQ/X!(?U26:W^(_8+ M``#__P,`4$L!`BT`%``&``@````A`-)O7*/*`0``X!$``!,````````````` M`````````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P M(_4```!,`@``"P`````````````````#!```7W)E;',O+G)E;'-02P$"+0`4 M``8`"````"$`[*=SQK,!``";$```&@`````````````````I!P``>&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`,1@Q-@`#``"2 M"```#P`````````````````<"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``& M``@````A`(9&81^E!@``\!@``!@`````````````````20T``'AL+W=O,' M``#E(@``&0`````````````````9'0``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`&,$M`6!`P``%0H``!@`````````````````8"@``'AL+W=OP,``($*```9```````` M`````````!&UL4$L!`BT`%``& M``@````A`'W.^"@4`P``)@D``!D`````````````````R2\``'AL+W=O&UL4$L!`BT`%``&``@````A`+?!>!BO"P``8&H` M``T`````````````````"&L``'AL+W-T>6QE&PO=V]R:W-H965T M"``!X;"]W;W)K&UL4$L!`BT` M%``&``@````A`,`X'1N"!P``QB```!D`````````````````)8<``'AL+W=O MC@``>&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`)C]?39U`@``\`4``!@`````````````````BY$` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`"?W[7--!```@@X``!D`````````````````2IT``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`'>,P>&2#```1#T``!D`````````````````4ZL``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#9+F"`Q`0``0`(``!$````` M````````````H,D``&1O8U!R;W!S+V-O&UL4$L!`BT`%``&``@````A M`!W'X.&L`@``CP<``!``````````````````",P``&1O8U!R;W!S+V%P<"YX M;6Q02P$"+0`4``8`"````"$`IY^\]Y4```"I````$`````````````````#J ISP``>&PO8V%L8T-H86EN+GAM;%!+!08`````(P`C`%X)``"MT``````` ` end XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
Subsequent Events (Details) (USD $)
Apr. 30, 2015
Oct. 31, 2014
Jun. 03, 2015
Subsequent events      
Common Stock, Par Value (in dollars per share) $ 0.01us-gaap_CommonStockParOrStatedValuePerShare $ 0.01us-gaap_CommonStockParOrStatedValuePerShare  
Subsequent Event | OPKO Health, Inc. ("OPKO") | Bamboo Acquisition, Inc. ("Sub")      
Subsequent events      
Per Share Conversion To Common Stock In Event Of Merger     2.75brli_PerShareConversionToCommonStockInEventOfMerger
/ us-gaap_BusinessAcquisitionAxis
= us-gaap_ParentCompanyMember
/ dei_LegalEntityAxis
= brli_BambooAcquisitionInc.Member
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
Common Stock, Par Value (in dollars per share)     $ 0.01us-gaap_CommonStockParOrStatedValuePerShare
/ us-gaap_BusinessAcquisitionAxis
= us-gaap_ParentCompanyMember
/ dei_LegalEntityAxis
= brli_BambooAcquisitionInc.Member
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
Number of fractional shares issued     0brli_NumberOfFractionalSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= us-gaap_ParentCompanyMember
/ dei_LegalEntityAxis
= brli_BambooAcquisitionInc.Member
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
Number of OPKO shares of common stock received in lieu of any fractional shares     1brli_NumberOfOpkoSharesOfCommonStockReceivedInLieuOfAnyFractionalShares
/ us-gaap_BusinessAcquisitionAxis
= us-gaap_ParentCompanyMember
/ dei_LegalEntityAxis
= brli_BambooAcquisitionInc.Member
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
Maximum termination fee     $ 54,000,000brli_MergerAgreementMaximumTerminationFee
/ us-gaap_BusinessAcquisitionAxis
= us-gaap_ParentCompanyMember
/ dei_LegalEntityAxis
= brli_BambooAcquisitionInc.Member
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
Maximum out of pocket expense reimbursement     $ 3,000,000brli_MaximumOutOfPocketExpenseReimbursement
/ us-gaap_BusinessAcquisitionAxis
= us-gaap_ParentCompanyMember
/ dei_LegalEntityAxis
= brli_BambooAcquisitionInc.Member
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember

XML 19 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
Revenue Recognition and Contractual Adjustments
6 Months Ended
Apr. 30, 2015
Revenue Recognition and Contractual Adjustments  
Revenue Recognition and Contractual Adjustments

 

[4] Revenue Recognition and Contractual Adjustments

 

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

 

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.  Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by BRLI are to patients covered under a third party payor contract.  In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly; in the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.  Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.  Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.  The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.  This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.  The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

 

 

 

($)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

[Unaudited]

 

[Unaudited]

 

 

 

2015

 

2014

 

2015

 

2014

 

Gross Service Revenues

 

1,175,282 

 

1,017,621 

 

2,240,575 

 

1,927,499 

 

 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

101,262 

 

94,520 

 

195,325 

 

183,439 

 

All Other Third Party Payors*

 

838,004 

 

706,234 

 

1,587,205 

 

1,330,379 

 

Total Contractual Adjustments and Discounts

 

939,266 

 

800,754 

 

1,782,530 

 

1,513,818 

 

Service Revenues Net of Contractual Adjustments and Discounts

 

236,016 

 

216,867 

 

458,045 

 

413,681 

 

Patient Service Revenue Provision for Bad Debts**

 

12,030 

 

15,501 

 

25,225 

 

31,046 

 

Net Revenues

 

223,986 

 

201,366 

 

432,820 

 

382,635 

 

 

* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

 

** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.  The remaining bad debt expense is presented as part of operating expenses.  The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

 

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries.  One such legislation is Protecting Access to Medicare Act of 2014 (Public Law 113—93)(“PAMA”) was signed into law on April 1, 2014.  The legislation directed CMS to conduct a market survey and to determine whether Medicare is reimbursing at a commercially reasonable rates.  To date, CMS has fallen behind the schedule legislated in PAMA. As the result, the current reimbursement rates remain unchanged, subject to typical annual reviews, until 2017.

EXCEL 20 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Y-3,W,F$S9%\Q,S'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E)E=F5N=65?4F5C;V=N:71I;VY?86YD7T-O;G1R83PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D%C8V]U;G1S7U)E8V5I=F%B;&5? M06QL;W=A;F-E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DEN=&%N9VEB;&5?07-S971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H M965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E M;%=O#I7;W)K#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I!8W1I=F53:&5E=#XP M/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^0DE/(%)%1D5214Y#12!,04)/ M4D%43U))15,@24Y#/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^07!R(#,P+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^,C`Q-3QS<&%N/CPO'0^ M43(\'1087)T7SDU M,S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D('-H87)E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Y-3,W,F$S9%\Q,S'0O:'1M;#L@8VAAF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU M+#`Y,3QS<&%N/CPO65E(%)E;&%T960@17AP96YS M97,\+W1D/@T*("`@("`@("`\=&0@8VQA2!3=7!P M;&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y-3,W,F$S9%\Q,S'0O:'1M;#L@ M8VAA2`H57-E9"!F;W(I($]P97)A=&EN9R!!8W1I M=FET:65S.CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B@T-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&5D($%S2!-971H;V0@*$EN8V]M92D@3&]S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6%B;&4@86YD($%C8W)U M960@3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y-3,W,F$S M9%\Q,S'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUA6QE/3-$)V1I3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$)V1I2P@86QL(&%D:G5S=&UE;G1S M(&YE8V5S2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!O9B!T:&4@9FEN M86YC:6%L('!O65A#(P,4,[0E),228C>#(P,40[(&]R('1H92`F(W@R M,#%#.T-O;7!A;GDF(W@R,#%$.RD@8V]N=&%I;F5D(&EN(&ET65A6QE/3-$)VUA6QE/3-$)V1I2!T:&4@0V]M<&%N>2!A28C>#(P,3D[F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I M=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX@ M/&1I=B!S='EL93TS1&UA3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)VUA6QE/3-$)V1I28C>#(P,3D[F4] M,T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I M=CX@/&1I=B!S='EL93TS1&UA3I4 M:6UE6QE/3-$)V1I3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.R<^4F5M;W9E9"!A M;F0@4F5S97)V960N/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4] M,T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`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`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`Q-3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C$R)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG M/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C$R)3MP861D:6YG.C!P=#L^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UE MF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^ M,C`Q-3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C$R)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,30\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`Q+C(V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G M/@T*"0D)"0D))FYB6QE/3-$)V1I'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#`Q-RPV,C$F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$R+C4P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I#1R!4:6UEF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C(V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^)FYB3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F6QE/3-$=VED=&@Z,3(N-3`E.W!A9&1I;F'0M86QI9VXZ3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)W=I9'1H.C$R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)W=I9'1H.C`S+C$R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M)FYB3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ6QE/3-$)W=I9'1H.C$R+C4R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)W=I9'1H.C`Q+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`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`F;F)S<#L-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W3I# M1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I9'1H.C,V+C(R)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX,S@L,#`T)FYB6QE/3-$ M)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I#1R!4:6UEF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXW,#8L,C,T)FYB6QE/3-$)W=I9'1H.C`S+C$R M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M"0D))FYB6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXQ+#4X-RPR,#4F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE M/3-$)W=I9'1H.C$R+C4R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O3I# M1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$=VED=&@Z,S8N,C(E.W!A9&1I;F6QE/3-$ M)V1I6QE/3-$)VUA3I#1R!4:6UEF4Z M(#$P<'0G/@T*"0D)"0D))FYB3I#1R!4 M:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXX,#`L-S4T)FYB6QE/3-$=VED=&@Z,#,N,3(E M.W!A9&1I;F6QE/3-$)W=I9'1H.C$R+C4P)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F6QE/3-$)W=I9'1H.C$R+C4R)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI9VXZ6QE/3-$=VED M=&@Z,#$N,C8E.W!A9&1I;F3H@:6YL:6YE M.R<^4V5R=FEC92!2979E;G5E6QE/3-$)W=I9'1H.C`S+C$R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ3I#1R!4 M:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C4P M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT-3@L,#0U)FYB6QE/3-$)W=I M9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`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`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P M<'0G/@T*"0D)"0D))FYB3I#1R!4:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C4P)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.V)A8VMG'0M86QI9VXZ M6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT M,S(L.#(P)FYB6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`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`@("`\ M+W1R/@T*("`@("`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`Q.3MS M('1I;65L>2!F:6QI;F<@;&EM:71S+B!!8V-O=6YT'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O M;G0M6QE/3-$=VED=&@Z-3`N-#@E.W!A9&1I M;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#0N-S`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)W=I9'1H.C$Y+C$R)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/EM5;F%U9&ET M961=/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G M/@T*"0D)"0D))FYB'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,#$N.3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I M;65S.V9O;G0M6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)FYB3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D%P M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/D]C=&]B97(F;F)S<#LS,2P\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`Q+CDP)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#0N-S`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I M;65S.V9O;G0M6QE/3-$)W=I9'1H M.C$Y+C$R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/C(P,34\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`T+C8X)3MP861D:6YG.C!P M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-' M(%1I;65S.V9O;G0M6QE/3-$ M)V1I6QE/3-$=VED=&@Z-3`N-#@E.W!A9&1I;F6QE/3-$)V1I M6QE/3-$=VED=&@Z,#0N-S`E M.W!A9&1I;F6QE/3-$)W=I9'1H.C$Y+C$R)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@ M.V)O3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C4P+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA6QE/3-$)W=I9'1H.C`T M+C6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU.#(L,3@P)FYB6QE/3-$)W=I9'1H.C`T M+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU,3,L-#8V)FYB6QE/3-$)W=I9'1H.C`Q M+CDP)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)"0D))FYB3H@:6YL:6YE.R<^1&]U M8G1F=6P@06-C;W5N=',\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`T+C6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P M<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE M/3-$=VED=&@Z,#0N-C@E.W!A9&1I;F6QE/3-$ M)W=I9'1H.C$Y+C$R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXX,RPR-S8F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I M9'1H.C4P+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV-C,L-C@U)FYB M6QE M/3-$)W=I9'1H.C`T+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`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`E.W!A9&1I;F'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M M6QE/3-$=VED=&@Z,30N-3@E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.D-'(%1I;65S.V9O;G0M6QE M/3-$)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.D-'(%1I;65S.V9O;G0M6QE/3-$ M=VED=&@Z,3@N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M M6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D%M;W)T:7IA=&EO M;B9N8G-P.U!E6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I M;65S.V9O;G0M6QE/3-$=VED=&@Z M,3(N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,30N-3@E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I M;65S.V9O;G0M6QE/3-$)V1I M6QE/3-$)VUA3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#AP="<^#0H)"0D)"0D\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L M9#MF;VYT+7-I>F4Z.'!T.R<^3F5T)FYB6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-' M(%1I;65S.V9O;G0M6QE/3-$)W=I M9'1H.C$R+C`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`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C(S+C6QE M/3-$)VUA6QE/3-$)W=I9'1H.C`S M+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)W=I9'1H.C$R+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I#1R!4:6UE MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#0V.29N8G-P M.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)VUA6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^-3PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#,N,3(E.W!A9&1I;F6QE/3-$)W=I9'1H.C$R M+C`P)3L[9F]N="UF86UI;'DZ0T<@5&EM97,[9F]N="US:7IE.C$P<'0[=&5X M="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$ M9FQO870Z;&5F=#X\+V1I=CXQ,2PQ,S$F;F)S<#L-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F6QE/3-$)W=I9'1H.C$X+C`P)3L[9F]N="UF86UI;'DZ0T<@ M5&EM97,[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+#@P M-B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`Q+C(P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)W=I9'1H.C$X+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^,3<\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C$T+C4X)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O3I#1R!4:6UEF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXS+#,W-29N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HP,2XR,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$=VED=&@Z,C,N-S(E.W!A9&1I;F6QE/3-$ M)V1I6QE/3-$=VED=&@Z,#,N M,3(E.W!A9&1I;F6QE/3-$=VED=&@Z,3@N,#`E M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.D-'(%1I;65S.V9O;G0M6QE M/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F6QE/3-$ M)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!N;VYE("-$.40Y1#D@.V)O3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUA6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;F'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^5&]T86QS/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$X+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB3I#1R!4:6UEF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W3I#1R!4:6UEF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^ M)FYB6QE/3-$)VUA6QE/3-$)V1I6QE/3-$=VED M=&@Z,#,N,30E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,3@N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/D%C8W5M=6QA=&5D/"]F;VYT/CPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,C,N-S(E.W!A9&1I M;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^06UOF%T:6]N)FYB3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/D%M;W)T:7IA=&EO;CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-' M(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,3@N,#`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE/3-$)W=I9'1H.C(S+C3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/DEN=&%N9VEB;&4F;F)S<#M!6QE/3-$=VED M=&@Z,#,N,30E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)W=I9'1H.C$X+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/EEE87)S/"]F;VYT/CPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUA3I#1R!4:6UEF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^0V]S="9N8G-P M.R@D*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M M6QE/3-$)W=I M9'1H.C$T+C4X)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/B@D*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I M;65S.V9O;G0M6QE/3-$)W=I9'1H.C$X+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y M1#D@.V)O3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/D%M;W)T:7IA=&EO;B9N8G-P.R@D*3PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)VUA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-' M(%1I;65S.V9O;G0M6QE/3-$=VED M=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$ M)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.D-'(%1I;65S.V9O;G0M6QE M/3-$=VED=&@Z,#$N,C`E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL M>3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0W5S=&]M97(@3&ES=',\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HP,RXQ-"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXX+#'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C$V+C3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)W=I9'1H.C`Q+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`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`S+C$T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I#1R!4:6UEF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y M1#D@.V)O3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M+#'0M86QI9VXZ6QE/3-$)VUA6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUA6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F6QE/3-$)W=I9'1H.C$X+C`P M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C$T)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I'0M M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\ M+W`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`R+C6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^,C`Q.#PO9F]N=#X\+W`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`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4@+2!"86YK/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\6%B;&4@+2!"86YK/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA M3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[)SY;-UT\+V9O;G0^ M/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[)SX@4F5V;VQV:6YG($YO=&4@4&%Y86)L92`M($)A;FL\+V9O;G0^#0H) M"3PO<#X-"@D)/'`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`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUA6QE M/3-$)V1I3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.R<^)FYB6QE/3-$)VUA6QE/3-$)V1I65A M29N8G-P.S(Y+"`R,#$Q(&]F("0V,2!I;F-L=61I;F<@<')I;F-I M<&%L(&%N9"!I;G1E2!A(&)A;&QO;VX@<&%Y;65N M="!O9B!T:&4@<')I;F-I<&%L(&%N9"!I;G1E6UE;G0@9&%T92!O9B9N8G-P.R9N8G-P.T1E8V5M M8F5R)FYB2`D,RPT,3(N/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I M>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX@/&1I M=B!S='EL93TS1&UA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE M/3-$)VUA6QE/3-$)V1I&5S/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA6QE/3-$)V1I3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^5&AE('!R;W9I&5S(&9O3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)VUA6QE M/3-$)V1I"!P"!P3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^3VX@07!R:6PF;F)S<#LS,"P@,C`Q-2P@=&AE($-O;7!A;GD@ M:&%D(&$@8W5RF4],T0Q/B`\ M+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^ M/&1I=CX@/&1I=B!S='EL93TS1&UA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$)V1I3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^3VX@2G5N929N8G-P.S,L(#(P,34@=&AE M($-O;7!A;GDL)FYB#(P,40[*2P@96YT97)E M9"!I;G1O(&%N(&%G2`H=&AE("8C>#(P,4,[365R9V5R)B-X M,C`Q1#LI(&%N9"!T:&4@0V]M<&%N>2!W:6QL(&)E('1H92!S=7)V:79I;F<@ M8V]R<&]R871I;VX@86YD($]02T\F(W@R,#$Y.W,@=VAO;&QY(&]W;F5D('-U M8G-I9&EA2!A MF%T:6]N('=I=&AI;B!T:&4@;65A;FEN9R!O9B!T:&4@ M26YT97)N86P@4F5V96YU92!#;V1E(&]F(#$Y.#8L(&%S(&%M96YD960@*'1H M92`F(W@R,#%#.T-O9&4F(W@R,#%$.RDN/"]F;VYT/@T*"0D\+W`^#0H)"3QP M('-T>6QE/3-$)VUA6QE/3-$)V1I#(P,4,[ M169F96-T:79E(%1I;64F(W@R,#%$.RDL(&5A8V@@:7-S=65D(&%N9"!O=71S M=&%N9&EN9R!S:&%R92!O9B!T:&4@0V]M<&%N>28C>#(P,3D[2!O2!O2!S=6)S:61I87)Y*2!W:6QL(&%U=&]M871I M8V%L;'D@8F4@8V]N=F5R=&5D(&EN=&\@86YD(&5X8VAA;F=E9"!F;W(@=&AE M(')I9VAT('1O(')E8V5I=F4@,BXW-2!S:&%R97,@*'1H92`F(W@R,#%#.T5X M8VAA;F=E(%)A=&EO)B-X,C`Q1#LI(&]F($]02T\F(W@R,#$Y.W,@8V]M;6]N M('-T;V-K+"!P87(@=F%L=64@)#`N,#$@<&5R('-H87)E("AT:&4@)B-X,C`Q M0SM/4$M/($-O;6UO;B!3=&]C:R8C>#(P,40[*2X@3F\@9G)A8W1I;VYA;"!S M:&%R97,@;V8@3U!+3R!#;VUM;VX@4W1O8VL@=VEL;"!B92!I2!C97)T:69I8V%T M97,@;W(@8F]O:RUE;G1R:65S+"!D96QI=F5R960@8GD@3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE M/3-$)V1I&5R M8VES92!P2`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`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/&1I=CX@/&1I=B!S='EL93TS1&UA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)V1I3I#1R!4:6UE3H@:6YL:6YE.SMF M;VYT+7-I>F4Z(#$P<'0[9F]N="UF86UI;'DZ0T<@5&EM97,[=&5X="UI;F1E M;G0Z,'!T.VUA3H@:6YL:6YE.R<^ M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I'0M:6YD96YT.C!P M=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^ M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I3I#1R!4:6UE3H@:6YL:6YE.SMF;VYT+7-I>F4Z(#$P<'0[ M9F]N="UF86UI;'DZ0T<@5&EM97,[=&5X="UI;F1E;G0Z,'!T.VUA3H@:6YL:6YE.R<^/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V1I'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP M<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V1I3I#1R!4:6UE3H@:6YL:6YE.SMF;VYT+7-I>F4Z(#$P<'0[9F]N="UF86UI;'DZ0T<@ M5&EM97,[=&5X="UI;F1E;G0Z,'!T.VUA3H@:6YL:6YE.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3I#1R!4:6UE3H@:6YL:6YE.SMF M;VYT+7-I>F4Z(#$P<'0[9F]N="UF86UI;'DZ0T<@5&EM97,[=&5X="UI;F1E M;G0Z,'!T.VUA3H@:6YL:6YE.R<^ M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I'0M:6YD96YT.C!P M=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^ M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I3I#1R!4:6UE3H@:6YL:6YE.R<^/"]F;VYT/@T*"0D\+W`^ M#0H)"3QD:78@6QE/3-$)V)O6QE/3-$=VED M=&@Z,S8N,C(E.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA M3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I M;65S.V9O;G0M6QE/3-$)W=I9'1H.C(X+C$R)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/E1H'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)W=I9'1H.C(X+C$T)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@ M.V)O3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E-I M>"9N8G-P.TUO;G1H6QE/3-$=VED=&@Z,S8N,C(E.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I#1R!4:6UEF4Z(#AP="<^#0H)"0D) M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z M8F]L9#MF;VYT+7-I>F4Z.'!T.R<^07!R:6PF;F)S<#LS,"P\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I# M1R!4:6UEF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^07!R:6PF;F)S<#LS,"P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`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`Q+C(V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-' M(%1I;65S.V9O;G0M6QE/3-$)W=I M9'1H.C$R+C4P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UE MF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^ M,C`Q-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M M6QE/3-$)W=I9'1H.C$R+C4P)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S M.V9O;G0M6QE/3-$)V1I6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,#$N,C8E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M3H@:6YL:6YE.R<^1W)O6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#$W-2PR.#(F M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$R+C4P)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@ M.V)O3I#1R!4:6UEF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W'0M M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C$R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ+#DR-RPT.3DF;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)VUA6QE/3-$)VUA M3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F6QE/3-$=VED=&@Z,3(N-3`E.W!A9&1I;F'0M86QI M9VXZ3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$=VED M=&@Z,#$N,C8E.W!A9&1I;F3H@:6YL:6YE M.R<^0V]N=')A8W1U86P@061J=7-T;65N=',@86YD($1I'0M86QI9VXZ6QE/3-$)W=I9'1H.C$R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`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`Q+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^5&]T86P@0V]N=')A8W1U86P@061J=7-T;65N M=',@86YD($1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I M;F6QE/3-$)W=I9'1H.C$R+C4P)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D M97(M'0M86QI9VXZ6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB3I#1R!4:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M+#6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#4Q,RPX,3@F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C,V+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)W=I9'1H.C$R+C4P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXR,S8L,#$V)FYB6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C4R)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M6QE/3-$)W=I9'1H.C`Q+C(V)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M)FYB3H@:6YL:6YE.R<^4&%T:65N="!3 M97)V:6-E(%)E=F5N=64@4')O=FES:6]N(&9O6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F6QE M/3-$)W=I9'1H.C$R+C4P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3(E.W!A M9&1I;F6QE/3-$)W=I9'1H.C$R+C4P)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F6QE/3-$)W=I9'1H.C$R+C4P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3(E M.W!A9&1I;F6QE/3-$)W=I9'1H.C$R+C4R)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,C8E.W!A9&1I;F3H@:6YL:6YE.R<^3F5T(%)E=F5N=65S/"]F;VYT/CPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$R+C4P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG'0M86QI9VXZ6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXR,#$L,S8V)FYB6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB3I# M1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I9'1H.C$R M+C4R)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@ M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG M'0M86QI9VXZ3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE M/3-$)V1I6]R7-I M8VEA;G,L(&AO3I#1R!4:6UEF4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB M6QE/3-$)VUA6QE/3-$)V1IF4],T0Q/B`\ M+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$P<'0[9F]N="UF86UI;'DZ0T<@5&EM97,[=&5X="UI;F1E;G0Z M,'!T.VUA3H@:6YL:6YE.R<^/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V1I'0M:6YD96YT.C!P=#MM M87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V1I3I#1R!4:6UE3H@:6YL:6YE.SMF;VYT+7-I>F4Z(#$P<'0[9F]N M="UF86UI;'DZ0T<@5&EM97,[=&5X="UI;F1E;G0Z,'!T.VUA3H@:6YL:6YE.R<^/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V1I'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[ M<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V1I3I# M1R!4:6UE3H@:6YL:6YE.SMF;VYT+7-I>F4Z(#$P<'0[9F]N="UF86UI;'DZ0T<@5&EM M97,[=&5X="UI;F1E;G0Z,'!T.VUA3H@:6YL:6YE.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3I#1R!4:6UE3H@:6YL:6YE.SMF;VYT M+7-I>F4Z(#$P<'0[9F]N="UF86UI;'DZ0T<@5&EM97,[=&5X="UI;F1E;G0Z M,'!T.VUA3H@:6YL:6YE.R<^/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V1I'0M:6YD96YT.C!P=#MM M87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V1I3I#1R!4:6UE3H@:6YL:6YE.SMF;VYT+7-I>F4Z(#$P<'0[9F]N M="UF86UI;'DZ0T<@5&EM97,[=&5X="UI;F1E;G0Z,'!T.VUA3H@:6YL:6YE.R<^/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V1I'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[ M<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V1I6QE/3-$=VED=&@Z-3`N-#@E.W!A M9&1I;F6QE/3-$)VUA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#0N-S`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)W=I9'1H.C$Y+C$R)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/EM5;F%U M9&ET961=/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P M<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,#$N.3`E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-' M(%1I;65S.V9O;G0M6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG M/D%P3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/D]C=&]B97(F;F)S<#LS,2P\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`Q+CDP)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#0N-S`E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-' M(%1I;65S.V9O;G0M6QE/3-$)W=I M9'1H.C$Y+C$R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/C(P,34\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`T+C8X)3MP861D:6YG M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.D-'(%1I;65S.V9O;G0M6QE M/3-$)V1I6QE/3-$=VED=&@Z-3`N-#@E.W!A9&1I;F6QE/3-$ M)V1I6QE/3-$=VED=&@Z,#0N M-S`E.W!A9&1I;F6QE/3-$)W=I9'1H.C$Y+C$R M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C4P+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)W=I9'1H M.C`T+C6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G M/@T*"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU.#(L,3@P)FYB6QE/3-$)W=I9'1H M.C`T+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G M/@T*"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU,3,L-#8V)FYB6QE/3-$)W=I9'1H M.C`Q+CDP)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G M/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^ M1&]U8G1F=6P@06-C;W5N=',\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`T+C6QE/3-$)VUA3I#1R!4:6UEF4Z M(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$=VED=&@Z,#0N-C@E.W!A9&1I;F6QE M/3-$)W=I9'1H.C$Y+C$R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$ M)W=I9'1H.C4P+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV-C,L-C@U M)FYB6QE/3-$)W=I9'1H.C`T+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA6QE/3-$)V1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Y-3,W,F$S9%\Q,S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)VUA M6QE/3-$)V1I3H@:6YL:6YE.W1E>'0M M9&5C;W)A=&EO;CIU;F1E6QE/3-$)VUA6QE/3-$)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P M6QE/3-$)VUA M3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E=E:6=H=&5D+4%V97)A9V4\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I#1R!4:6UEF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I#1R!4:6UEF4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^06-C=6UU;&%T960\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I#1R!4:6UEF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S M.V9O;G0M6QE/3-$=VED=&@Z,3@N M,#`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`M,3!P=#MF;VYT+69A;6EL>3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$=VED=&@Z,#,N,3(E.W!A M9&1I;F6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUA6QE/3-$=VED=&@Z,#$N,C`E M.W!A9&1I;F'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^0W5S=&]M97(@ M3&ES=',\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO M'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I M;65S.V9O;G0M6QE/3-$)W=I9'1H.C`S+C$R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$ M9FQO870Z;&5F=#X\+V1I=CXX+#'0M M86QI9VXZ6QE/3-$)W=I9'1H.C$X+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C(P)3MB86-K9W)O M=6YD+6-O;&]R.B`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`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C(S+C6QE/3-$)VUA6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$)V1I6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#DR M,B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)VUA6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z M(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUA6QE/3-$=VED=&@Z,#,N,3(E.W!A M9&1I;F6QE/3-$)W=I9'1H.C$X+C`P)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXR-2PQ-C8F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I M9'1H.C$T+C4X)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,2PW,38F M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$X+C`P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,RPT-3`F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUA6QE/3-$)V1I3H@:6YL:6YE.W1E>'0M9&5C;W)A=&EO;CIU;F1E M3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)V)O6QE/3-$=VED=&@Z,C,N-S(E.W!A M9&1I;F6QE/3-$)VUA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#AP="<^#0H)"0D)"0D\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF M;VYT+7-I>F4Z.'!T.R<^5V5I9VAT960M079E6QE/3-$=VED M=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I M;65S.V9O;G0M6QE/3-$=VED=&@Z M,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,30N-3@E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S M.V9O;G0M6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S M.V9O;G0M6QE M/3-$=VED=&@Z,3@N,#`E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O M;G0M6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYB3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D%M;W)T:7IA M=&EO;B9N8G-P.U!E6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-' M(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I M;65S.V9O;G0M6QE/3-$=VED=&@Z,30N-3@E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^3F5T)FYB6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-' M(%1I;65S.V9O;G0M6QE/3-$ M)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S M.V9O;G0M6QE M/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/D-O6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G M/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S M.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I#1R!4:6UE MF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)W=I9'1H.C$T M+C4X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)W=I9'1H.C$X+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^,C`\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q M+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C$S+C(X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I#1R!4:6UEF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU+#0V,R9N8G-P.PT*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP M,2XR,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$=VED=&@Z,C,N-S(E M.W!A9&1I;F6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,30E.W!A M9&1I;F6QE/3-$=VED=&@Z,3@N,#`E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.D-' M(%1I;65S.V9O;G0M3I#1R!4:6UEF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3I#1R!4:6UEF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#$N M,C`E.W!A9&1I;F3H@:6YL:6YE.R<^4&%T96YT M'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)W=I9'1H M.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G M/@T*"0D)"0D))FYB6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU+#(Y-R9N8G-P.PT*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP M,RXQ,B4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C$X+C`P)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I#1R!4:6UEF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C(P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M"0D))FYB3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$=VED=&@Z,#,N M,3(E.W!A9&1I;F6QE/3-$ M)W=I9'1H.C$T+C4X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!N;VYE("-$.40Y1#D@.V)O3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M6QE/3-$)W=I9'1H.C(S+C6QE/3-$)VUA'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I#1R!4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB3I#1R!4 M:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S M+C(X)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,"PW-C,F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q M+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T* M"0D)"0D))FYB'!E M;G-E(')E;&%T960@=&\@6QE M/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$P M<'0[9F]N="UF86UI;'DZ0T<@5&EM97,[=&5X="UI;F1E;G0Z,'!T.VUA3H@:6YL:6YE.R<^/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V1I'0M:6YD96YT.C!P=#MM87)G:6XM;&5F M=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`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`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V1I3I#1R!4:6UE3H@:6YL:6YE.SMF;VYT+7-I>F4Z(#$P<'0[9F]N="UF86UI;'DZ M0T<@5&EM97,[=&5X="UI;F1E;G0Z,'!T.VUA3H@:6YL:6YE.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W=I9'1H.C4W+C3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/D]C=&]B97(F;F)S<#LS,2P\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`V+C@R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D) M"0D))FYB'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.D-'(%1I;65S.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$)V1I'0M86QI9VXZ6QE M/3-$)W=I9'1H.C`R+C6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB3H@:6YL M:6YE.R<^,C`Q-CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#8N.#(E.W!A9&1I;F6QE/3-$)W=I9'1H.C,R+C6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M+#4T,"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`R+C6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)V1I'0M M86QI9VXZ6QE/3-$)VUA3I#1R!4:6UEF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`R+C6QE/3-$)VUA3I#1R!4:6UEF4Z M(#$P<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE M.R<^5&AE6QE/3-$=VED=&@Z,#8N.#(E.W!A9&1I;F6QE/3-$)W=I9'1H.C,R+C6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX+#`Y-R9N8G-P M.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`R+C6QE/3-$ M)VUA3I# M1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)W=I9'1H.C`V+C@R)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB3I#1R!4:6UEF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$=VED=&@Z-36QE/3-$)V1I'0M9&5C;W)A=&EO;CIU;F1E6QE/3-$=VED=&@Z,#8N.#(E.W!A9&1I;F6QE M/3-$)W=I9'1H.C,R+C'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-S(E.W!A M9&1I;F6QE/3-$)VUA6QE/3-$)V1I3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y-3,W,F$S9%\Q,S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6]R6]R M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y-3,W,F$S9%\Q,S'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N(&5X<&5N'!E;G-E(')E;&%T960@=&\@:6YT86YG:6)L92!A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^,C`@>65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%SF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS M+#0V.3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S MF%T M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#(V.3QS<&%N M/CPO'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E(')E;&%T960@=&\@:6YT86YG:6)L92!A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^,R!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%SF%T M:6]N(&5X<&5N'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N M(%!E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3<@>65A M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N(&5X<&5N M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\Y-3,W,F$S9%\Q,S'0O:'1M;#L@8VAA2`P-2P@,C`Q-3QB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&EM=6T@ M8W)E9&ET(&QI;F4@879A:6QA8FQE(&%S('!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@+2!"86YK/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@+2!"86YK/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6%B;&4@+2!"86YK/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6%B;&4@+2!"86YK/"]S=')O;F<^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&EM M=6T\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Y-3,W,F$S9%\Q,S'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y-3,W,F$S9%\Q,S'0O M:'1M;#L@8VAA&5S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!!'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC XML 21 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
New Accounting Pronouncements
6 Months Ended
Apr. 30, 2015
New Accounting Pronouncements  
New Accounting Pronouncements

 

[3] New Accounting Pronouncements

 

Removed and Reserved.

XML 22 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Apr. 30, 2015
Oct. 31, 2014
CURRENT ASSETS:    
Cash and Cash Equivalents $ 25,146us-gaap_CashAndCashEquivalentsAtCarryingValue $ 17,507us-gaap_CashAndCashEquivalentsAtCarryingValue
Accounts Receivable - Net 285,361us-gaap_AccountsReceivableNetCurrent 263,346us-gaap_AccountsReceivableNetCurrent
Inventory 20,783us-gaap_InventoryNet 20,791us-gaap_InventoryNet
Other Current Assets 9,224us-gaap_OtherAssetsCurrent 10,165us-gaap_OtherAssetsCurrent
Deferred Tax Assets 39,456us-gaap_DeferredTaxAssetsNetCurrent 40,040us-gaap_DeferredTaxAssetsNetCurrent
TOTAL CURRENT ASSETS 379,970us-gaap_AssetsCurrent 351,849us-gaap_AssetsCurrent
PROPERTY AND EQUIPMENT - AT COST 172,893us-gaap_PropertyPlantAndEquipmentGross 156,342us-gaap_PropertyPlantAndEquipmentGross
LESS: Accumulated Depreciation (101,250)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment (89,954)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
PROPERTY AND EQUIPMENT - NET 71,643us-gaap_PropertyPlantAndEquipmentNet 66,388us-gaap_PropertyPlantAndEquipmentNet
OTHER ASSETS:    
Investments in Unconsolidated Affiliate 5,290us-gaap_EquityMethodInvestments 5,153us-gaap_EquityMethodInvestments
Deposits 1,127us-gaap_DepositsAssetsNoncurrent 1,056us-gaap_DepositsAssetsNoncurrent
Goodwill - Net 35,185us-gaap_Goodwill 35,185us-gaap_Goodwill
Intangible Assets - Net 13,450us-gaap_IntangibleAssetsNetExcludingGoodwill 14,403us-gaap_IntangibleAssetsNetExcludingGoodwill
Other Assets 1,615us-gaap_OtherAssetsNoncurrent 1,415us-gaap_OtherAssetsNoncurrent
Deferred Tax Asset 4,438us-gaap_DeferredTaxAssetsNetNoncurrent 3,414us-gaap_DeferredTaxAssetsNetNoncurrent
TOTAL OTHER ASSETS 61,105us-gaap_AssetsNoncurrent 60,626us-gaap_AssetsNoncurrent
TOTAL ASSETS 512,718us-gaap_Assets 478,863us-gaap_Assets
CURRENT LIABILITIES:    
Accounts Payable 66,073us-gaap_AccountsPayableCurrent 71,166us-gaap_AccountsPayableCurrent
Accrued Salaries and Commissions Payable 26,950us-gaap_EmployeeRelatedLiabilitiesCurrent 15,822us-gaap_EmployeeRelatedLiabilitiesCurrent
Accrued Taxes and Expenses 11,493us-gaap_AccruedIncomeTaxesCurrent 15,620us-gaap_AccruedIncomeTaxesCurrent
Other Short Term Acquisition Payable 1,695us-gaap_OtherLoansPayableCurrent 1,924us-gaap_OtherLoansPayableCurrent
Revolving Note Payable - Bank 49,315us-gaap_LinesOfCreditCurrent 33,380us-gaap_LinesOfCreditCurrent
Current Maturities of Long-Term Debt 541us-gaap_LongTermDebtCurrent 524us-gaap_LongTermDebtCurrent
Capital Lease Obligations - Short-Term Portion 6,259us-gaap_CapitalLeaseObligationsCurrent 6,128us-gaap_CapitalLeaseObligationsCurrent
TOTAL CURRENT LIABILITIES 162,326us-gaap_LiabilitiesCurrent 144,564us-gaap_LiabilitiesCurrent
LONG-TERM LIABILITIES:    
Capital Lease Obligations - Long-Term Portion 10,863us-gaap_CapitalLeaseObligationsNoncurrent 12,252us-gaap_CapitalLeaseObligationsNoncurrent
Long-Term Debt -- Net of Current Portion 2,871us-gaap_LongTermDebtNoncurrent 3,145us-gaap_LongTermDebtNoncurrent
TOTAL LONG-TERM LIABILITIES 13,734us-gaap_LiabilitiesNoncurrent 15,397us-gaap_LiabilitiesNoncurrent
SHAREHOLDERS' EQUITY:    
Preferred Stock $.10 Par Value; Authorized 1,666,667 shares, including 3,000 shares of Series A Junior Preferred Stock None Issued      
Common Stock, $.01 Par Value; Authorized 35,000,000 shares: Issued and Outstanding 27,798,976 and 27,272,644 at April 30, 2015 and at October 31, 2014, respectively 278us-gaap_CommonStockValue 277us-gaap_CommonStockValue
Additional Paid-In Capital 40,640us-gaap_AdditionalPaidInCapital 39,979us-gaap_AdditionalPaidInCapital
Retained Earnings 295,740us-gaap_RetainedEarningsAccumulatedDeficit 278,646us-gaap_RetainedEarningsAccumulatedDeficit
TOTAL SHAREHOLDERS' EQUITY 336,658us-gaap_StockholdersEquity 318,902us-gaap_StockholdersEquity
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 512,718us-gaap_LiabilitiesAndStockholdersEquity $ 478,863us-gaap_LiabilitiesAndStockholdersEquity
XML 23 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Basis of Presentation
6 Months Ended
Apr. 30, 2015
Basis of Presentation  
Basis of Presentation

 

[1] Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the instructions to Form 10-Q and, therefore, do not include all information and footnotes necessary for complete audited financial statements. However, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial position and operating results have been included in these statements. Interim results are not necessarily indicative of results for a full year. Reference is made to the October 31, 2014 audited consolidated financial statements of Bio-Reference Laboratories, Inc.(“BRLI” or the “Company”) contained in its Annual Report on Form 10-K for the year ended October 31, 2014.

 

The consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes for the year ended October 31, 2014 as filed with the Securities and Exchange Commission in the Company’s Annual Report on Form 10-K. Significant accounting policies followed by the Company are set forth in Note 2 to the Company’s 2014 Annual Report on Form 10-K.

XML 24 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
Revolving Note Payable - Bank (Details) (USD $)
In Thousands, unless otherwise specified
0 Months Ended 6 Months Ended 0 Months Ended
Feb. 03, 2014
Apr. 30, 2015
Apr. 30, 2015
Oct. 31, 2014
May 05, 2015
Revolving note payable - Bank          
Amount of credit utilized   49,315us-gaap_LinesOfCreditCurrent 49,315us-gaap_LinesOfCreditCurrent $ 33,380us-gaap_LinesOfCreditCurrent  
Revolving Credit Facility          
Revolving note payable - Bank          
Maximum amount of the credit line available pursuant to the loan agreement 70,000us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
      120,000us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
Maximum credit line available as percentage of accounts receivable 50.00%brli_LineOfCreditFacilityMaximumBorrowingCapacityAsPercentageOfAccountsReceivable
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
       
Amount of credit utilized   49,315us-gaap_LinesOfCreditCurrent
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
49,315us-gaap_LinesOfCreditCurrent
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
   
Revolving Credit Facility | Debt Instrument, Variable Rate Base Rate          
Revolving note payable - Bank          
Variable rate basis base rate        
Variable rate of interest (as a percent)   3.50%brli_DebtInstrumentReferenceRate
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateBaseRateMember
3.50%brli_DebtInstrumentReferenceRate
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateBaseRateMember
   
Revolving Credit Facility | Debt Instrument, Variable Rate Base Rate | Minimum          
Revolving note payable - Bank          
Percentage of additional interest 1.00%us-gaap_DebtInstrumentBasisSpreadOnVariableRate1
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateBaseRateMember
       
Revolving Credit Facility | Debt Instrument, Variable Rate Base Rate | Maximum          
Revolving note payable - Bank          
Percentage of additional interest 4.00%us-gaap_DebtInstrumentBasisSpreadOnVariableRate1
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateBaseRateMember
       
Revolving Credit Facility | Debt Instrument, Variable Rate Eurodollar          
Revolving note payable - Bank          
Variable rate basis Eurodollar rate        
Revolving Credit Facility | Debt Instrument, Variable Rate Eurodollar | Minimum          
Revolving note payable - Bank          
Percentage of additional interest   1.00%us-gaap_DebtInstrumentBasisSpreadOnVariableRate1
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateEurodollarMember
     
Revolving Credit Facility | Debt Instrument, Variable Rate Eurodollar | Maximum          
Revolving note payable - Bank          
Percentage of additional interest     4.00%us-gaap_DebtInstrumentBasisSpreadOnVariableRate1
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateEurodollarMember
   
XML 25 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
Provision for Income Taxes (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended
Apr. 30, 2015
Apr. 30, 2014
Apr. 30, 2015
Apr. 30, 2014
Oct. 31, 2014
Provision for Income Taxes          
Current tax provision $ 9,400us-gaap_CurrentIncomeTaxExpenseBenefit $ 7,508us-gaap_CurrentIncomeTaxExpenseBenefit $ 13,131us-gaap_CurrentIncomeTaxExpenseBenefit $ 4,291us-gaap_CurrentIncomeTaxExpenseBenefit  
Deferred Tax Asset:          
Current Deferred Tax Asset - Net 39,456us-gaap_DeferredTaxAssetsNetCurrent 35,964us-gaap_DeferredTaxAssetsNetCurrent 39,456us-gaap_DeferredTaxAssetsNetCurrent 35,964us-gaap_DeferredTaxAssetsNetCurrent 40,040us-gaap_DeferredTaxAssetsNetCurrent
Long Term Deferred Tax Asset - Net 4,438us-gaap_DeferredTaxAssetsNetNoncurrent 2,291us-gaap_DeferredTaxAssetsNetNoncurrent 4,438us-gaap_DeferredTaxAssetsNetNoncurrent 2,291us-gaap_DeferredTaxAssetsNetNoncurrent 3,414us-gaap_DeferredTaxAssetsNetNoncurrent
Net deferred tax benefit          
Deferred tax provision (benefit) $ (1,580)us-gaap_DeferredIncomeTaxExpenseBenefit $ 457us-gaap_DeferredIncomeTaxExpenseBenefit $ (440)us-gaap_DeferredIncomeTaxExpenseBenefit $ 5,976us-gaap_DeferredIncomeTaxExpenseBenefit  
XML 26 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 27 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value Measurements
6 Months Ended
Apr. 30, 2015
Fair Value Measurements  
Fair Value Measurements

 

[2] Fair Value Measurements

 

As of April 30, 2015, the Company’s financial instruments primarily consist of cash, short-term trade receivables and payables for which their carrying amounts approximate fair values, and long term debt, for which based on the borrowing rates currently available to the Company for bank loans with similar terms and average maturities, its carrying amount approximates its fair value.

XML 28 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
Apr. 30, 2015
Oct. 31, 2014
Preferred Stock, Par Value (in dollars per share) $ 0.10us-gaap_PreferredStockParOrStatedValuePerShare $ 0.10us-gaap_PreferredStockParOrStatedValuePerShare
Preferred Stock, Authorized shares 1,666,667us-gaap_PreferredStockSharesAuthorized 1,666,667us-gaap_PreferredStockSharesAuthorized
Preferred Stock, Issued shares 0us-gaap_PreferredStockSharesIssued 0us-gaap_PreferredStockSharesIssued
Common Stock, Par Value (in dollars per share) $ 0.01us-gaap_CommonStockParOrStatedValuePerShare $ 0.01us-gaap_CommonStockParOrStatedValuePerShare
Common Stock, Authorized shares 35,000,000us-gaap_CommonStockSharesAuthorized 35,000,000us-gaap_CommonStockSharesAuthorized
Common Stock, Issued shares 27,798,976us-gaap_CommonStockSharesIssued 27,272,644us-gaap_CommonStockSharesIssued
Common Stock, Outstanding shares 27,798,976us-gaap_CommonStockSharesOutstanding 27,272,644us-gaap_CommonStockSharesOutstanding
Series A Preferred Stock    
Preferred Stock, Authorized shares, including Series A Junior Preferred Stock 3,000brli_PreferredStockSharesAuthorizedIncludingSeriesAJunior
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesAPreferredStockMember
3,000brli_PreferredStockSharesAuthorizedIncludingSeriesAJunior
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesAPreferredStockMember
XML 29 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accounts Receivable Allowances (Tables)
6 Months Ended
Apr. 30, 2015
Accounts Receivable Allowances  
Schedule of amounts for contractual credits and doubtful accounts

 

 

($)

 

 

 

[Unaudited]

 

 

 

 

 

April 30,

 

October 31,

 

 

 

2015

 

2014

 

 

 

 

 

 

 

Contractual Credits/Discounts

 

582,180 

 

513,466 

 

Doubtful Accounts

 

81,505 

 

83,276 

 

Total Allowance

 

663,685 

 

596,742 

 

 

XML 30 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
Document and Entity Information
6 Months Ended
Apr. 30, 2015
Jun. 03, 2015
Document and Entity Information    
Entity Registrant Name BIO REFERENCE LABORATORIES INC  
Entity Central Index Key 0000792641  
Document Type 10-Q  
Document Period End Date Apr. 30, 2015  
Amendment Flag false  
Current Fiscal Year End Date --10-31  
Entity Current Reporting Status Yes  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   27,802,976dei_EntityCommonStockSharesOutstanding
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q2  
XML 31 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets (Tables)
6 Months Ended
Apr. 30, 2015
Intangible Assets  
Schedule of information on intangible assets

 

April 30, 2015

 

 

 

Weighted-Average

 

 

 

Accumulated

 

 

 

 

 

Amortization Period

 

 

 

Amortization

 

Net of Accumulated

 

Intangible Asset

 

Years

 

Cost ($)

 

($)

 

Amortization ($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

8,738 

 

3,469 

 

5,269 

 

Covenants Not-to-Compete

 

5

 

11,131 

 

6,325 

 

4,806 

 

Patents and Licenses

 

17

 

5,297 

 

1,922 

 

3,375 

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

25,166 

 

11,716 

 

13,450 

 

 

October 31, 2014

 

 

 

Weighted-Average

 

 

 

Accumulated

 

 

 

 

 

Amortization Period

 

 

 

Amortization

 

Net of Accumulated

 

Intangible Asset

 

Years

 

Cost ($)

 

($)

 

Amortization ($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

$

8,738 

 

$

3,275 

 

$

5,463 

 

Covenants Not-to-Compete

 

3

 

11,131 

 

5,738 

 

5,393 

 

Patents and Licenses

 

17

 

5,297 

 

1,750 

 

3,547 

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

$

25,166 

 

$

10,763 

 

$

14,403 

 

 

Schedule of estimated amortization expense related to remaining intangible assets

October 31,

 

($)

 

2015

 

900 

 

2016

 

1,540 

 

2017

 

1,063 

 

2018

 

946 

 

2019

 

904 

 

Thereafter

 

8,097 

 

 

 

 

 

Total

 

13,450 

 

 

XML 32 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Apr. 30, 2015
Apr. 30, 2014
Apr. 30, 2015
Apr. 30, 2014
CONSOLIDATED STATEMENTS OF OPERATIONS        
NET REVENUES: $ 223,986us-gaap_SalesRevenueServicesNet $ 201,366us-gaap_SalesRevenueServicesNet $ 432,820us-gaap_SalesRevenueServicesNet $ 382,635us-gaap_SalesRevenueServicesNet
COST OF SERVICES:        
Depreciation and Amortization 5,091us-gaap_CostOfServicesDepreciationAndAmortization 4,659us-gaap_CostOfServicesDepreciationAndAmortization 10,057us-gaap_CostOfServicesDepreciationAndAmortization 9,234us-gaap_CostOfServicesDepreciationAndAmortization
Employee Related Expenses 56,491us-gaap_LaborAndRelatedExpense 51,566us-gaap_LaborAndRelatedExpense 110,176us-gaap_LaborAndRelatedExpense 100,676us-gaap_LaborAndRelatedExpense
Reagents and Laboratory Supplies 42,977us-gaap_CostOfServicesDirectMaterials 38,352us-gaap_CostOfServicesDirectMaterials 83,559us-gaap_CostOfServicesDirectMaterials 75,583us-gaap_CostOfServicesDirectMaterials
Other Cost of Services 20,444us-gaap_OtherCostOfServices 18,240us-gaap_OtherCostOfServices 40,290us-gaap_OtherCostOfServices 36,439us-gaap_OtherCostOfServices
TOTAL COST OF SERVICES 125,003us-gaap_CostOfServices 112,817us-gaap_CostOfServices 244,082us-gaap_CostOfServices 221,932us-gaap_CostOfServices
GROSS PROFIT ON REVENUES 98,983us-gaap_GrossProfit 88,549us-gaap_GrossProfit 188,738us-gaap_GrossProfit 160,703us-gaap_GrossProfit
General and Administrative Expenses:        
Depreciation and Amortization 1,606us-gaap_DepreciationAndAmortization 1,586us-gaap_DepreciationAndAmortization 3,174us-gaap_DepreciationAndAmortization 2,700us-gaap_DepreciationAndAmortization
General and Administrative Expenses 58,797us-gaap_GeneralAndAdministrativeExpense 50,992us-gaap_GeneralAndAdministrativeExpense 117,056us-gaap_GeneralAndAdministrativeExpense 100,578us-gaap_GeneralAndAdministrativeExpense
Bad Debt Expense 19,654brli_BadDebtExpense 17,092brli_BadDebtExpense 37,654brli_BadDebtExpense 32,665brli_BadDebtExpense
TOTAL GENERAL AND ADMINISTRATIVE EXPENSES 80,057brli_TotalGeneralAndAdministrativeExpense 69,670brli_TotalGeneralAndAdministrativeExpense 157,884brli_TotalGeneralAndAdministrativeExpense 135,943brli_TotalGeneralAndAdministrativeExpense
INCOME FROM OPERATIONS 18,926us-gaap_OperatingIncomeLoss 18,879us-gaap_OperatingIncomeLoss 30,854us-gaap_OperatingIncomeLoss 24,760us-gaap_OperatingIncomeLoss
OTHER (INCOME) EXPENSE:        
Interest Expense 666us-gaap_InterestExpense 597us-gaap_InterestExpense 1,226us-gaap_InterestExpense 1,206us-gaap_InterestExpense
Interest Income (23)us-gaap_OtherNonoperatingExpense (12)us-gaap_OtherNonoperatingExpense (45)us-gaap_OtherNonoperatingExpense (26)us-gaap_OtherNonoperatingExpense
Other (Income) Expense 2us-gaap_OtherNonoperatingIncomeExpense 56us-gaap_OtherNonoperatingIncomeExpense (112)us-gaap_OtherNonoperatingIncomeExpense 86us-gaap_OtherNonoperatingIncomeExpense
TOTAL OTHER (INCOME) EXPENSES - NET 645us-gaap_NonoperatingIncomeExpense 641us-gaap_NonoperatingIncomeExpense 1,069us-gaap_NonoperatingIncomeExpense 1,266us-gaap_NonoperatingIncomeExpense
INCOME BEFORE INCOME TAXES 18,281us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments 18,238us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments 29,785us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments 23,494us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Provision for Income Taxes 7,820us-gaap_IncomeTaxExpenseBenefit 7,965us-gaap_IncomeTaxExpenseBenefit 12,691us-gaap_IncomeTaxExpenseBenefit 10,267us-gaap_IncomeTaxExpenseBenefit
NET INCOME $ 10,461us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 10,273us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 17,094us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 13,227us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
NET INCOME PER COMMON SHARE - BASIC: (in dollars per share) $ 0.38us-gaap_EarningsPerShareBasic $ 0.37us-gaap_EarningsPerShareBasic $ 0.62us-gaap_EarningsPerShareBasic $ 0.48us-gaap_EarningsPerShareBasic
WEIGHTED AVERAGE NUMBER OF SHARES BASIC: (in shares) 27,786,309us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,716,644us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,781,143us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,712,525us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
NET INCOME PER COMMON SHARE - DILUTED: (in dollars per share) $ 0.38us-gaap_EarningsPerShareDiluted $ 0.37us-gaap_EarningsPerShareDiluted $ 0.61us-gaap_EarningsPerShareDiluted $ 0.47us-gaap_EarningsPerShareDiluted
WEIGHTED AVERAGE NUMBER OF SHARES - DILUTED: (in shares) 27,881,908us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,857,467us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,874,074us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,855,141us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
XML 33 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
Revolving Note Payable - Bank
6 Months Ended
Apr. 30, 2015
Revolving Note Payable - Bank  
Revolving Note Payable - Bank

 

[7] Revolving Note Payable - Bank

 

On February 3, 2014, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A. (“PNC Bank Credit Line”).  This amendment increased the maximum credit line to $70,000.  The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i) $70,000 or (ii) 50% of the Company’s qualified accounts receivable, as defined in the agreement.  The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank’s base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage.  The additional interest percentage charge on bank’s base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company.  At April 30, 2015, the Company elected to have all of the total advances outstanding to be subject to the bank’s base rate of interest of 3.50%.  The credit line is collateralized by substantially all of the Company’s assets. The line of credit is available through October 2016 and may be extended for annual periods by mutual consent, thereafter.  The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, and the prohibition of the payment of cash dividends by the Company. As of April 30, 2015, the Company utilized $49,315 of the available credit under this revolving note payable loan agreement.

 

On May 14, 2015 a date subsequent to the period covered in these financial statements the Company further amended its PNC Bank Credit Line to increase the maximum that can be borrowed under the credit line to $120,000 as well as extended the credit line through October 2020. This amendment is effective as of May 5, 2015.  The other terms of the amendment remained substantially unchanged.

XML 34 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets
6 Months Ended
Apr. 30, 2015
Intangible Assets  
Intangible Assets

 

[6]  Intangible Assets

 

The following disclosures present certain information on the Company’s intangible assets as of April 30, 2015 (Unaudited) and October 31, 2014. All intangible assets are being amortized over their estimated useful lives, as indicated below, with no estimated residual value.

 

April 30, 2015

 

 

 

Weighted-Average

 

 

 

Accumulated

 

 

 

 

 

Amortization Period

 

 

 

Amortization

 

Net of Accumulated

 

Intangible Asset

 

Years

 

Cost ($)

 

($)

 

Amortization ($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

8,738 

 

3,469 

 

5,269 

 

Covenants Not-to-Compete

 

5

 

11,131 

 

6,325 

 

4,806 

 

Patents and Licenses

 

17

 

5,297 

 

1,922 

 

3,375 

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

25,166 

 

11,716 

 

13,450 

 

 

October 31, 2014

 

 

 

Weighted-Average

 

 

 

Accumulated

 

 

 

 

 

Amortization Period

 

 

 

Amortization

 

Net of Accumulated

 

Intangible Asset

 

Years

 

Cost ($)

 

($)

 

Amortization ($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

$

8,738 

 

$

3,275 

 

$

5,463 

 

Covenants Not-to-Compete

 

3

 

11,131 

 

5,738 

 

5,393 

 

Patents and Licenses

 

17

 

5,297 

 

1,750 

 

3,547 

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

$

25,166 

 

$

10,763 

 

$

14,403 

 

 

The aggregate intangible amortization expense for the three months ended April 30, 2015 and 2014 was $474 and $730, respectively.  The aggregate intangible amortization expense for the six months ended April 30, 2015 and 2014 was $952 and $959, respectively.  The estimated intangible asset amortization expense for the remainder of fiscal year ending October 31, 2015 and for the four subsequent years is as follows:

 

October 31,

 

($)

 

2015

 

900 

 

2016

 

1,540 

 

2017

 

1,063 

 

2018

 

946 

 

2019

 

904 

 

Thereafter

 

8,097 

 

 

 

 

 

Total

 

13,450 

 

 

XML 35 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
Long-Term Debt - Bank (Details) (Medium-term Notes, USD $)
In Thousands, unless otherwise specified
1 Months Ended 6 Months Ended
Dec. 31, 2010
Apr. 30, 2015
item
Medium-term Notes
   
Long-term debt    
Term of debt 7 years  
Debt issued $ 5,408brli_DebtInstrumentIncreaseInExistingBorrowings
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember
 
Debt instrument interest rate (as a percent)   6.12%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember
Number of equal monthly installments   84brli_DebtInstrumentNumberOfEqualPeriodicPayments
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember
Monthly installment including principal and interest   61us-gaap_DebtInstrumentPeriodicPayment
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember
Debt outstanding   $ 3,412us-gaap_LongTermDebt
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember
XML 36 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
Revenue Recognition and Contractual Adjustments (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended
Apr. 30, 2015
item
Apr. 30, 2014
Apr. 30, 2015
Apr. 30, 2014
Revenue Recognition and Contractual Adjustments        
Gross Service Revenues $ 1,175,282us-gaap_SalesRevenueServicesGross $ 1,017,621us-gaap_SalesRevenueServicesGross $ 2,240,575us-gaap_SalesRevenueServicesGross $ 1,927,499us-gaap_SalesRevenueServicesGross
Contractual Adjustments and Discounts:        
Medicare/Medicaid Portion 101,262brli_ContractualAdjustmentsAndDiscountsMedicareMedicaidPortion 94,520brli_ContractualAdjustmentsAndDiscountsMedicareMedicaidPortion 195,325brli_ContractualAdjustmentsAndDiscountsMedicareMedicaidPortion 183,439brli_ContractualAdjustmentsAndDiscountsMedicareMedicaidPortion
All Other Third Party Payors 838,004brli_ContractualAdjustmentsAndDiscountsAllOtherThirdPartyPayors 706,234brli_ContractualAdjustmentsAndDiscountsAllOtherThirdPartyPayors 1,587,205brli_ContractualAdjustmentsAndDiscountsAllOtherThirdPartyPayors 1,330,379brli_ContractualAdjustmentsAndDiscountsAllOtherThirdPartyPayors
Total Contractual Adjustments and Discounts 939,266brli_ContractualAdjustmentsAndDiscounts 800,754brli_ContractualAdjustmentsAndDiscounts 1,782,530brli_ContractualAdjustmentsAndDiscounts 1,513,818brli_ContractualAdjustmentsAndDiscounts
Service Revenues Net of Contractual Adjustments and Discounts 236,016brli_SalesRevenueServicesNetBeforeProvisionForBadDebts 216,867brli_SalesRevenueServicesNetBeforeProvisionForBadDebts 458,045brli_SalesRevenueServicesNetBeforeProvisionForBadDebts 413,681brli_SalesRevenueServicesNetBeforeProvisionForBadDebts
Patient Service Revenue Provision for Bad Debts 12,030brli_ProvisionForBadDebtsOfSalesRevenueServices 15,501brli_ProvisionForBadDebtsOfSalesRevenueServices 25,225brli_ProvisionForBadDebtsOfSalesRevenueServices 31,046brli_ProvisionForBadDebtsOfSalesRevenueServices
Net Revenues $ 223,986us-gaap_SalesRevenueServicesNet $ 201,366us-gaap_SalesRevenueServicesNet $ 432,820us-gaap_SalesRevenueServicesNet $ 382,635us-gaap_SalesRevenueServicesNet
Number of distinct payors included in all other third party and Direct 800brli_NumberOfDistinctPayorsIncludedInAllOtherThirdPartyAndDirectPayors      
XML 37 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Subsequent Events
6 Months Ended
Apr. 30, 2015
Subsequent Events  
Subsequent Events

 

[10] Subsequent events

 

On June 3, 2015 the Company,  OPKO Health, Inc., a Delaware corporation (“OPKO”) and Bamboo Acquisition, Inc., a New Jersey corporation and a direct wholly owned subsidiary of OPKO (“Sub”), entered into an agreement and plan of merger (the “Merger Agreement”). Pursuant to the Merger Agreement, Sub will be merged with and into the Company (the “Merger”) and the Company will be the surviving corporation and OPKO’s wholly owned subsidiary. The Merger is intended to qualify as a reorganization within the meaning of the Internal Revenue Code of 1986, as amended (the “Code”).

 

At the effective time of the Merger (the “Effective Time”), each issued and outstanding share of the Company’s common stock, par value $0.01 per share (the “Company Common Stock”), (other than any shares of the Company Common Stock (including shares held in treasury by the Company) held by OPKO or any OPKO subsidiary or the Company or any Company subsidiary) will automatically be converted into and exchanged for the right to receive 2.75 shares (the “Exchange Ratio”) of OPKO’s common stock, par value $0.01 per share (the “OPKO Common Stock”). No fractional shares of OPKO Common Stock will be issued in the Merger, and the Company’s shareholders will receive one share of OPKO Common Stock in lieu of any fractional shares, after taking into account all of the shares of the Company Common Stock represented by certificates or book-entries, delivered by such shareholder.

 

In addition, subject to certain limitations described in the Merger Agreement, each option to purchase shares of the Company Common Stock will be converted into and become rights with respect to the OPKO Common Stock and OPKO will assume each such option, in accordance with the terms of the applicable option plan and/or stock option agreement. The number of shares of OPKO Common Stock subject to such options will be equal to the number of shares of Company Common Stock subject to such options multiplied by 2.75, rounded down to the nearest whole share. The per share exercise price under each option will be adjusted by dividing the per share exercise price of such option by 2.75 and rounding up to the nearest cent.

 

The obligations of the Company and OPKO to consummate the Merger are subject to customary conditions, including, but not limited to, obtaining the required approval of the Company’s shareholders.

 

Subject to the satisfaction or waiver of the foregoing conditions and the other terms and conditions contained in the Merger Agreement, the transaction is expected to close in the second half of 2015.

 

The Merger Agreement contains certain termination rights for both the Company and OPKO in certain circumstances.

 

If the Merger Agreement is terminated under certain circumstances specified in the Merger Agreement, the Company will be required to pay OPKO a termination fee of up to $54,000,000. In addition, under certain circumstances, the Company would be obligated to reimburse OPKO’s out of pocket expenses incurred in connection with the Merger Agreement up to $3,000,000.

ZIP 38 0001104659-15-044096-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-15-044096-xbrl.zip M4$L#!!0````(`!`PR48T7M7\F%8``"Y#!0`1`!P`8G)L:2TR,#$U,#0S,"YX M;6Q55`D``S^Y=E4_N795=7@+``$$)0X```0Y`0``[%UY<^.XE?\[J`=OW?@/5`\^,?-V"=75$C&@_<[9L/8(31PN<>"X?N=6-8=Z3*V M\X\/?_OKP=_K=?)14">B'NG?DJ]4".;[Y",7(1=.!!.0>CT9^.^C\Q/B<3<> MTR`B;G+7-8M&V7U'@GE#2DBK85H-&U:>W'WD2!@-\ZEIK(:974G7YT&/M'>[ MNY9AMDBSUVKV[!8Y^ZK'W?2%3X"O0+[?&451V-O=O;Z^;N#7#2Z&<)-A[[)` M1D[@TAT]LN>SX,<]P_%R'\A*A]_<&7]MJ]'FWM[>KKJ:#86)/):-S<_;WM47 MTZ'P@4U-VF=M,S.?8SJ$>D-H-.AXX39#0-' M]M7@Y`*N8-<-LVZ;>0;8"J+TZ`RWDKJ-(;_:A0OSII=LGB!A:G/WWU]/OKLC M.G;JV2*@84(.4,`]J2Z=TP%1`N]%MR%]OR/9./21&/7=".3W?@R:]Q( M;X?LZHD05#R(Z$U$OE,74:Q`!%?G@\OFI6U#`?_I[%GMIGFP.[EM M,I6D0S3+[`OX2L.P1V]"G[DLTK00C\$X[1D2#GK+,;SS(1W_,,<'NW,7GY"[ M.TWOP>Z4:`Y"*ACW[Z7?I#+E[#G83/1>N=,3RMQ7G80F,:E;2(*FI7I;X7I-^NF`3%F4UJO M;+\4ME\("NX&`,W'%\=E/M`Q9>;G](K[5Y`]3X_9#AW?Y6MBS?<0#K#%G?IX=2TD@> MW7YU?@=/Y#M23NGZ&X>][CBD$3T<"DJ1ORUQQRMP.T'`8G:+5C\H6D2?8*N> M>&$3MGPP1_9M-I`&7CHLL_3TN_+@Y&,L(SZFXH3)%PV0.7Q6R)B+#)7@G0$M M8$*0!YTP%Q1`7R(V5$*WB-.7B`X;T3$G]:\"3%D#C+T<4++=0`F!4D68"AI5 MB'GV$/,\\%A83:I"2HE"RC-4#ZO(L-'(4#(-5PY^*[1\=Z-XPH-A1,7X$^U' M=QH]7ZG'XO$%7/[&HVW1YCR.)J8YEZ7RUGRS;,RZM+/M?O;W4TO`N5:08`Z` M_AQP/;%GE.`QD"W4T9?\F,^QX![W?4=L!R;65DM>A8A9(2>^9'DIK[E"85AU MPWXX?4R&/7%W42X\XRDM_+="\_K0/"WCEX3E252=6XM],IK/(269"STUZ:J56,Y6XIJ>0:HZB67I))9`P54C<;N47*9P5/#C<65BK9#N;UOO-\JF ML[;*^XIU.=\C,"RT#V5PIX/O$7=_3$60[S`_E8=GZIETV`NH$=OA9A8R-XD; M]W!7=M._UFM/PGV1\ZXS_FA^T?,),,:R7'@ M-F;J%4>Q9`&%R#D9-:7^,T>@`"$C=H+9FLCWN"_I'S%<_WP%_^_.(9>9Z^4& M#4BQ-R/%)).X1XQ%EAH6:&*"U3FJ*'+]!=K,VBK'D]55D?;5'F)9P[G!![KFU?'/%]:_-2VM;T,]M6,EJ;11*?S9%&[4 M36L)A:MA!3RFE>A[^NS9QG?XLP>%EI'(>@\*E4LDSWZJXZY$-E_?FM,G7.+Q MM34\(5U2D2S]1-_*(OE[O?Y;P.[\3&",WZ&8\&+.9#QV!9Q,%L=QWR`W`EGR MJ<1K3!T9"_HA^:'&WF_?/QWLIE].O.O\^]6TGVC`QRQ8-+'Z_<:>',$F4RZ: M^>X4![LY#O2@>0Q/U/_PQ@DP=HY_ESE0Q9'<'$U4I--/.JR ML>/+]SMU$*5MM=LML*B#W3D+K4C!?"_X``%FQ]BS"B)@061Z2`2==JM9K`A: M*Q%@[BU'0.[GT0Z]WV,9C9/>5O8K:44BPVR9=M?L3NAZ>/D":'T4AH#(3EZ" MST+IX\!F=KI6RS8V(]758+EG0Y1MKXW20]\_C4947(R8\,X@`-^>.;=<%(MA MVS;LSMXJ/"PB:XV\/0KS':-MV2MA?@.TE?R/!Y^BX%;$=,,5C6AM2,=.R\=&#K;30,NS4?$5.\YB1RP@)Z.M`TH[GX M'#>U%R"((Y^[/U9R1Q]^\:-]CUW],HSV2?(WD=&M3]_OC!TQ9$'=IX.H9X31 M?O)9L.%(?[&#=_WMKW_Y"]X83M^F!@R`DOK`&3/_MO?QG^2"C:G47TKV)^T1 M$P9EDZA9\&(ZD<=DZ#NW/<("'UC6R_WBC,/]H"_#?1R^B^/S5.R&STN3NO&: M*I'TN>]I(O_3^>\4=8^;A63X)&AN!(P#,4;JY,@)?I2"_3*J1(T\#<@7VA>Q M(VXGY-DU@A90(Y"YD>2L!@%#`ROSX.Z($R<@#IB>!Y]%)OP`A1\FPO"9#\<\>H04S)33/YZR)WFS/&L$KX0$V6G\2Y M"`QT`W:@R-4M&T4(93$2:<'*B M.`D\+.O%`GP^R1XH(*'@6#659`"DPS"F`"(C(C#D0%;D>%?JU_-QLCXE,N[_ M3MT(*(O4W-37I<(9)FLXG#+<-*BO^VC#4XSCVXF21?20R1.WR=>#"3&A'\L: M2L"E(G(8DJE?KP/?(F^>ITXI.7[N%BI<8-`9TFG,T0=&$W<$MJI8OX_H_B3= M0LG"Z%GZ-;MJ9AD"+L7O7F]`A_VPTPB5F5Y`V482H'8H1;P#3^U*S">NJ( M!$C"O\U3.M>H''4)D3!/&VEH+%S MB^Q"@J']I+:2`(R6Z,Z+1.K&,:;VF(I(`)&2,KBR`7`PRRCJ6FK:D9+,##&+ M`7W7T'&!D+DR'&6;V`@'E`OZ1\R$?@A(43&&X7@+ZB1U$3X@PU?3NT[(4(44 M"[C`-Z1,&J@#=@,#$XR[_`J$/$0_$VBW"TN.6)_E+3K46:J>58Z(;K,$FO,\ M!,FA6GHI[,41T[K]N;E7L\U6NMA$-XF^8A"[T-):*D8URA.52YHI?'5R20+F M!Z@=XA`/C55F)RM3T]8PUU#)HA#8]L0SR?1PLYQ2\2`6"L5IBL'@^KS\`!=* M8_]4Z(]&$&-<4&X_=:;H'1,\T#N9@6GI$`PA\YJ"@X!_,[.],WZQX5M&XTYF M`C,-!ACGT$LJD$\)L:5EN#`@:VO.F7X^1H--.\IXIUU<'("-0M3PE@+T=-H- MX'B_8^YDNYRIS#R[4WW(;X;2#\GV[(&-UX(M6K:MU$K,=O4?G1"NP)94GF6A M]G20OE_I/$MYYNQRBSLX>]_NU,+=:;8W+9*EG*22*4[CZ'1P!D*D:8?MG+)Q M'Q+02328EL&V'K&_IT1D['Q0/:BL0K2<IFR5+W'G#"7D$U.E&E]ZI,JQKF1KN\#VW[LX8..=SL`JGH)6Y7HR?V).R6T MC(DG4S6'PR]8B%79_W=UY.-8RA@SHI<*DV9>NL??OH";FY'N?(G,$=UI^(/K M(>`:^1@R5?60DO9TJ(\31F/P@,'M[)2O2;SFC'@?+[6<"B#"J.\^\B!Y^_$% MSTUV'"@23P?:[%^3N*U&IY5(?#4AY:4[]="=%OYA'(VXP#V*]C<0\)-']/X' M2.+S9%SX4XT/,F]/'/YC>"A>!$4_I?NL$DAVVU^X2(X_(;F.3R&7`^#$%.Z\ M8BXM]'2(;1K-=IZ'98DHD/+'G9EKM0QSPX0_KNMLM:Q\TWF3(E^QK6P9^5-; MCR(\N0+1AP\#Y<"KIEHIFVK-_Y)$5R2G+%6HRQTG(+GS!*7@IHP25B,36\`J M(@I5$@@/)!2PK6"AJK@,:8"'U;'(BW5ZW^ES=7;]ED14G5`@,C5IEL82@L\) M,!?TX#%G&'`8YZKADLC8'6&QJ.]S[H':'/]6,EDCL5!=J.2STB>NG-Z(D^9J MP+)!YA(N-"2P@IHT8B*0D?YCEEK%*!4#+L8X'!;4,X1<1-G]3!"\;ZP$`.3` M=:R^JY*,;J;)JK2Z&L#Z%$1.)U5\5;;O.QYX=?#42@FYYH^NB*/BAH)+F:IO M,ATJ!6OP.>-W)L:O].JEQXGFEB(Q^P55J\(GRQJ:D"2%/)"LKVI+`, M;-]Q,5@JM9WT5%2-I.>BL%GH@`S&8RI4\9D%$+FP2Y5V,D5*LVH2X>@P.=^E M60.@CP#:T0@GUOT1";I/*L^_KI/RL70`6^C)WV;JB<<@0L#+6!_:L2EZCA) MW4MRP2Z8*]^1ZQ&#P2*MX&D)>JI$X]_NITC117!/-]95L5Y+0HUF.1TH!Y>3 M+R(0;6:6:4GI#YFUKI1#G[UUTDG0E7E%-@]T;S@KU-]5)MJ"1E!F!RGT)/'9 M#\WC?`MT0!9Z8CEG:JG:C1X;P#9&*9<'$)>4E0C8L0O5JL40!9+IQQ$@7/+9 MRXMX246!5S2Y*GPE#4#R5N1KK.\4DS*$['.0!K3Y#&4A8RHZP7@('$R.LJ8V MJ@7%Q:BB9@39#K"&/V_HTQLDR*5>UJ/\/?:&:3_)B=+6)YH$>#MT/REA,X8, MLZ,!J`@7:/UF;6LM`NR;4G"!GEXH$MC';)!_*3?+Z#7A,=J)[\:^DX@."8=X M'"&]P`M3WHV+Q-&,'=!W:KZ*VFN:9!8<"-*]:M4M4")%1,4!MKRXG"\R3-4TT242#"X/$!HK-J",0JK#(5_[0T5(%\\ M"S$M2F`=[J<(+$PA_\S%I5D!SVH%F5*U[G[F;]*V?S(T3,_2*H6!J++\!/PX M@"J'NQIAL`(>]$&T!Y1Z"YF`F134^Q0(`7'P:YUYY%&<+K@@]\&()(1JOT9) M=JJOU))NJCKME:6T7`,X:TPKZPJIWL<^.H_%'7$=DN)AT'/5.;J-9[:YG?8U M\Z)1SS2,-SMIIU=+W:6^'^*1IV"(W17U66+C,OF0B3JSZ)R0:_> M!=D/N""KJQB=<4'SGT(\<;]O7O/O1?(?)I&ZT*D>5#9!4@JW)G!?W7"?UFY7HK_%6NMW*]RT&_<+F^8NBOP_56VYV^X_[` M`Z:!AX?AN.B1GSY^_/SYRY=5I4+2_S/O%1$>>P^B'JF;JS^7LNQ&Z9_J5&7Z M@$KR6)EB1&+)J M5M.HM3JM"D,;3\5@2*?36XNAS7412I0\;TF7H0RNQ"A\ MZZB->M.\56JJU%2IJ5+3HOSI9:JIN%K@=J0H+['RM^"GHM2#W]G+IWI5)?!) M._"U,ED^OU"IME)MI=I*M>54[=J9+)]JJRK3]E>9TI^ZV\U^Z2YY!6A5='K8 MEV^F5&R8-:M=:-.S4LG35++7K+4LH])(>31B[K5JME5H1^ZEJ,3:E$JZ=JUI M%]K@*KE*JAK1O:G'H>\3]1H=HMZC0]2+=(A^@M?N MU@RC61W-J!#T2`1UC';-LBL$50AZ_.&>5K=3LXSJ@-C*%;4*0QF&;-NHV9WJ M@%A5NDORYPOULO2E.JU5,:_7 M#4*07[>[!?T4057AW?X*[UGR-N29/)N<3;W:^FV%H2=@R#!K=K%G5RH, MO3(,-6VKUBWVL;V7CZ%"T^+MQY#=M6IMNZ`-U,LJV>J/#BAW5FCIU7DTKT;? M4EGL#`=I#IO1&&Z`IE_)_*??]`D)0=TH>1".N#R03$82SU4X_IC+B"B-DA$@ M1%"/P/P1"^"&4-U0@W5":C`45^BB&XXU9`'<+ M)\*5'$FN*5`%_X:"#ZC$"K/C^[>DSWP?5G)!C0(SN+\BDOR"2 M_L+;0)_C<7/G>``(_-H)7*KUZJ7'>-Z1,!8R=F`:6/+P^V_D&V],Q`F)FEGO M5)J^EZ9_C6A``GI-^K&$+Z74FG0INP+-]6_)T?G)<6U639+,4]/,<:M,3\01 ME+B.[\:^$^E9!:+A_]F[UMZVC:S]?8']#X2W"[0%[?!^21H#MN,4P2:Q:SO[ MHE@4QH@:6=Q2I,HA[7A__7MFAI(HZF+>)%'RH-B-9)%SGG.=,V=N-$X\L'L: M%IJ'1ZC588@O(_;.4GLX@0"&I8I354!DA67WX)$^M6R<63;]UTNX14>>E\82 M-+;*?*/`8CQ"$*Y#"`F6?S/O/&$(TA1A! MHT`?7LF>)"M;7VBS7(-%\2PT$V.N19`)MQ/:SQ+NU0MZ[.,$QQ#J*=$!?)02 M]"A:,F;@0!&@?>B'X,Z0>`0W9($@6[;/&A".OQ43]E"HD>@BAB7[. MM,&EJ21[!.(S-5QJEU&?,*]8B+!O9EX+JECJG>]F-C%"S](0/8*58`@C/``` M[>B1:AH`$#3"4WI@;>#-F+9+[3Z!_T&<(L*B4S0V)) M`P<[^=N)]`6%Z`'3B`,HJ&,_^OAIPOLREG+R62X32J:'`Q](D#D1\C[-']%H M%$-6R`5%`GC..""0M3`\!?O`)^!6-5O`UQ@]I]HT& M/I_&%XX`,B^6U!`O94F2]#3TP4>`OZ#/5<'BYF#`/&C`>$R@A_19-C4-NY.S ME^`O_J@'O2CF<9MBX3D4"#I`,"*B"9H/PH`?0&=QE#7@T6R0#%%,OS!H(1[0 MA(P^G(M)TA4,H9@;YUF$\`;1.0&,]/4SSZ,=#[0RA77&T;,KGZ9M_7@-XS7? MDSZC)TE5=?;#/[[39]ZY^D\_SKY?O+L^^W(V^_[AW4_2$Q@(@1$04SV0"J`1 M0%*X;EZ5&F42=;3^B%W`>(-0=_!##XW>RJ;$^F,VS>$^C1(9/89_#"FSC!G$YQRUE>!^7E# M%#[@ODPMZ[_4R(#'Y'G,#`:%8>:@X(>0C8/G^`$5:+DL;-Z1P$O?'ZG<<5;/ M`.0'=U+^RR]O>G'@O\V2@1ON^%2!=!5X$-&QR!V,R,^#R/OS].]_DZ1?V/.W M"#JS[*4LH2!?<7*.P3/P-*/X&,603_!T@CHH-'2#!^^//M!(!K_?J^J]>@^, MZ_=WT;UQKROTBW$$$O'YD]_@@WH$UN%!@A.0]T?'^M&IH>J6HRJ*DH&O#*9] M1C3.AU&)#TVU',ON%!\3AF6HEHM\9%%E:L! MO)&]/)FINZ.Q:NI6E31QFE6^IHZS\F.EE*?2&X(%P8)@0;`@6!`L"!8$"X*%@V1A M\8WE.7-N`)`M`E"4?TY?9M.[DH>#(&/F_9%RQ+Z3,?(FW[/WLYE]6EE&8X+? M3CZ\XPU+CG(";<^)B8KEW7SZO9U-0"W-G3<8PK2R8J/%-=E;O5=]PAR8"!@2 M<&&)+9]TM(JOH;,]57 MI\%M>XGQ"F6\"2^Y];]OWT=$/R[Z\7U2?-U^_'#"1&%UA:[(PCJ:]E_".D2G M(3H-$1;6#_Y$_:E.1/K/MQ"E?3_!_3^$1;8\T!(6V3V+%)VCZ!SW2?&EF.O` M@4J'$W_HVDQ1[A2F_SI-WQ"A5]B?"+TB].[%P7T'9?J;"+UBN'.(1P7^RC8I M%R^$V5SDW-=#S9<,5-WGO=A:A0\GSGLPR="&4**T/';E3 M[YHWH2:A)J$FH:95^=-AJDE<$K+_E;]2ESV_%97`1B/PC3+9O;@@5"M4*U0K M5-M-U6ZZI5E29]K_*-#GR]@W_X/>EZRBFIT&*HM/+L7PWI6)%E36KU4E/ MH9)F*G$-V6SWSBBAD89.XIJR+NZP79&H[$8ECBX;>JL37!U7B:@1K4T]EE]V MQ6^X^EF4AAH-,G>WP:]C$^N.[LB*8K39$0@+>E469"N6K.G"@H0%U5_<8SJV MK"EB@5CEBIJPH:D-Z;HBZ[98("9*=UG^?!O])7?/;[;G'1O1S7[TA]U;&BLZ9:LJ*WFL<*$7ID)J9;L6+8P(6%" M=4W(,!U9,42)=Y_RZ*Z9$.37EM/2402BPKO_%=YKE/A`I'B"CC2]!UP:1+%T MCB"KIE>!_[RY51,=MY9]Z;-V,W#79$64<80U9-9@RJ;2ZG$WPAKVUQHT4];$ M,MD.IJ8[L09=A2%,2X444=_=__HN+>>*4QN[U;%H\'L_2ND5VWLZS-4T778= M4:\5-M3`AA15UMM=NR)LZ)79D*%KLM/NMKW#MZ%6T^+]MR'=T61+;VD`=5@E M6_X5@7*+0IO\N@QS-7RELM@"!Y,<=HIQO`-,/TO+=[_Q%1(Q]I)L(YSD12'Q M24+HN@H4C"*22$RCTA`L),9]"=I/_!!>&+,79*#C!2DU%'AW-,*QYZ-`&F(4 M)$/XC:0QCOE2#-0?^2&\':.$4D)$>L*`"OX=Q]$`$UIA1D'P+/7\(`!*R.,K M-R22>D/VV/"9^-!\"%2'$1G["0K@HP=\^AZG$3$6^YRE0CLGW=%')VWD9QA\ MC6-,V-H9D*.$1E1NU!(F-7_I\OL8AP3#SRB1?"+%^*_4IV:11%(/2]GK5.B@ M#ZF/^ZF7L(F#.!J!Q?#Y!9+-+\39_,*/(5_'X^76\8`A1$\H]##7:W^RC.A(FN&!`:N^/5"8(:?78,Q]6I/R7 M7][TXL!_>^L-@>4`7PU@+)M-HTQ&M'1-Z?IW__FR3]4GCIWRA( M$9776=C_#:3@#Y[!K\XR^YUO@$D+OMS@P?NC#VG,WKM7U7OUGEZ:<7\7W1OW MND*_F$>G61(<[%_,\98>'!Y:_D:1`[D%'2NKY)T M:U;5>#?K0O,*?=E!J[Q1Y%6P(%@0+`@6!`N"!<&"8$&P5$0H#'!;R M>G`X]U3^^,-/&[!$]<3=1TLL5&9%"'IM(6C]M([[.N\=WD38^<^W$*5]/\'] M/S9BA9;S"A4E'&`_Y2JZ2]%=[I7BJT2+P^FSSL:Q'\R$I"ORQKHN81%[81%7 M7A+U<)RS"743-B&Z!]$][)/B&R23HHA3)P[1I1*B+Q+FMSOS,T2WM_MNKT,[ MHO:D6^QF%-KCBDI';EQKK^?:-2O"0C9C(>UU+OO1E1SBMMO\\8D7,>[["7FS MR6,3>;^SM_M.*L6;;FT?,AU-5IV6MJ!ELT-"C=M7HZK+1EN[47D$WULUBF$" M//PA2GO)(`VDR581,5KH=,UB)U'#466SK3N!#GU@27WL^2,4D/='Q_K1J:J;KJ&#/V8,E*'?"EQMR1D!+Z*U7,M6 M=@!VQ8D&+\G6M!W'V)ULS4IH'44Q[=I@_R_V$[#ZP=7@.H[&.$Z>X:7+OU)_ M3*_!:=-B72UG`>O)MH2OHM95TZP&L(_]MV?PM4__]#%`#]6.U1@`:?S+FX56 M9HU?I'%,_^@3#P6_8Q1?AOT/**EF[*?'D/L?ZRJGM*K)&=$/D9>.IH]#>^M>7^J$1MX+/WW]")*U M'45S;6L.RQIB"\"X@=_@<10G\/MM@I*JMO0[)G/DES99)/S1#W!\`6I_B.** M&H#L`L/+B)Y]Q)K)4Y]KMTCT!C^PX!XF7]&HHFF=?[J2;BX_7MY*+P)$R-EWG]S3G/S^&O0`<04$^]GWZ#B&?,&C M'HY?BQ`F[URD)('0$7^F9VV^3A%\C6CT'.,$GSW$&+,K6[['L<8L@ZQ4^7%/;A2BK5;D,VZ@/Q"FE<%4JE^315S5:= MDH3:R)9U4W4,=PG!Y4GI"W1+\ZG;$.N4:F1IT&^!8TNQ-&L)Y5GSE8F7'U*J MJF)6H)U%V<\8$7S5"_P'9O"M*-Y2M7D[6T^K(:[R$M(*D;T%6)^XY>BV0[,TKZB&8:C[`IE!6NT3:7H*EL7 MYLL5-U,M5`'KH)Q5U*]1?!73DC;NLP>O<&P!7 M"K$C^";3(/=][-]_Q@\HX`7V68WC'(UZ4<1&IH2-MR`LG_"1[73P>YX2/\0P M(IX]-3[?P^_(Q]2:ER2=XSM)D M&,7^_PI=X4MFN#B=I)M\V=)2<$5:34"M-+W-8OI$2-I82)H-_UF&L080IU,7 M3`7A:+;M.FS^KQF6]?.1+4MG83ZR)JQVY50&5?->$X"LLN7U'4_SGM!V*E$F MR=4@NU>EU5J4IJFN7LC"YHA5!U*KW*3"B$XM*J,9CGI##LCW%&*,AZA@L@U[O=9D19 ML5ZON0MY07F0O)@R72&1+5L]QR$>^*TN2@68!3]:2[HYS'KS2*;B;!5ES8BJ MPW^[D&8UTW2-XNBK`DIZD>&GD"0Q6XMYCHA/;B'6HOY5^&\$IMP+\`T8M;H* MKSX5Z_3S=%J?'9_Q$7E^,"D)3'ZZP8]1\`AY_/PSA;']#0H?YD?S7]!W?Y2. M"L_E@EZ^&BL%Y(9*9>6UUU+VPUU(6=VME)?'B.[+ M^3*-HSZ]"B?>%TG/A+LU2;<2-VI(NN7(\0$3+_;'?)%`P=G\E>G.)J-'PZAP MVH/O$ETIODI0ZUD^;&$M&-SI["\;$MHG>I0E)@E]F)>YKW%,#[A$#^56OWV. MP@=H8D2;7:C&?P'AI*,[^/EKE*Q:[J@OJ\9;JK:*V760U['*][;XWC5ZKKKW MJD5N%YFW_O@HS?;8(=(#IS/P6 MQD.F:UL%>:ZEW0+0>I6G0NEF\S#K#8F.C<(RRJW)L]J8Z%@UG1:`PF/9>J8R MFTM*K$US+6,IJB6$FB"JL!!0459HM&5(Y5?2N8:YW&=K(2JU=*;$E(A;C,OK M2#6$56&UHZ&^;%"MX2I?+3-TIP&L<43\A+2Z2%)5%HQJ.97:6"KLH-**P;XD ME&W,WS!L!73E:N_;F:.!P+Z@R`WAJ]=%ZJI==,D-"[#B)**EM"#`55O&6CT3 M1'7UU:)["FJ8KY$<0A#23)96T0';5X3P9H+A0G#F0%<2JXV MHE).O0A(MS<%J)P>%Q%9VH9%M-YMEXBHF;G[!^D5YS>.67 M`5EN83]U571_I:PHF`PC&(<^8I*PC9Z-1&:JYOPZA!5$ZB(IOX1#^9=_YD7]SA]MU M]I2XC6-:N)6)7ZJL_2%1'4E\=>,7C*B*F"([@;J+DN0W>Q(I&DB+]WM*U%AE M*1EB*5O1SG[^QW?XN_N.2`,_1"&DBP&T-BFA$@F:`;@`C[H$\4E"&_<0&

>4P+ME(2HSZ6XNDY)41"85\:\\-=H.DHEIZ&OC>DU$&E7K:?0D(C=L") MA,;C./H.E!(L#:C2'ZG2B"O\$$B@DTI.?#"7B@S)0S`AR-M`CCNDD M!*!+8Q9C9BSP3A#TPX^1D!\*T1Z31F]>,V=,TV#U8>]<_>,.U"F;,38JE0B+15J\/X M=^#W;F'X<0`":>+VAN4>JCCJ>[VE:]L+AKF7L@G+LP'D1.P44'BAB?L[BFN7 MYN,%'$T8NL$C1*]UB*\&LR-.FS#F*N4[[Y)PFO#7AJY7;)SG*F=R;-O3=ICU M;]_1=I;1;]_/=IVM;]#-ON*&LUV&H91.)(!8:\"V[V*Z:91VL9USVL"_3*-\ M:M@9/AL4P'1WB^Q66(1CE*_?MHAK!WZEER_,[IK1)FZEE2]$=87-^EYE.$KI MY*L"M]\('J3!9W]0YN*NC786I]=J?K](&:\H!L;C&F$^O]1TS MNF)OUD'9:PL\=MQ<6^1PK;6:C?C\%?GA9Q@D7(6WB%ZO.'=%QD;NF3M6E?F^ MKQR$]F%7W"FF%NX:J@5[BQ=0TN.3YL?&I6X=;`2UU@X(4W%=;W MW6Q-IA7/GW+L0@VH&M`HZC_Y0S4(QK+(.*!PK,>8(R#D>1#'.70+VQ0^CV$^>)]OSP9/F6RFS!KGI9C;=<."]?8K.IJC=E&`6XA?QX6]KKO! M7#7IT]K!#(J;K946>T(ZM"?$_4.").'1)W2!'EV]SQ4F,5?K!/`N"I,]>3?$ MTGA.=CZ774)EQ_Y`MT8D='W0\0A:&Q()AWW"5R'SLVT,L70C8K'V4;%I4\;LJ$[U&*"E!J% M#TH#BC%_@ISDI#7]M!*M40DK$GI,Z&V[K=XW MX12N`RS0:@"DXKC',I>62EY"LKG##U5%6R6;=8??;>'\=]=:5A)I$U=-'6J6 MNZS6L`&)52N"V.SZF1JX8GJUXP?,__T4GGD>V^I]S?>$T]D-SXO3N:,K6BU@ MZ,5-1O4P;9ZOJI>0*@N^OD&V;J9;^EN-#[JFE57.#$';F"N64Q7-6*CH-\8\ M61(Q.8FO71=XR5**U-M%6W':WEZ(?PW1TBI?F$1QRY'%^7_VKO6W;23)?[X# M[G]H>#+`#"!K^);D;`9PG&0W=YDXEV3N/BP&09MJ69RA2"T?=G1__55UDQ+U MLD2J*9%R[V(WDD5VUZNKJE^_LM="R/:.I=%84IB[-%^"Q%M,^C)4H>OULNP' M+S3O<@3K_,W+$,50EO_B+`TP.+,N0H%B<<8&E(4GY.DOC>`\>)0E*'GLM_ MNF,@@8Z`$K=_'OV_ET8 M@:`N72R:,HW95?[AI6B8]+4NM/VR&#.X]I;92Z+Y5_%]B,;KW0?800+Y\,4R MO8;9[1D_OLSH6PXZ_[9=[BBNR['PRKKF=)W>CR5U<:`ZEE61J289EF->,[NZ M).:YU?.^KK"B"XLJB&.9TT.9T_O<7D[#7+^DJM>B_**M?D[X__*?V?#R6@#L M*7LH9P_&">VA;N;.6W-6U^Z?TT@N@$VI0=P>IU[[(-:[1AN9$]^CI>\J#U-# MM@%#MA;O78#86LA*5/Q3MJ%RLN>AN;/+R8JC6HWB9^WA/[)D(:)PM/A<;^*N MTK]L#3`)IU?Z-"%!&##RPYL!_I?D/_*5OZV_BM;Y[W'H>T/R`]\3T^8/B,VE M]?>/D7G68:N++9^"F>+>@')B59Q8RRVP&?X3$6=C97]54F%E?Q+L[R:,"P'\ MIQ<_*UNLDMPK6Y1@B\KZ5"1NR*RV9H^HIB\K)KO9Z/:VV8V_2S+9^0$8_4D= M8'F-(+DBEWKYPR9[6'";%M:;Z14;;&*[1C;OYN1B/2<+V3B#4!:B+.3IO%Y9 MB+(0%67:6-)BZ?]U'81H,\31O&%V1'VYNWKY]]Z[%66I^F8YP M,.;:,E5IHFNT=ZF521F3QWTLPM"4%1R4IVYE%?)BO^?@+""2/$9V^NA#_ MSF\A%.XHC/R0)E<8N.:_YF@9_4[/["\X54K<+Y5LEA+-CN4,E!*E^>.3*-'N M&+*4*-*NUBI15D+6XK0K?&`!1>#3CV$"\Y'+&U$N0BT5-O4\5C4]VTJANS.F MDWAC74>=1"%6IZ\Y,A.6ABM$K1-M#V19 M:3(.YI`7)U/K!&JU2.\I*SAHM>ATIX&:-ST>]-0:1\E,3=G//*'O#`Q#V4_9 M**3L9[[&:O8D33^>U_*?R!6_A@GUU7+HF2^'UA(7SERWDA0869'8L6U-+G>M9K?B*Z.ZK,LM_;2)8?;,* M`6PM]5"-DY-+5Y4":#L$K76NZ]-G!U"H2@'L8@Y M'1RM*A$@PRS.>M=5`2ZI7*U-BG^>N9HJ%Z#R-J7%9Y.WJ3("K4_<5$F!4]N+ MQ!2QY3"RI[#5(Y<4./=4MN46V`S_J4H*2$F7E2U*L$557D#Z!$#9I02[5)8H M8E M\LJ`5*Z]5Z[]K.YD'J.P@=7BFP^EPBR_[Z-FL;=;1$H6676`_B6=^MN5`RJY>GRAN2I[=G)UR M3E@FQ.Z8`ZE)3<.5HU9=MP>[XY4)46NO;4J"5)F0V@X@/&/(?E4RY-!L3MG2 MHGQ(3Q8FVK.SI9.?,&Z8+9D=VY+DEY[7,I\J):+6]IJ2UC;VC%JC7/^YG8EM M2$F`,[66=?YYWKK-CT`U$NK_>1V_ MR@[)-E(3)UD34H5?U%ANZ5C.3@I,]H8YM_A:LAC2?)IL.J7GOX=LILP)/D4]H:]C1NC]?<3N:<+@EQQF MDM`"7A!AWZ=X'HJ,PH@D\$8RCA@C$VA\'!,6#-F07$\CSU]P:&J\OA`Q.(I&&5D6R$J07+>RBA, M(Q*G=S'[5PI3==Y"3+P8*(#??#]\C*^:8VFEK/^(E:M,9ZURE=Y?=G-5MG[M MGL*ZK894MLGX:U@Q=+K]-B-O/,F<:9R#\34#.*\>B#Q#6K&4=L%V;':+Q]P9 M.\=M%4P-:G.1K9T4'.`JFV&0)YE5#C1)9TD-N;N8K=O&S5Q=J[V*T^C$JR&^ MXT2'OFU+ZD!MN$*D91[G&?[KN*3TG,)_LV*PWM%D;=*H*-S^*-Q74;BA47A@ M23H7H6)P^V/P0,7@,XK!`\U2$5A%X'N^1QHQ.DI8I.)PHS<=3N(G^AU-UDW^ MZ9"Y8<2/'EVE>,QH MY0*62F..F,94.&=ZFC5'LV/)@I%I8R(COI8\,WKR@W+3G%C1+/3YZD+GS9#M MH[S('"E^^=LO:7QY3^GT:E%PG)<9C]]XL>N'<1JQKV!WK_W0_>O7__AW0OZV M[86/+'G[W?53M("_A^'PT?-]X@(U\/IG-GIU<1U_NQU]T[5OIOX-#V%>D#3P MQ$^_PP?]@H`7\R;4CU]=7)H7O^J6I9DP>K;3N*E+*41:WTP-:;1WTFC"$#J< M1IANQO"8.#-:).=-*KSZ-UW_QJ5F?OL:SLG;+4)# M]"23DC]P=XD/$!: M%48S&%`'N15#ZPWTE4X739?J=&\^H<_^JBO;UN<'"LG"=3#\S'P\:%Z'5]`T MI[>L^LV=5B>LFI?0;:=>LJI:J:8?1U[EO(CM6"N6O!=9'KWS?"_Q6`Q/?DD@ ML(]A'L&B^.V_4B^9'32XK%Z_[RQ;^J[^#J9N?WGI1D_ORR'N)HTBO()Q8((# M*MQ&3]9#!0KV-VS',%<"8@D"/H:!*T,*MKF2'6SLHQH9)1*YGKE5%=NI"-CM MZ"9B0R]Y1UU\>O8^<"-&8_:&B7]ODS&+5L/'@0[\4N]IQLK(+T%*74R4\ZJ7 MNCTP[1J9^(U^]R;IY'481>$C9-\W%.\*;70AQC=3,)"U]VVYI>OO7CS_Z3-[ M"/T';&^Y-S:Y8]$NIGMB06`'S]LHE\JS#?_E(:=NGF$2(I?I.']5AA,V3;._ M3MQJ%Y6(V'LH6`-37Q\)%X&@:QQY.. M&=X3QK].P;IQ9"+ MR)A1/QEC:_DMZ?@E=AV#!*8@!%Z3`ZF>T#^AA<+[T"XG%X6`[6?\#XK(HH2``%Y*&N,-;7(@&A!"3("S0#6T.0X9_3/+V"K]Z M`70ZX9[F92[5I3O=^(>L)Z0`U3NG2ER@7\@6M867O@N-=D@:I]P4[G)K&+$H MPJ>FXUGL@9#A&;P+'C/V5[P0111.UMKG.T#BKRR:B`(GX#/!"4-/<4[MNK91 MKD([<\/*>(ABXGM_L4RX;RE8A6@EWM!.#)J;D:$W`@ZX.,,`^.(VAO?ZX6&P MD0A-L4/NT@14&8>K/V\C/.=;_/+`(GK/\.]X==\;>2Z\&"B_.G'L0>F@^`+"*(0"<]! M`II`?.^2ZWNT=Q`@S4-+M`@M,*`F(?BQ,!+C/!]$T'(_`,X(M1!7.Q\_&%&X/)*/47/#Z.&?!K2$?"`DX(;Q#](\Z7PD!`)ZPSCD.;N^L[!MV!IT>V@;(N^93%G+R' M#C89L:5X!.H8@KVX";>[+'+Y;.Z;N>]?>,CE*)"W3/@9.^X[T!3RP8UB8@'^ M!?2\(2QUUE@6[6#+`7I4GPS3(.`*G[E`%%IZZ/(I_!!>!@<7IO?C;`"CLP(1 M+$P;XS%X_;@PF)9H*,@2O$_@SK+N[QCV6""K2[ZN^=BGM<;-@'UW618UX)T, M%^&'[WC>^"6,:D@_@,*1QZW?]R8>^KM-R5@HPM0=];GUQ6/&N-X"^"?3@Q@N MV!"=B/='/*XOG(;+D_?,9ZW:;E6PD4-OL,O/^XX(/V*;Z_`C6G]IQ[S2"3NM M:_5/M05_\G-R%H<*:QVZ0L[<'&?0< M06>*1\O$^>KXES?YD;+:XDYK$4-*^9MFH=+9?:.C]R7!-&2[0TJ-QU#*"<&2WQ94[E?4W8Y6A_66&'8[ MZW%,?%6X@P=``*RB"`3W7UDT>2[(6OLRE;`D'`&\[I!-OC5.T' M?F!:'.6BR-:"INW4R@"PL`UK:\];0!?V(6!_5"5+K]Z_)`PA4[?LK41L1>_9 MEX[]8=[ZO>VRV(<,A7&QP?&<"N.BOWX^OWPK!-5[B?HEW#U=DM+YY8S1B.,&X*5V<1'Y MA=VQM#ZAXB(V7MW'BZ]>AC&)GQU,W/`..:%!D$[X6_QBK!?`G"J[CAZP1X+7 MXZ=X.WGCK?"O_.9QPF^I3^E,7%@/2-_"]V"2-@&6Q_X,`25@SN8+&``.GY%U M$I#_I$%*HUF!X4&'`-,Z4O#"T0NWV*<1?/:F5%QYG[,C+O.*V_$4K_WZ(;0[ MOU2=X8EL?C=,$Z`L&&;$X).0VR$L0/[^4$AO$_<;E"5H[VT55GXIF??EQ4)X ME*,GK)\UQJ9L%"V=3J/PNX?8`2#,%V8'HF[WI+G+!M>][-T_LN2&QN-/&1;( MZ]GO,1N^#W#_S@M2$/(G\OK[DG:<=CL^3XU&R[5R>?[P/(;=B',(ZO'ZCG8SKT M-82T#=*@(L3N:QI[KE0':QK&&F-EB*F!DTI(V+IF]-8&W(D9J6AK/6U@-8R3 M2F#;NF8YNDQ&'K.-?QA*,.X"^.AR2#($HKX9T^">Q>^#XC,\NAK6J& MJSF#XTFN7.0!R=E5:+M=?@:CE$QK,RQ>$Z-`UX8.*U)4+6GJ]WN#F@BJ9E:F MUK>M>D54,HGI#U;J/>PF*+JG@?=_O%-(_OFF-O\"GO"3@.OE7V]'V6R>^AQG MF'M+A=[=R&Q%_X-@2LJ76XLZ;`3-392C.&^5`9?RW0=,\=(^/B^81%GDMY)B40K^,D*L`)OPNCR4*VNG;YW_@HWU>)V"A$A.]AR%&! MQ78#AZ\M`E5G*+MA@BOV!;#<##AT`@3C2GXFETVBZ))_A(_L@46=G(MPZ@4% M<%B8,]![5MRTR'9\.IR8(I+R4C*@7D6G!HN=`IW-"IF'LS1F9AU'$L$W] M)3UE`LAE#2&]R`,O5.9-YN\AG"N*+:?(X[L]B)6.X,Q(1OYD1FD*K."651(_%G473X/Z[/RV0 M9F\XO/'B^YN7)-L9*SZ3Z:7XV,_%_ MS??=^"8>"U#L6[G?:V;PO-W4;KM`ZQ=#F`]]L+AX'*;^$*&0(T:Y\J"5/V'B MPT<+=T\X#!)"G"]QK[H5S>/CBYFIQ$QK'?004"]DZK!\;*&:P2 MW31OE24J"=7D8B;,$YN1U_R>AX29ZFF8ZUL)&_HL")%%6>I MW%9J(:C:+-72C$%=%%6:I1J:96T83SL)XD=)/XGC-U+6B.E8=5U<4MO1Y"&755AQ7CN3605C%Y49K@S+K$5G)I4;#E$%8 M?2O<_1VV]M1R:`4JJ]F=?5PBJQ8UWC$ZZA%E67NL3..GK(#3U_#:Y:6-7J+:JLIB'P?04D)`!Y/"38Y\C[VKP/-?7211 MRBY*SDA^D=#^$UYIK?D0:X_%[Z)PPGNXG?*M@[??LR33X/D.AB^S6^3_#U:W>`M/4FU'=-:(^Z)W@ZDK,3) M/Z._C+"LQQS)53OD]U=1!1^]]VT!UK3U%MHNG!PT7P=V&4@PK- MRP%*/5UD62N5TI_J6A:190_R]%:N8.Y/X^?\KE-\.\IO]MS0J9=0_P.C,;N] M\[U[^8?.C8&YK/H2=-3$0,E3+H9AU\?`VJ7N@X\M[9;V^J7M:I25G7?U*E$F M=EO?T@@KGL9@V^DDY45YW["1YWJ'>4NCUWED" MOU"?Q9]%]>)\>7D]_!V:[0R,GC58GO-M[?@@^BK>.-![CJ$?@;R*@\.P-'OE M5EFMXBMYL$[OV4;?D$7>:CIQZ"98WW#,W;);2RU*D5;)[)"5E3/+\BFKN"UF M"H4>0V@E]\<,<]"O(C1WS(:IST+"0WNL7:W6&9ZEV(Q]NL) M%NP6V__9\NI7?KOE[(YQKCRXN;4BIEN!R#G1!0`B8CH+E+B7"URD?6$DRK^Q MRJMB0;&@6%`L*!84"XH%Q8)BX2Q86']C\XG@0FZ=H9-JVH_SESGN)'&9[V?, MO+K0+OCW>$K=_'OV?@8YZH:^3Z$B6PM9?8"K;(9![A).+:#G`TU2G:Y,L&VU'EFN MKM5>Q6ETXM40WW&28:IW;$OJ0&VX0J1E'N<9_GLJ_!\4_IL5@_6.YI@J"JLH M+`9W7T7AAD;A@26IEIV*P>V/P0,5@\\H!@\T2T5@%8'O.1A1Q.@H89&*PXW> M=#B)G^AWM$%/)0&E.#WC/&`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`\Y?OI"`.=N'`VYF/7`,E4I`'N[GE0^NE0*H.Y' MT-I-S4\W[H!"*@7P4.<@9$!@@=ZU#^@(VMIV;GTK-NXX6BH14`8L&OW4E0Y< M(JY6)\/O)U>C<@'$V\B*>\/;J(Q`[8D;E12H&B\E4L2:'R-;!5:?N*1`TZEL MS1&H1_RDD@*ET&7"8@E8I/("I2\`")A25)P`1UUZ+:^_5.YE/4=C`KO&; M#QMQ9NW?S5P'$5388/OP:&GXDL\Z-G]6OLG-UE%/O\/EJ?%G'SM;. M5ATU,>BF"?9*(O/>E@/9-'M=T;Q9\NJF<<:IL$Q(Q[".2R4UFAN'LJYW3W9/ M5R:$PEI:H MYEE!R^B5M8^3?)E\^>FW16MIB6I\V3;L%NW)7K'F3C_6KAA2KFPJ%MI\QN=RIVCA4_O'Z9R,,+QYG\]MV]Y%X2\//1!S_T8_[)O^+>[$1)=8ZD_(&C M]0,0^BZ(W)]O__H7QEY/!5PZ@K]S)/?41N]0JE.$F`OZP`W?^.C-P5F2EE0: MF.;`'+1;IC7X$0WL@=7"#_8!2Z!E=>6_X!_S@'G<]<=.(-\<'%H';]O'Z(`% ME5>V^'BM[*)6G8>TLK=0*H;1NXP"""/R_:_$CV_G%#J1@_/1P&P-+'.M<;', M_G&K/:_%4@M;:+#V$%A6M]OI;Z9`,I3\5\+#^/T5[JB;@FHCT[S-XN`4UX68 M6*PRA8Z;?4[#]ER$TM;5=ZZ3NK%X)IBZ];]FZW]L9B#&E86T4%C'0517GH?L M]R0L'+QKJ:)P'19?&(25:0CCU7U_W]!N2?JOMGG\]>O5![4]\YXV$4L1,77$_Z>-<*X5_X M-?L=_)/?SHG'^QWF^8*[,;L&'PYN670=0@W.F'<02"F7,A.!\CJ+`5&,80)8VYN.""/<>Q*LK[G'Y_DM\T)_R(?4V$ M3!R0!;+QUL7+#00QN_:#@`UYVH@''^-+U;A2J6"=NYI?'MSB3;ET_$XFXLJ_ M`@*T-)SS1CI^)>\:UR/V8]817Z*2//3@$M#U5P+D;'3+'`GF$3P2%TZ8G=6G M>N6'2HLQAZ]!!QA7_/@1+1`Z`?N&;IR@YA[''\WC?M=0PL9I$TO]QROGAUP? M?],Q!IS$:L3Y:`2>`_2)Q2`TM\/G.S#^?GHUJK#H/HY["3"0"9@'<10EL01& MAB2;220:N?0,CO,8Z27?(`_9#%@CO@/+=L>%N\ M_45Z`7RI0DTD5$OJ_V(D$G--9E?E'V<7ODA]U4E@80-.XSKH?T.,K.$5%_$L M2'F,W[C0+XP6HTRZ8@WHA!`4.1JK?=3KY-U8MFEV/_N&WCD?0++`69*EU&#< M::8C]B5B(^&X&",@!,R,M'3?-)!E:,N"28I:8S'LS6NOQ&9<+Y63CQ(NC*@/(BO50FX(*%'E(,O%>GCQ`./"]E'.A\ M?R*)`+/AB#O*WF,_5G.6A'&6KO"'BV@K3N`J`$83-<>!E$DBP+/D6B;/`;W" MOX<<'"YS:IDR`I`VR51%BBD9Y M@.+Q5%UG,@D`>YA4RKJFB!"T\!*PJ()`_L.4+Z7$($S&0Q@@D'.?*Q>&O:"; MG(X(1R:1]W25R)7C>9?4<1+$/G0H=1>,BP93V2'XP@-^,VV(H_B4468&3#LU M"V_\A@O7!_-.A`^CIPHOST$@[X'C_9G(S)=AR>>K226^3Q;V;Z9UKJFRJE(6 M!22315WQX7:3'+Z07,0!!#:9?I5]^`WIICCT/1Y="&=RN8L^H,6C(:B0!8$% M%YZZ&<8,^#T9PV3-B]$!C5L,+.H<-"0"<'D:>"2Z848U##9,,$,;IY%',6D# M%,!@E(-&@$/X&.[!,44$,^^]K*HXVVV+#0WLT`0L?9_!0/$`@)04W&9E64QN\*EV`^"L!RWRRE(KQP0IFU#0LW?H/3 M2;IPFU&.E_1@215@\/!00 M%C-$TUD&>:R3K6.=.5R-N"(J*0]YUK&-5JN%?T=LCE;?H]Q"TU&"Z^?IA)LV M+K@_'B9"\A4+T0@F2]!@`H2/QRJ(X1ON.)TF(LWCH6>$W)UFG5:/9M8%:]J# M*I]LW?6H8?Z)Q+]AQ:W,5Y(<3]B[X!=[$#KX&V[U^]T3-NQHD5 M/>G9K9ZM4T\RDW0V[4C?/&[U=]N1I;O>.=)WR_61GMGNM#L/]F.U*J7W8DO_ MZ)G=KOTPJIZH$]OZ1J]OFK:E2R^V](M>OVNUCA_5B;\='GZ(HCB,8LZ^I^N. MPT/XZ?7+&YCFX9__`U!+`P04````"``0,,E&IMJ/2Y,,``!RO0``%0`<`&)R M;&DM,C`Q-3`T,S!?8V%L+GAM;%54"0`#/[EV53^Y=E5U>`L``00E#@``!#D! M``#M7=USXC@2?[^J^Q]\[,O>`^$K(2$UN2U"R&RJ2$@%]F[O:4K8`K1K+%:V M\W%__4G&!!LL6S)DW#'S,F1,JZ5?_UJMEBR)+[^\+FSC&3.74.>JTCBI5PSL MF-0BSNRJXKM5Y)J$5'[YU]__]N4?U:K18QAYV#(F;\8]9HS8MM&C;$D9\K@" MHUH-!7^_?AH8%C7]!78\PPQ+O1!O_E[NFA%KA@WC[*31/&GQFC>EKY'+I;F^ M0$WSI/'^S;I^ZEP:[=I%K5EOG!FGEV>GEZV.\7C_+G?/$4Q)EJ!-G#\OQ3\3 M7J'QZI)+UYSC!1I0,\!S59E[WO*R5GMY>3EYG3#[A+(95U5OU=Y+227$_ZIK ML:IX5&TTJQSHJVM5#&YVQPWJ5JAD+CH/%5XK@>VQ%<5ERR6MJ@[ M>#9G>'I5$5JK@H'Z::LN\/\T\CB-PC=ZU'&I32S!ZC6RA?+1'&//K1A"^V]/ M=['F3`CE&C'C/HI/3+JH":&:BK8`H)*M:Q\"[OVA.YP.EWC58?9'*5,+"6X/ MN?-;F[X<%FU$ZW<$>T-X,]1&PM^/O54XA![AP>&V9D8N.NZ^(]44N508+60[;9/"B^4*,V2).7 M\^V@\P_X=R$P4>>APF?$>OC5PXZ%K?>GQ!/U\%&HS@=QXUT=_[LW?!@-!W-O*U;6FFTTP?959?VP5EB#>C[CY'E; M[4J4^=9NG;4[K?-.\_SBHGW6.>O4(RV/.$R7Q4$@9J[U\S]W?"C.42A1<_W% M(M!6)9S\=?DIHXN-V<)*J$Z#*;,PXXEIQ?!=W@ZZ%'4@NV*\8#*;>\$W1=`A M1A\1A_E'_R^?/"-;!."NUT.,O?'D^=_(]K&$)J6R<.A3)VN7X/Q0H1+?-4WJ M6!-*P*'7'DRJ]U^J(.@%,A71MWM.9%: M(3C\Y69+@W`Y9,!9K;\0%&#K!B\9-DE@/_ZWC<,EI^Z",H_\+W@N12[/@`^B M/F[3-K=IX_.[T8<:)S/&5(ORN-7H1AU384EC(P;'`[)6-3+:##6G%N[DO=UC M;TXM,3$(EY8E]$BDX;"DQ&M%1`4&/I]DL>GA/T7TW;%[LK,@A4*5H:+%PPB?1UU5Q".3ZHR$75$13Q04_3U^[-']"9>GJF]3HP+Q_&> M<[S-@F.*(B?RMXD*`*$2VE\L;?J&\1,.UG64^V5FN1+1G`\KU`D9=UKF8^O. M,>D"\_$PBVFI?(D8UL,(=187I+`#BARU\"P3+Q&O6A"ASM$&Q,%B&S%/7TG& M6^LKMMHG`<[P7'V_K$]&I@A-J1,QRR*HI MCXA8=TXXX,O6_)*E2T2F#D*HH?5)',5UL-5'S"'.S(WMSYP2D\A2GNR")6(Z M)UCUU<`OM:U#S1]UTEEZA4+$_M(CS\WT(\^C,?^X[S^,1\;PUA@^]I^ZXSLN M4`%]^/D!>ZLU^P%UW>XS(K98Y!W32*@.7>8:N<3+XW(\W#G"-IU2BMW7V.[8@UA//Z[PG MGA44=G)Z5GRS6+%V@YI)AOB=V0::[`W5KB0<#X%"<\);+T6S0760X%32(Z-3 M:0(3D8#G$*KFWR4N"Q94PD;(QFYX_<\(LV=B8E=^?%(B#8_(+#H2UFHTH$$E MLT==;SA=MUXZS8\*E8$Z!41@CZC%VQX]F[=U)$^)S93R\(A6H"V+:UV\4#ON M`$THXP#";6K]UR5V7-DZ7;)P2?C5``=UO6[+10GW4.^>@V$$V6I!>:M,2:C5 MQPAU]2[8FZ8TV"9(EH1-562'WYJW>XFB>/)M3#UD?\4.S^!M,198"^(0UQ/Y M_#-.CJC*Y>!QIC]3V0\LV`1*/V523AH:''J[()[W8VNWN^J"AIHIZ75PQ5+E MI3T/\,/G59*(?8TLL:LE)3;')3C4PET;UC.> M2B]>,A(T.!`K+)'6=:+T0O`\2:^IDDP[%_FIH_>&_")G45%1XD?^DGD89#\,'V#*AAU)A-%[)% M*?J[)Q&S2W1FF\GS1Y/SDO+A;H\AY+TP]O!JB+,?OM MXK?"1.L<>QLF\T:6H5\>'.UFAM+!_-+Z2WS:9E\84Z"I,7+!P@U>? M=\[NSY')/26SZ/$Z2C[39-XY4Y2?!/82OW-^2]D-]2?>U+?7F"3^D5;D2/U" MVR2A/UQ`RT=V'7S].WA$NF4PMZ)/XDL$[1 M'PZB9YKUDEC]LSC*QFXY7&6K\`]GT37.VEWD2ZAPW*7GNQ[/P]GZMVB4766[ MX`\WT3',VD7`+9_*L^WPAEVQ-KRZ33ERV97VK"9-6=Q@+6ZPB^/TI-S&6GL7 MO*V@R89(8+EH3'MFG_YA&$.VO(%/IR: M\&26@^,,'\AJPE0ZEUTR7Q07MKZR#>?:=\7-XFYP6'^U<2G\QE+UE!05/YPF MGXG`GA:3F.^6.,@Q#SQ**2J%XV,?,TKM8P:HYUZ>\#+L(L-I]()>B8/(Q.%0 M_X$<[CJ*ECG`#D5)*"1W<6NXA43##T_)92&PX]"`#Z?K7T.Y1::8\;UMSQ)7 MQT"D=S'IJ#A2]]G;1$IG,0IZSVAB;`4OV(.]G\.@:6[_%3.3N/+D-ZO]'L#7%-F[H^P^&U94_8I#.'A-L\A348,CT?V5WK#S_<=G$CKM2UU=`QV5EU2X.H('B;?3CGR*8D[_2EW^D[!P4#'\)M>?D#T4+?0 M)Z$+;M+3\.!`'@[G!V1M-^#KX3\\ZY)^GART>307,3AI%Y%BJ9*SNH\5/F". MD)O<>YZIFHCAU2>Q'L5)C9W=Z_LI`^8*.5G3YE['&H"Z>]>V@QG*>$Z8]8C$ MCFOT1EG.,"#3=J0^H66.[W8M4E+\&TZ30F:2$ZB7AD/Z`;*[/6$7?"!_,\.Z M9D?$)/O>4`7D6L_VX478G9EG"1:3D M*6U*R\RSBL'IMFH,1;/N7-B@3KE2P$1^J$CA#+.^HI+Z@`Y:Z!&[Q[4WE<-V M4R-L&S\+W4;S1_PNKG]'O#,\./V$%XAP=MEP>LN)1/9_,6(Y.KRBYGB?..NT MZ_521(!]X'_&@6(7KX`W?J$'<9U0U_$X2QI@J%L>1/L9;ZA]F_%DK.RX7D2*&>O=%#HA<]G`>PF6/S$-DB#,OO/@4'M*=>I@= MU$UB&H_'5[)A9UY[D3J5_5);41/.]?B3_P-02P,$%`````@`$##)1G$L!-A8 M#```W*```!4`'`!B:06"&>F]JK[R^N&XWW]_>SCREUS@B= MRR\ML9%(G%N84SZO1W)MAJ_ M/PXGH?%U[#'?]*Q-J\155NU:W6ZW$?ZZ%N67QPJ#$JKYK[:_;K`MW&DL?ZSQ MCC:,KY0X:(QF1GBY:_]S@6YJ#+L+1^@*OWNE:'93$P;4!5G-+^VFZ*J?)CYG M7+A1GWB,.-@6#G!K.L*.R2M"/GLV*?_Y%?G8,IV:(2[UZW@0@S'%A*M'7,Y" M9Q9Q&T*HD5MUB%J+L,:^L.\PLQS"`HIZED4"SV=C9"'\9DX=U',<\BZ,9'?( M-['#\H#.J;@2R`./N]D<"XL8XS3L!5.JK!)H8_1&G#<>7I^(CY[-3]'MMZ;W M?2^(F4HK@3HDWOP%4?<.3?V](4J550)M$DP9^A'PV'#_QO_9ST&ERG)#"ZTW MJ15!7'W<-FBM`7M^P\9N8R73,!VGEMDG$E.B8"_27"?LJE!;"5;QS\@3DY.Z M35P3>R6:F%1=AKVAJKJ+W"FB91H;UUN"I:_<*&H%4U1?=T2)]J9J+]%E/"(=>[TB[L.<@D8PL/^O"19R-[_2WVQ47YA*_9,>K& M6C?_W!\]34;#P5WOY?[.N.T->T_]>V/RK_O[EXGQ<^P2?\\164+\@C-BQ0QS MQ!29T-2>#E7-3#8-]?%%Q-PT%V(&WFX@QV?1-R*VMNO-UFI._-/JZV]K4"\B MC457<,PI!69;-2?FU^1M/Z]$X$#X"(KVK MP5!PC!-J(\K7>I&V&26NO&-7)A`M&`'C1I&%,-]TJB%EVZB[6,K882--\$`T M)#.-)@BV+[OGEU=7EYWN1;-Y#&JBF']0;E*Q`:!K M@BA&K/<<)C"*[-#DQ]@L9C>:J5H\UADC`[-96LDLU.?R\G:-<6\7P^$;IW0E$^R4-S\6'S.U]& M(?NFYM.@HIE`W'OX9&M$0VCV;Z83H&=$)Z]\`B8A3K?Q4%76"_Q7?M4_D#WP+"<0E>Y5#/AWX&&R&^[VT'-4 MPMI%"-L#7'G<'6(([J+0&GK)1D=E\$MY0RZ)Y!3H&C`6Y*(J:G!4FCIETQ2A M@$91G[@N\8ID-*V61R7M8A_2M.``9D\S&"I;')6MRY+8@A\&$\8J8Z!4^JCL M7)7*S@E$OZ6AH\`7F]]B*J1+3ZS)43GJELI1#$DW-AH-S;JC9]7%P!>/Q>)*3R^TO/L_P2F@V>?G+@(VP:P MJKR>4T<5`W1CXIHA;NP8,43?$'OAEU>4XG4;PZG+%V)U>U3K0@80>]6F*JO) M>DV!U/GSN;`^F8"V`0Y,9;R0)0U#J9D$1!1#V#O*X[;J0EA,G@-&Y;?$=":;^+'"BE*+<_-%I M"*%>G9?'//@`\*<[*FU/Z_.H54*/^NV\(: MYJ6XA!)OM>M?^6%FG37O17+-NU%H+#6>RC)7W.U@!PX:S1Y$OW)NW\1N5;Q[ ME$?('<2[0`'*XPMZ-M4^F MBY2+I=Q:@"R!"SBY)MGIL/]?"8^M%J^:?+78@;-0/JX3I'8%`+_H!\PG+J)# MS#)67ZF2$);-!5T[MOF0A@T`.T_$X].Q!?)1;TY1..%7DZ1J`&'.7`)7*H@' M.D M,D)W0C3V+"MP`T<<:.NYA/KXC[`$EI]8J2((9V@/0+44[PF1_X3\_$2'C2"< MN#T`J2$V:`3VK!\!ILB6VSU&#-N!Z81'4F4[=GFU0#B?6Y3BW&"K+>IG/[Y# MI[A_F2SNKQ4;0K.Q4LU_$-I/I=`OF![-EKOH#Z:%'](0K]^>=R^:EW!* MV<6I284%@*UU#HD;K:Q]9K2!4*I6.>$V51E0`!#TFTFQ",1COA91'GG>%:L@ MN4BJ*KF22Q((,!(R3K4F!8&D%9DCR3H?4$K9H_M!IY-BE)2?2B0;,N)A?`./ M^31\SNNV(>(1KN)_^0:-?EL(Z4+N8.L]&7U`QZ7B/J#$)HYCTB)D)%M#*,/O M14<2$H`(-C:]N2I];_U>0=Z6E-!SY>TM!%#Z6SV)W98`DJ(37I+H8&@NK=O% M\9S5YCGK"DX:UNWV5!``F'CDG><&KI*+'1D(23?%@;8[?L=B"/UL?F3WXQ0#Z.2WO)#8$-,K"0PAG2K3`;/.AR+JG>G8D#=+*[6X)I>1=%&#, M!?_%_\S!KUP%A&%7"O%RB`=_NEH>(612'!HUF.VMGZ9HHGPH(!U%R#_E\$&%S'!HY65!DVB-O MV_J6%K^JYA#.H^S)K0K>P4-YW)1Q=%A!7#Z[7+0C#N'@2+Y`JX0#;4P)&"S" MU@\H7<[D9%.BI"B$1[D5FOHDH51[;$?^2IJMKI0>U[E*'M<1"NM"HR%4GM@Q MG?@@4AW0296L9"CQ_O97!&8\,"I=%,[Q'$7OQX91*@P(46W',.4FGDP82)%6 MY58J,@#MIY9`1[P6VNE>M`"]Q6$_BE*A`6#MD2?'P!4)1!SW5-^>*)&%4/95 M.U^L,ID.`@`5\7B<59N42E=7E&4/'38",W+F@KTEW;>>Q&S!>KY^63 MTC>52:VAI%8`H8I7>(BIH1UYZ#T%`NMH=O\C,!UN!R8VMI[-S_`V_NRQE]$< M0D6NV.#+``9[].W8JS7@$FT@5/`*C[$$&FB$;9>-%"NJC0B$@ET..N+&5UNB MD[]:6:-$UVHF2W0;A<92XZF4YW9Z0OE@O%312EY^MV.)ND8GE893IE.Q$'M> MB`P*@/B58INR/*20!U*PRW"S#&(`E>U*HR9>X;KL7K3.X13ORJ`K%2`\!M5O M8$V7A5#"RW1$!4F`JGBW`1/[CBQ\G@!;=J4\_TBEX=QHIYM_I%"`DK)\WH,Z MV&FT`Y*/,MPNBZ@=4']FRD#GJ3)IA)JOGDUQ$J-/W(7IJ>\)3Y6$D*NTG3/V M(L\T-*7QP9!U-B=O?&&,EU3P#[L,\*^^#='<=.X]/_W!(JD2<&X>R\I%J>8? MO8N7%T^-4LF?*\X?"I>(.C1N+^3>C$>\*Q[QVM6']IP]G(KA$)7]6].=$K(5 MP0:>=2:_W5S1T3GDF=*Y]0`X3B`#H&%P$$;;'^FUY7K MS9B4@_'(+RV7C+EH+_5!O`LO5*QXS;56"PC[_]IC*@O,T?I_M/A.5N]RGFUY MQO+^,/%PS"%&P6C6\SYW355QM(]6".<#I`.S\CRNJ.`I\UG[B?(O_]8B+`L``00E#@``!#D!``#E?6N/XSB6Y?<%]C]P:P;H+,"1C\IZ3.5VS\`1XNWWR#LV;Y#O-U?OHG#*RNT"?GFO_[S?_Z//_^O MJRMT$V`KP@[:O*!['`3$==&-'QS\P(JH`71UE23\^_5RAAS?CO?8BY"=Y/I" MHL/[RS6,4'3Z\>?/ERY?7SYO`?>T'.VKJ[?LW62YI"O:OJS39%?OHZMUW5Q3H M<^A\@VC8O9"7K5!(FIQZ6$C]Y7V:]MV;O]_/5MSY*^*%D>79QUQGI23YWOW\ M\\]O^+=94EH\J7`H,TVCA]"?`]_%2[Q%W,:'Z.6`__)-2/8'EY7-/WL,\+;< MGAL$;UC^-Q[>L9^41>AG%J%W/[((_5OR\I(>Z^L*2:KV&8&!A6R#@H(K(".W6"_ED3H"3%&]NG1#E$5V[RD_'LV\#? M-X,@W/`;9/K-W;2H(BGV`O``AWX MODN4_M^2CW];193$S+.UM3GJ21(?:2*@%;@:%*NMY2D`5LT:1]O6P\P<^I4; M_+\`:AZ5?CRE?X9U(<@G'$H-/`-76@NS5$.HB>?.:JB-S"CB5L^JI!9D$1U+ MX)DA>)>2+,3VZYW_],;!1/"+_G%**_K1;Z)A6>(=8#Z5@8DK6;Y[X#6KE(7 M+QXW,6M]UZ0''!"?#@J=6]J.5R`]33>`NE4*[;22%1(!KVWEOEY<[819.F)W M$#/<5PTV`KFH520%7,OJ`*853I8.:-VK=;=M-4P,(V$9,=.]BUS2#16> M+/'!#R+B[=B@.3Z="E)(#KARJ@`]&4>4I@5:295!>"$C)(I!N7+Z M'ED?.S1W]).RUEZ>$G#=K8%W.KX^20:TEM9Y>_$8.]\'Y:;-U$8QU%>KC\6T M@ZF1)1#+ZV0NX2!J99F_NNIE,@6DI69J6"U?;.^(9WDVH:C]D%3L2&J8%6@M M;A.`TC7VBGP`ZW@K]UO/!BSFJ\5L>CM>3V[1]7@VGM],T.J7R62],E?CQV&( MH["F;I\E`EZ+RT'EZVLQ!>":*7&T]<0H-X=^30T:V@:B&]5J!8!$R>R)$I?. MTPZ"4A*(Y\PZ20B>8#)_+^/9*)M1@T$XW2AO/BV7D_D:"?Y],$?`&RM\''L. M^\_DCY@\62Z%&8ZC&RL(7NC(^[/EQK)MMZIY@1.T40CRA%7*")C`S?QO7=6I M>;ZMG/^1*VB$K`BE92%>6"<4/Z1+[U4T[RD6X]4O:#R_1?R/R5\_33^/9U0' M5FB\1A/Z^>(./4R6T\7M69NL,12TSQY$P(-Q/?DXG<^G\X]=AZ2V`3#,$H-] M,]OV8^K!$MN8>K-Q\1Q'24,H:RRKLP!O"%0`%SIL%>D!R[Z2VZV[;XEQ=+0^ M0M1^UJ$SU(OK&3.Z8J#-<7?J/5%D?O!"O9"$Y"0)<&Z6`7I])Y*L"$JG"V;2WD)M') M/(09=G6&+IU=$;;-T>T6;S'UQ%E;S\*5VBYF=0[@!%2`FV=B17+`E%3QNO7B M9V(;4>,91:E]Y&_Y#(*X3V7LNOX7=N&&8?KV'(E.0#[A8..;@YD*U3E)LOU/_@L.IM`?[AG=+YB$^@WB]7:Z-QQO(]==@'7+3X$V":\ M9T;_=C'?&N0YXST[*?$O_KDT3O+I/%WF@:N$[D">S%]KL0U8>;1#O&"..'4$ MY3T9H%95M5)0VO9I6?A<@Z*#.)JO5!R0++<#^C'PVOB8+<)52 M`:S4DX$]>Z_D=D>]F,YF^.L&'MV"EO5@YA.3O1 M@)I:H>L8J3DR?O1]YPMQ9V\Y/TUSN/1Z0MG]J!#KS:6]IC8,]V#V@ MM2HVO%Z$2@=B0'T'[4UJ7QT&M5VA&H&)C:'Y-1_3[*I$/A0FR?D#GC6:N&*2 M'YI889H/,V)MB$LB@L.QY_#+4A]]UZ$=$;'B5+--H4%VX)QJ&H@\ZU3S`N9E M8PBMNU['@K+M2-&+\:T._>&?CJ^GL^EZ.EGQ#4JK7\;+R2^+V>UDN?H3WZZT M_@<(.5"[0*TRPW`HKW"5FCSU,&BM^[JQG&DX-ZMUB#<]V)0CL,&M2^G](`_6 M"[L;1.T*G;/$P`E:#;+LVIQB2L#$K''XXFMC$KM`KLCI&*7!'83[@^N_8+S$ M_*S`N?Q(`J.2#S@YE:$7]A?690),677?6^\Y3$JX"D01J*R--;3_L'/PE-1! M3#&O+-<*TM$!>\2#A"'Q/0!D3SR<>K:_QVOKN8[D5>F!D[L6ZDGC6YX8,)GK M?;ZT'@O3B-LVWPQW#)8;%>/YYP/V0FQP49@O3<]\RU/K'%.[3]B(I[2,-^@SHB'P\7V)L`.J;FB M2Y(4.$.K`!;GEL[3`69FI;OMYY,\S#9>"*N&"=D)PB5^\MTGME%S[D6][NIG1:=(!WOV?B<_9HVMXOBB(X6_H4=@UKC>SNF@+=X4RH`7/&V MR]RB,`C**=\S4Y=G.$14NW&F,L,PZ-G!?2P%I@*Z@*9CU(OYQZOU9'D/9$^' MI.=0>Q1`)1]P'BM#5^@9#^+T@+KO'?2/31]C,@B>]I*/XU_SG>3C!`C'D[3(,)4>-#`YW'X+D[#V'7/4H?'E*X)2M@%>\ MMOPL&6"25GG;^K[NU";B1D?BV?81FH9A?+YCH*]]$3T@1?_^^MU;ICL"\?]& MXSAZ]`.V3P*]&_WXXX_T?S^A\)$*$^U:$"\=!+P?O7W[-OF<=8Y7F.^7'J/_ M$WO$#]!I,;0G@"71['%RR]_O?:^6ZB7)@/-*9C9 M1K M.O@\<>MS`>9P`^?;;W$61:"T#/2J^)06+\;0_;0F\$.:'U.><8#/7CFXZGDP MP.RL<+:'>2\ST]4=8!9SU6!OU2F]7*A^,E^6#3A-58$WN4P+,(657==[>9;Q MI:9NP":K3J#ORUI%M/?`7D^Z<:TP7&QY&,;/1';#9%5ZX%RNA5IL>26)`;.W MWN?6TT/,()^IY?.QOS*C9\M+/4[%YO#=^GO:897-DY4E!%Y-Y>`*$[)GJ0!7 MS`IG+ZN1BZQ&"K.&ECP[P^?7X>NQH>!K-./BJM(]WF]P().CRAS`6:@`M]!< MR),#YJ6*UZV';NF:WNEBWJ^B`%.[$PQ`AK)#@0Z4%P'O)#A\8>U@A`=:##X^NG93+**.-"R":/\#V^_?_^6$YY]<@*1XPF/2[?3=/M% M(H%BK\5)M"ZQ`U0&+@X-4X361@R+@^/;,1L1\K,CNG[KRR=&'C':6\]D'^^1 M%[.VE_5T/=^C?F"\YQ.[AXQ(R3ZA5U10!;QKH]B9@D13[:))\[:$.S>8A&B40O?PJ13+VM.T4Z0PNM9"["Y,VRJ M\2EF&1I)2P!7,C67?DAT+7-;+V=S)0`A;G>8\R<]35-8/`N4[7ZLN45%GAHX M<6M@YCDK20J8KG4>MZZUB_EJ,9O>CM>36[1:T__<3^;K%5K3VD" M@[OJ+!>'2_R$O1BO%\YXSVX'_5?99JTV^0?%5X50R"EJDX=H)=&2)@;.^FJ0A7/4I2D! M\[G&X=9GIIE97DT3P^D3Q89NSNX&9?H^^RE(,+WF6T(U([JGO@7$G$N2*=KB8`3!7U?S6V-[R$E!6!(@F5C/J);9VV(O$=GDN$XR9+V@5'PYN MR4W_/;^H7@0OB5!Y2N"LK8!W]H1Z,1E@AE9YV[:&BM?$3]EI\,ET(_A,M:!* MH@2?;?5$&PS'-%>_?HA5-Y6K&53R3N+)%)(Y3GT,_#!\"/RM]';+8@K@;"J! MDZ=2[FO`/"KSLFU]X[:0,&:&0%K1+!>K%7I8+NZFE#_S;)G'('^PAP/+97-* MSIYXA,TQLPNFD_%FS>*(>F[HO&L6A@(GU;)"YFM#!*UKORA'S#$62DJG-XPO MN<`)16AP6:;Y0LR@EUX:+K8,2>-O^VA\2(NSR#;XH8`U'R)<+V!4]UMZ//3YYM+$@"D5BS*8MF;7J3?)`% MI0GT3&94,D$7GT88NI`D/D^&=KG6T"JVAHE`A;E+G)S"N,#*]87%=6(GVM:S MA/434AXV4YTGV=QFC_CY>L''R7RRI/]E-_Z/;^^G\^EJS4Z;?)Z@R=\?)O.5 MR2G0!6U`+=:2BE,W,S^4+H>7I@2JEPKP"LOAY\D`CW:JO&V]7)S:1,(H>L7, M=O2X5=VJ0Q<`I_.;Q?T$W2T7]R".>_'U^;GO^46L:DL/RIFAT[-1$,XVL-3F MA$SB9@`NVP:2+R%+4M\;7'?H*Q?J7R1*]$D+P;=KV&EQIF'HT-#B43'C( M4P$GM016\5!R(0E@FLH\;=T,)?;,SAOVCXPBXG>\@'F"EVA M^61M^DXL-HEV1^OXC>]1_#$-03++YGOA-=[Z`1;IUM8S#N^)YPDG[$&// M*5H1S^+>X^C1I]\\T21LV40V==RO!\"EQ<#/<7X?6"_%`Y8_$U%HWY'/3<@C M5IG0T6%T]!AMN,O)0]I(.()RGHQ2.>9X1K1#$066'SC$LX(7-(WP/N2;%&DE MCF@$72'@`JV9A8!!_4QB@>%ZKEO[N7M;'WW7H2&[MD)B2R+6W`IP)K<,2V$TULP$8.:W M17+)!87%SD96*'LE,7_K;U+N"/&2SR3KHQYF1R8@4>[>^% MZ0,O56(H2PM<\BHAYH6M-"%@^:KVM_7E4(G5XVM$1D6H&Y!'ZJ&'R1+1/^X7 M<[3Z94Q'%E?H>KR:WGP`]R;1WS#9/4;8&3_1P=D.S_EKOHOMV?7S51QN:@,X MMUN%),_Y1@8`:T$['&WIDY:&DN+0/'M9.GGZ*%>D4?GH.2Z3Z<=?V.WWX\^3 MY?CC!,T_W5]3?6&7F3!M6>6E13SE8%!/3J7UEKAQ)'TI29X:N$;4P*SJ`21) M`?.^SF.=O8#$-HQ^@"Z@U3V!V^GL$^7S8/H"25147U=J;@4XUUN&1:%'(#,! M6!O:(NFI5V!43GJ/36W/X$1LC/<.LO>!%ML;*WR\<_TO=:]9U&0!KATJ@`NO MYU2D!ZP*2FZWOI50_@34S7CU"[J;+?YF<+ENCB.&F:]7.-BY?OD48F?J9<>A MQG9$GDA$<%BV%%I3^[49!\X3O4$\65G08!DP]S0#O&2BG?F!4D?0Y@6]8KX@ MXGV+,G?0T9^19$N$Z:--0"*:''BRA6.#:V%?@\ZK9=9F`];0WZ&UU(>>@V/G% M5#?9"!;Y*',3G2\-LP7A9AIM7(R']'-(PR^/^]8/R@,/Y#+-[&K$YK=J5F0% MKKA-`B"[9U.6#[#R-7*_ZYLWS5^UV4L(`-VY>8NW.`BPTVS_:7TN\&17@EWD M>646T!17\[Q]U1;V$;R-JB:@9Y`[/:[\A(.-#P1\1%$?LJV[KS:2G[S'*>=D M@P]V;OP]PUS5?9$F!JYAU2`+$\RE*0$K5HW#;2LL-WO%_G90WK"AA]D[`LFV MEZ+K6I`]WNMM$8\-TQ8>>[!]L:4#(CKVB5X>*,*('?(YL(&4)$K*F8&SM5D0 M"I=]*^4$S.:&`%I?@4V+2><\V.YW6A9;,4Y+0[PXE)5GZBJ"GJ+QBI7S+6(E ML6CACBR."Y&GW'E+^2`\:MCP8/_5!OC\=QI2=N3:E! M/Y'XY#GLRERRB?DCS84@9+>6,">,RD&`J;.W6/PW-W][8QU(9+DU:T:-#,`7 MAH;!.%$'Q=RP):(IB`MT@A>!7J6%?8MH5^(X09\4:'Q9I,>8W#S2?)B%0?03 MQ//0Q-H0-UG&?Y5Z\RU*_:')C5[2>1J=L6VS!RK");8Q>6)G\)0#6YIU<*HA M#T"U7ISG&Y125+BO62/2DM"Q*(,]B>[#H("W/\)GMP7<^<&M'V^B;>RF#DJ" M5),%.,%5`.>)794>,*&5W-9SQ41J/B.RF88=$F*3#38;\WBT-")]=[XN#W`& M*T&N;IMS&0!S6,UOS:UQK@@XK;!>W,+6"R32\LM/;^(@H*Z)P8+Z\*4LZ^`H M+`]`S:C\+-^@"%WAONZ1.+]>-RE*,G%MCN`=Q$$%L''*'_=7MB#]>>9ATEX2 M!`7BG^0<'O5E`#HA?VZW+$3ZZXZ%``V/^#=Q&/E['-SB@Q^2!J0OR3@XPLO` M5Y/]-->@B"YU7C/)TW)06A"4"7;M`9`!!+'2EIO@;[_:5FYD<&Q7"8KBJEN) MA4&I@!*0SE;?K!>V&L".3=AV$-->U#$>C5N%*GD`ZY.RM`+N[3J,@'6%'7?6^]>2DI@UZDD9:!C(897@[J'S^V&A-\: MX6^/I]?$?FPV+&0OB:#IGIV_QJ5'60PR_SH.B8=I)$(JE>*:R.0;V>7@#4T, M30\4`E(I#17YAZ02*C!T"L:QO!&_H8DRB7=!TD+!Z$>7@4EMHYRFB',=2^PR M3VDO*S0I'Y=UISKIH\&7&#U!TS<0`BQ#FH"9'_B`FM?I+7S'>9VR`0\XV;HC MGN79'7BRUA9@1_*6N3/<>9V^(WHWG8_G-V#F=9;X MD'17%]N9[^W6.-C?XHU,N2J2`]>B.J!Y=9&E!:P7M2ZWK:]'PVR`Q4Q?4:KM M$3-N:H35&=B'4ZAK&52S#$TN!N!318N-2W:5HZ5F%@;(XYIPU%%;DGU@;*]# MH5L`TOLS>($H5R(D5>@J*'FA4`Y$?YHQ(QY>;&\"[)#HSK+9YIZ7TYU'_#0" M[11)HMG0!'#5:!.0O&PTR0]8-UK!:,L15ACG!R\.I>6-4,G&O9$X$<0G7.(GWWT2&Z3ST3-Z'X>-L<-O,N.WD"X.7-PFSSBP22A?\U'(!UPT ME*&?7,]1G0FP/*C[?L&U%;P$<7&?N-4V*01EI1B[KJ-7\*E=1O*DJ*%.=W8R MXP)?'_0$3=^T)F!ET03,_#0FJ%6:WL)W7*4IF[X$)UN7:]17)4@7JL_7(34F M=`6^@G0F%]/YS7(R7DWH^&8B_OJ6?B949#R_%7],_OII^GD\8V\`&WQ6)#X< M7+[)SG+3)X^GWM8/]CP<=8]:*^<&KAT-PU!XB40M*V#-:(J@]3,>N7*$<+"2 M4*XHX\NDO87BT\/#C+__/9ZAV^GJ9K98?6(OW>2<;=8WH_7T\6\U2(I M+9PPXO_P]OOW;SGMV2>_<2FTB",AMRP-4`I70F)$+4T`D([5?K:^]9HWT-2B M,6YUB.O`<#EQP/H8T2-&M!4G/G^,U.B%`C04.(P87(G,G"0!RJPJ0,4C_6J`Q_7C.VGK&825S3E.!)T\IK/.G;[(DH"E4[NF% MS]EP@T:9U!TL8Y? M:A.P*&B#=E%7D'DP0HD/N9,'[#!0V0PW.CIB?-1I/(*%X>CJYI?)[:?9A(U% MYXOY%1^/YLXGS&]+Y\$-]K@E^YRH#+/KAF5=B?IV8SX&6/#'>Q/L+-MU2M\6)YT>,GBPWYAM%#NF[MZQ1Q]F]`5^H-Q%F MEPEL:7J+?D"'LF@;N^X+CRVF"N%[((=I9'_L5))(U8-/.=!U&?^S\4VZ=19[HI^ M(FZXJ!ETZ;(-5$$["6&^WZ/%,.#>D5Y\K:]CL$(2"CTZ%CE00AY'66O\'%U3 M-W_O(O;EQ7S--*T(K#;&EI3QM9*W"FKKISIR#O&=@$>7>&.;=XK1/7,+'?TJ MS*\PUQ#WS=`,"[@0`Y/*.XL$GUDW^XBUKDM2DP6XA*D`SLM157K`TJ+D=NO# M_-0XXM;1/;:8;<.7M96AK6N]Z_(,L!Y7MJN5&096D_7)<:XJY^P#:+AZ@PV# MP7/\);FLGWB[A\#WZ)]V,DKQG)M'"A.'V:L!/`VAK?7!K6VN]%@&K@8:PU?< M&G^Q6<#*HA-=^ZWT7]"Q`%3T8I!TK&MW-9G^>@E9V8KKL/MU4E)?XUC)23X. M3AS)O;LC$J:^`.@_P(^DR;N%GK`7XR6V_9U'%(Z[5&8`KD3U8(L7!?<1BUKM.29?1S4/4STXTR`JVWS<%G:^M* MN:`OL3<#T;9>KQ])B+`X\82"XK*[7(9 MGM;7UK%2V3[ZB%T"PTOFTL_+SM$+V/JNF6!!E9V/ON]\(:Y+PS"E74QO1]C3 MNOSU)N5C/DUM`)>95B')RTLC`X!EI1V."XZ5)D5(GC7K]5BV!&U=RZN6$S@! M&L`_.=M=EPUP96_BO;8J#JME-!("@_<9/?I!Q.Z^OO:#P/]"O%W=R+`Z!W!6 M*\`MW%4D3PZ8Q2I>7S#5D5PYS'J/Z,%ZX;VX*W1M>;]KG,:=Y:Y75IS`K<\" MM'(V`9Q-VM:DASY=J^J^WHE:9(4G5V7G&I^>IV>[CH`4I^DYV:Z!:Y?*D<,]"17+@K*T#6KRRO#PM8+;6NMS^4O+4,!*6X=35NF:F*OW`:FME M`R--/*#ZJD]ESRHL@&:E1[0:Y^17]B-V8ACK)O>I[Q[S%F:5$L4NS9H:0TE!9'-9!/BIM="3`4 M$!U5IQ-992?+TUM6_AI;+MF^\)MLQ:ZY)A+;T-(PY+9->$JDMXF9X; M"[%S!V=LOE`L#A`[?KR)MK&;52B#@\\L8G?$(Q&>T4;B;(=HI61?9@FH9&L( M3V$HV]P,Y$'N!6AT4$R4>L6+1>?[,$TK$90PD=P#>_3_R#%0ENG=FHF7?E5D M[N*(K3'M_2!*;O";/!^P%^)&:J2IB('(E,Z`ENF7#OL#$#:M,+M7O!$2/J&\ M4RCQ"IP<@@LN>W1ESVZ*9WVW8_QP$K\`N_Q+.H8.\-ZBOM-N+R0QM5P<)M,- MR>1#^)%-`\A^AXKTT&6N#FI!LV2)(0M0K<^M*SRSG,Z;C=*)-"H=_,"D(47H M#"VW/(+G5LI/3%HG#'(R/XJ5JG=-W51Z+8_YKJ\J[M^)('S8`71RX/UX@>GHZ3+ MK0U;H^O"U*3_)C$U?)6N109'IB/F(CI0']GCMSZ_SB=ZM+QR_1XAGZV&!MB. M$AO@%+VSV*M).BT^N12).X"X!TBX`%+5.XM7DTATJNSMXC)XI6ZAR,-77MT* M&_GL$5PUG:5JNL'(P4YL,[EE/U;Y?BMPFMF/-G8C?^P'ND#^+M\CQ&M(JP!< MLIFN9&ITCJ-KO/4#G!VXN?.#:\MA1SY+1;"-$MQFS@D'@[#$95;!B.17&;T4#AJMK&H/#-0?>_'ZSWHA=6;;/&&;XE.8E0\ MA$<+YB?!36BR@>B<[@IG<6%7QO0LVF7@%MNR>)3%K5%NR#+=/`R9/JMGA2[, M+9#H4F0^!\#J/Y]"B(.`G:)*I#C=U&`_6L&.[7C86<0+:6KZ/<="59=E\[?; MD)+HRR.Q'Q$)T0Y[-('KOH@Y!9S;(%U08OXO+OUQ++55[VG^P(S$[ M,?5L-W;8YJ/SR1$^=F#S7_+981U&(>NWMJ!ELGZQ1>AJKP^@ID;`XPXQP7$2 ME]"!%T1[W<(IUOVF(IY-":?3Q"]I0C'YP:>"Q2<]Z[7YF,ZS(*8^)-.;:)H+ M8OD\J.AC\N@9FQR&%,'FU?`807-[*ZM/$>4N4V$=FI.?H*T-H$W#12')[\ML M9`#@WJ_+<+1E4OT!O,*%0ZS,LUU@)GB3/8M!H[04QRC#-2U^_$QD&Y25,P^& M*2I!**=(52#R#98%)^YKY<`XSX%?14F&COV8"X*E$H0+)A>RHN[\(#?5+&X$#W/;ZE@? MN*Q_WM0`4):W#T8V0=`H-_3)@'9@=,W^9O.RN6UATGL(4E]Z'MKW&Z&L-$2+ M*RP*)07FCU"(,DT'/1FIB>KE(^"+?)+1GI"*=42!ME!"J@S<'G M.TGUN0!WD1HXKX?^:2&YBVN,4+['`)Q!AC`2JIXSF1$/3R.\KY\B4+<#G/RM M0]-F;BTS`E@:VF/I9XZ-E8MXP=U(QQ,.-K[JV*JO$$%XYK9Z1'EMN>RC5J/1 M8][!B(5""-1G5)*,@Q`%%?\[FTX8H:0HB',JNJ(@=CYG19B_+JK^(BU)O!H9 M`$[]YL%H=Q$=8!%H`:*W:^<,+C-4!./ZY=[ZIQ_(&(EVA\4:XB,L>XS*T]KER?:VYEN*RI"HLB<\I, M#),]E4@N8Q"2,2A/'U:JX94],]&17X*H')[^1.8F#B-_CX,9"6OFK\M3`A>+ M"GAY02A)!ICT5=ZV7FU);")NU/"4<_<`S1%N[K/GYPXXPN-=@/FSZ=6\J\P` MG'[U8/,LE*<&3$8%IUOO3$`J_ M0A2S,^O4@"N"PEY3HF'@!.W[&&-7/U!BF.\=3$V;W`_3.5`K!Q3D/,2L9A5< M,2M0/6T3`,5IAO/U3G@]FT;N=S0EU_D:]B5S"/JBD`-N^K)^.=Y/(=[&[HQL M98M8BED'R_;S`*BQ_9AOD&PO<;\3MH^0*`FQHJ"176,0_H99CPT[5V/:=[1V M)X^B//`.($3^5[[9H9!ML+R7O^!1EV>0?-?TPD7=9#@O!1K--6&_\4.#9\(K MX(UM.KJ.^;&+O.HTCY/)+K`Q3"NK`="4.N7(+S2,XO>@J0*H! M`*$JEM'O59`]X4YN>H3'Y[']1TP" M[,CQ+W%(G-ARV69>V9B_N17@C&\9EL)YMV8F`&M"6R3M6SU17KJ3U95,%*2E M\E??#W[:BS:19YT"0[SN$75RV2W(Z7[Y2\>2AT,UF03.?QT!4QPOU-H#K!U: M8'4XUAB5/D4^HAV/T*8MZS^P%:![BSI*HA=CSY:"".9$^?%Q0$^.5\W8G,=J MR5]-=]A-I.+W9S]_B[D@=UFT^"'H MC*Y(4"MO0JO+`YR32I#SY*S,`)BE:GZWOZ8IL7[> MTS%Z,YHAU"9?N0@(ZUHNK:CZL=RS9,")*@-6?*:BF`8P':6NMG]\0AA$S*+Q MOEP>7LU+M24)!U05JUZA/4TUD.JH[7'50H4T_)JL(7@77(MYBS?1U`NC@-^\ MF$=P31U@_Y5?D]D@+U"NM0I!=HVF:D;HUVHVQJ'IFLV-Y?W^IQ"Q[U#`ZG<< M)D_"6J[-#TSS9$\I!WB:Y'I-A_J,2.9TS_=<]A8Q5A`ZEH2*>L`*2Y3!W%68 MIF(QD@6C%W6I5A[+,S@-2)%531[DOPU$]H5Q(,83Z53%9?/P:>AW3U4"*6F9VTE<_'N-+,_?$(_MX7\F0@+`_"GWLVV-2ZP9YE`GF`S2QWJNI\])&NCT*8-4H$\^`63ZE/K9 MNJH):Z;ITP4F6)L=9S7/C-3E`4XO)DTL2UBY+*064\6<;F, M'.(@C*WC^W:N;WG(2M]^U+C,TB0"X_`!TU_`BZP=S3.V;88C7&(;DZ>2@Q%= MV`D+"@/Q1^ MK]0M=/3+P`H4J+"FX2MO?&@$BS6^I)Z;Z^$6E_)N<6@'Y""N#3[9`2%=WVIH M`FBCSV MTQNQ,UG+S!O0L<[1?C[]<5.]0J_X:#X9&'T+I5]3=2-)>4J@`J<`3]XQ@7[_ M2)6W;6OJRG[$3NSR2CKSO=T5K:=[=,+6T/Q%),PWYAKS;$T+J]AW*DD*O,96 M`2RL))6D`UQG*]UM/9]7J*@CQ`P;W[)ZBK3R/*LT\KZE?6$#`C MJ_UMO6K!K2)F%G&[IO<`=HA2$)+;A3+4F-7L!Y2G!D[#&ICR8<=L`+O_ZCS6 M=>K/_'Z_KI`>VTFGAU@6MS4F]!19T2\7;;]XK1A:YX;*,E:AD&REE"5=5A+ M"TI(--TD<-SU29)2Z1_YA;%L2UB(^$.OPB%D>0[R\)?3!8;0Z`I#IX$[[5E, M<_%*BSMN_.IY7X618)`PC+$#I>Y4:BQH#0$6T?3#D M/9BJW(/IV2B!T-;C24OCBX\C)`K,[?B$T!OJ/B+'AN"X0,E7+"]?I53J1QV$[89F@*CO@.L1^L%]XTU4MF77:@$M`V$)*.5&7>8?6DU*!HZDIYO##6 ME<*L.%;;>7GL$)Y8]$Q/XVU>Q)8.+^I_'WV?`3KM,LVS"/'R4%H@2DLTWFGJ M-A[SDQJR][WHT7WALFFY;FD(3'6G3L`K-3#G>8`J9B/(\G[228;!=(UD?FOK M#9T2&T+O1S?H^W/RLC&T&SML('@(Z-_D0$G.1LJ7["[5MYE@G2S25JSCYI(` MIVX9H-/M`NGW@(E9ZJ:>)7-SNP&T`>+"XL<199C':&7PD:`X",2DBK_':^LY M>5_N&GMX2V2,JLT$G&-JH`M/"%7F`,Q#17X7A#>PZ6+>-V.TO` M"7]!>/(JT,(,8&FX!$U;VE3IQ`@=BT;'LM&O:>F&-CJ8B--#*BG\&`P14:-: M8W9[TA93T7-H),2[M',+V[<%9H!R]M+`9&L&+6P`Y/;%4#0V M\$FQZ%@N.A9L3`>,18B)GY/J`QL^;$2AYAKV5;P)\1\Q'S MV@KBA&,)VLI#CE7IAU=KY4<=I8F'57,U'024U%VC9QZAH#7&U5. M^`:QDDY<>0J@]*J`PTA5\C5`*E5YV7JYGME#PJ"FOIAJ]1*%EG:V2KX&7+'* M@*2U*O\=T"I5ZF+;^I36)",]H[[17#`O?&WM-[X_MO^(2_5K^:&]U M=6I(6^YUO%=0U[O(FW]8,]]X+M[8YHK60KL)&/A`,HYP$[$&+W MO+.[RS"<(^0`3;Z=VR]<\8.B5]_0#N$W!J_9.^GESFHNOZA(#E2X5(%6C,=F M`[C_HM9E?:.RF>D;,/K`BI_:'IZ0=!(><+!ZM`)\XWM/%""5@+5_X^_WOK>* M?/OWJ<>Q++;W.-B5]QL:6P#*R`O"D?4NFF6'WN%HB:9M-;_S`X0M^Q$]^JXC MS@^QXV,!/O@!/W4N#I+]*40V=P*%S`MQ;;"=N2@.8M+>R@:C.,0.Z\.@D,%@ M'XITV8,P>4-I>19K#0,2Q`,'E$$U+;['H80!C_!?O0)D6 MA]]]@6*QS4FQ>",*.U-O1G"\V(Z]EU/451&ZR.H0%.[RL)VI8'N30U%*#0@O MY];BX;\7Q=Y20K$@<8/)JDL=X>^->"_G9!PA:QNQ#I7U.^O+$8]VP9*7S9#E MNFGO*S&;/L_I[P_,6J'D()VKHJ5NZ'>T/T>VA)*8Y0O0QO=_9UW%@-!_.]BE MW@4B91C3SB4O0/0P#8F_^1]TD?R@2=-`_UGHW*6>L%X>\X4EH-Z<-RH&6Q/S M04Q9<:RQ)[54D1@:FR?1$Q^GXY3DG4%V3)5X7&?N<.F;/(KY(#^&S#V>&AU-HRU.GEQE8GV3B/470N5\PP;N?"#ML,'VP7I!9)L? M39,PLT23B.=7;;'<@&P24-3L-+1-F14>L"U>?"UTW8V-QWN)N"@$9:5D;Z[F MRD&T(`,2W`_^\MJF4RQ%"8LX6FP?J&+C*-GUO\1DOXEI!$HNA&F6$[1@-H)_ ME$RE;.!%LQD*';+IQ_SZT0,OC6ICKIRB>OJQZS#Y]#>*PQORU$"551%F?E%7DA3PFFZ=QZUW(R1V"]LO3)_=*`,K M%HBJSW"HY!M@)2Z%7E>="YD&5K'+?==:Q=,R#)_U,(-^5`^_/[(_6.P2GZ0G M5GGTHSPE<$)7P,M3N"098-)6>=MZ"9S;S+KD9@]\=`&03US^@BTW>LQV_+'/ MBEO^_OSFZ,^,_D4_3#]*+-%/_A]02P,$%`````@`$##)1DLX(&;#'P```#4" M`!4`'`!B*>>M)[M.G$W2/3.? MNA09.TS+PA=)3C*_?D&2;A#N_/6___,_?OJOW5WG`@,W`A/G^=VY M!1A#WW+;WM[KZ^N7 MMV?L?T%X1D3M'^VM:S%+T/_:717;I;_:/3C<)4#?PLF.0]0>A,FW!3ZR*DY: M6"C]>K0J>[#WC]O18]+X71B$D1MXFUJEKV3U#@:#P5[RUW51\GG(:=!:--&> MX_R$D0\>P-1)9'R+WA?@YYT0SA<^_7;RNQ<,IC_O4*F[U`+[QT?[%/^?+C-J MK/X=!I.K((+1^TTP17B>:'_'H?)_?;@I-.@9(B(38,)2\,5#\SU::$],7@)2 M2-][;0$^1H2GM"47*`B1#R>4MN>N3[7W^`)`%,K`$Y%F%+A[ER"(7D`$/==7 MBW1+M&[8ZU^&X^EX`=*!L+UQ66)-@GOAAB_7/GI5BS8G]0/!7L+0\U$88T`F M'TB:<8]!2!HD/Q+Q!6F!=.U"_)OKQ^`6N/2_$TTW`\40I076'7@=>AZ*R4`? MS.XQ"LB/7AMP7(%:(#Z`)0AB\H^'9@&D%"(S&^DY$7:]*';]X>1?<1BU@"SU M`2TJR"P2DB8"N'2??3#TR?!`)X2&F/D2M8"\(0-$,(.T*6$HZ1SPI.@B+?*7 MI`O=H0CXR?0_`])@/7U;+Y\%B68OHT\$3[1_>3P>HSQDT) M;?"+R#5B>F@#DB7+=&)?@LB%?O?,7G_'.&JWTH"08"/(W0HF4YA1GE!;+O.% M&N$7M8+(%&:2E]0*89U,(WRF5@B9PJ2A):U?X:MJ2K[^(&U'`&8TL#1RGX&_ M4ZN4*ED^Q@51-(0_H"'\@]-$;<4OM&_J$XI MEQE:[DT`I)MS1_0'VORCW?V#;)?L3^17OZSL\'IX/3P(-?B/(&&N-AZ%WNK;Y`?2YPJFBLKL;=(-B9VO1?H MKUDRQ6@NI="L%4@2%<(3@'_>(3_%(6DK6E"IKO]Q!KH`U)?V;T@7>?M?\,ZT MT%8Y6TPD`BNST:$&&ZV`/1&Q%:;)_[G_%JE%DQGB2*,A[@&&B$":7)+IC6.1 M0KDBF*\$S&%/35,/*[/1L08;#4D+)[25U[X[J[!-X>_]MTD]G,P6)QIL<1%C M"OB:K"I<_Y_`Q>PNPRK:?PM)(/^- M)HTN,]Q7;8:[AC[`%X17,X39#ERAE"UFJ@>56>=,7[="\SD*'B/D_?'X0O00 MCN.()N/13$UVY^)4LL5VTA@S4PXTNG^;H?R:_*9J<&24[+_19("M5K7[VDV5 M.JQBQLJ5M3;N4QFEU=J$C/`:'GL9Z>)V,( MVNDDX#"#?HNDD^!LS1%;0I=R`LL= MB#)=LD8+3A6KR"$-E+D7T2].W`0TM8"LV0E2TPYC9'OVP\CEX` M+BB*8>ER0:OL+0B/N7'2+ZM?9HU]&53R0QD7(41&`'L[ MOW"_+^_[2)JYE![VL6:^QV@!^W?R>Z:BV(L$)>+MH%FG MVFCKD5;F]BXP1!A&[XG/8]20Q5Z4\*K8P2-IA*K\5LWS5^:2H<"3B&>6B]M! M`BETEOBIE.C1^RV(7M"$+M$WA^>K[,\H;:CY!2U9)H(,3$O"E63&I+L\X;;F MF*O7ZN)Y%0W(#'AZ>-)K)DCAM,2!_06AR2OT?8;I5W^VS=1<7)8$)[>/FQ+O MYNK-\V.:?%1C=I&JME&B,69+HIJY&&[MC%!9UC9"B(.TQ#VLBMX*.`>\2K9Q MH@%:5<%/W9$NL9'!]D%!9CPHI\OW,5[`-;2AYFUDU$Y[KV93CJ#[#'T801`. M@TF2D/Z"?`(M3)>_-:$@T>K&T*%I9F,KH)8L"7,Z$$M\9%AO1.J.@T;18A5/@7DL@M M"5;>KUJ;P.==^U%1TCA*2-JP3`)1D(K\A27`SVAM?^VGJ7+7^7$O@-DJ9A\- MA!`J\A2*'-"R@369P+3M]RZWC1T/,EFQLE=4G[%':1P5!C*JVM,P)758ZW@V3+(LJ M.R8J&UBUP&B$O[.CV;JN@[U/U/X"(NAM7(S:NV%/Q.^&=?Y<^,1?=G[<%?OA M8))W39GS0;Z0,9V^:4:U`)P.'HA28*,+WPW#\309AX9OD'4.@EF^"/5T<'JD MZ;$B"4MPS"<$SRA+YEM\B>;$%V6MUTL%S;6=D!DJ%NQB$"W9YGD$F#H1Q6#5 M+9@_`\SJQ>P:QG%!T)85?5D2I"UL6/4=XJZ!&_)C[5"^+FB<[=N-X7QE-?-TQ3A0P22*5]P`G+[$(!?%9E& M7TGQAJH5LYI&SK0V@HV:[4?Z:TP&G) M;D`5\ILPC*4HD5:PFPXAT!->\C1%*PE9UU*SP'63B*<&E:R M0F;ZZ/W9EVW8W+F#4=IB%M3/>_WB+Q;JI(E:*JOA)5:7K143T7ZE"J.O12 M(L0';@.N?QF.I^,%P&EBON`6X"'_>N,TL9TY!H#%(*,$E"T MAXY4#=]A-)ZNP-8DCE<7[J.E)9!8$O\I(LZ_/;'UY(20[3GUC:%#`UO7$446 MMB6#!/DTP@1O=O7/U=L"!"$K&%!=V"Y62&"T<_B`I!M$MP0[AJ[/VHODUK&+ M$/)0+8D?)_?]%-$SV%!1TBX.B`*T)EPL8'2;[2UNZKXG@R=/X-UC-&6>#%Z146<$44<66/RQO@M>7HUV\\+9JEC-6*_%UY1TAAB2'B% MHC`L6>4E\8L[%*`B;+'%@5CE7K*@.3)+DGQN`M("$#(F?D:I@D(.]HE"-#^` MT,*.95*(@+7$ZR_IC4\#5G&[^2"%N@/_?G.MU*$A+"EHL]&D\Y!=$+(G]9DB))#B/3T_FP M%AC#:0F'6;=Z+'FY=*V>K)^?@P"P-^`8I?O+'S$HG>5,?_`<"*(-WX=+%_KT M:/P3RN609]=(G;LA]%@SHYR4/G)#!<2,,X.>CP^K*PE7A\YXS*@LVT?[BP-9 MK;[W>SXT_!W`V0OQP89+,GO.P%U,KSH93TM'2GCFEY)1U.8!T>:I\;1H#W!% ME[Y':[8[R"7TXXAY((]1NH\4D(&R,G;?DW(9M,^@BQ['DY321W*H@+@BC?K] M7$WG\R[<\.7:1Z^BQ_..9([G70P?_^9&N'&C!8BAMY::70%WY*- M(0,6K1KY]`$\4;S\M8M]P\F_XBP*2)]Y(B9(#N<_H0?@D?^&/B@HB^A(S$HU MHV+7G_W<_-:B7>WIENH3N,G//FB6RDBWBOV""?%\J`9XHUMUX1\4JZ:8A+:T)[@K.M;BPH!J M=!S0^U_&4Z)3HL7H_=YW@XAN/"^H45BG6X0J%]5W2-2G^2%W0\C60GMJ,URT M[_.KR$012I+X0;[VRFN;\&\2]S!]1/T2I/_FU)J]A%BS'!878!P+/W1AVU)/ MELRT92T,/0_%I)N1G@_@DO.BE$A5XRC6TNHB-!+40MO%9DWJ\($>/B5]-R1( MKA&^1/%S-(W]E4(8/.)5L9\_TN@[73QJ8DU9JW2^#\C7(/,>&VX=^WDC#[_C MLPK&4">]]"G&U"3#,`0\5[VVZF?:=+7KK=ZGDX)N`V:I(.)/"$&<=+!521"2](Z\:2 MW>UVW;^3S$KCJ/C1&7"J=6?)]3T,S:1[&1TE`TL*+ZK_B*C_3`]U%24#JX!O M2?89F2"2_;(G-/2^QQ`#HJM)3-4"N(O8VGK&<.8#N%`1L&VDGHZC_9JNF"GI MXCP.80"(&N@C/6E/SO["?+Q40L0/XK725-MQS9@]\G9J[V0^_=S4[$!WEMSO MSM#,-0SCE`P>P)X3N](9O")5=P8 MAGR`Y*=3)PO_^0$DU&4-7[= MB+BS9.PG#8;1M>O18.;[=@`TO<&/^?2IC(C/S;K6FNHDGT13SIH'P"3).4X. M[(X3*.'5&\`>#-E+U[IZGYM@S=1CR=L][33=B;__N=G8@>XZV*70OK'+4%-[ MDAK-2$4K3UGF]/WYD23B&$SH/_2LSM+UJ1,[)+K!^)UHX3?7CUFG!X3J]I8@ MS=$I&E0(_R"B=TOAZ),1Y,!NAAPH2VQ+*7(5Z'2]'^/%PD_4YOHKM=T$4X3G MJCX*8USW4EU;L<;0J(D3J!RX)0\P,'9`2&^C)]-8`TQ-+6.8 MTBD#JH@FKQ;M$Q/#@_P[AA$83Z>;NVF(LEB7`@G4^&R<:*J2SN:P;B[;WNB% M7KP:4J`;<3L%.S+NUS[8)_]S=IV-)/(?B3`'39TM<09?J#W&,S?([CW MWHF81S&>9O1R_\BMFGZA@M/A#7GI)E_,&8BU9\Q9IA22J?" M^XL?H;'.9K6N1[%K%^(D*'A+)G'RWX5+R&K&L]MH[\)H=V"1.&W&U M`O*C)]5WC\I]EPAU-E*=DEB#>S!''W0WY,4-9B!<'W)-RD`RTB]\9D=7(E'/ M5GOCAM<-&RI$&S.Z**1,<0^_(QWU=JQZ`$L0Q(!>^3D+8.9XT9P&JL+8]7.7 MA`J.7%H#JRW';A\\^30]]$K62H!T1Y[4NZQ*ZG.1JQ3D&MT!UTUF>4^5);0 MDOR.W""\0Q&97K`[H?=Z)-G7N?:)QQX:R3*HDS.-5DA@5P:RMQW^AL@(9I!V M],*)_II.?EKNY!M)SEJ4P?WZ%X0FK]#WDU?IBSJHW764K*LI48+1KKJ>+U#3 MF'[>R(A;N16-P/:VOQ.?!OE+LA:APUYV`=2Y&_PAV.^_5KKCJ42'BG0RF227N]RAWF$K0\:ZI8DPO%5#SVN=N M@JFWG3%_%EBB$YZ5.R&5M$M%.516+SI?'CRCUU47T>-:;UI2[SI7E"T2]XP0 M]TA/9^2IO>@;BZ+H;??+7YR?2\$3[(6#TQ$72W%X\@'^^7>NI'DK$49 MW$FW@;,\568Q/:=SBJVIZYO,\L9TS#HS%$_?R*#I;9>4V/5Y2J)J0GWV:/]X M_ZCEWH_SY_2#?S&[:YNS"?3HO8!)3%]MO`/1(\!+Z*W,F]J.NR`5KVU,=Y;8 M#FJ)KK?=F[]N;MR/>4CWXM-R#2]L^/>FTEN__;*A^#LSA/NDQ)SW='U(%7OM)*+6L0CQU7,<1U>HG MQ_N#P<'1Z<')0--(Y1(7)&MGME8+?\$H9-TYQBQOS!C24/D58XD45.TS%^L6 MF,HN3OH^[;&)%\^]'T:XMCWV5P%<^RT4C=EP"R;0(\I-_X63>SI+;H[QRI&# M([]UWA+?GE9;2/C>3I+32WR&I M&64^-S5X%-#WT@LK.%OA:=V!Z!Q,43'[Y-R=T#R;2D9("S&&(&H\%C7X3:5( M%8#QM`IS%3?$:UM&BI;`+;DBGM$U)):XVR\S])H938!J?R>6,2[D,IT:F`J@#QXQBZ+7WNE<18`]$ MZW@)PB?R^>$;9(6_Q2H;8V%U)N310EH5/>+#)9J[<#OZ*5/58"Y(VTV6!!P- MF!K87.,@"Z98SMM:"=(&I&E[PB+E'\ M'$UC?S7N5I)(O**-Y&F)7GN,^V-=4K*(`3<1F-=[*X)R#*94%XY+&ZTHHMH2 MX&=D"-FJ>NVYZ]-?-7*`LKJ])16?`++.$$\;UF1)RX4_1&['Z4O$XT>>=);@ MVSH]VICQX@.SHLU?)G,0G+_?NO\B?K[OAB$G=B(AP1@**+)DF1IME=$7;FR@ MW+ESP(VF2$HQCB-M32I%$F&-6+*.OHC#",T!'L&P9N%<4;)/5!$V;)DNHL@M MH01]M`?-%R`"PQD&Z7W27&:P*WP2@D@J0'LTA94+Y$99NML(>O3<#B<Q3^;O2?Z8LCR! M&((^*:5DM&&_/\3.@.97^J3D82%7E2/?.#-:4:*"]SV&I+%L#3R`$$YBUT_> MDV-E+=Q),;K`=3UE/:6Q3B5O)&.:TWB1J@--^!XAY14O- MC1MM1-I#*>5:L-\9JM#(`Z"!M@D]^')-U.[Z_P0N*[2L0+(Q].N,17*^>ANU MV1]0J%`/U<;3*U+"T$S6#TZV493]TS1+(>3S\D%2KK0?3&RGJD\Y@U.57*-8 MS:2]$O:#B:TT9Y0B>S3JWTY8*+E$58U M31_E'BN]=CWHP^B==U:$6=Z8$4#PJ=9F@(S*[2\VFG.\HUS0&&LU,T/9C((0 M#;8?]P!&55'C;"AH@SKC<=!9$CQ>3WI%X-P,>6X=PZG`L6B9#/)`+6'%;RZ& M=,1[<"/^/4?%8L;9ONU0+@20&<#7;;F:6XFV"QIG/2'M\XUF\@#..+=";U^] M"8B7&-.3-WDPYV1-0?]EGV,1K6NTJ86&Z/9P^V?_JQBC"?)]%S=AP'9MZSD@ M!-B2W=<'-YCQ9NKUWPM*.-H?G)YHOG.V[13-1\;,XU:Z&,F8;EM*ULVGH\MAC7?:LW;KZ,#<:MQ6/)G%DU M\XQJ3O]RZQAG_+9SJSQ:2_(VJH!G_6(=RK]P%^0OT;L$4U@B>D$2V:VX+KX$H8?A(CT] MM!4H82X:940457E(5*DYS4S%$-9:`9;DTQ;UD,!])`C6TP\NZJB^B? MUGFI=A4EC>FP/)6S)V(V!J/RLBBX*`-7\^A455%CC"1KA(JQ5!2>T?;CIF14 M%S;.AL*6J#&%9L+PA`ML7]Q MP*O;7F"4-HX#S8=Q&8161N(H]\6\+%+0<,/SS5?K@K$`:N_Z0E&/F\##@"PS M;H*KM^3%X]GFE$=]$(17VQ*KJT!MY1!P$Y#V@#"B(:''B-XSN=FF$!H:>`(L M(8\BX-H#\$)#R>KE]*OOL>L31!!-H'?OOB=7[]>/)=SJ1;4<$;5H3O-4-IC( MP]8>3N]B--E"+C2`;-6QA"/-L=H2@\^%PC@QAE41R\Q>"ZVS.Q.ZCK'?8[2$ M(1%RC?`-?9P%/+EO0/(9Q4$YU+Z6ZTP1=E+)3B*Z+_'VM39J7T_DEM3S5E6R M'[1N5W;SPSD(P!2RNB^_DC$=6L`LQ2>II%%I7R,JYF\1,GT,'08Q61:-%P`G M%F-=X]!"4E_IH@JJ-8O+M+%$(>LK7VK(PJMB#"M4F[O*4914@R6C3A5N?LH& MIX9Q?)&VJA@Q>'`5\:*8O[$@ZQ8,H_=$KBDTH8\#2C-E4^FSD*4&L:*91QE? M&%$JQL@[G$Q@VN!:K[NI&&-X(NB:*,6I/6BI=OB06^'4U#*&&$HMSAY4-*R) M6*/*X*/"'8_Q&-;$ZRK_)C%=/3[ MK=;P\@JKBA:I?4RH/=#3P^N4G^^NPD",RD[;;C4_P9!1VAA[2=NBWHP\B*9; MDIMJR"QOO#5Y)A$R*`>G),M33@H+2$`N=Q2,^>A,GS M@F'BC')&=D9IXVD@,;++0#3J0K^JAJ=O1O)'^-IZQEE7QD1B!J[':TEWOT^4 M>X'F"S?@W]U:4;(71*@W99D2HEB-(D$(O"\SM-R;`)C:G_RP;7;RJ]]'8.;Z M5T%4?=UV10GCS-Q@-!>%U<&U;Z)V25M6.31O_]D8BXBJM6B(6BC:^Q4CK'WN MSI\1RHTN-X'WA7VE)J>X41:LM<=6N%H65P?FU+[%M34&C6K.Y["*&\,#]3$0 M/D;M&;6,+GX/\.,+T=(%"I9$-FG4$R*.P!P%CQ'R_K@)$FSCZ2W`L^I>+R?! M=`+PK;@U,"B`KFBL\`T9)G+HB5,YQNG9@]]:GO=1V65()^'-D550) M``,_N795/[EV575X"P`!!"4.```$.0$``.U<7W/B.!)_OZK[#CJ>YAZ`$)+< M)C79+2!DERL(7.!VYVU+V`)T8R16EA-RG_Y:\A\,MH6-,SNDSB^)L;I;W?V3 M6]V6Y,\_;=<.>B'"I9S=UUJ-BQHBS.(V9P"-=&Z1E=WUU=W[5LT M&45T([!@08\1;EW[SK569(V1Q&))Y!->$W>#+7)?6TFYN6LV7U]?&W/*!5D0 M`8XA#8NOM;"+JS;X"DLIZ-R3Y)&+]0-98,^1X#?VAX<=K0"XTR'*"7L$L6;P M/W/O0).]+E_;#2Z6T-%%J_EE-)QJ)4/BN7!H7@5]#H>RKWL<6Y`1]M!NJN8Y M^#PD!V&9U#=-:`T)F;=.)[2E:,JW#6D"!1'4BA@XR\'#6?V`3Q'9,N*+*W3= M]!NC+LA2#9%,`VZ;@CO0B4\6WMTW= M&I+:A.X#X!*KL>0O36B(:P)/%D+ZV<*,<:DC@[X7WMUL*%OPX!;<5)W<*5!F M8!12%_]^'I@'N(9P"K+UL]7CS.4.M16@7>PH^Z8K0J1;0Q0&0@ZZ2)E0'9LL M**-:=4#I`H(3BL3`=6_\-!T/!P^=6?\!=3O#SE.OCZ:_]/NSZ>?FH8!#V1Y$ MMS'[45]O!'%!I':2&C(!=T!BXK2P8WG."8P[S;+Y@KLA*-\(J^BF.UZ,-\2? M1$R@93"8T;LTHS>=P;]1_VDV1>-'-)[TGSNS`1!4.)Z$8P^[JT>'O^:%<4=O M1K%=!,5>9_H+>AR.?ZM03$7Q@;J6PUU/D&?R0I@'_RR^]-7H,!NPD@);$K*4 MCOT?SY4:JP@%%7#X'R)CGTDJWP:0`(NU-B/`+@^E>8:\N%4S9"@@?JE" MI2\-Q<15D)U65$PPL,@5D10LRUMA[#,=*S>N\Y<;Z-.>Z.I!/!)&N]BED'9. M8H8?1L\T$A-B+4`L,=-I(8@O4%Q,!8X9G$=,Q:_8\!#*6A MG3BTDU?A5JRT.U;.'<$G3]U=07(T8G+G!6::)R[)!+^I$=W%:C$D$1[3Z"1BP$#`C+#V^1F'& M[ZAZ2U4BDT\'.P>'&=WK)+KFK+X"\\3T/AW`#"HS:#=)T%)6:RJ<2C]T&0NC M>5C,ZVV%B^EJQ;1L#9>]D<%(;L:Q:$57P7AJ;9DZ\V=]?#S?V_@[F-[=H)291\P\YO#?*AAX*.0Q%86`DIB?W@((1O MB)"4N,U0^1IJOIM9@$51LP[@.T>K8*`4M6I_;)VC40Z>%S4*6(CS;>SYW#P\ M7A#NNRWKII0-^APB?I M$3\:4TP7SI[>2YV44S1Y='&$V.,Z21'3R9,L+5)YU$5]QWRZ*^*':O*X0;.H M7]&)'^6(MG)$$372ST#E5"!D4#U?Y^_3>"K*Y/Q4QB9QI!O>,4$1'*'3"MW7 MHE(84L;8>\:>(#:%+`0R"UT]C\AZ3H2?M*BH]7M!/C\&^@?6[FR^QI0-)%FK M&1QLA91%4NDI2W\6W-OZ;[L3T1[$7+M+N+;560]+<;PE38BPP[;/`U]_M894GFB`.NHQP=3N!-Z)F9!LBAL!]Z"*_K[>3W]OWF%V-'#BYN0@/EN4CNJ> MAE\!IH^'+$2.L5P1,5M184^PD&\3_,9%,<2SA7S]-7Q]HF61"T8Y+%]A2F^.,(5=P9EDBR) M*#D(2MGX'+XX>88,-M.F`ZH@E8`\`OJV%/[O9X&?0\KB@+U)IO.SV'!D*&6JSD=^;I-T]&XXR'*[A)$% ME1W;UB](L!-;DTO:?!+WN;E@2!D9+_QR9:?OC&QEU^'6UYBY1RGWQK`,[[_W M'%/"OD=L40?&Y@AOZ=I;1[-C#T,]"O<[[L2/I'@)/,E5V`QGE!?[?4-Y.%<^ MZ*3!DGX&":/;\6QB#U@RQ]29EB`A:K["/`T3E>0%+L=3ZZXH/]5B"AD8+!.02HT_--CE.]9>A+[7I33 M/'_JB(ZO_P7O,=SQ8HH=X@9[RT#?%QH=8`@LS<]TKE5$.:;GI"\9V=]E M'*0=*PBYEY`N^W1+A4=:2^ZV1[#LPD8$%@3&":O[LK#>M8WT\Y:0^T*C6V329E1#+UH:\\'Z++'`Z_">A[O%BHX]-ZJ4YE M#5#:TXTBBL%^C/`\XG8"\BY>SSGO6*"HJZ,PS*N-,*,(W].;2%(!/BT),>); M$,F$H9`(ZQ2BQUGP><@9[_$U0*'3BP'36S7&BQ$1RYWMA;D,X[U@-F+(/DH[ M(\R5'U7.IPM&/[T:N*ZG5C_WL_-,JH]E['CSE?L&0/FTP]"OAE1".:3$@RJ) MO1T:?.B04I(^AM/\`=U9"J(;@@)3[2*D3#^2CR2:"G+2?MNI8&=Z1L93VB.^ M66,/'O<)H$W"!U?R85@``+D,%`!$`&````````0```*2!`````&)R;&DM,C`Q M-3`T,S`N>&UL550%``,_N795=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M$##)1J;:CTN3#````Q0````( M`!`PR49Q+`386`P``-R@```5`!@```````$```"D@<5C``!B`L``00E#@``!#D!``!02P$"'@,4```` M"``0,,E&+K-K;-LY``#AH0,`%0`8```````!````I(%L<```8G)L:2TR,#$U M,#0S,%]L86(N>&UL550%``,_N795=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`$##)1DLX(&;#'P```#4"`!4`&````````0```*2!EJH``&)R;&DM,C`Q M-3`T,S!?<')E+GAM;%54!0`#/[EV575X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`!`PR48LF/L%$`H``&Q7```1`!@```````$```"D@:C*``!B XML 39 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
Long-Term Debt - Bank
6 Months Ended
Apr. 30, 2015
Long-Term Debt - Bank  
Long-Term Debt - Bank

 

[8] Long-Term Debt - Bank

 

In December 2010, the Company issued a seven-year term note for $5,408 at the rate of interest of 6.12% per annum for the financing of new equipment.  The note is payable in 84 equal monthly installments commencing on January 29, 2011 of $61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of  December 29, 2017.  The balance on this note as of April 30, 2015 is approximately $3,412.

XML 40 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Provision for Income Taxes
6 Months Ended
Apr. 30, 2015
Provision for Income Taxes  
Provision for Income Taxes

 

[9] Provision for Income Taxes

 

The provision for income taxes for the three-months ended April 30, 2015 consists of a current tax provision of $9,400 and a deferred tax benefit of $1,580.

 

The provision for income taxes for the six-months ended April 30, 2015 consists of a current tax provision of $13,131 and a deferred tax benefit of $440.

 

The provision for income taxes for the three-months ended April 30, 2014 consists of a current tax provision of $7,508 and a deferred tax provision of $457.

 

The provision for income taxes for the six-months ended April 30, 2014 consists of a current tax provision of $4,291 and a deferred tax provision of $5,976.

 

On April 30, 2015, the Company had a current deferred tax asset of $39,456 and a long-term deferred tax asset of $4,438 included in other assets.  On April 30, 2014, the Company had a current deferred tax asset of $35,964 and a long-term deferred tax asset of $2,291 included in other assets.

XML 41 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
Revenue Recognition and Contractual Adjustments (Tables)
6 Months Ended
Apr. 30, 2015
Revenue Recognition and Contractual Adjustments  
Schedule of adjustments made to gross service revenues to arrive at net revenues

 

 

 

($)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

[Unaudited]

 

[Unaudited]

 

 

 

2015

 

2014

 

2015

 

2014

 

Gross Service Revenues

 

1,175,282 

 

1,017,621 

 

2,240,575 

 

1,927,499 

 

 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

101,262 

 

94,520 

 

195,325 

 

183,439 

 

All Other Third Party Payors*

 

838,004 

 

706,234 

 

1,587,205 

 

1,330,379 

 

Total Contractual Adjustments and Discounts

 

939,266 

 

800,754 

 

1,782,530 

 

1,513,818 

 

Service Revenues Net of Contractual Adjustments and Discounts

 

236,016 

 

216,867 

 

458,045 

 

413,681 

 

Patient Service Revenue Provision for Bad Debts**

 

12,030 

 

15,501 

 

25,225 

 

31,046 

 

Net Revenues

 

223,986 

 

201,366 

 

432,820 

 

382,635 

 

 

* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

 

** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

XML 42 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2015
Apr. 30, 2014
Apr. 30, 2015
Apr. 30, 2014
Oct. 31, 2014
Intangible assets          
Cost $ 25,166us-gaap_FiniteLivedIntangibleAssetsGross   $ 25,166us-gaap_FiniteLivedIntangibleAssetsGross   $ 25,166us-gaap_FiniteLivedIntangibleAssetsGross
Accumulated Amortization 11,716us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization   11,716us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization   10,763us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
Net of Accumulated Amortization 13,450us-gaap_FiniteLivedIntangibleAssetsNet   13,450us-gaap_FiniteLivedIntangibleAssetsNet   14,403us-gaap_FiniteLivedIntangibleAssetsNet
Estimated residual value 0us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue   0us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue    
Amortization expenses 474us-gaap_AmortizationOfIntangibleAssets 730us-gaap_AmortizationOfIntangibleAssets 952us-gaap_AmortizationOfIntangibleAssets 959us-gaap_AmortizationOfIntangibleAssets  
Estimated amortization expense related to intangible assets          
2015 900us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear   900us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear    
2016 1,540us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo   1,540us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo    
2017 1,063us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree   1,063us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree    
2018 946us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour   946us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour    
2019 904us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive   904us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive    
Thereafter 8,097us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive   8,097us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive    
Net of Accumulated Amortization 13,450us-gaap_FiniteLivedIntangibleAssetsNet   13,450us-gaap_FiniteLivedIntangibleAssetsNet   14,403us-gaap_FiniteLivedIntangibleAssetsNet
Customer Lists          
Intangible assets          
Weighted-Average Amortization Period     20 years   20 years
Cost 8,738us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
  8,738us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
  8,738us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
Accumulated Amortization 3,469us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
  3,469us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
  3,275us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
Net of Accumulated Amortization 5,269us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
  5,269us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
  5,463us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
Estimated residual value 0us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
  0us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
   
Estimated amortization expense related to intangible assets          
Net of Accumulated Amortization 5,269us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
  5,269us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
  5,463us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember
Covenants Not-to-Compete          
Intangible assets          
Weighted-Average Amortization Period     5 years   3 years
Cost 11,131us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
  11,131us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
  11,131us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
Accumulated Amortization 6,325us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
  6,325us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
  5,738us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
Net of Accumulated Amortization 4,806us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
  4,806us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
  5,393us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
Estimated residual value 0us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
  0us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
   
Estimated amortization expense related to intangible assets          
Net of Accumulated Amortization 4,806us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
  4,806us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
  5,393us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember
Patents and Licenses          
Intangible assets          
Weighted-Average Amortization Period     17 years   17 years
Cost 5,297us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
  5,297us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
  5,297us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
Accumulated Amortization 1,922us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
  1,922us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
  1,750us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
Net of Accumulated Amortization 3,375us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
  3,375us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
  3,547us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
Estimated residual value 0us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
  0us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
   
Estimated amortization expense related to intangible assets          
Net of Accumulated Amortization $ 3,375us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
  $ 3,375us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
  $ 3,547us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember
XML 43 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
6 Months Ended
Apr. 30, 2015
Apr. 30, 2014
OPERATING ACTIVITIES:    
Net Income $ 17,094us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 13,227us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Adjustments to Reconcile Net Income to Cash Provided by (Used for) Operating Activities:    
Depreciation and Amortization 13,231us-gaap_DepreciationDepletionAndAmortization 11,934us-gaap_DepreciationDepletionAndAmortization
Deferred Income Tax (Benefit) Expense (440)us-gaap_DeferredIncomeTaxExpenseBenefit 5,976us-gaap_DeferredIncomeTaxExpenseBenefit
Stock Based Compensation 40us-gaap_ShareBasedCompensation 290us-gaap_ShareBasedCompensation
(Gain) Loss on Disposal of Fixed Assets 173us-gaap_GainLossOnSaleOfPropertyPlantEquipment 109us-gaap_GainLossOnSaleOfPropertyPlantEquipment
Undistributed Equity Method (Income) Loss (112)us-gaap_IncomeLossFromEquityMethodInvestments 86us-gaap_IncomeLossFromEquityMethodInvestments
Change in Assets and Liabilities, (Increase) Decrease in:    
Accounts Receivable (20,244)us-gaap_IncreaseDecreaseInAccountsReceivable (13,227)us-gaap_IncreaseDecreaseInAccountsReceivable
Provision for Doubtful Accounts (1,771)us-gaap_ProvisionForDoubtfulAccounts (14,480)us-gaap_ProvisionForDoubtfulAccounts
Inventory 8us-gaap_IncreaseDecreaseInInventories (855)us-gaap_IncreaseDecreaseInInventories
Other Current Assets 941us-gaap_IncreaseDecreaseInOtherCurrentAssets 87us-gaap_IncreaseDecreaseInOtherCurrentAssets
Other Assets (200)us-gaap_IncreaseDecreaseInOtherOperatingAssets (200)us-gaap_IncreaseDecreaseInOtherOperatingAssets
Deposits (71)us-gaap_IncreaseDecreaseInCustomerDeposits (38)us-gaap_IncreaseDecreaseInCustomerDeposits
Increase (Decrease) in:    
Accounts Payable and Accrued Liabilities 1,908us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (3,097)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
NET CASH - OPERATING ACTIVITIES 10,557us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (188)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
INVESTING ACTIVITIES:    
Acquisition of Equipment and Leasehold Improvements (15,739)us-gaap_PaymentsToAcquireProductiveAssets (7,048)us-gaap_PaymentsToAcquireProductiveAssets
Business Acquisitions and Related Costs (254)us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired (258)us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
NET CASH - INVESTING ACTIVITIES (15,993)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (7,306)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
FINANCING ACTIVITIES:    
Payments of Long-Term Debt (257)us-gaap_RepaymentsOfLongTermDebt (243)us-gaap_RepaymentsOfLongTermDebt
Payments of Capital Lease Obligations (3,225)us-gaap_RepaymentsOfLongTermCapitalLeaseObligations (2,933)us-gaap_RepaymentsOfLongTermCapitalLeaseObligations
Increase (Decrease) in Revolving Line of Credit 15,935us-gaap_LineOfCreditFacilityIncreaseDecreaseOtherNet 17,021us-gaap_LineOfCreditFacilityIncreaseDecreaseOtherNet
Proceeds from Exercise of Options 622us-gaap_ProceedsFromStockOptionsExercised 177us-gaap_ProceedsFromStockOptionsExercised
NET CASH - FINANCING ACTIVITIES 13,075us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 14,022us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 7,639us-gaap_NetCashProvidedByUsedInContinuingOperations 6,528us-gaap_NetCashProvidedByUsedInContinuingOperations
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIODS 17,507us-gaap_CashAndCashEquivalentsAtCarryingValue 17,952us-gaap_CashAndCashEquivalentsAtCarryingValue
CASH AND CASH EQUIVALENTS AT END OF PERIODS 25,146us-gaap_CashAndCashEquivalentsAtCarryingValue 24,480us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash paid during the period for:    
Interest 1,189us-gaap_InterestPaid 1,166us-gaap_InterestPaid
Income Taxes 16,538us-gaap_IncomeTaxesPaid 9,867us-gaap_IncomeTaxesPaid
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Capital Leases 1,967us-gaap_CapitalLeaseObligationsIncurred 5,905us-gaap_CapitalLeaseObligationsIncurred
Write-off of property and equipment $ 1,155brli_WriteOffOfPropertyAndEquipment $ 920brli_WriteOffOfPropertyAndEquipment
XML 44 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accounts Receivable Allowances
6 Months Ended
Apr. 30, 2015
Accounts Receivable Allowances  
Accounts Receivable Allowances

 

[5] Accounts Receivable Allowances

 

It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary.   BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

 

 

 

($)

 

 

 

[Unaudited]

 

 

 

 

 

April 30,

 

October 31,

 

 

 

2015

 

2014

 

 

 

 

 

 

 

Contractual Credits/Discounts

 

582,180 

 

513,466 

 

Doubtful Accounts

 

81,505 

 

83,276 

 

Total Allowance

 

663,685 

 

596,742 

 

 

XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 41 153 1 false 15 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.bioreference.com/role/DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.bioreference.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bioreference.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.bioreference.com/role/StatementConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bioreference.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.bioreference.com/role/DisclosureBasisOfPresentation Basis of Presentation false false R7.htm 10201 - Disclosure - Fair Value Measurements Sheet http://www.bioreference.com/role/DisclosureFairValueMeasurements Fair Value Measurements false false R8.htm 10301 - Disclosure - New Accounting Pronouncements Sheet http://www.bioreference.com/role/DisclosureNewAccountingPronouncements New Accounting Pronouncements false false R9.htm 10401 - Disclosure - Revenue Recognition and Contractual Adjustments Sheet http://www.bioreference.com/role/DisclosureRevenueRecognitionAndContractualAdjustments Revenue Recognition and Contractual Adjustments false false R10.htm 10501 - Disclosure - Accounts Receivable Allowances Sheet http://www.bioreference.com/role/DisclosureAccountsReceivableAllowances Accounts Receivable Allowances false false R11.htm 10601 - Disclosure - Intangible Assets Sheet http://www.bioreference.com/role/DisclosureIntangibleAssets Intangible Assets false false R12.htm 10701 - Disclosure - Revolving Note Payable - Bank Sheet http://www.bioreference.com/role/DisclosureRevolvingNotePayableBank Revolving Note Payable - Bank false false R13.htm 10801 - Disclosure - Long-Term Debt - Bank Sheet http://www.bioreference.com/role/DisclosureLongTermDebtBank Long-Term Debt - Bank false false R14.htm 10901 - Disclosure - Provision for Income Taxes Sheet http://www.bioreference.com/role/DisclosureProvisionForIncomeTaxes Provision for Income Taxes false false R15.htm 11001 - Disclosure - Subsequent Events Sheet http://www.bioreference.com/role/DisclosureSubsequentEvents Subsequent Events false false R16.htm 30403 - Disclosure - Revenue Recognition and Contractual Adjustments (Tables) Sheet http://www.bioreference.com/role/DisclosureRevenueRecognitionAndContractualAdjustmentsTables Revenue Recognition and Contractual Adjustments (Tables) false false R17.htm 30503 - Disclosure - Accounts Receivable Allowances (Tables) Sheet http://www.bioreference.com/role/DisclosureAccountsReceivableAllowancesTables Accounts Receivable Allowances (Tables) false false R18.htm 30603 - Disclosure - Intangible Assets (Tables) Sheet http://www.bioreference.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) false false R19.htm 40401 - Disclosure - Revenue Recognition and Contractual Adjustments (Details) Sheet http://www.bioreference.com/role/DisclosureRevenueRecognitionAndContractualAdjustmentsDetails Revenue Recognition and Contractual Adjustments (Details) false false R20.htm 40501 - Disclosure - Accounts Receivable Allowances (Details) Sheet http://www.bioreference.com/role/DisclosureAccountsReceivableAllowancesDetails Accounts Receivable Allowances (Details) false false R21.htm 40601 - Disclosure - Intangible Assets (Details) Sheet http://www.bioreference.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) false false R22.htm 40701 - Disclosure - Revolving Note Payable - Bank (Details) Sheet http://www.bioreference.com/role/DisclosureRevolvingNotePayableBankDetails Revolving Note Payable - Bank (Details) false false R23.htm 40801 - Disclosure - Long-Term Debt - Bank (Details) Sheet http://www.bioreference.com/role/DisclosureLongTermDebtBankDetails Long-Term Debt - Bank (Details) false false R24.htm 40901 - Disclosure - Provision for Income Taxes (Details) Sheet http://www.bioreference.com/role/DisclosureProvisionForIncomeTaxesDetails Provision for Income Taxes (Details) false false R25.htm 41001 - Disclosure - Subsequent Events (Details) Sheet http://www.bioreference.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 180 days and at least 29 values. Shorter duration columns must have at least one fourth (7) as many values. Column '2/1/2014 - 4/30/2014' is shorter (88 days) and has only 3 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 180 days and at least 29 values. Shorter duration columns must have at least one fourth (7) as many values. Column '2/1/2015 - 4/30/2015' is shorter (88 days) and has only 3 values, so it is being removed. Process Flow-Through: 00100 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Apr. 30, 2014' Process Flow-Through: Removing column 'Oct. 31, 2013' Process Flow-Through: 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS brli-20150430.xml brli-20150430.xsd brli-20150430_cal.xml brli-20150430_def.xml brli-20150430_lab.xml brli-20150430_pre.xml true true XML 46 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accounts Receivable Allowances (Details) (USD $)
In Thousands, unless otherwise specified
Apr. 30, 2015
Oct. 31, 2014
Allowances    
Total Allowance $ 663,685us-gaap_ValuationAllowancesAndReservesBalance $ 596,742us-gaap_ValuationAllowancesAndReservesBalance
Contractual Credits/Discounts    
Allowances    
Total Allowance 582,180us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsDiscountsMember
513,466us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsDiscountsMember
Doubtful Accounts    
Allowances    
Total Allowance $ 81,505us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember
$ 83,276us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember